CA2716898A1 - Compound having 6-membered aromatic ring - Google Patents
Compound having 6-membered aromatic ring Download PDFInfo
- Publication number
- CA2716898A1 CA2716898A1 CA2716898A CA2716898A CA2716898A1 CA 2716898 A1 CA2716898 A1 CA 2716898A1 CA 2716898 A CA2716898 A CA 2716898A CA 2716898 A CA2716898 A CA 2716898A CA 2716898 A1 CA2716898 A1 CA 2716898A1
- Authority
- CA
- Canada
- Prior art keywords
- groups
- substituted
- group
- substituents selected
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 483
- 125000003118 aryl group Chemical group 0.000 title claims abstract description 77
- 125000001424 substituent group Chemical group 0.000 claims abstract description 172
- 125000005843 halogen group Chemical group 0.000 claims abstract description 132
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 95
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 58
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 36
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 29
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 18
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 16
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims abstract description 15
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000005977 Ethylene Substances 0.000 claims abstract description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 63
- 125000003277 amino group Chemical group 0.000 claims description 50
- 125000000623 heterocyclic group Chemical group 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 36
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 26
- 150000002430 hydrocarbons Chemical group 0.000 claims description 25
- 101000871149 Homo sapiens G-protein coupled receptor 52 Proteins 0.000 claims description 23
- 125000004043 oxo group Chemical group O=* 0.000 claims description 23
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 22
- 102100033046 G-protein coupled receptor 52 Human genes 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 14
- 239000000651 prodrug Substances 0.000 claims description 14
- 229940002612 prodrug Drugs 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 11
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 9
- 125000001041 indolyl group Chemical group 0.000 claims description 9
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 7
- 239000008177 pharmaceutical agent Substances 0.000 claims description 7
- OAFGVWMOLWMCQS-UHFFFAOYSA-N 3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=N1 OAFGVWMOLWMCQS-UHFFFAOYSA-N 0.000 claims description 5
- KATFHIKVXDSOBQ-UHFFFAOYSA-N 3-[6-(2,4-dichloroanilino)pyridin-2-yl]-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(NC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 KATFHIKVXDSOBQ-UHFFFAOYSA-N 0.000 claims description 4
- WGQZUQHRYZBLRR-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 WGQZUQHRYZBLRR-UHFFFAOYSA-N 0.000 claims description 4
- TUTYSSZQIXHTGZ-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]-n-(2-methylsulfinylethyl)benzamide Chemical compound CS(=O)CCNC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 TUTYSSZQIXHTGZ-UHFFFAOYSA-N 0.000 claims description 4
- CTMHCQQWOFHODY-UHFFFAOYSA-N 4-amino-n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]butanamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCCN)C=CC=2)=N1 CTMHCQQWOFHODY-UHFFFAOYSA-N 0.000 claims description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
- HWWOKDQFVVBKJU-UHFFFAOYSA-N n-(2-aminoethyl)-3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]benzamide;hydrochloride Chemical compound Cl.COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCN)=C1 HWWOKDQFVVBKJU-UHFFFAOYSA-N 0.000 claims description 4
- UYYBGHIXHMWBND-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCO)=C1 UYYBGHIXHMWBND-UHFFFAOYSA-N 0.000 claims description 4
- JAGGGUUOOPMDRG-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-[6-[2-[3-(trifluoromethyl)phenyl]ethoxy]pyridin-2-yl]benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(C=CC=3)C(F)(F)F)C=CC=2)=C1 JAGGGUUOOPMDRG-UHFFFAOYSA-N 0.000 claims description 4
- RGXVKDIVNWUAGU-UHFFFAOYSA-N n-cyclopropyl-3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(=O)NC2CC2)=N1 RGXVKDIVNWUAGU-UHFFFAOYSA-N 0.000 claims description 4
- ZCNGUTRDVSCUJO-UHFFFAOYSA-N 1-[2-[(3-chlorophenyl)methoxy]-6-methylpyridin-4-yl]-2-methylimidazole-4-carboxamide Chemical compound CC1=NC(C(N)=O)=CN1C1=CC(C)=NC(OCC=2C=C(Cl)C=CC=2)=C1 ZCNGUTRDVSCUJO-UHFFFAOYSA-N 0.000 claims description 3
- DLLGOXCLNUZCNO-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenyl)sulfanylpyridin-2-yl]-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(SC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 DLLGOXCLNUZCNO-UHFFFAOYSA-N 0.000 claims description 3
- QZMNAUXWFYSKBP-UHFFFAOYSA-N 3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]-n-(pyridin-3-ylmethyl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCC=2C=NC=CC=2)=N1 QZMNAUXWFYSKBP-UHFFFAOYSA-N 0.000 claims description 3
- JBTGVKGAYSVOKV-UHFFFAOYSA-N n-(2-pyrrolidin-1-ylethyl)-3-[2-[2-[3-(trifluoromethyl)phenyl]ethylamino]pyrimidin-4-yl]benzamide Chemical compound FC(F)(F)C1=CC=CC(CCNC=2N=C(C=CN=2)C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=C1 JBTGVKGAYSVOKV-UHFFFAOYSA-N 0.000 claims description 3
- XYSMWXMCANWVPN-UHFFFAOYSA-N n-[3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(NC(C)=O)C=CC=2)=N1 XYSMWXMCANWVPN-UHFFFAOYSA-N 0.000 claims description 3
- VACXCUOVEFQJCJ-UHFFFAOYSA-N tert-butyl n-[5-[6-(3-chlorophenoxy)pyrazin-2-yl]pyridin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=CC(C=2N=C(OC=3C=C(Cl)C=CC=3)C=NC=2)=C1 VACXCUOVEFQJCJ-UHFFFAOYSA-N 0.000 claims description 3
- QVWJURNPFOJFHG-UHFFFAOYSA-N 5-[6-[3-(trifluoromethyl)phenoxy]pyridin-2-yl]-1,3,4-oxadiazole-2-carboxamide Chemical compound O1C(C(=O)N)=NN=C1C1=CC=CC(OC=2C=C(C=CC=2)C(F)(F)F)=N1 QVWJURNPFOJFHG-UHFFFAOYSA-N 0.000 claims description 2
- ZJSHUCRNGJYFKI-UHFFFAOYSA-N n-hydroxy-5-[6-[methyl(2-phenylethyl)amino]pyridin-2-yl]thiophene-2-carboxamide Chemical compound C=1C=CC(C=2SC(=CC=2)C(=O)NO)=NC=1N(C)CCC1=CC=CC=C1 ZJSHUCRNGJYFKI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000556 agonist Substances 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 757
- 238000005160 1H NMR spectroscopy Methods 0.000 description 231
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 226
- -1 methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy Chemical group 0.000 description 179
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 165
- 101150041968 CDC13 gene Proteins 0.000 description 163
- 238000002844 melting Methods 0.000 description 163
- 230000008018 melting Effects 0.000 description 163
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 139
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 135
- 238000006243 chemical reaction Methods 0.000 description 113
- 239000000243 solution Substances 0.000 description 108
- 239000000203 mixture Substances 0.000 description 81
- 239000002904 solvent Substances 0.000 description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 66
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 61
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- 238000010898 silica gel chromatography Methods 0.000 description 38
- 125000000217 alkyl group Chemical group 0.000 description 37
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 34
- 235000002639 sodium chloride Nutrition 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- 239000000126 substance Substances 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000000284 extract Substances 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 23
- 125000003545 alkoxy group Chemical group 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 22
- CTMNYWOMVGJWDD-UHFFFAOYSA-N 4-(3-aminophenyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(N)C=CC=2)=N1 CTMNYWOMVGJWDD-UHFFFAOYSA-N 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 21
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 21
- 239000002585 base Substances 0.000 description 21
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 21
- 239000007864 aqueous solution Substances 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 125000004076 pyridyl group Chemical group 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
- 229910000029 sodium carbonate Inorganic materials 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- AYQKLPOXUVXOHY-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]benzoic acid Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(O)=O)=C1 AYQKLPOXUVXOHY-UHFFFAOYSA-N 0.000 description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 229910052731 fluorine Inorganic materials 0.000 description 16
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 16
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 16
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 125000002541 furyl group Chemical group 0.000 description 15
- 229930195733 hydrocarbon Natural products 0.000 description 15
- 125000002883 imidazolyl group Chemical group 0.000 description 15
- 125000002757 morpholinyl group Chemical group 0.000 description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 15
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 14
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- 125000005936 piperidyl group Chemical group 0.000 description 14
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 13
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 13
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 13
- 150000001408 amides Chemical class 0.000 description 13
- 125000003710 aryl alkyl group Chemical group 0.000 description 13
- 125000001153 fluoro group Chemical group F* 0.000 description 13
- 230000035484 reaction time Effects 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 description 13
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- 238000007796 conventional method Methods 0.000 description 12
- UKJFVOWPUXSBOM-UHFFFAOYSA-N hexane;oxolane Chemical compound C1CCOC1.CCCCCC UKJFVOWPUXSBOM-UHFFFAOYSA-N 0.000 description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- HTGIFRPHFHFKSJ-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 HTGIFRPHFHFKSJ-UHFFFAOYSA-N 0.000 description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 11
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 11
- 229910052794 bromium Inorganic materials 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 125000003226 pyrazolyl group Chemical group 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 10
- 125000004434 sulfur atom Chemical group 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000002170 ethers Chemical class 0.000 description 9
- 150000008282 halocarbons Chemical class 0.000 description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
- 150000003462 sulfoxides Chemical class 0.000 description 9
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 9
- REHVCPNQQBDOJJ-UHFFFAOYSA-N (3-ethoxycarbonylphenyl)boronic acid Chemical compound CCOC(=O)C1=CC=CC(B(O)O)=C1 REHVCPNQQBDOJJ-UHFFFAOYSA-N 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- WNTGMDKMTBEAAP-UHFFFAOYSA-N 2-chloro-6-(2,4-dichlorophenoxy)pyridine Chemical compound ClC1=CC(Cl)=CC=C1OC1=CC=CC(Cl)=N1 WNTGMDKMTBEAAP-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 238000009833 condensation Methods 0.000 description 8
- 230000005494 condensation Effects 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 8
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 150000002825 nitriles Chemical class 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 8
- 125000004193 piperazinyl group Chemical group 0.000 description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 238000000638 solvent extraction Methods 0.000 description 8
- 125000003831 tetrazolyl group Chemical group 0.000 description 8
- 125000001544 thienyl group Chemical group 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 7
- MGMDLYRUAOQKNX-UHFFFAOYSA-N 3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(O)=O)=N1 MGMDLYRUAOQKNX-UHFFFAOYSA-N 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- SVYKKECYCPFKGB-UHFFFAOYSA-N N,N-dimethylcyclohexylamine Chemical compound CN(C)C1CCCCC1 SVYKKECYCPFKGB-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 150000001447 alkali salts Chemical class 0.000 description 7
- 229940052651 anticholinergic tertiary amines Drugs 0.000 description 7
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 7
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 7
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 125000003373 pyrazinyl group Chemical group 0.000 description 7
- 125000002098 pyridazinyl group Chemical group 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 150000003512 tertiary amines Chemical class 0.000 description 7
- 125000000335 thiazolyl group Chemical group 0.000 description 7
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 7
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 7
- ADBHRXHGPOXISC-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 ADBHRXHGPOXISC-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 6
- 229910017711 NHRa Inorganic materials 0.000 description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 208000010877 cognitive disease Diseases 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 125000001485 cycloalkadienyl group Chemical group 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 6
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 229940124001 GPR52 agonist Drugs 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000001270 agonistic effect Effects 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 150000004703 alkoxides Chemical class 0.000 description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 5
- 150000004982 aromatic amines Chemical class 0.000 description 5
- 125000005018 aryl alkenyl group Chemical group 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 125000003838 furazanyl group Chemical group 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 5
- 125000001786 isothiazolyl group Chemical group 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229910000105 potassium hydride Inorganic materials 0.000 description 5
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 5
- 125000001984 thiazolidinyl group Chemical group 0.000 description 5
- 229930192474 thiophene Natural products 0.000 description 5
- DYVOLUUJJDFBFC-UHFFFAOYSA-N tripotassium butan-1-olate Chemical compound [K+].[K+].[K+].CCCC[O-].CCCC[O-].CCCC[O-] DYVOLUUJJDFBFC-UHFFFAOYSA-N 0.000 description 5
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 4
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
- PZIYRFAEGNAHCN-UHFFFAOYSA-N 2-chloro-6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridine Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(Cl)=N1 PZIYRFAEGNAHCN-UHFFFAOYSA-N 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 4
- GLIRAAUXIXYGFB-UHFFFAOYSA-N 3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(C=CC=2)C(O)=O)=N1 GLIRAAUXIXYGFB-UHFFFAOYSA-N 0.000 description 4
- XJHYDVUXMJAELN-UHFFFAOYSA-N 3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]aniline Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(N)C=CC=2)=N1 XJHYDVUXMJAELN-UHFFFAOYSA-N 0.000 description 4
- JXWNZLDIWGUOTM-UHFFFAOYSA-N 3-[6-[2-(3-fluorophenyl)ethoxy]pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(F)C=CC=3)C=CC=2)=C1 JXWNZLDIWGUOTM-UHFFFAOYSA-N 0.000 description 4
- XGBOTDXTECRPIE-UHFFFAOYSA-N 4-bromo-n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]butanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCCBr)C=CC=2)=N1 XGBOTDXTECRPIE-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 4
- 150000008046 alkali metal hydrides Chemical class 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- NRMLEFNSHQKMEJ-UHFFFAOYSA-N ethyl 3-[2-[2-(3,4-dimethoxyphenyl)ethoxy]pyrimidin-4-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(OC)C(OC)=CC=3)N=CC=2)=C1 NRMLEFNSHQKMEJ-UHFFFAOYSA-N 0.000 description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 description 4
- 229910052723 transition metal Inorganic materials 0.000 description 4
- 150000003624 transition metals Chemical class 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 3
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 3
- SRQAJMUHZROVHW-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)ethanol Chemical compound COC1=CC=C(CCO)C=C1OC SRQAJMUHZROVHW-UHFFFAOYSA-N 0.000 description 3
- SUXNBUFCTRYPCK-UHFFFAOYSA-N 3-[6-(2,4-dichloroanilino)pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(NC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 SUXNBUFCTRYPCK-UHFFFAOYSA-N 0.000 description 3
- QPUIYQVWUIQJAM-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C(=CC=C(OC=3C(=CC(Cl)=CC=3)Cl)N=2)C(F)(F)F)=C1 QPUIYQVWUIQJAM-UHFFFAOYSA-N 0.000 description 3
- UTJXAIMWTFHFRN-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=C(C=2)C(F)(F)F)=C1 UTJXAIMWTFHFRN-UHFFFAOYSA-N 0.000 description 3
- LIABKHWUERWFQX-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1F LIABKHWUERWFQX-UHFFFAOYSA-N 0.000 description 3
- YOKCYKDRWHKEQP-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 YOKCYKDRWHKEQP-UHFFFAOYSA-N 0.000 description 3
- CQKGYMSWIXLEPE-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1C1=CC=CC(OC=2C(=CC(Cl)=CC=2)Cl)=N1 CQKGYMSWIXLEPE-UHFFFAOYSA-N 0.000 description 3
- LWXWKJHINCKWDY-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-5-fluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 LWXWKJHINCKWDY-UHFFFAOYSA-N 0.000 description 3
- RECSRCCZGLQXIH-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound ClC1=CC(Cl)=CC=C1OC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=N1 RECSRCCZGLQXIH-UHFFFAOYSA-N 0.000 description 3
- YPCIHIIBWDOLLJ-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenyl)sulfanylpyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(SC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 YPCIHIIBWDOLLJ-UHFFFAOYSA-N 0.000 description 3
- DUHWSTCMWZPZAI-UHFFFAOYSA-N 3-[6-[(2,4-dichlorophenyl)methoxy]pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OCC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 DUHWSTCMWZPZAI-UHFFFAOYSA-N 0.000 description 3
- KGBHRPFGEVGVFA-UHFFFAOYSA-N 3-[6-[2-(2,4-dichlorophenyl)ethoxy]pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OCCC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 KGBHRPFGEVGVFA-UHFFFAOYSA-N 0.000 description 3
- NJYFAYFGPHTMRH-UHFFFAOYSA-N 3-[6-[2-(3-methylphenyl)ethoxy]pyridin-2-yl]benzoic acid Chemical compound CC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(O)=O)=C1 NJYFAYFGPHTMRH-UHFFFAOYSA-N 0.000 description 3
- BXRYAFSYRBBPEC-UHFFFAOYSA-N 3-[6-[2-[3-(trifluoromethyl)phenyl]ethoxy]pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(C=CC=3)C(F)(F)F)C=CC=2)=C1 BXRYAFSYRBBPEC-UHFFFAOYSA-N 0.000 description 3
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 3
- VUNSTVKPOJRASV-UHFFFAOYSA-N 5-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-2-fluorobenzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 VUNSTVKPOJRASV-UHFFFAOYSA-N 0.000 description 3
- VYAAVRVLUZEGTC-UHFFFAOYSA-N 5-[6-(2,4-dichlorophenoxy)pyridin-2-yl]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 VYAAVRVLUZEGTC-UHFFFAOYSA-N 0.000 description 3
- YTHMOBMZVVFNBE-UHFFFAOYSA-N 6-fluoropyridin-3-amine Chemical compound NC1=CC=C(F)N=C1 YTHMOBMZVVFNBE-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- ZKDZOSMXELUVEN-UHFFFAOYSA-N ethyl 3-(2-chloropyrimidin-4-yl)benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(Cl)N=CC=2)=C1 ZKDZOSMXELUVEN-UHFFFAOYSA-N 0.000 description 3
- ZDHCIVRTOUWRPH-UHFFFAOYSA-N ethyl 3-[4-[2-(3,4-dimethoxyphenyl)ethoxy]pyrimidin-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(OC)C(OC)=CC=3)C=CN=2)=C1 ZDHCIVRTOUWRPH-UHFFFAOYSA-N 0.000 description 3
- GQNWAVFXHZEZKP-UHFFFAOYSA-N ethyl 3-bromo-2-fluorobenzoate Chemical compound CCOC(=O)C1=CC=CC(Br)=C1F GQNWAVFXHZEZKP-UHFFFAOYSA-N 0.000 description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 3
- 235000002864 food coloring agent Nutrition 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 102000057295 human GPR52 Human genes 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 229960005017 olanzapine Drugs 0.000 description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 3
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000004149 thio group Chemical group *S* 0.000 description 3
- 125000005950 trichloromethanesulfonyloxy group Chemical group 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- CFGDUGSIBUXRMR-UHFFFAOYSA-N 1,2-dihydropyrrol-2-ide Chemical class C=1C=[C-]NC=1 CFGDUGSIBUXRMR-UHFFFAOYSA-N 0.000 description 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- CFHVXBFHOJGTOS-UHFFFAOYSA-N 1-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]indole-5-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(N2C3=CC=C(C=C3C=C2)C(O)=O)=N1 CFHVXBFHOJGTOS-UHFFFAOYSA-N 0.000 description 2
- SECJUCOOLJRSBD-UHFFFAOYSA-N 1-[3-(6-chloropyridin-2-yl)oxyphenyl]ethanone Chemical compound CC(=O)C1=CC=CC(OC=2N=C(Cl)C=CC=2)=C1 SECJUCOOLJRSBD-UHFFFAOYSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- TYPVHTOETJVYIV-UHFFFAOYSA-N 2,4-dichloropyridine Chemical compound ClC1=CC=NC(Cl)=C1 TYPVHTOETJVYIV-UHFFFAOYSA-N 0.000 description 2
- FEYDZHNIIMENOB-UHFFFAOYSA-N 2,6-dibromopyridine Chemical compound BrC1=CC=CC(Br)=N1 FEYDZHNIIMENOB-UHFFFAOYSA-N 0.000 description 2
- BLMLGZFEZUFGPI-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)ethoxy]-6-(3-nitrophenyl)pyridine Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)[N+]([O-])=O)=N1 BLMLGZFEZUFGPI-UHFFFAOYSA-N 0.000 description 2
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 2
- AWQDSIGGIIAIBP-UHFFFAOYSA-N 2-chloro-4-[2-(3,4-dimethoxyphenyl)ethoxy]pyridine Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=NC(Cl)=C1 AWQDSIGGIIAIBP-UHFFFAOYSA-N 0.000 description 2
- YROHPZYBJOCGRO-UHFFFAOYSA-N 2-chloro-6-(2,3-dihydro-1h-inden-5-yloxy)pyridine Chemical compound ClC1=CC=CC(OC=2C=C3CCCC3=CC=2)=N1 YROHPZYBJOCGRO-UHFFFAOYSA-N 0.000 description 2
- FDYUZICCMROFAX-UHFFFAOYSA-N 2-chloro-6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC(Cl)=NC(OC=2C(=CC(Cl)=CC=2)Cl)=C1 FDYUZICCMROFAX-UHFFFAOYSA-N 0.000 description 2
- UOFFXFMRUZIUAN-UHFFFAOYSA-N 2-chloro-6-(2,4-dichlorophenyl)sulfanylpyridine Chemical compound ClC1=CC(Cl)=CC=C1SC1=CC=CC(Cl)=N1 UOFFXFMRUZIUAN-UHFFFAOYSA-N 0.000 description 2
- ZYVUKPOVALTKEX-UHFFFAOYSA-N 2-chloro-6-(2,4-difluorophenoxy)pyridine Chemical compound FC1=CC(F)=CC=C1OC1=CC=CC(Cl)=N1 ZYVUKPOVALTKEX-UHFFFAOYSA-N 0.000 description 2
- VUNVBAYCZQHFOG-UHFFFAOYSA-N 2-chloro-6-(2,5-dichlorophenoxy)pyridine Chemical compound ClC1=CC=C(Cl)C(OC=2N=C(Cl)C=CC=2)=C1 VUNVBAYCZQHFOG-UHFFFAOYSA-N 0.000 description 2
- BRKCPUXYXWHSMD-UHFFFAOYSA-N 2-chloro-6-(2-chlorophenoxy)pyridine Chemical compound ClC1=CC=CC(OC=2C(=CC=CC=2)Cl)=N1 BRKCPUXYXWHSMD-UHFFFAOYSA-N 0.000 description 2
- AMIUIRPGPVUBGZ-UHFFFAOYSA-N 2-chloro-6-(3-chlorophenoxy)pyridine Chemical compound ClC1=CC=CC(OC=2N=C(Cl)C=CC=2)=C1 AMIUIRPGPVUBGZ-UHFFFAOYSA-N 0.000 description 2
- XQWWPGSDLMHYGG-UHFFFAOYSA-N 2-chloro-6-(3-methoxyphenoxy)pyridine Chemical compound COC1=CC=CC(OC=2N=C(Cl)C=CC=2)=C1 XQWWPGSDLMHYGG-UHFFFAOYSA-N 0.000 description 2
- AQNXHEDDEVEWOK-UHFFFAOYSA-N 2-chloro-6-(4-chlorophenoxy)pyridine Chemical compound C1=CC(Cl)=CC=C1OC1=CC=CC(Cl)=N1 AQNXHEDDEVEWOK-UHFFFAOYSA-N 0.000 description 2
- QUKLGQFEWNSMBQ-UHFFFAOYSA-N 2-chloro-6-(5-chloropyridin-3-yl)oxypyridine Chemical compound ClC1=CN=CC(OC=2N=C(Cl)C=CC=2)=C1 QUKLGQFEWNSMBQ-UHFFFAOYSA-N 0.000 description 2
- GNDKBVKLOMHEBH-UHFFFAOYSA-N 2-chloro-6-[2-(2,4-dichlorophenyl)ethoxy]pyridine Chemical compound ClC1=CC(Cl)=CC=C1CCOC1=CC=CC(Cl)=N1 GNDKBVKLOMHEBH-UHFFFAOYSA-N 0.000 description 2
- PIIIUVUYCCPKPF-UHFFFAOYSA-N 2-chloro-6-[2-(3-fluorophenyl)ethoxy]pyridine Chemical compound FC1=CC=CC(CCOC=2N=C(Cl)C=CC=2)=C1 PIIIUVUYCCPKPF-UHFFFAOYSA-N 0.000 description 2
- ZCVAGCIMFYCNQA-UHFFFAOYSA-N 2-chloro-6-[2-(3-methoxyphenyl)ethoxy]pyridine Chemical compound COC1=CC=CC(CCOC=2N=C(Cl)C=CC=2)=C1 ZCVAGCIMFYCNQA-UHFFFAOYSA-N 0.000 description 2
- LERMBTNZYDCZCH-UHFFFAOYSA-N 2-chloro-6-[2-(3-methylphenyl)ethoxy]pyridine Chemical compound CC1=CC=CC(CCOC=2N=C(Cl)C=CC=2)=C1 LERMBTNZYDCZCH-UHFFFAOYSA-N 0.000 description 2
- MCFJWZCAMPBUAH-UHFFFAOYSA-N 2-chloro-6-[2-[3-(trifluoromethyl)phenyl]ethoxy]pyridine Chemical compound FC(F)(F)C1=CC=CC(CCOC=2N=C(Cl)C=CC=2)=C1 MCFJWZCAMPBUAH-UHFFFAOYSA-N 0.000 description 2
- SAUOBWAJHJCQBK-UHFFFAOYSA-N 2-chloro-6-cyclohexyloxypyridine Chemical compound ClC1=CC=CC(OC2CCCCC2)=N1 SAUOBWAJHJCQBK-UHFFFAOYSA-N 0.000 description 2
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 2
- DSXKRMRFCSAUNO-UHFFFAOYSA-M 2-fluoro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1F DSXKRMRFCSAUNO-UHFFFAOYSA-M 0.000 description 2
- GNCLPNMQEGMNTG-UHFFFAOYSA-N 2-methylpyridin-4-amine Chemical compound CC1=CC(N)=CC=N1 GNCLPNMQEGMNTG-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- FWORNQIBSKOYRD-UHFFFAOYSA-N 3-(6-chloropyridin-2-yl)oxy-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC(OC=2N=C(Cl)C=CC=2)=C1 FWORNQIBSKOYRD-UHFFFAOYSA-N 0.000 description 2
- QFVUWJKGFPKXBB-UHFFFAOYSA-N 3-[2-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-4-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC(C=2C=C(C=CC=2)C(O)=O)=CC=N1 QFVUWJKGFPKXBB-UHFFFAOYSA-N 0.000 description 2
- QCZKFUWHCSYVGN-UHFFFAOYSA-N 3-[2-[2-(3,4-dimethoxyphenyl)ethoxy]pyrimidin-4-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=NC=CC(C=2C=C(C=CC=2)C(O)=O)=N1 QCZKFUWHCSYVGN-UHFFFAOYSA-N 0.000 description 2
- NFUWVMUPPRLHON-UHFFFAOYSA-N 3-[3-[2-(3,4-dimethoxyphenyl)ethoxy]phenyl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(O)=O)=C1 NFUWVMUPPRLHON-UHFFFAOYSA-N 0.000 description 2
- HJASWCNNEYYSIW-UHFFFAOYSA-N 3-[4-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=NC(C=2C=C(C=CC=2)C(O)=O)=C1 HJASWCNNEYYSIW-UHFFFAOYSA-N 0.000 description 2
- AQQNBQDDZPOQGG-UHFFFAOYSA-N 3-[4-[2-(3,4-dimethoxyphenyl)ethoxy]pyrimidin-2-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=NC(C=2C=C(C=CC=2)C(O)=O)=N1 AQQNBQDDZPOQGG-UHFFFAOYSA-N 0.000 description 2
- QHZNLAOCXQFYQZ-UHFFFAOYSA-N 3-[5-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-3-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CN=CC(C=2C=C(C=CC=2)C(O)=O)=C1 QHZNLAOCXQFYQZ-UHFFFAOYSA-N 0.000 description 2
- AAFVANCKZWGZGX-UHFFFAOYSA-N 3-[6-(2,3-dichlorophenoxy)pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OC=3C(=C(Cl)C=CC=3)Cl)C=CC=2)=C1 AAFVANCKZWGZGX-UHFFFAOYSA-N 0.000 description 2
- SKQIIZWUBZGUAP-UHFFFAOYSA-N 3-[6-(3,4-dichlorophenoxy)pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C(Cl)=CC=3)C=CC=2)=C1 SKQIIZWUBZGUAP-UHFFFAOYSA-N 0.000 description 2
- CZKPIEAUWGHVIB-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]-n-(2-methylsulfanylethyl)benzamide Chemical compound CSCCNC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 CZKPIEAUWGHVIB-UHFFFAOYSA-N 0.000 description 2
- ZJJNKXUDRKDFAP-UHFFFAOYSA-N 3-[6-[(2,4-dichlorophenyl)methylamino]pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(NCC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 ZJJNKXUDRKDFAP-UHFFFAOYSA-N 0.000 description 2
- QHDDBBFCFRNHPZ-UHFFFAOYSA-N 3-amino-n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]butanamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CC(C)N)C=CC=2)=N1 QHDDBBFCFRNHPZ-UHFFFAOYSA-N 0.000 description 2
- KLIAPELNJXDMLM-UHFFFAOYSA-N 3-bromo-n-(2-cyanoethyl)benzamide Chemical compound BrC1=CC=CC(C(=O)NCCC#N)=C1 KLIAPELNJXDMLM-UHFFFAOYSA-N 0.000 description 2
- VTWKBKAHNULFCR-UHFFFAOYSA-N 3-chloro-5-[2-(3,4-dimethoxyphenyl)ethoxy]pyridine Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CN=CC(Cl)=C1 VTWKBKAHNULFCR-UHFFFAOYSA-N 0.000 description 2
- IHCCAYCGZOLTEU-UHFFFAOYSA-N 3-furoic acid Chemical compound OC(=O)C=1C=COC=1 IHCCAYCGZOLTEU-UHFFFAOYSA-N 0.000 description 2
- LUJMEECXHPYQOF-UHFFFAOYSA-N 3-hydroxyacetophenone Chemical compound CC(=O)C1=CC=CC(O)=C1 LUJMEECXHPYQOF-UHFFFAOYSA-N 0.000 description 2
- XHQZJYCNDZAGLW-UHFFFAOYSA-N 3-methoxybenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1 XHQZJYCNDZAGLW-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- OYRKBXAYKQKUHX-UHFFFAOYSA-N 4-[2-(3-bromophenoxy)ethyl]-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(Br)=C1 OYRKBXAYKQKUHX-UHFFFAOYSA-N 0.000 description 2
- BWZRBWUBBMHHSX-UHFFFAOYSA-N 5-(6-chloropyridin-2-yl)oxy-1h-indole Chemical compound ClC1=CC=CC(OC=2C=C3C=CNC3=CC=2)=N1 BWZRBWUBBMHHSX-UHFFFAOYSA-N 0.000 description 2
- TUIDQYRZDZRHPQ-UHFFFAOYSA-N 5-chloropyridin-3-ol Chemical compound OC1=CN=CC(Cl)=C1 TUIDQYRZDZRHPQ-UHFFFAOYSA-N 0.000 description 2
- XXDDAAOYXRKTHN-UHFFFAOYSA-N 6-bromo-n-[(2,4-dichlorophenyl)methyl]pyridin-2-amine Chemical compound ClC1=CC(Cl)=CC=C1CNC1=CC=CC(Br)=N1 XXDDAAOYXRKTHN-UHFFFAOYSA-N 0.000 description 2
- UWUKKFNNGCRXHW-UHFFFAOYSA-N 6-bromo-n-[2-[3-(trifluoromethyl)phenyl]ethyl]pyridin-2-amine Chemical compound FC(F)(F)C1=CC=CC(CCNC=2N=C(Br)C=CC=2)=C1 UWUKKFNNGCRXHW-UHFFFAOYSA-N 0.000 description 2
- CLNNBQDAAGDAHI-UHFFFAOYSA-N 6-chloro-1h-pyridin-2-one Chemical compound OC1=CC=CC(Cl)=N1 CLNNBQDAAGDAHI-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 2
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007269 Carcinogenicity Diseases 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 2
- 206010041243 Social avoidant behaviour Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 125000005604 azodicarboxylate group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000007670 carcinogenicity Effects 0.000 description 2
- 231100000260 carcinogenicity Toxicity 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000007681 cardiovascular toxicity Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 2
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 2
- OSKDUASHCBRTRG-UHFFFAOYSA-N ethyl 3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(NCCC=3C=C(OC)C(OC)=CC=3)N=CC=2)=C1 OSKDUASHCBRTRG-UHFFFAOYSA-N 0.000 description 2
- HPOPZTBGFMIDFT-UHFFFAOYSA-N ethyl 3-[6-(2,4-dichloroanilino)pyridin-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(NC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 HPOPZTBGFMIDFT-UHFFFAOYSA-N 0.000 description 2
- IDDCWSMMHCCDJO-UHFFFAOYSA-N ethyl 3-[6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C(=CC=C(OC=3C(=CC(Cl)=CC=3)Cl)N=2)C(F)(F)F)=C1 IDDCWSMMHCCDJO-UHFFFAOYSA-N 0.000 description 2
- RMBKTYRNWHSIAE-UHFFFAOYSA-N ethyl 3-[6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=C(C=2)C(F)(F)F)=C1 RMBKTYRNWHSIAE-UHFFFAOYSA-N 0.000 description 2
- GJFOZCUYAXHPNP-UHFFFAOYSA-N ethyl 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-2-fluorobenzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1F GJFOZCUYAXHPNP-UHFFFAOYSA-N 0.000 description 2
- RPCYHBQZIAIEBR-UHFFFAOYSA-N ethyl 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 RPCYHBQZIAIEBR-UHFFFAOYSA-N 0.000 description 2
- BKAMOUWVEAMGEV-UHFFFAOYSA-N ethyl 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-5-fluorobenzoate Chemical compound CCOC(=O)C1=CC(F)=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 BKAMOUWVEAMGEV-UHFFFAOYSA-N 0.000 description 2
- IFUCAIBUGMFVAY-UHFFFAOYSA-N ethyl 3-[6-(2,4-dichlorophenyl)sulfanylpyridin-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(SC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 IFUCAIBUGMFVAY-UHFFFAOYSA-N 0.000 description 2
- NXLQOVWASVDMHM-UHFFFAOYSA-N ethyl 3-bromo-5-fluorobenzoate Chemical compound CCOC(=O)C1=CC(F)=CC(Br)=C1 NXLQOVWASVDMHM-UHFFFAOYSA-N 0.000 description 2
- RXCOOBAWFQJOGM-UHFFFAOYSA-N ethyl 5-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-2-fluorobenzoate Chemical compound C1=C(F)C(C(=O)OCC)=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 RXCOOBAWFQJOGM-UHFFFAOYSA-N 0.000 description 2
- KIECJJUIAHJFPJ-UHFFFAOYSA-N ethyl 5-[6-(2,4-dichlorophenoxy)pyridin-2-yl]pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 KIECJJUIAHJFPJ-UHFFFAOYSA-N 0.000 description 2
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- PEUAQQQCNMYRCA-UHFFFAOYSA-N methyl 3-[6-(2,3-dichlorophenoxy)pyridin-2-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C=2N=C(OC=3C(=C(Cl)C=CC=3)Cl)C=CC=2)=C1 PEUAQQQCNMYRCA-UHFFFAOYSA-N 0.000 description 2
- IKYOGWQGMGGAJG-UHFFFAOYSA-N methyl 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 IKYOGWQGMGGAJG-UHFFFAOYSA-N 0.000 description 2
- QOJHUOBOSXUNJI-UHFFFAOYSA-N methyl 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 QOJHUOBOSXUNJI-UHFFFAOYSA-N 0.000 description 2
- SQHXZSKWCZHAOS-UHFFFAOYSA-N methyl 3-[6-(3,4-dichlorophenoxy)pyridin-2-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C(Cl)=CC=3)C=CC=2)=C1 SQHXZSKWCZHAOS-UHFFFAOYSA-N 0.000 description 2
- WSQWGVYGRULXDL-UHFFFAOYSA-N methyl 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 WSQWGVYGRULXDL-UHFFFAOYSA-N 0.000 description 2
- HAPIXNBOBZHNCA-UHFFFAOYSA-N methyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate Chemical compound COC(=O)C1=CC=C(C)C(B2OC(C)(C)C(C)(C)O2)=C1 HAPIXNBOBZHNCA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- OHCFJIQYAPNPAM-UHFFFAOYSA-N n-(2-cyanoethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(C(=O)NCCC#N)=C1 OHCFJIQYAPNPAM-UHFFFAOYSA-N 0.000 description 2
- SOQQFNVAHLYNHM-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]-4-piperidin-1-ylbutanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCCN3CCCCC3)C=CC=2)=N1 SOQQFNVAHLYNHM-UHFFFAOYSA-N 0.000 description 2
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 2
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004181 riluzole Drugs 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- FHOSYFVRWROIGV-UHFFFAOYSA-N tert-butyl 4-[[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]carbamoyl]piperidine-1-carboxylate Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)C3CCN(CC3)C(=O)OC(C)(C)C)C=CC=2)=N1 FHOSYFVRWROIGV-UHFFFAOYSA-N 0.000 description 2
- CMEWHEWAGUGMTA-UHFFFAOYSA-N tert-butyl n-[2-[[3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]benzoyl]amino]ethyl]carbamate Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCNC(=O)OC(C)(C)C)=C1 CMEWHEWAGUGMTA-UHFFFAOYSA-N 0.000 description 2
- DEPIZWLVXVRGND-UHFFFAOYSA-N tert-butyl n-[3-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]anilino]-3-oxopropyl]carbamate Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCNC(=O)OC(C)(C)C)C=CC=2)=N1 DEPIZWLVXVRGND-UHFFFAOYSA-N 0.000 description 2
- NWDIRFXKYZDYIS-UHFFFAOYSA-N tert-butyl n-[3-[[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]benzoyl]amino]propyl]carbamate Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(C=CC=2)C(=O)NCCCNC(=O)OC(C)(C)C)=N1 NWDIRFXKYZDYIS-UHFFFAOYSA-N 0.000 description 2
- IUKAVDHSQJCYJM-UHFFFAOYSA-N tert-butyl n-[4-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]anilino]-4-oxobutyl]carbamate Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCCNC(=O)OC(C)(C)C)C=CC=2)=N1 IUKAVDHSQJCYJM-UHFFFAOYSA-N 0.000 description 2
- BHLHJYCVLZLKPX-UHFFFAOYSA-N tert-butyl n-[5-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]anilino]-5-oxopentyl]carbamate Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCCCNC(=O)OC(C)(C)C)C=CC=2)=N1 BHLHJYCVLZLKPX-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- PGYDXVBZYKQYCS-VPWBDBDCSA-N (1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-4-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@H]2[C@@H](COC)[C@]3(CC[C@@](C2)(N3C)[H])[H])=CC=C(Cl)C(Cl)=C1 PGYDXVBZYKQYCS-VPWBDBDCSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- SJUKJZSTBBSGHF-UHFFFAOYSA-N (2,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1Cl SJUKJZSTBBSGHF-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WDGWHKRJEBENCE-UHFFFAOYSA-N (3-carbamoylphenyl)boronic acid Chemical compound NC(=O)C1=CC=CC(B(O)O)=C1 WDGWHKRJEBENCE-UHFFFAOYSA-N 0.000 description 1
- ALTLCJHSJMGSLT-UHFFFAOYSA-N (3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=CC(B(O)O)=C1 ALTLCJHSJMGSLT-UHFFFAOYSA-N 0.000 description 1
- PPBSMPOYVPZOFM-SCSAIBSYSA-N (3r)-3-aminobutanenitrile Chemical compound C[C@@H](N)CC#N PPBSMPOYVPZOFM-SCSAIBSYSA-N 0.000 description 1
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 1
- PPBSMPOYVPZOFM-BYPYZUCNSA-N (3s)-3-aminobutanenitrile Chemical compound C[C@H](N)CC#N PPBSMPOYVPZOFM-BYPYZUCNSA-N 0.000 description 1
- 108700002662 (R)-(N-(3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl))sarcosine Proteins 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- RTWOAVKBRMACKZ-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)ethanol Chemical compound COC1=CC=C(C(C)O)C=C1OC RTWOAVKBRMACKZ-UHFFFAOYSA-N 0.000 description 1
- CEIIEALEIHQDBX-UHFFFAOYSA-N 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methyl-3-isoxazolyl)urea Chemical compound C1=C(Cl)C(OC)=CC(OC)=C1NC(=O)NC1=NOC(C)=C1 CEIIEALEIHQDBX-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- XEWXTCSFABWLCW-UHFFFAOYSA-N 1-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]-n-[2-(dimethylamino)ethyl]indole-5-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(N2C3=CC=C(C=C3C=C2)C(=O)NCCN(C)C)=N1 XEWXTCSFABWLCW-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- NNHQJFUEZWGOLX-UHFFFAOYSA-N 1h-indol-5-ol Chemical compound C1=C(O)C=C[C]2NC=C=C21 NNHQJFUEZWGOLX-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- LKAMDVZMKOKABK-UHFFFAOYSA-N 2,2,2-trichloroethyl n-(6-fluoropyridin-3-yl)carbamate Chemical compound FC1=CC=C(NC(=O)OCC(Cl)(Cl)Cl)C=N1 LKAMDVZMKOKABK-UHFFFAOYSA-N 0.000 description 1
- UMPSXRYVXUPCOS-UHFFFAOYSA-N 2,3-dichlorophenol Chemical compound OC1=CC=CC(Cl)=C1Cl UMPSXRYVXUPCOS-UHFFFAOYSA-N 0.000 description 1
- KQCMTOWTPBNWDB-UHFFFAOYSA-N 2,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C=C1Cl KQCMTOWTPBNWDB-UHFFFAOYSA-N 0.000 description 1
- FGBVJFREPSJSNG-UHFFFAOYSA-N 2,4-dichlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1Cl FGBVJFREPSJSNG-UHFFFAOYSA-N 0.000 description 1
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- NVWVWEWVLBKPSM-UHFFFAOYSA-N 2,4-difluorophenol Chemical compound OC1=CC=C(F)C=C1F NVWVWEWVLBKPSM-UHFFFAOYSA-N 0.000 description 1
- RANCECPPZPIPNO-UHFFFAOYSA-N 2,5-dichlorophenol Chemical compound OC1=CC(Cl)=CC=C1Cl RANCECPPZPIPNO-UHFFFAOYSA-N 0.000 description 1
- ZFDGMMZLXSFNFU-UHFFFAOYSA-N 2,5-dimethylpyrazol-3-amine Chemical compound CC=1C=C(N)N(C)N=1 ZFDGMMZLXSFNFU-UHFFFAOYSA-N 0.000 description 1
- UPWAAFFFSGQECJ-UHFFFAOYSA-N 2,6-dichloro-3-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)N=C1Cl UPWAAFFFSGQECJ-UHFFFAOYSA-N 0.000 description 1
- KVNQWVYYVLCZKK-UHFFFAOYSA-N 2,6-dichloro-4-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC(Cl)=NC(Cl)=C1 KVNQWVYYVLCZKK-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- JIJGKPVJAALUQQ-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)ethanol Chemical compound OCCC1=CC=C(Cl)C=C1Cl JIJGKPVJAALUQQ-UHFFFAOYSA-N 0.000 description 1
- MZNBGEKFZCWVES-UHFFFAOYSA-N 2-(3-fluorophenyl)ethanol Chemical compound OCCC1=CC=CC(F)=C1 MZNBGEKFZCWVES-UHFFFAOYSA-N 0.000 description 1
- UPPGEJSCUZMCMW-UHFFFAOYSA-N 2-(3-methoxyphenyl)ethanol Chemical compound COC1=CC=CC(CCO)=C1 UPPGEJSCUZMCMW-UHFFFAOYSA-N 0.000 description 1
- KWHVBVJDKLSOTB-UHFFFAOYSA-N 2-(3-methylphenyl)ethanol Chemical compound CC1=CC=CC(CCO)=C1 KWHVBVJDKLSOTB-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- YZJRZSPSHKFLBY-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)ethoxy]-4-iodopyridine Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC(I)=CC=N1 YZJRZSPSHKFLBY-UHFFFAOYSA-N 0.000 description 1
- QODUFVRYFSJELG-UHFFFAOYSA-N 2-[2-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]anilino]-2-oxoethyl]pyrrolidine-1-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CC3N(CCC3)C(O)=O)C=CC=2)=N1 QODUFVRYFSJELG-UHFFFAOYSA-N 0.000 description 1
- BPVYCXMGJPKOTQ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]ethanamine Chemical compound NCCC1=CC=CC(C(F)(F)F)=C1 BPVYCXMGJPKOTQ-UHFFFAOYSA-N 0.000 description 1
- YDKIPCCKZKQMDT-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]ethanol Chemical compound OCCC1=CC=CC(C(F)(F)F)=C1 YDKIPCCKZKQMDT-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- FDORQEIHOKEJNX-UHFFFAOYSA-N 2-[[3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid Chemical compound C=1C=C(F)C=CC=1C(CCN(C)CC(O)=O)OC(C=C1)=CC=C1C1=CC=CC=C1 FDORQEIHOKEJNX-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- GGYWMNYWEYFFHY-UHFFFAOYSA-N 2-acetamido-n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CNC(C)=O)C=CC=2)=N1 GGYWMNYWEYFFHY-UHFFFAOYSA-N 0.000 description 1
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 description 1
- KDVMZMNQYCXRCG-UHFFFAOYSA-N 2-amino-n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]acetamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CN)C=CC=2)=N1 KDVMZMNQYCXRCG-UHFFFAOYSA-N 0.000 description 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- PLUSXPQZOFZYIS-UHFFFAOYSA-N 2-chloro-4-(3-nitrophenyl)pyrimidine Chemical compound [O-][N+](=O)C1=CC=CC(C=2N=C(Cl)N=CC=2)=C1 PLUSXPQZOFZYIS-UHFFFAOYSA-N 0.000 description 1
- LIEPVGBDUYKPLC-UHFFFAOYSA-N 2-chloro-4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC(Cl)=C1 LIEPVGBDUYKPLC-UHFFFAOYSA-N 0.000 description 1
- WRBOVIJYPTZULE-UHFFFAOYSA-N 2-chloro-6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridine Chemical compound N1=C(Cl)C(C(F)(F)F)=CC=C1OC1=CC=C(Cl)C=C1Cl WRBOVIJYPTZULE-UHFFFAOYSA-N 0.000 description 1
- POIOQMLGZWWMGU-UHFFFAOYSA-N 2-chloro-6-(2,4-dimethylphenoxy)pyridine Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC(Cl)=N1 POIOQMLGZWWMGU-UHFFFAOYSA-N 0.000 description 1
- MEZRZVWPLXVLSO-WMZOPIPTSA-N 2-chloro-n-[(s)-phenyl-[(2s)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)N[C@H]([C@H]2NCCCC2)C=2C=CC=CC=2)=C1Cl MEZRZVWPLXVLSO-WMZOPIPTSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ADPRIAVYIGHFSO-UHFFFAOYSA-N 2-fluoro-4-iodopyridine Chemical compound FC1=CC(I)=CC=N1 ADPRIAVYIGHFSO-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- NGZVNONVXYLYQW-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-amine Chemical compound NCCC(F)(F)F NGZVNONVXYLYQW-UHFFFAOYSA-N 0.000 description 1
- WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 1
- VPOMSPZBQMDLTM-UHFFFAOYSA-N 3,5-dichlorophenol Chemical compound OC1=CC(Cl)=CC(Cl)=C1 VPOMSPZBQMDLTM-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- MESJRHHDBDCQTH-UHFFFAOYSA-N 3-(dimethylamino)phenol Chemical compound CN(C)C1=CC=CC(O)=C1 MESJRHHDBDCQTH-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- PYNDHEONPQYIAN-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound OC(=O)CC(C)NC(=O)OC(C)(C)C PYNDHEONPQYIAN-UHFFFAOYSA-N 0.000 description 1
- AGBWOJIPYBDBNG-UHFFFAOYSA-N 3-[2-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-4-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=CC=N1 AGBWOJIPYBDBNG-UHFFFAOYSA-N 0.000 description 1
- AGUAOTQVPUBFSH-UHFFFAOYSA-N 3-[2-[2-(3,4-dimethoxyphenyl)ethoxy]pyrimidin-4-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=NC=CC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=N1 AGUAOTQVPUBFSH-UHFFFAOYSA-N 0.000 description 1
- ZMFAZBCNZGCGDJ-UHFFFAOYSA-N 3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]-n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(C=CC=2)C(=O)NCCCN2CCCC2)=N1 ZMFAZBCNZGCGDJ-UHFFFAOYSA-N 0.000 description 1
- IWBFJLAOWCLXFK-UHFFFAOYSA-N 3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]-n-[3-(dimethylamino)propyl]-n-methylbenzamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(C=CC=2)C(=O)N(C)CCCN(C)C)=N1 IWBFJLAOWCLXFK-UHFFFAOYSA-N 0.000 description 1
- XKGZUIVXQHEEIC-UHFFFAOYSA-N 3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]-n-[3-(dimethylamino)propyl]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(C=CC=2)C(=O)NCCCN(C)C)=N1 XKGZUIVXQHEEIC-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- ZKUQXLVWAXCIFT-UHFFFAOYSA-N 3-[3-[2-(3,4-dimethoxyphenyl)ethoxy]phenyl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=C1 ZKUQXLVWAXCIFT-UHFFFAOYSA-N 0.000 description 1
- SETRAPYWUCBLPA-UHFFFAOYSA-N 3-[4-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=NC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=C1 SETRAPYWUCBLPA-UHFFFAOYSA-N 0.000 description 1
- CQOBNZQLUUOBDB-UHFFFAOYSA-N 3-[4-[2-(3,4-dimethoxyphenyl)ethoxy]pyrimidin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=NC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=N1 CQOBNZQLUUOBDB-UHFFFAOYSA-N 0.000 description 1
- JWSWPVZRIRAOES-UHFFFAOYSA-N 3-[5-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-3-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CN=CC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=C1 JWSWPVZRIRAOES-UHFFFAOYSA-N 0.000 description 1
- BWWUOMFZSSWCSV-UHFFFAOYSA-N 3-[6-(2,3-dichlorophenoxy)pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound ClC1=CC=CC(OC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=C1Cl BWWUOMFZSSWCSV-UHFFFAOYSA-N 0.000 description 1
- JURHIXQNEGZUHN-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl]-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2C(=CC=C(OC=3C(=CC(Cl)=CC=3)Cl)N=2)C(F)(F)F)=C1 JURHIXQNEGZUHN-UHFFFAOYSA-N 0.000 description 1
- FZHFGXZPDWZDMS-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl]-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=C(C=2)C(F)(F)F)=C1 FZHFGXZPDWZDMS-UHFFFAOYSA-N 0.000 description 1
- GNQGKMUDIHGKLU-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-2-fluoro-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1F GNQGKMUDIHGKLU-UHFFFAOYSA-N 0.000 description 1
- VZRPAQVPOPZCRA-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-4-fluoro-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=C(F)C(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 VZRPAQVPOPZCRA-UHFFFAOYSA-N 0.000 description 1
- MACLILONKNFZEJ-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-5-fluoro-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC(F)=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 MACLILONKNFZEJ-UHFFFAOYSA-N 0.000 description 1
- SZCXRAFZICOELN-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-n-(2-hydroxyethyl)-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NCCO)C=C1C1=CC=CC(OC=2C(=CC(Cl)=CC=2)Cl)=N1 SZCXRAFZICOELN-UHFFFAOYSA-N 0.000 description 1
- YUBUOVJRPCJORH-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-n-(3,3,3-trifluoropropyl)benzamide Chemical compound FC(F)(F)CCNC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 YUBUOVJRPCJORH-UHFFFAOYSA-N 0.000 description 1
- QZBANNNTAYNMHJ-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-n-(3-hydroxy-3-methylbutyl)benzamide Chemical compound CC(C)(O)CCNC(=O)C1=CC=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 QZBANNNTAYNMHJ-UHFFFAOYSA-N 0.000 description 1
- JDXJLZATFHMEIV-UHFFFAOYSA-N 3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-n-(oxan-4-yl)benzamide Chemical compound ClC1=CC(Cl)=CC=C1OC1=CC=CC(C=2C=C(C=CC=2)C(=O)NC2CCOCC2)=N1 JDXJLZATFHMEIV-UHFFFAOYSA-N 0.000 description 1
- PLWROHIAOIZFIW-UHFFFAOYSA-N 3-[6-(2-chlorophenoxy)pyridin-2-yl]-n-(2-cyanoethyl)benzamide Chemical compound ClC1=CC=CC=C1OC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCC#N)=N1 PLWROHIAOIZFIW-UHFFFAOYSA-N 0.000 description 1
- NTFLNFXOLNUKKJ-UHFFFAOYSA-N 3-[6-(3,4-dichlorophenoxy)pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C1=C(Cl)C(Cl)=CC=C1OC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=N1 NTFLNFXOLNUKKJ-UHFFFAOYSA-N 0.000 description 1
- WRBVVHMNDQKYQS-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]-2-methylbenzoic acid Chemical compound CC1=C(C(O)=O)C=CC=C1C1=CC=CC(OC=2C=C(Cl)C=C(Cl)C=2)=N1 WRBVVHMNDQKYQS-UHFFFAOYSA-N 0.000 description 1
- RBTNGRQJVNMRJF-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]-n-(1,3-dihydroxypropan-2-yl)benzamide Chemical compound OCC(CO)NC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 RBTNGRQJVNMRJF-UHFFFAOYSA-N 0.000 description 1
- DAJKKAYKDASUIV-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]-n-(1-hydroxy-2-methylpropan-2-yl)benzamide Chemical compound OCC(C)(C)NC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 DAJKKAYKDASUIV-UHFFFAOYSA-N 0.000 description 1
- HWANMWQIQNHQTC-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]-n-(2,3-dihydroxypropyl)benzamide Chemical compound OCC(O)CNC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 HWANMWQIQNHQTC-UHFFFAOYSA-N 0.000 description 1
- YCWHBSVGPDVSHR-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound ClC1=CC(Cl)=CC(OC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=C1 YCWHBSVGPDVSHR-UHFFFAOYSA-N 0.000 description 1
- VQJVAZTXIVWHLA-UHFFFAOYSA-N 3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]-n-(6-fluoropyridin-3-yl)benzamide Chemical compound C1=NC(F)=CC=C1NC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 VQJVAZTXIVWHLA-UHFFFAOYSA-N 0.000 description 1
- SQVQVXXEFKVBCA-UHFFFAOYSA-N 3-[6-(3-acetylphenoxy)pyridin-2-yl]-n-(2-cyanoethyl)benzamide Chemical compound CC(=O)C1=CC=CC(OC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 SQVQVXXEFKVBCA-UHFFFAOYSA-N 0.000 description 1
- WWYYUHHTYOWVIV-UHFFFAOYSA-N 3-[6-(3-chlorophenoxy)pyridin-2-yl]-n-(2-cyanoethyl)benzamide Chemical compound ClC1=CC=CC(OC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 WWYYUHHTYOWVIV-UHFFFAOYSA-N 0.000 description 1
- ZLJZOWNUUZWOLZ-UHFFFAOYSA-N 3-[6-(4-chlorophenoxy)pyridin-2-yl]-n-(2-cyanoethyl)benzamide Chemical compound C1=CC(Cl)=CC=C1OC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCC#N)=N1 ZLJZOWNUUZWOLZ-UHFFFAOYSA-N 0.000 description 1
- JQHPZEKGPKPKPV-UHFFFAOYSA-N 3-[6-(5-chloropyridin-3-yl)oxypyridin-2-yl]-n-(2-cyanoethyl)benzamide Chemical compound ClC1=CN=CC(OC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 JQHPZEKGPKPKPV-UHFFFAOYSA-N 0.000 description 1
- DETRWYWPBNAFPX-UHFFFAOYSA-N 3-[6-[(2,4-dichlorophenyl)methoxy]pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound ClC1=CC(Cl)=CC=C1COC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=N1 DETRWYWPBNAFPX-UHFFFAOYSA-N 0.000 description 1
- RBFLQXSWMFDZAJ-UHFFFAOYSA-N 3-[6-[(2,4-dichlorophenyl)methoxy]pyridin-2-yl]-n-pyridin-2-ylbenzamide Chemical compound ClC1=CC(Cl)=CC=C1COC1=CC=CC(C=2C=C(C=CC=2)C(=O)NC=2N=CC=CC=2)=N1 RBFLQXSWMFDZAJ-UHFFFAOYSA-N 0.000 description 1
- FTISSYMBNJVCEI-UHFFFAOYSA-N 3-[6-[(2,4-dichlorophenyl)methylamino]pyridin-2-yl]-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(NCC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 FTISSYMBNJVCEI-UHFFFAOYSA-N 0.000 description 1
- HNMAKAMQCSBRFH-UHFFFAOYSA-N 3-[6-[(2,4-dichlorophenyl)methylamino]pyridin-2-yl]-n-(2-hydroxyethyl)benzamide;3-[6-[(2,4-dichlorophenyl)methyl-ethylamino]pyridin-2-yl]-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(NCC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1.C=1C=CC(C=2C=C(C=CC=2)C(=O)NCCO)=NC=1N(CC)CC1=CC=C(Cl)C=C1Cl HNMAKAMQCSBRFH-UHFFFAOYSA-N 0.000 description 1
- SOTLMEGGXNXCBQ-UHFFFAOYSA-N 3-[6-[2-(2,4-dichlorophenyl)ethoxy]pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound ClC1=CC(Cl)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=N1 SOTLMEGGXNXCBQ-UHFFFAOYSA-N 0.000 description 1
- NQQXOWGOBCRVIK-UHFFFAOYSA-N 3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]-n-(oxan-4-yl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(=O)NC2CCOCC2)=N1 NQQXOWGOBCRVIK-UHFFFAOYSA-N 0.000 description 1
- FBYZGRLEOXPTRG-UHFFFAOYSA-N 3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(OC)C(OC)=CC=3)C=CC=2)=C1 FBYZGRLEOXPTRG-UHFFFAOYSA-N 0.000 description 1
- IIVOQNOYPJUHAF-UHFFFAOYSA-N 3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]-n-prop-2-ynylbenzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCC#C)=N1 IIVOQNOYPJUHAF-UHFFFAOYSA-N 0.000 description 1
- MEWRVJHMYXOFMF-UHFFFAOYSA-N 3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCOC1=CC=CC(C=2C=C(C=CC=2)C(N)=O)=N1 MEWRVJHMYXOFMF-UHFFFAOYSA-N 0.000 description 1
- YJLVMAVFHBKPRP-UHFFFAOYSA-N 3-[6-[2-(3-fluorophenyl)ethoxy]pyridin-2-yl]-n-(1,3-thiazol-2-yl)benzamide Chemical compound FC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2SC=CN=2)=C1 YJLVMAVFHBKPRP-UHFFFAOYSA-N 0.000 description 1
- JZSHNNIZYFFHKK-UHFFFAOYSA-N 3-[6-[2-(3-fluorophenyl)ethoxy]pyridin-2-yl]-n-(2-hydroxyethyl)benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(F)C=CC=3)C=CC=2)=C1 JZSHNNIZYFFHKK-UHFFFAOYSA-N 0.000 description 1
- WHGOKTYCSCLVMW-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]-n-(1,3,4-thiadiazol-2-yl)benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2SC=NN=2)=C1 WHGOKTYCSCLVMW-UHFFFAOYSA-N 0.000 description 1
- IBNWNNMKUKMWDR-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]-n-(1,3-thiazol-2-yl)benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2SC=CN=2)=C1 IBNWNNMKUKMWDR-UHFFFAOYSA-N 0.000 description 1
- PFGYHUFFGLSQDZ-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]-n-(2-methylpyridin-4-yl)benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2C=C(C)N=CC=2)=C1 PFGYHUFFGLSQDZ-UHFFFAOYSA-N 0.000 description 1
- QMKLQAUKANQDFS-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCN2CCCC2)=C1 QMKLQAUKANQDFS-UHFFFAOYSA-N 0.000 description 1
- PSMPKXYAGYBOPT-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]-n-(3-methyl-1,2-thiazol-5-yl)benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2SN=C(C)C=2)=C1 PSMPKXYAGYBOPT-UHFFFAOYSA-N 0.000 description 1
- DSWITNGKRHWAOX-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]-n-(5-methyl-1h-pyrazol-3-yl)benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2NN=C(C)C=2)=C1 DSWITNGKRHWAOX-UHFFFAOYSA-N 0.000 description 1
- KCSIQWAYAWARGD-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]-n-(oxan-4-yl)benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC2CCOCC2)=C1 KCSIQWAYAWARGD-UHFFFAOYSA-N 0.000 description 1
- DISBFSKJKZEIQV-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(OC)C=CC=3)C=CC=2)=C1 DISBFSKJKZEIQV-UHFFFAOYSA-N 0.000 description 1
- BIRULOQTTXBXMN-UHFFFAOYSA-N 3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]-n-pyridin-2-ylbenzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2N=CC=CC=2)=C1 BIRULOQTTXBXMN-UHFFFAOYSA-N 0.000 description 1
- JFYUNCKRQKTHMH-UHFFFAOYSA-N 3-[6-[2-(3-methylphenyl)ethoxy]pyridin-2-yl]-n-(2-methylpyridin-4-yl)benzamide Chemical compound CC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2C=C(C)N=CC=2)=C1 JFYUNCKRQKTHMH-UHFFFAOYSA-N 0.000 description 1
- PBPDGPNUPWGVPV-UHFFFAOYSA-N 3-[6-[2-[3-(trifluoromethyl)phenyl]ethylamino]pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(NCCC=3C=C(C=CC=3)C(F)(F)F)C=CC=2)=C1 PBPDGPNUPWGVPV-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-VKHMYHEASA-N 3-aminopropane-1,2-diol Chemical compound NC[C@H](O)CO KQIGMPWTAHJUMN-VKHMYHEASA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UVKURTLVTLRSSM-UHFFFAOYSA-N 3-bromo-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Br)=C1F UVKURTLVTLRSSM-UHFFFAOYSA-N 0.000 description 1
- ONELILMJNOWXSA-UHFFFAOYSA-N 3-bromo-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(Br)=C1 ONELILMJNOWXSA-UHFFFAOYSA-N 0.000 description 1
- KLSLJMGWUPAQGZ-UHFFFAOYSA-N 3-bromo-5-fluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC(Br)=C1 KLSLJMGWUPAQGZ-UHFFFAOYSA-N 0.000 description 1
- VOIZNVUXCQLQHS-UHFFFAOYSA-N 3-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC(Br)=C1 VOIZNVUXCQLQHS-UHFFFAOYSA-N 0.000 description 1
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 1
- BKUIZWILNWHFHD-UHFFFAOYSA-N 3-cyano-n-(2,5-diphenylpyrazol-3-yl)benzamide Chemical compound C=1C=CC(C#N)=CC=1C(=O)NC1=CC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 BKUIZWILNWHFHD-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- CQMHIXRPQGPCNT-UHFFFAOYSA-N 3-methyl-1,2-thiazol-5-amine Chemical compound CC=1C=C(N)SN=1 CQMHIXRPQGPCNT-UHFFFAOYSA-N 0.000 description 1
- VPBWZBGZWHDNKL-UHFFFAOYSA-N 3-pyrrolidin-1-ylpropan-1-amine Chemical compound NCCCN1CCCC1 VPBWZBGZWHDNKL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OXOWTLDONRGYOT-UHFFFAOYSA-N 4-(dimethylamino)butanoic acid Chemical compound CN(C)CCCC(O)=O OXOWTLDONRGYOT-UHFFFAOYSA-N 0.000 description 1
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
- HIDJWBGOQFTDLU-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC(O)=O HIDJWBGOQFTDLU-UHFFFAOYSA-N 0.000 description 1
- DJKNRCWSXSZACF-UHFFFAOYSA-N 4-acetamido-n-tert-butylbenzamide Chemical compound CC(=O)NC1=CC=C(C(=O)NC(C)(C)C)C=C1 DJKNRCWSXSZACF-UHFFFAOYSA-N 0.000 description 1
- PUSZHIWAFZLOMD-UHFFFAOYSA-N 4-amino-2-methylbutan-2-ol Chemical compound CC(C)(O)CCN PUSZHIWAFZLOMD-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- FYTLHYRDGXRYEY-UHFFFAOYSA-N 5-Methyl-3-pyrazolamine Chemical compound CC=1C=C(N)NN=1 FYTLHYRDGXRYEY-UHFFFAOYSA-N 0.000 description 1
- GFMRZAMDGJIWRB-UHFFFAOYSA-N 5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)NCCCCC(O)=O GFMRZAMDGJIWRB-UHFFFAOYSA-N 0.000 description 1
- RYWXINYIPJXUGY-UHFFFAOYSA-N 5-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-2-fluoro-n-(2-hydroxyethyl)benzamide Chemical compound C1=C(F)C(C(=O)NCCO)=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 RYWXINYIPJXUGY-UHFFFAOYSA-N 0.000 description 1
- UBAJBJUERXDSQL-UHFFFAOYSA-N 5-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-n-(2-hydroxyethyl)pyridine-3-carboxamide Chemical compound OCCNC(=O)C1=CN=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 UBAJBJUERXDSQL-UHFFFAOYSA-N 0.000 description 1
- APKOYCKDPZIUHL-UHFFFAOYSA-N 5-amino-n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]pentanamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCCCN)C=CC=2)=N1 APKOYCKDPZIUHL-UHFFFAOYSA-N 0.000 description 1
- PEXAZYDITWXYNJ-UHFFFAOYSA-N 5-bromo-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1F PEXAZYDITWXYNJ-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- LSNPJGIHAPIXRA-UHFFFAOYSA-N 6-chloro-n-(2,4-dichlorophenyl)pyridin-2-amine Chemical compound ClC1=CC(Cl)=CC=C1NC1=CC=CC(Cl)=N1 LSNPJGIHAPIXRA-UHFFFAOYSA-N 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 1
- YHAVLFWOQYPPDS-UHFFFAOYSA-N C(CCC)(=O)N.N1CCCC1 Chemical compound C(CCC)(=O)N.N1CCCC1 YHAVLFWOQYPPDS-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 229940123603 Dopamine D2 receptor antagonist Drugs 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043434 Thinking disturbances Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
- 229960000793 aniracetam Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 229950000234 emricasan Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
- FNJBLWWJUSZNMF-UHFFFAOYSA-N ethanol;oxolane;hydrate Chemical compound O.CCO.C1CCOC1 FNJBLWWJUSZNMF-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
- FYSROUWCKUYSAP-UHFFFAOYSA-N ethyl 2-bromo-4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C=C1Br FYSROUWCKUYSAP-UHFFFAOYSA-N 0.000 description 1
- QOFKYVXBHUEWBX-UHFFFAOYSA-N ethyl 2-bromopyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1Br QOFKYVXBHUEWBX-UHFFFAOYSA-N 0.000 description 1
- MWEVHMZZMWGBHC-UHFFFAOYSA-N ethyl 3-[6-[(2,4-dichlorophenyl)methylamino]pyridin-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(NCC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 MWEVHMZZMWGBHC-UHFFFAOYSA-N 0.000 description 1
- HOZIEGGWFWQCSB-UHFFFAOYSA-N ethyl 3-[6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(OC)C(OC)=CC=3)C=CC=2)=C1 HOZIEGGWFWQCSB-UHFFFAOYSA-N 0.000 description 1
- GDZVZZVVPATNAL-UHFFFAOYSA-N ethyl 3-[6-[2-[3-(trifluoromethyl)phenyl]ethylamino]pyridin-2-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2N=C(NCCC=3C=C(C=CC=3)C(F)(F)F)C=CC=2)=C1 GDZVZZVVPATNAL-UHFFFAOYSA-N 0.000 description 1
- FDVAAQDTTZNHKG-UHFFFAOYSA-N ethyl 3-bromo-4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C(Br)=C1 FDVAAQDTTZNHKG-UHFFFAOYSA-N 0.000 description 1
- GUCUASPPYGNFNZ-UHFFFAOYSA-N ethyl 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate Chemical compound CCOC(=O)C1=CC(F)=CC(B2OC(C)(C)C(C)(C)O2)=C1 GUCUASPPYGNFNZ-UHFFFAOYSA-N 0.000 description 1
- WYTDYNDPAJSCTK-UHFFFAOYSA-N ethyl 5-bromo-2-fluorobenzoate Chemical compound CCOC(=O)C1=CC(Br)=CC=C1F WYTDYNDPAJSCTK-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960004404 etizolam Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- SCMLRESZJCKCTC-KMYQRJGFSA-N gtpl8173 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 SCMLRESZJCKCTC-KMYQRJGFSA-N 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229950001996 hexestrol Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 229940053999 hypnotics and sedatives melatonin receptor agonists Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- PEHSSTUGJUBZBI-UHFFFAOYSA-N indan-5-ol Chemical compound OC1=CC=C2CCCC2=C1 PEHSSTUGJUBZBI-UHFFFAOYSA-N 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- JMPOIZCOJJMTHI-UHFFFAOYSA-N leteprinim Chemical compound C1=CC(C(=O)O)=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 JMPOIZCOJJMTHI-UHFFFAOYSA-N 0.000 description 1
- 229950011566 leteprinim Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- DLOQQPFDOHMYTA-UHFFFAOYSA-N methyl 1-(2-chloropyrimidin-4-yl)indole-5-carboxylate Chemical compound C1=CC2=CC(C(=O)OC)=CC=C2N1C1=CC=NC(Cl)=N1 DLOQQPFDOHMYTA-UHFFFAOYSA-N 0.000 description 1
- OOMWPZBUZQWHQL-UHFFFAOYSA-N methyl 1-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]indole-5-carboxylate Chemical compound C1=CC2=CC(C(=O)OC)=CC=C2N1C(N=1)=CC=NC=1NCCC1=CC=C(OC)C(OC)=C1 OOMWPZBUZQWHQL-UHFFFAOYSA-N 0.000 description 1
- DRYBMFJLYYEOBZ-UHFFFAOYSA-N methyl 1h-indole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC=CC2=C1 DRYBMFJLYYEOBZ-UHFFFAOYSA-N 0.000 description 1
- MASRAGFWFYHMFI-UHFFFAOYSA-N methyl 3-bromo-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(Br)=C1 MASRAGFWFYHMFI-UHFFFAOYSA-N 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
- SORARJZLMNRBAQ-UHFFFAOYSA-N n,n',n'-trimethylpropane-1,3-diamine Chemical compound CNCCCN(C)C SORARJZLMNRBAQ-UHFFFAOYSA-N 0.000 description 1
- CZFNISFYDPIDNM-UHFFFAOYSA-N n,n-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 1
- MIVPSKTVQJVYIH-UHFFFAOYSA-N n-(2,5-dimethylpyrazol-3-yl)-3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2N(N=C(C)C=2)C)=C1 MIVPSKTVQJVYIH-UHFFFAOYSA-N 0.000 description 1
- DKXCWJCYGXKLSY-UHFFFAOYSA-N n-(2-cyanoethyl)-3-(6-cyclohexyloxypyridin-2-yl)benzamide Chemical compound N#CCCNC(=O)C1=CC=CC(C=2N=C(OC3CCCCC3)C=CC=2)=C1 DKXCWJCYGXKLSY-UHFFFAOYSA-N 0.000 description 1
- WYZXYIQJNAEXBQ-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(1h-indol-5-yloxy)pyridin-2-yl]benzamide Chemical compound N#CCCNC(=O)C1=CC=CC(C=2N=C(OC=3C=C4C=CNC4=CC=3)C=CC=2)=C1 WYZXYIQJNAEXBQ-UHFFFAOYSA-N 0.000 description 1
- CRFDHTKNBMCNPH-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,4-dichloroanilino)pyridin-2-yl]benzamide Chemical compound ClC1=CC(Cl)=CC=C1NC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCC#N)=N1 CRFDHTKNBMCNPH-UHFFFAOYSA-N 0.000 description 1
- QKRCZSWATSVZTM-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl]benzamide Chemical compound N1=C(C=2C=C(C=CC=2)C(=O)NCCC#N)C(C(F)(F)F)=CC=C1OC1=CC=C(Cl)C=C1Cl QKRCZSWATSVZTM-UHFFFAOYSA-N 0.000 description 1
- WTTBPQZGPZQBKC-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl]benzamide Chemical compound N=1C(C=2C=C(C=CC=2)C(=O)NCCC#N)=CC(C(F)(F)F)=CC=1OC1=CC=C(Cl)C=C1Cl WTTBPQZGPZQBKC-UHFFFAOYSA-N 0.000 description 1
- KRFHBTAHSFKEFS-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-2-fluorobenzamide Chemical compound FC1=C(C(=O)NCCC#N)C=CC=C1C1=CC=CC(OC=2C(=CC(Cl)=CC=2)Cl)=N1 KRFHBTAHSFKEFS-UHFFFAOYSA-N 0.000 description 1
- TWOFLAZIQXNIJQ-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-4-fluorobenzamide Chemical compound FC1=CC=C(C(=O)NCCC#N)C=C1C1=CC=CC(OC=2C(=CC(Cl)=CC=2)Cl)=N1 TWOFLAZIQXNIJQ-UHFFFAOYSA-N 0.000 description 1
- ONHSEYWMEMVVTD-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NCCC#N)C=C1C1=CC=CC(OC=2C(=CC(Cl)=CC=2)Cl)=N1 ONHSEYWMEMVVTD-UHFFFAOYSA-N 0.000 description 1
- SCWUGHZMYHLESY-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-5-fluorobenzamide Chemical compound FC1=CC(C(=O)NCCC#N)=CC(C=2N=C(OC=3C(=CC(Cl)=CC=3)Cl)C=CC=2)=C1 SCWUGHZMYHLESY-UHFFFAOYSA-N 0.000 description 1
- QEGILNHEMMCQPK-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,4-dichlorophenyl)sulfanylpyridin-2-yl]benzamide Chemical compound ClC1=CC(Cl)=CC=C1SC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCC#N)=N1 QEGILNHEMMCQPK-UHFFFAOYSA-N 0.000 description 1
- ZYEPEQUIMHNHQW-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,4-difluorophenoxy)pyridin-2-yl]benzamide Chemical compound FC1=CC(F)=CC=C1OC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCCC#N)=N1 ZYEPEQUIMHNHQW-UHFFFAOYSA-N 0.000 description 1
- ZYJSJKZTJQTKGS-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(2,5-dichlorophenoxy)pyridin-2-yl]benzamide Chemical compound ClC1=CC=C(Cl)C(OC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 ZYJSJKZTJQTKGS-UHFFFAOYSA-N 0.000 description 1
- IUSLNUMFIMJBMC-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]benzamide Chemical compound ClC1=CC(Cl)=CC(OC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 IUSLNUMFIMJBMC-UHFFFAOYSA-N 0.000 description 1
- NFLIWDHSVIJRAY-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-(3-methoxyphenoxy)pyridin-2-yl]benzamide Chemical compound COC1=CC=CC(OC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 NFLIWDHSVIJRAY-UHFFFAOYSA-N 0.000 description 1
- OOWWLWQBUUOLMP-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-[2-(3-fluorophenyl)ethoxy]pyridin-2-yl]benzamide Chemical compound FC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 OOWWLWQBUUOLMP-UHFFFAOYSA-N 0.000 description 1
- ASZNYZOKGCTJCQ-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 ASZNYZOKGCTJCQ-UHFFFAOYSA-N 0.000 description 1
- MZZORDSZDKMVCF-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-[2-[3-(trifluoromethyl)phenyl]ethoxy]pyridin-2-yl]benzamide Chemical compound FC(F)(F)C1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 MZZORDSZDKMVCF-UHFFFAOYSA-N 0.000 description 1
- HHFMLOUDRKULNL-UHFFFAOYSA-N n-(2-cyanoethyl)-3-[6-[3-(dimethylamino)phenoxy]pyridin-2-yl]benzamide Chemical compound CN(C)C1=CC=CC(OC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCC#N)=C1 HHFMLOUDRKULNL-UHFFFAOYSA-N 0.000 description 1
- YWSQOQIKYCPDSF-UHFFFAOYSA-N n-(2-cyanoethyl)-5-[6-(2,4-dichlorophenoxy)pyridin-2-yl]-2-fluorobenzamide Chemical compound C1=C(C(=O)NCCC#N)C(F)=CC=C1C1=CC=CC(OC=2C(=CC(Cl)=CC=2)Cl)=N1 YWSQOQIKYCPDSF-UHFFFAOYSA-N 0.000 description 1
- KLPPXDRSNSBCAY-UHFFFAOYSA-N n-(2-cyanoethyl)-5-[6-(2,4-dichlorophenoxy)pyridin-2-yl]pyridine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1OC1=CC=CC(C=2C=C(C=NC=2)C(=O)NCCC#N)=N1 KLPPXDRSNSBCAY-UHFFFAOYSA-N 0.000 description 1
- YGBKICSHNOMWHF-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-[6-[2-(3-methylphenyl)ethoxy]pyridin-2-yl]benzamide Chemical compound CC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NCCO)=C1 YGBKICSHNOMWHF-UHFFFAOYSA-N 0.000 description 1
- CANXTRAYPBAKQC-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-[6-[2-[3-(trifluoromethyl)phenyl]ethylamino]pyridin-2-yl]benzamide Chemical compound OCCNC(=O)C1=CC=CC(C=2N=C(NCCC=3C=C(C=CC=3)C(F)(F)F)C=CC=2)=C1 CANXTRAYPBAKQC-UHFFFAOYSA-N 0.000 description 1
- MIFFJUNWQXHSJC-UHFFFAOYSA-N n-(2-methoxyethyl)-3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]benzamide Chemical compound COCCNC(=O)C1=CC=CC(C=2N=C(OCCC=3C=C(OC)C=CC=3)C=CC=2)=C1 MIFFJUNWQXHSJC-UHFFFAOYSA-N 0.000 description 1
- OIHMRTJNGYVQQX-UHFFFAOYSA-N n-(3-aminopropyl)-3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]benzamide;dihydrochloride Chemical compound Cl.Cl.C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(C=CC=2)C(=O)NCCCN)=N1 OIHMRTJNGYVQQX-UHFFFAOYSA-N 0.000 description 1
- MNUHRUPDSVVRLB-UHFFFAOYSA-N n-(6-fluoropyridin-3-yl)-3-[6-[2-(3-methoxyphenyl)ethoxy]pyridin-2-yl]benzamide Chemical compound COC1=CC=CC(CCOC=2N=C(C=CC=2)C=2C=C(C=CC=2)C(=O)NC=2C=NC(F)=CC=2)=C1 MNUHRUPDSVVRLB-UHFFFAOYSA-N 0.000 description 1
- SKMNFRJHGHADGL-UHFFFAOYSA-N n-(cyanomethyl)-3-[6-(2,4-dichlorophenoxy)pyridin-2-yl]benzamide Chemical compound ClC1=CC(Cl)=CC=C1OC1=CC=CC(C=2C=C(C=CC=2)C(=O)NCC#N)=N1 SKMNFRJHGHADGL-UHFFFAOYSA-N 0.000 description 1
- ACOGIKFYSUVSAH-AWEZNQCLSA-N n-[(2s)-1-cyanopropan-2-yl]-3-[6-(3,5-dichlorophenoxy)pyridin-2-yl]benzamide Chemical compound N#CC[C@H](C)NC(=O)C1=CC=CC(C=2N=C(OC=3C=C(Cl)C=C(Cl)C=3)C=CC=2)=C1 ACOGIKFYSUVSAH-AWEZNQCLSA-N 0.000 description 1
- QVWGQOSMKGVGLR-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-nitrophenyl)pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(C=CC=2)[N+]([O-])=O)=N1 QVWGQOSMKGVGLR-UHFFFAOYSA-N 0.000 description 1
- SMEDYMZWMTVFAH-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]-2-methylpropanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)C(C)C)C=CC=2)=N1 SMEDYMZWMTVFAH-UHFFFAOYSA-N 0.000 description 1
- RYQKBZBCNLWODF-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]-2-pyrrolidin-2-ylacetamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CC3NCCC3)C=CC=2)=N1 RYQKBZBCNLWODF-UHFFFAOYSA-N 0.000 description 1
- DYRUTLRELCEBTA-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(NCCC=3C=C(OC)C(OC)=CC=3)N=CC=2)=C1 DYRUTLRELCEBTA-UHFFFAOYSA-N 0.000 description 1
- DKVXVHXRXJHMSX-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]-3-phenylpropanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCC=3C=CC=CC=3)C=CC=2)=N1 DKVXVHXRXJHMSX-UHFFFAOYSA-N 0.000 description 1
- CUEDKESSAVBXCL-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]-4-(dimethylamino)butanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCCN(C)C)C=CC=2)=N1 CUEDKESSAVBXCL-UHFFFAOYSA-N 0.000 description 1
- KKLREIUDOCJMJN-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]-4-piperidin-1-ylbutanamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CCCN3CCCCC3)C=CC=2)=N1 KKLREIUDOCJMJN-UHFFFAOYSA-N 0.000 description 1
- WRRBIFYAEWGUHH-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=N1 WRRBIFYAEWGUHH-UHFFFAOYSA-N 0.000 description 1
- ASFHQONMAFVFOE-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]furan-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)C3=COC=C3)C=CC=2)=N1 ASFHQONMAFVFOE-UHFFFAOYSA-N 0.000 description 1
- REVKQGGUMVVQCO-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]oxolane-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)C3COCC3)C=CC=2)=N1 REVKQGGUMVVQCO-UHFFFAOYSA-N 0.000 description 1
- GIITXNZILCJZGR-UHFFFAOYSA-N n-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]phenyl]pentanamide Chemical compound CCCCC(=O)NC1=CC=CC(C=2N=C(NCCC=3C=C(OC)C(OC)=CC=3)N=CC=2)=C1 GIITXNZILCJZGR-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- BOTREHHXSQGWTR-UHFFFAOYSA-N oxolane-3-carboxylic acid Chemical compound OC(=O)C1CCOC1 BOTREHHXSQGWTR-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- DUCKXCGALKOSJF-UHFFFAOYSA-N pentanoyl pentanoate Chemical compound CCCCC(=O)OC(=O)CCCC DUCKXCGALKOSJF-UHFFFAOYSA-N 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960001495 pravastatin sodium Drugs 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960001150 ramelteon Drugs 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229950000659 remacemide Drugs 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- RXLOZRCLQMJJLC-UHFFFAOYSA-N ssr-180,711 Chemical compound C1=CC(Br)=CC=C1OC(=O)N1C(CC2)CCN2CC1 RXLOZRCLQMJJLC-UHFFFAOYSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229950008418 talipexole Drugs 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
- KYKOVTOSCPUMNC-UHFFFAOYSA-N tert-butyl n-[4-[3-[2-[2-(3,4-dimethoxyphenyl)ethylamino]pyrimidin-4-yl]anilino]-4-oxobutan-2-yl]carbamate Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1=NC=CC(C=2C=C(NC(=O)CC(C)NC(=O)OC(C)(C)C)C=CC=2)=N1 KYKOVTOSCPUMNC-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- PSZXPGFNGPBEFR-UHFFFAOYSA-N trisodium butan-1-olate Chemical compound [Na+].[Na+].[Na+].CCCC[O-].CCCC[O-].CCCC[O-] PSZXPGFNGPBEFR-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 description 1
- 229960002263 vortioxetine Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 description 1
- 229960004664 xaliproden Drugs 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
An object of the present invention is to provide an agent for preventing or treating schizophrenia or the like, wherein the compound of the present invention has agonist activity.
[Means]
A compound represented by the following formula (I) or salt thereof:
wherein A represents -(CH2)n-CO-NR a- (n is an integer of 0 to 3) or -NR a-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, or the like, X1, X2, X3, and X4 represent the same or different -CR x=, or -N=, Y represents -O-, -S-, -S(O)-, -S(O)2-, or -NR y-, Z represents a bond, methylene, or ethylene, Ar1 represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, Ar2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, and which may be condensed with an optionally substituted five-to six-membered ring, and R a, R b, R x, and R y represent the same or different hydrogen atom, halogen atoms, or the like].
Formula (I)
[Means]
A compound represented by the following formula (I) or salt thereof:
wherein A represents -(CH2)n-CO-NR a- (n is an integer of 0 to 3) or -NR a-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, or the like, X1, X2, X3, and X4 represent the same or different -CR x=, or -N=, Y represents -O-, -S-, -S(O)-, -S(O)2-, or -NR y-, Z represents a bond, methylene, or ethylene, Ar1 represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, Ar2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, and which may be condensed with an optionally substituted five-to six-membered ring, and R a, R b, R x, and R y represent the same or different hydrogen atom, halogen atoms, or the like].
Formula (I)
Description
[DESCRIPTION]
[Title of Invention] Compound Having 6-Membered Aromatic Ring [Technical Field]
[0001]
The present invention relates to a novel compound containing a six-membered aromatic ring, particularly a pyridine derivative, a method for manufacturing the same, and a pharmaceutical composition containing the same. More specifically, the present invention relates to a compound having an agonistic effect on GPR52, which is effective as a pharmaceutical agent for preventing and treating mental disorders such as schizophrenia.
[Background of the Invention]
[Title of Invention] Compound Having 6-Membered Aromatic Ring [Technical Field]
[0001]
The present invention relates to a novel compound containing a six-membered aromatic ring, particularly a pyridine derivative, a method for manufacturing the same, and a pharmaceutical composition containing the same. More specifically, the present invention relates to a compound having an agonistic effect on GPR52, which is effective as a pharmaceutical agent for preventing and treating mental disorders such as schizophrenia.
[Background of the Invention]
[0002]
Schizophrenia is a disease that occurs in people from adolescence to adulthood and shows characteristic thinking disturbances, disturbances of ego, and behavioral abnormalities associated therewith. The disease reportedly develops in about I% of the entire population but is chronic in most cases, and is associated with a decrease in initiative, interpersonal contact, or the like, which leads to considerable social hardship.
The core symptoms of schizophrenia are broadly classified into (1) positive symptoms such as delusions and hallucination, (2) negative symptoms such as hypesthesia, social withdrawal, and loss of motivation or concentration, and (3) cognitive dysfunction In these core symptoms, hyperactivity of the dopamine nervous system in the mesolimbic system is believed to be intimately involved in the development of positive symptoms, whereas depression of the nervous system such as the glutamic acid nervous system in the cortex of the frontal lobe is believed to be intimately involved in the development of negative symptoms or impaired cognitive function.
Typical antipsychotic drugs with dopamine D2 receptor antagonist action such as chlorpromazine have shown effect in improving positive symptoms. On the other hand, multi-acting receptor targeted agents such as clozapine and olanzapine show consistent effects toward negative symptoms or cognitive impairment, but it is known that many -------- --- ---t I
patients respond poorly to these drugs. Other problems with typical antipsychotics are the side effects, which include the development of akathisia, dystonias, and extrapyramidal symptoms such as Parkinson-like movement disorders, as well as hyperprolactinemia. Granulocytopenia is also a serious side effect of clozapine, and side effects such as weight gain, lipidosis, oversedation, and prolonged QT
interval on electrocardiogram are problems associated with atypical antipsychotics such as olanzapine.
Human GPR52 (Sawzdargo et al., Molecular Brain Research, 64: 193-198, 1999) is a G protein-coupled receptor (GPCR). GPR52 agonists, ligands, and the like were recently found to increase intracellular cAMP levels in nerve cells expressing GPR52 or so on, and are thus believed to be capable of improving positive symptoms of schizophrenia by suppressing mesolimbic dopamine pathway hyperactivity, which is thought to be one of the causes of positive symptoms in schizophrenia. These were also found to be capable of improving cognitive disorders and negative symptoms in schizophrenia by improving decreased function of NMDA receptors in the cerebral cortex, which is thought to be one of the causes of such troubles (WO
2006/098520).
There is thus a need to develop a compound that would have an agonistic effect on GPR52 and that would be useful as a pharmaceutical agent for preventing and treating mental disorders such as schizophrenia.
Schizophrenia is a disease that occurs in people from adolescence to adulthood and shows characteristic thinking disturbances, disturbances of ego, and behavioral abnormalities associated therewith. The disease reportedly develops in about I% of the entire population but is chronic in most cases, and is associated with a decrease in initiative, interpersonal contact, or the like, which leads to considerable social hardship.
The core symptoms of schizophrenia are broadly classified into (1) positive symptoms such as delusions and hallucination, (2) negative symptoms such as hypesthesia, social withdrawal, and loss of motivation or concentration, and (3) cognitive dysfunction In these core symptoms, hyperactivity of the dopamine nervous system in the mesolimbic system is believed to be intimately involved in the development of positive symptoms, whereas depression of the nervous system such as the glutamic acid nervous system in the cortex of the frontal lobe is believed to be intimately involved in the development of negative symptoms or impaired cognitive function.
Typical antipsychotic drugs with dopamine D2 receptor antagonist action such as chlorpromazine have shown effect in improving positive symptoms. On the other hand, multi-acting receptor targeted agents such as clozapine and olanzapine show consistent effects toward negative symptoms or cognitive impairment, but it is known that many -------- --- ---t I
patients respond poorly to these drugs. Other problems with typical antipsychotics are the side effects, which include the development of akathisia, dystonias, and extrapyramidal symptoms such as Parkinson-like movement disorders, as well as hyperprolactinemia. Granulocytopenia is also a serious side effect of clozapine, and side effects such as weight gain, lipidosis, oversedation, and prolonged QT
interval on electrocardiogram are problems associated with atypical antipsychotics such as olanzapine.
Human GPR52 (Sawzdargo et al., Molecular Brain Research, 64: 193-198, 1999) is a G protein-coupled receptor (GPCR). GPR52 agonists, ligands, and the like were recently found to increase intracellular cAMP levels in nerve cells expressing GPR52 or so on, and are thus believed to be capable of improving positive symptoms of schizophrenia by suppressing mesolimbic dopamine pathway hyperactivity, which is thought to be one of the causes of positive symptoms in schizophrenia. These were also found to be capable of improving cognitive disorders and negative symptoms in schizophrenia by improving decreased function of NMDA receptors in the cerebral cortex, which is thought to be one of the causes of such troubles (WO
2006/098520).
There is thus a need to develop a compound that would have an agonistic effect on GPR52 and that would be useful as a pharmaceutical agent for preventing and treating mental disorders such as schizophrenia.
[0003]
International Publication WO 2005/066139 pamphlet discloses compounds represented by the following general formula, which include compounds containing six-membered aromatic rings:
A
f N R
Cy1 International Publication WO 2004/096797 pamphlet discloses compounds represented by the following general formula, which include compounds containing six-membered aromatic rings:
R~H
W1 z NY
NPL 1 below describes 1-{2-[(3-chlorobenzyl)oxy]-6-methylpyridin-4-yl}-2-methyl-1 H-imidazole-4-carboxamide.
NPL 2 below describes tert-butyl {5-[6-(3-chlorophenoxy)pyrazin-2-yl]pyridin-3-yl}carbamate.
International Publication WO 2004/096797 pamphlet discloses compounds represented by the following general formula, which include compounds containing six-membered aromatic rings:
Qa - X N Qb [PTL 1 ]
International Publication WO 2006/098520 Pamphlet [PTL 2]
International Publication WO 2005/066139 Pamphlet [PTL 3]
International Publication WO 2004/096797 Pamphlet [NPL 1]
Sawzdargo et al., Molecular Brain Research, 64: pp. 193-198, 1999 [NPL 2]
Kuo, Gee-Hong et al, Journal of Medicinal Chemistry, 48(15): pp. 4892-4909, [Summary of Invention]
[Technical Problem]
[0004]
An object of the present invention is to provide a compound that has an agonistic effect on GPR52 and that is useful as a pharmaceutical agent for preventing and treating mental disorders such as schizophrenia.
[Solution to Problem]
International Publication WO 2005/066139 pamphlet discloses compounds represented by the following general formula, which include compounds containing six-membered aromatic rings:
A
f N R
Cy1 International Publication WO 2004/096797 pamphlet discloses compounds represented by the following general formula, which include compounds containing six-membered aromatic rings:
R~H
W1 z NY
NPL 1 below describes 1-{2-[(3-chlorobenzyl)oxy]-6-methylpyridin-4-yl}-2-methyl-1 H-imidazole-4-carboxamide.
NPL 2 below describes tert-butyl {5-[6-(3-chlorophenoxy)pyrazin-2-yl]pyridin-3-yl}carbamate.
International Publication WO 2004/096797 pamphlet discloses compounds represented by the following general formula, which include compounds containing six-membered aromatic rings:
Qa - X N Qb [PTL 1 ]
International Publication WO 2006/098520 Pamphlet [PTL 2]
International Publication WO 2005/066139 Pamphlet [PTL 3]
International Publication WO 2004/096797 Pamphlet [NPL 1]
Sawzdargo et al., Molecular Brain Research, 64: pp. 193-198, 1999 [NPL 2]
Kuo, Gee-Hong et al, Journal of Medicinal Chemistry, 48(15): pp. 4892-4909, [Summary of Invention]
[Technical Problem]
[0004]
An object of the present invention is to provide a compound that has an agonistic effect on GPR52 and that is useful as a pharmaceutical agent for preventing and treating mental disorders such as schizophrenia.
[Solution to Problem]
[0005]
The present inventors found that compounds represented by formula (I) or salts thereof (herein also referred to as compounds (I)) have an agonistic effect on GPR52, and the present invention was perfected upon further investigation.
The present inventors found that compounds represented by formula (I) or salts thereof (herein also referred to as compounds (I)) have an agonistic effect on GPR52, and the present invention was perfected upon further investigation.
[0006]
Specifically, the present invention is intended to provide the following [1]
to [ 16]
and the like.
[1] a compound represented by formula (I):
B
A
Ar1 x 1 X4 (I
X \X YI-' Z Ar2 I
() wherein A represents -(CH2)n-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-R b, optionally substituted C1_14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CV=, or -N=, Y represents -0-, -S-, -S(O)-, -S(O)2-, or -NR'"-, Z represents a bond, methylene, or ethylene, Arl represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, Ar 2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and Ra, Rb, R", and Ry represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1.6 alkyl groups, or optionally halogenated C1_6 alkoxy groups, providing that 1-{2-[(3-chlorobenzyl)oxy]-6-methylpyridin-4-yl}-2-methyl-IH-imidazole-4-carboxamide, tert-butyl { 5-[6-(3-chlorophenoxy)pyrazin-2-yl]pyridin-3-yl}carbamate, 5-{6-[3-(trifluoromethyl)phenoxy]pyridin-2-yl}-1,3,4-oxadiazole-carboxamide, and N-hydroxy-5-{6-[methyl(2-phenylethyl)amino]pyridin-2-yl}thiophene-2-carboxamide are excluded, or a salt thereof.
[2] the compound according to [1] above, wherein A is -CO-NH- or -NH-CO-;
[3 ] the compound according to [1], wherein B is a (1) hydrogen atom, (2) C 1.6 alkyl group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C1_6 alkyl groups, C6-1o aryl groups, C1_6 alkoxy-carbonyl groups, C1_6 alkyl-carbonyl groups, and carbamoyl groups, (e) C6-lo aryl groups which may be substituted with 1 to 3 substituents selected from halogen atoms, hydroxy group, and amino group, (f) C1_6 alkylsulfanyl groups, (g) C I-6 alkylsulfinyl groups, (h) C1_6 alkylsulfonyl groups, (i) C1_6 alkoxy groups, (j) C6-1o aryloxy groups, (k) C7_13 aralkyloxy groups, (1) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from C1_6 alkyl groups, C1_6 alkyl-carbonyl groups, and oxo group, and (m) carbamoyl, (3) C2_6 alkenyl group which may be substituted with a five- to six-membered heterocyclic group, (4) C3_10 cycloalkyl group, (5) C6_10 aryl group which may be substituted with one or more substituents selected from (a) hydroxy group, (b) cyano group, (c) C I-6 alkoxy groups, (d) mono- or di-C1_6 alkyl-amino groups, and (e) C1_6 alkyl-carbonylamino groups, (6) amino group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups which may be substituted with mono- or di-C1.6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from halogen atoms and oxo group, or (7) five- to ten-membered heterocyclic group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) C1_6 alkyl groups which may be substituted with one or more substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups, (c) C 1.6 alkoxy groups, (d) C1_6 alkyl-carbonyl groups, (e) C1_6 alkoxy-carbonyl groups, and (f) carbamoyl groups;
[4] the compound according to [1] above, wherein one or two of X1, X2, X3, and X4 are -N=;
[5] the compound according to [1] above, wherein Y is -0-;
[6] the compound according to [1] above, wherein Arl is a benzene ring or indole ring which may be substituted with one or more substituents selected from halogen atoms and optionally halogenated C1_6 alkyl groups;
[7] the compound according to [I ] above, wherein Rx is a hydrogen atom or optionally halogenated C1_6 alkyl group;
Specifically, the present invention is intended to provide the following [1]
to [ 16]
and the like.
[1] a compound represented by formula (I):
B
A
Ar1 x 1 X4 (I
X \X YI-' Z Ar2 I
() wherein A represents -(CH2)n-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-R b, optionally substituted C1_14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CV=, or -N=, Y represents -0-, -S-, -S(O)-, -S(O)2-, or -NR'"-, Z represents a bond, methylene, or ethylene, Arl represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, Ar 2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and Ra, Rb, R", and Ry represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1.6 alkyl groups, or optionally halogenated C1_6 alkoxy groups, providing that 1-{2-[(3-chlorobenzyl)oxy]-6-methylpyridin-4-yl}-2-methyl-IH-imidazole-4-carboxamide, tert-butyl { 5-[6-(3-chlorophenoxy)pyrazin-2-yl]pyridin-3-yl}carbamate, 5-{6-[3-(trifluoromethyl)phenoxy]pyridin-2-yl}-1,3,4-oxadiazole-carboxamide, and N-hydroxy-5-{6-[methyl(2-phenylethyl)amino]pyridin-2-yl}thiophene-2-carboxamide are excluded, or a salt thereof.
[2] the compound according to [1] above, wherein A is -CO-NH- or -NH-CO-;
[3 ] the compound according to [1], wherein B is a (1) hydrogen atom, (2) C 1.6 alkyl group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C1_6 alkyl groups, C6-1o aryl groups, C1_6 alkoxy-carbonyl groups, C1_6 alkyl-carbonyl groups, and carbamoyl groups, (e) C6-lo aryl groups which may be substituted with 1 to 3 substituents selected from halogen atoms, hydroxy group, and amino group, (f) C1_6 alkylsulfanyl groups, (g) C I-6 alkylsulfinyl groups, (h) C1_6 alkylsulfonyl groups, (i) C1_6 alkoxy groups, (j) C6-1o aryloxy groups, (k) C7_13 aralkyloxy groups, (1) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from C1_6 alkyl groups, C1_6 alkyl-carbonyl groups, and oxo group, and (m) carbamoyl, (3) C2_6 alkenyl group which may be substituted with a five- to six-membered heterocyclic group, (4) C3_10 cycloalkyl group, (5) C6_10 aryl group which may be substituted with one or more substituents selected from (a) hydroxy group, (b) cyano group, (c) C I-6 alkoxy groups, (d) mono- or di-C1_6 alkyl-amino groups, and (e) C1_6 alkyl-carbonylamino groups, (6) amino group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups which may be substituted with mono- or di-C1.6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from halogen atoms and oxo group, or (7) five- to ten-membered heterocyclic group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) C1_6 alkyl groups which may be substituted with one or more substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups, (c) C 1.6 alkoxy groups, (d) C1_6 alkyl-carbonyl groups, (e) C1_6 alkoxy-carbonyl groups, and (f) carbamoyl groups;
[4] the compound according to [1] above, wherein one or two of X1, X2, X3, and X4 are -N=;
[5] the compound according to [1] above, wherein Y is -0-;
[6] the compound according to [1] above, wherein Arl is a benzene ring or indole ring which may be substituted with one or more substituents selected from halogen atoms and optionally halogenated C1_6 alkyl groups;
[7] the compound according to [I ] above, wherein Rx is a hydrogen atom or optionally halogenated C1_6 alkyl group;
[8] the compound according to [1] above, wherein A is -CO-NH- or -NH-CO-, B is a (1) hydrogen atom, (2) C 1.6 alkyl group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C I.6 alkyl groups, C6-10 aryl groups, C, -6alkoxy-carbonyl groups, C1_6 alkyl-carbonyl groups, and carbamoyl groups, (e)C6-lo aryl groups which may be substituted with 1 to 3 substituents selected from halogen atoms, hydroxy group, and amino group, (f) C1_6 alkylsulfanyl groups, (g) C1_6 alkylsulfinyl groups, (h) C1.6 alkylsulfonyl groups, (i) C1_6 alkoxy groups, (j) C6-1o aryloxy groups, (k) C7_13 aralkyloxy groups, (1) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from C 1.6 alkyl groups, C I.6 alkyl-carbonyl groups, and oxo group, and (m) carbamoyl, (3) C2_6 alkenyl group which may be substituted with a five- to six-membered heterocyclic group(s), (4)C3-1 Ocycloalkyl group, (5) C6_lo aryl group which may be substituted with one or more substituents selected from (a) hydroxy group, (b) cyano group, (c) C 1.6 alkoxy groups, (d) mono- or di-C16 alkyl-amino groups, and (e) C1_6 alkyl-carbonylamino groups, (6) amino group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups which may be substituted with mono- or di-C1_6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from halogen atoms and oxo group, or (7) five- to ten-membered heterocyclic group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) C1_6 alkyl groups which may be substituted with one or more substituents selected from hydroxy group and mono- or di-C 1.6 alkylamino groups, (c) C1_6 alkoxy groups, (d) C1_6 alkyl-carbonyl groups, (e) C 1.6 alkoxy-carbonyl groups, and (f) carbamoyl groups;
X', X2, X3, and X4 are the same or different -CRX=, or -N=, and one or two of X', X2, X3, and X4 are -N=, Y is -0-, Ar' is a benzene ring or indole ring which may be substituted with one or more substituents selected from halogen atoms and optionally halogenated C 1.6 alkyl groups, Ar 2 is a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and RX is a hydrogen atom or optionally halogenated C1_6 alkyl group.
[9] a compound according to [11 above, selected from:
4-amino-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride, N-(3-(2-((2-(3,4-dim ethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3,N3-dimethyl-3-alaninamide hydrochloride, 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide, N-(2-hydroxyethyl)-3 -(6-(2-(3 -(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzamide, N-(2-hydroxyethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide, 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide, N-(2-aminoethyl)-3 -(6-(2-(3 -methoxyphenyl)ethoxy)pyridin-2-yl)benzamide hydrochloride, 3 -(6-(2,4-dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide, 3-(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide, N-(2-pyrrolidin- l -ylethyl)-3 - [2-({ 2- [3 -(trifluoromethyl)phenyl] ethyl }
amino)pyrimidin-4-yl]benzamide, N-cyclopropyl-3 - { 6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl } benzamide, N-(3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)acetamide, 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(pyridin-3-ylmethyl)benzamide, 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-(methylsulfinyl)ethyl)benzamide, and 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide;
[ 10] a prodrug of the compound according [ 1 ] above;
[ 11 ] a pharmaceutical agent comprising the compound according to [ 1 ]
above or the prodrug according to [10] above;
[12] a GPR52 activating agent comprising a compound represented by formula (I):
B
A
Art II
X
X3 Y / Z Are wherein A represents -(CH2)n-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-R b, optionally substituted C1_14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CR"=, or -N=, Y represents -0-, -S-, -S(O)-, -S(0)2-, or -NR'"-, Z represents a bond, methylene, or ethylene, ArI represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C I-6 alkyl groups, and optionally halogenated C I-6 alkoxy groups, Ar 2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C 1.6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and Ra, Rb, R', and Ry represent the same or different hydrogen atom, halogen atoms, optionally halogenated C 1.6 alkyl groups, or optionally halogenated C 1.6 alkoxy groups, or a salt or prodrug thereof;
[13] the GPR52 activating agent according to [12] above, which is an agent for preventing or treating schizophrenia.
[14] a method for preventing or treating diseases involving GPR52 activity in a mammal, comprising administering a compound represented by formula (I):
B
A
Art (I
X
X3 Y Ar2 wherein A represents -(CH2)õ-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-R' , optionally substituted C1.14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X', X2, X3, and X4 represent the same or different -CR'=, or -N=, Y represents -0-, -S-, -S(O)-, -S(0)2-, or -NRI-, Z represents a bond, methylene, or ethylene, Ar' represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C 1.6 alkyl groups, and optionally halogenated C, _6 alkoxy groups, Ar 2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and Ra, R', R", and Ry represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1_6 alkyl groups, or optionally halogenated C1_6 alkoxy groups, or a salt or prodrug thereof, to the mammal;
[15] the method according to [14] above, wherein the disease involving GPR52 activity is schizophrenia;
[ 16] the use of a compound represented by formula (I):
B
A
Ar1 II
X
X3 Y Z Ar2 wherein A represents -(CH2)n-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-Rb, optionally substituted C1_14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CR"=, or -N=, Y represents -0-, -S-, -S(O)-, -S(0)2-, or -NRI-, Z represents a bond, methylene, or ethylene, ArI represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C I-6 alkyl groups, and optionally halogenated C I-6 alkoxy groups, Ar 2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and Ra, Rb, R', and Ry represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1_6 alkyl groups, or optionally halogenated C1_6 alkoxy groups, or a salt or prodrug thereof, for the manufacture of a GPR52 activating agent;
and [ 17] the use according to [ 16] above, wherein the GPR52 activating agent is as an agent for preventing or treating schizophrenia.
[Advantageous Effects of Invention]
[0007]
The compound of the present invention has an agonistic effect on GPR52 and is useful as a pharmaceutical agent for preventing and treating mental disorders such as schizophrenia.
[Description of Embodiments]
[0008]
The present invention will be described in detail below.
[0009]
Unless otherwise noted, examples of the "halogen atoms" used herein include fluorine, chlorine, bromine, and iodine.
Unless otherwise noted, examples of the "C1_6 alkyl groups" and "C1_6 alkyl"
in substituents used herein include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, and hexyl. Of these, "C1_4 alkyl (groups)" are preferred. Unless otherwise noted, examples of the "optionally halogenated C1_6 alkyl groups" used herein include C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms selected from fluorine, chlorine, bromine, and iodine atoms.
Unless otherwise noted, examples of the "C 1.6 alkoxy groups" and "C16 alkoxy"
in substituents used herein include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, and hexyloxy. Of these, "C1_4 alkoxy (groups)" are preferred. Examples of the "optionally halogenated C1_6 alkoxy groups"
used herein include C1_6 alkoxy groups which may be substituted with one or more (preferably one to three) halogen atoms selected from fluorine, chlorine, bromine, and iodine atoms.
X', X2, X3, and X4 are the same or different -CRX=, or -N=, and one or two of X', X2, X3, and X4 are -N=, Y is -0-, Ar' is a benzene ring or indole ring which may be substituted with one or more substituents selected from halogen atoms and optionally halogenated C 1.6 alkyl groups, Ar 2 is a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and RX is a hydrogen atom or optionally halogenated C1_6 alkyl group.
[9] a compound according to [11 above, selected from:
4-amino-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride, N-(3-(2-((2-(3,4-dim ethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3,N3-dimethyl-3-alaninamide hydrochloride, 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide, N-(2-hydroxyethyl)-3 -(6-(2-(3 -(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzamide, N-(2-hydroxyethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide, 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide, N-(2-aminoethyl)-3 -(6-(2-(3 -methoxyphenyl)ethoxy)pyridin-2-yl)benzamide hydrochloride, 3 -(6-(2,4-dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide, 3-(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide, N-(2-pyrrolidin- l -ylethyl)-3 - [2-({ 2- [3 -(trifluoromethyl)phenyl] ethyl }
amino)pyrimidin-4-yl]benzamide, N-cyclopropyl-3 - { 6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl } benzamide, N-(3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)acetamide, 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(pyridin-3-ylmethyl)benzamide, 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-(methylsulfinyl)ethyl)benzamide, and 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide;
[ 10] a prodrug of the compound according [ 1 ] above;
[ 11 ] a pharmaceutical agent comprising the compound according to [ 1 ]
above or the prodrug according to [10] above;
[12] a GPR52 activating agent comprising a compound represented by formula (I):
B
A
Art II
X
X3 Y / Z Are wherein A represents -(CH2)n-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-R b, optionally substituted C1_14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CR"=, or -N=, Y represents -0-, -S-, -S(O)-, -S(0)2-, or -NR'"-, Z represents a bond, methylene, or ethylene, ArI represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C I-6 alkyl groups, and optionally halogenated C I-6 alkoxy groups, Ar 2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C 1.6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and Ra, Rb, R', and Ry represent the same or different hydrogen atom, halogen atoms, optionally halogenated C 1.6 alkyl groups, or optionally halogenated C 1.6 alkoxy groups, or a salt or prodrug thereof;
[13] the GPR52 activating agent according to [12] above, which is an agent for preventing or treating schizophrenia.
[14] a method for preventing or treating diseases involving GPR52 activity in a mammal, comprising administering a compound represented by formula (I):
B
A
Art (I
X
X3 Y Ar2 wherein A represents -(CH2)õ-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-R' , optionally substituted C1.14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X', X2, X3, and X4 represent the same or different -CR'=, or -N=, Y represents -0-, -S-, -S(O)-, -S(0)2-, or -NRI-, Z represents a bond, methylene, or ethylene, Ar' represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C 1.6 alkyl groups, and optionally halogenated C, _6 alkoxy groups, Ar 2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and Ra, R', R", and Ry represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1_6 alkyl groups, or optionally halogenated C1_6 alkoxy groups, or a salt or prodrug thereof, to the mammal;
[15] the method according to [14] above, wherein the disease involving GPR52 activity is schizophrenia;
[ 16] the use of a compound represented by formula (I):
B
A
Ar1 II
X
X3 Y Z Ar2 wherein A represents -(CH2)n-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-Rb, optionally substituted C1_14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CR"=, or -N=, Y represents -0-, -S-, -S(O)-, -S(0)2-, or -NRI-, Z represents a bond, methylene, or ethylene, ArI represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C I-6 alkyl groups, and optionally halogenated C I-6 alkoxy groups, Ar 2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and Ra, Rb, R', and Ry represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1_6 alkyl groups, or optionally halogenated C1_6 alkoxy groups, or a salt or prodrug thereof, for the manufacture of a GPR52 activating agent;
and [ 17] the use according to [ 16] above, wherein the GPR52 activating agent is as an agent for preventing or treating schizophrenia.
[Advantageous Effects of Invention]
[0007]
The compound of the present invention has an agonistic effect on GPR52 and is useful as a pharmaceutical agent for preventing and treating mental disorders such as schizophrenia.
[Description of Embodiments]
[0008]
The present invention will be described in detail below.
[0009]
Unless otherwise noted, examples of the "halogen atoms" used herein include fluorine, chlorine, bromine, and iodine.
Unless otherwise noted, examples of the "C1_6 alkyl groups" and "C1_6 alkyl"
in substituents used herein include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, and hexyl. Of these, "C1_4 alkyl (groups)" are preferred. Unless otherwise noted, examples of the "optionally halogenated C1_6 alkyl groups" used herein include C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms selected from fluorine, chlorine, bromine, and iodine atoms.
Unless otherwise noted, examples of the "C 1.6 alkoxy groups" and "C16 alkoxy"
in substituents used herein include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, and hexyloxy. Of these, "C1_4 alkoxy (groups)" are preferred. Examples of the "optionally halogenated C1_6 alkoxy groups"
used herein include C1_6 alkoxy groups which may be substituted with one or more (preferably one to three) halogen atoms selected from fluorine, chlorine, bromine, and iodine atoms.
[0010]
Unless otherwise specified, examples of the "C1_14 hydrocarbon groups" in "optionally substituted C1_14 hydrocarbon groups" include C1.10 alkyl groups, C2_lo alkenyl groups, C2.1o alkynyl groups, C3_lo cycloalkyl groups, C3.1o cycloalkenyl groups, C4.1o cycloalkadienyl groups, C6_14 aryl groups, C7_13 aralkyl groups, C8_13 arylalkenyl groups, and C3_10 cycloalkyl-C1_6 alkyl groups.
Unless otherwise specified, examples of the "C1_14 hydrocarbon groups" in "optionally substituted C1_14 hydrocarbon groups" include C1.10 alkyl groups, C2_lo alkenyl groups, C2.1o alkynyl groups, C3_lo cycloalkyl groups, C3.1o cycloalkenyl groups, C4.1o cycloalkadienyl groups, C6_14 aryl groups, C7_13 aralkyl groups, C8_13 arylalkenyl groups, and C3_10 cycloalkyl-C1_6 alkyl groups.
[0011]
Here, examples of C1_10 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1, 1 -dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, and decyl.
Here, examples of C1_10 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1, 1 -dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, and decyl.
[0012]
Unless otherwise noted, examples of C2_10 alkenyl groups used herein include ethenyl, 1-propenyl, 2-propenyl, 2-methyl- l -propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3-hexenyl, 5-hexenyl, 1-heptenyl, and 1-octenyl. Unless otherwise noted, the C2_6 alkenyl groups used herein include the ones above that have a carbon number of 2 to 6.
Unless otherwise noted, examples of C2_10 alkenyl groups used herein include ethenyl, 1-propenyl, 2-propenyl, 2-methyl- l -propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3-hexenyl, 5-hexenyl, 1-heptenyl, and 1-octenyl. Unless otherwise noted, the C2_6 alkenyl groups used herein include the ones above that have a carbon number of 2 to 6.
[0013]
Unless otherwise noted, the C2_10 alkynyl groups and "C2.10 alkynyl" in substituents used herein include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-heptynyl, and 1-octynyl.
Unless otherwise noted, the C2_10 alkynyl groups and "C2.10 alkynyl" in substituents used herein include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-heptynyl, and 1-octynyl.
[0014]
Unless otherwise noted, examples of the C3_10 cycloalkyl groups and "C3-1o cycloalkyl" in substituents used herein include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
Unless otherwise noted, examples of the C3_10 cycloalkyl groups and "C3-1o cycloalkyl" in substituents used herein include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
[0015]
Unless otherwise noted, examples of the C3_]o cycloalkenyl groups used herein include 2-cyclopenten-l-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl, and 3-cyclohexen-1-yl.
Unless otherwise noted, examples of the C3_]o cycloalkenyl groups used herein include 2-cyclopenten-l-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl, and 3-cyclohexen-1-yl.
[0016]
Unless otherwise noted, examples of the C4.10 cycloalkadienyl groups used herein include 2,4-cyclopentadien-1-yl, 2,4-cyclohexadien-l-yl, and 2,5-cyclohexadien-l-yl.
Unless otherwise noted, examples of the C4.10 cycloalkadienyl groups used herein include 2,4-cyclopentadien-1-yl, 2,4-cyclohexadien-l-yl, and 2,5-cyclohexadien-l-yl.
[0017]
The above C3-1o cycloalkyl groups, C3_lo cycloalkenyl groups, and C4-10 cycloalkadienyl groups may each be condensed with a benzene ring, wherein examples of such condensed cyclic groups include indanyl, dihydronaphthyl, tetrahydronaphthyl, and fluorenyl. Examples of the above hydrocarbon groups also include crosslinked hydrocarbons such as bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl, bicyclo[4.2.1]nonyl, bicyclo[4.3.1]decyl, adamantly, and norbornanyl.
The above C3-1o cycloalkyl groups, C3_lo cycloalkenyl groups, and C4-10 cycloalkadienyl groups may each be condensed with a benzene ring, wherein examples of such condensed cyclic groups include indanyl, dihydronaphthyl, tetrahydronaphthyl, and fluorenyl. Examples of the above hydrocarbon groups also include crosslinked hydrocarbons such as bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl, bicyclo[4.2.1]nonyl, bicyclo[4.3.1]decyl, adamantly, and norbornanyl.
[0018]
Unless otherwise noted, examples of the C6_14 aryl groups used herein include phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, and biphenylyl.
Examples of C6-1o aryl groups and "C6-1o aryl" in substituents used herein include the ones above that have a carbon number of 6 to 10 (such as phenyl and naphthyl).
Unless otherwise noted, examples of the C6_14 aryl groups used herein include phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, and biphenylyl.
Examples of C6-1o aryl groups and "C6-1o aryl" in substituents used herein include the ones above that have a carbon number of 6 to 10 (such as phenyl and naphthyl).
[0019]
Unless otherwise noted, examples of C7-20 aralkyl groups and "C7_20 aralkyl"
in substituents used herein include C1-6 alkyl groups substituted with one to three C6-lo aryl groups, more specific examples of which include benzyl, phenethyl, naphthylmethyl, biphenylylmethyl, and trityl. Examples of C7-13 aralkyl groups and "C7-13 aralkyl" in substituents used herein include the ones above that have a carbon number of 7 to 13.
Examples of C7-13 aralkyloxy groups include C1-6 alkoxy groups substituted with one to three C6-lo aryl groups.
Unless otherwise noted, examples of C7-20 aralkyl groups and "C7_20 aralkyl"
in substituents used herein include C1-6 alkyl groups substituted with one to three C6-lo aryl groups, more specific examples of which include benzyl, phenethyl, naphthylmethyl, biphenylylmethyl, and trityl. Examples of C7-13 aralkyl groups and "C7-13 aralkyl" in substituents used herein include the ones above that have a carbon number of 7 to 13.
Examples of C7-13 aralkyloxy groups include C1-6 alkoxy groups substituted with one to three C6-lo aryl groups.
[0020]
Examples of C8-13 arylalkenyl groups include styryl or the like.
Examples of C3-1o cycloalkyl-C1-6 alkyl groups include cyclohexylmethyl or the like.
Examples of C8-13 arylalkenyl groups include styryl or the like.
Examples of C3-1o cycloalkyl-C1-6 alkyl groups include cyclohexylmethyl or the like.
[0021]
The C1_10 alkyl groups, C2-10 alkenyl groups, and C2-lo alkynyl groups given above as examples of "C1_14 hydrocarbon groups" may have one or more (preferably one to three) substituents in substitutable positions.
Examples of such substituents include:
(1) C3_10 cycloalkyl groups (such as cyclopropyl and cyclohexyl);
(2) C6.14 aryl groups (such as phenyl and naphthyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, (d) halogen atoms, and (e) amino group;
(3) aromatic heterocyclic groups (such as thienyl, furyl, pyridyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, tetrazolyl, oxadiazolyl, pyrazinyl, quinolyl, indolyl, and benzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C6 alkoxy groups, and (d) halogen atoms;
(4) non-aromatic heterocyclic groups (such as tetrahydrofuryl, morpholinyl, piperidyl, pyrrolidinyl, piperazinyl, tetrahydropyranyl, and tetrahydroquinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, (d) oxo group, (e) halogen atoms, and (f) C7_20 aralkylthio groups (such as benzylthio and tritylthio);
(5) amino group which may be mono- or di-substituted with substituents selected from (a) optionally hydroxyl-substituted C1_6 alkyl groups (such as methyl and hydroxymethyl), (b)C6-lo aryl groups (such as phenyl), (c) C 1.6 alkyl-carbonyl groups (such as acetyl), (d) C1_6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), (e) C6_14 aryl-carbonyl groups (such as benzoyl), (f) C7_13 aralkyl-carbonyl groups (such as benzylcarbonyl and phenethylcarbonyl), (g) carbamoyl groups (such as carbamoyl, methylcarbamoyl, benzylcarbamoyl, and dimethylcarbamoyl) which may be mono- or di-substituted with substituents selected from C1_6 alkyl groups, C6_14 aryl groups, and C7_13 aralkyl groups;
(h) C1_6 alkylsulfonyl groups (such as methylsulfonyl, ethylsulfonyl, and isopropylsulfonyl), (i) C6_14 arylsulfonyl groups (such as benzenesulfonyl, toluenesulfonyl, 1-naphthalenesulfonyl, and 2-naphthalenesulfonyl), and (j) C7_13 aralkylsulfonyl groups such as (benzylsulfonyl);
(6) amidino group;
(7)C 1-6alkyl-carbonyl groups which may be substituted with one or more (preferably one to three) halogen atoms;
(8)C 1-6alkoxy-carbonyl groups which may be substituted with one or more (preferably one to three) halogen atoms;
(9) aromatic heterocyclic-carbonyl groups (such as thienylcarbonyl and indolylcarbonyl) which may be substituted with one or more (preferably one to three) amino groups (the amino groups may be mono- or di-substituted with substituents selected from C1_6 alkyl groups and aromatic heterocyclic-sulfonyl groups (such as thienylsulfonyl));
The C1_10 alkyl groups, C2-10 alkenyl groups, and C2-lo alkynyl groups given above as examples of "C1_14 hydrocarbon groups" may have one or more (preferably one to three) substituents in substitutable positions.
Examples of such substituents include:
(1) C3_10 cycloalkyl groups (such as cyclopropyl and cyclohexyl);
(2) C6.14 aryl groups (such as phenyl and naphthyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, (d) halogen atoms, and (e) amino group;
(3) aromatic heterocyclic groups (such as thienyl, furyl, pyridyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, tetrazolyl, oxadiazolyl, pyrazinyl, quinolyl, indolyl, and benzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C6 alkoxy groups, and (d) halogen atoms;
(4) non-aromatic heterocyclic groups (such as tetrahydrofuryl, morpholinyl, piperidyl, pyrrolidinyl, piperazinyl, tetrahydropyranyl, and tetrahydroquinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, (d) oxo group, (e) halogen atoms, and (f) C7_20 aralkylthio groups (such as benzylthio and tritylthio);
(5) amino group which may be mono- or di-substituted with substituents selected from (a) optionally hydroxyl-substituted C1_6 alkyl groups (such as methyl and hydroxymethyl), (b)C6-lo aryl groups (such as phenyl), (c) C 1.6 alkyl-carbonyl groups (such as acetyl), (d) C1_6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), (e) C6_14 aryl-carbonyl groups (such as benzoyl), (f) C7_13 aralkyl-carbonyl groups (such as benzylcarbonyl and phenethylcarbonyl), (g) carbamoyl groups (such as carbamoyl, methylcarbamoyl, benzylcarbamoyl, and dimethylcarbamoyl) which may be mono- or di-substituted with substituents selected from C1_6 alkyl groups, C6_14 aryl groups, and C7_13 aralkyl groups;
(h) C1_6 alkylsulfonyl groups (such as methylsulfonyl, ethylsulfonyl, and isopropylsulfonyl), (i) C6_14 arylsulfonyl groups (such as benzenesulfonyl, toluenesulfonyl, 1-naphthalenesulfonyl, and 2-naphthalenesulfonyl), and (j) C7_13 aralkylsulfonyl groups such as (benzylsulfonyl);
(6) amidino group;
(7)C 1-6alkyl-carbonyl groups which may be substituted with one or more (preferably one to three) halogen atoms;
(8)C 1-6alkoxy-carbonyl groups which may be substituted with one or more (preferably one to three) halogen atoms;
(9) aromatic heterocyclic-carbonyl groups (such as thienylcarbonyl and indolylcarbonyl) which may be substituted with one or more (preferably one to three) amino groups (the amino groups may be mono- or di-substituted with substituents selected from C1_6 alkyl groups and aromatic heterocyclic-sulfonyl groups (such as thienylsulfonyl));
[0022]
(10) non-aromatic heterocyclic-carbonyl groups (such as morpholinylcarbonyl);
(11) C1_6 alkylsulfonyl groups (such as methylsulfonyl) which may be substituted with one or more (preferably one to three) halogen atoms;
(12) carbamoyl group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) C6_14 aryl groups (such as phenyl), (c) C7_13 aralkyl groups (such as benzyl), and (d) aromatic heterocyclic-C1_6 alkyl groups (such as furfuryl);
(13) thiocarbamoyl group which may be mono- or di-substituted with C1_6 alkyl groups optionally substituted with one or more (preferably one to three) halogen atoms;
(14) sulfamoyl groups which may be mono- or di-substituted with C1_6 alkyl groups optionally substituted with one or more (preferably one to three) halogen atoms;
(15) carboxy groups;
(16) hydroxy group;
(17) C1_6 alkoxy groups (such as methoxy) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms, (b) carboxy groups, (c) C1_6 alkoxy groups, and (d) C1_6 alkoxy-carbonyl groups;
(18) C2_6 alkenyloxy groups (such as ethenyloxy) which may be substituted with one or more (preferably one to three) halogen atoms;
(19) C3_10 cycloalkyloxy groups (such as cyclohexyloxy);
(20)C7-13 aralkyloxy groups (such as benzyloxy) which may be substituted with one or more (preferably one to three) halogen atoms;
(10) non-aromatic heterocyclic-carbonyl groups (such as morpholinylcarbonyl);
(11) C1_6 alkylsulfonyl groups (such as methylsulfonyl) which may be substituted with one or more (preferably one to three) halogen atoms;
(12) carbamoyl group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) C6_14 aryl groups (such as phenyl), (c) C7_13 aralkyl groups (such as benzyl), and (d) aromatic heterocyclic-C1_6 alkyl groups (such as furfuryl);
(13) thiocarbamoyl group which may be mono- or di-substituted with C1_6 alkyl groups optionally substituted with one or more (preferably one to three) halogen atoms;
(14) sulfamoyl groups which may be mono- or di-substituted with C1_6 alkyl groups optionally substituted with one or more (preferably one to three) halogen atoms;
(15) carboxy groups;
(16) hydroxy group;
(17) C1_6 alkoxy groups (such as methoxy) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms, (b) carboxy groups, (c) C1_6 alkoxy groups, and (d) C1_6 alkoxy-carbonyl groups;
(18) C2_6 alkenyloxy groups (such as ethenyloxy) which may be substituted with one or more (preferably one to three) halogen atoms;
(19) C3_10 cycloalkyloxy groups (such as cyclohexyloxy);
(20)C7-13 aralkyloxy groups (such as benzyloxy) which may be substituted with one or more (preferably one to three) halogen atoms;
[0023]
(21) C6_14 aryloxy groups (such as phenyloxy and naphthyloxy);
(22) C1_6 alkyl-carbonyloxy groups (such as acetyloxy and tert-butylcarbonyloxy);
(23) mercapto groups;
(21) C6_14 aryloxy groups (such as phenyloxy and naphthyloxy);
(22) C1_6 alkyl-carbonyloxy groups (such as acetyloxy and tert-butylcarbonyloxy);
(23) mercapto groups;
(24) C1_6 alkylthio groups (such as methylthio and ethylthio) which may be substituted with one to three substituents selected from halogen atoms and C6_14 aryl groups;
(25) C6_14 arylthio groups (such as phenylthio and naphthylthio);
(26) aromatic heterocyclic thio groups (such as tetrazolylthio) which may be substituted with one or more (preferably one to three) C1.6 alkyl groups;
(27) sulfo groups;
(28) cyano group;
(29) azide groups;
(30) nitro groups;
(31) nitroso groups;
(32) halogen atoms;
(33)C 1-6alkylsulfinyl groups (such as methylsulfinyl);
(34) oxo group;
(35) C3_10 cycloalkyl-C1_6 alkyloxy groups (such as cyclopropylmethyloxy);
(36) C 1.3 alkylenedioxy groups;
(37) aromatic heterocyclic-carbonylthio groups (such as indolylcarbonylthio) which may be substituted with one or more (preferably one to three) amino group (the amino group may be mono- or di-substituted with substituents selected from C 1.6 alkyl groups and aromatic heterocyclic-sulfonyl groups (such as thienylsulfonyl)); and (38) formyl groups.
[0024]
The C3_10 cycloalkyl groups, C3_10 cycloalkenyl groups, C4_10 cycloalkadienyl groups, C6_14 aryl groups, C7_13 aralkyl groups, C8_13 arylalkenyl groups, and cycloalkyl-C1_6 alkyl groups given above as examples of "hydrocarbon groups"
may have one or more (preferably one to three) substituents in substitutable positions.
Examples of such substituents include:
(1) C3_10 cycloalkyl groups (such as cyclopropyl and cyclohexyl);
(2) C6.14 aryl groups (such as phenyl and naphthyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, and (d) halogen atoms;
(3) aromatic heterocyclic groups (such as thienyl, furyl, pyridyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, tetrazolyl, oxadiazolyl, pyrazinyl, quinolyl, and indolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, and (d) halogen atoms;
(4) non-aromatic heterocyclic groups (such as tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, dioxolyl, dioxolanyl, 1,3-dihydro-2-benzofuranyl, thiazolidinyl, and thiazolinyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C 1.6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, (d) C 1.6 alkyl-carbonyl groups, (e) C 1.6 alkyl-sulfonyl groups, (f) oxo group, and (g) halogen atoms;
(5) amino group which may be mono- or di-substituted with substituents selected from (a) C 1.6 alkyl groups, (b) C1_6 alkyl-carbonyl groups, (c) C1_6 alkoxy-carbonyl groups, (d) C6_14 aryl-carbonyl groups (such as benzoyl), (e) C7_13 aralkyl-carbonyl groups (such as benzylcarbonyl and phenethylcarbonyl), (f) carbamoyl groups (such as carbamoyl, methylcarbamoyl, benzylcarbamoyl, and dimethylcarbamoyl) which may be mono- or di-substituted with substituents selected from C1_6 alkyl groups, C6_14 aryl groups, and C7_13 aralkyl groups;
(g) C1_6 alkylsulfonyl groups (such as methylsulfonyl, ethylsulfonyl, and isopropylsulfonyl), (h) C6_14 arylsulfonyl groups (such as benzenesulfonyl, toluenesulfonyl, 1-naphthalenesulfonyl, and 2-naphthalenesulfonyl), and (i) C7_13 aralkylsulfonyl groups (such as benzylsulfonyl);
(6) amidino group;
[0025]
(7) C1_6 alkyl-carbonyl groups which may be substituted with one or more (preferably one to three) halogen atoms;
(8) C1_6 alkoxy-carbonyl groups which may be substituted with one or more (preferably one to three) halogen atoms;
(9) aromatic heterocyclic-carbonyl groups (such as thienylcarbonyl and indolylcarbonyl) which may be substituted with one or more (preferably one to three) amino groups (the amino groups may be mono- or di-substituted with substituents selected from C1.6 alkyl groups and aromatic heterocyclic-sulfonyl groups (such as thienylsulfonyl));
(10) non-aromatic heterocyclic-carbonyl groups (such as morpholinylcarbonyl and pyrrolidinocarbonyl);
(11) C1_6 alkylsulfonyl groups (such as methylsulfonyl and ethylsulfonyl) which may be substituted with one or more (preferably one to three) halogen atoms;
(12) carbamoyl groups which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) C6_14 aryl groups (such as phenyl), (c) C7_13 aralkyl groups (such as benzyl), and (d) aromatic heterocyclic-C1_6 alkyl groups (such as furfuryl);
(13) thiocarbamoyl groups which may be mono- or di-substituted with C1_6 alkyl groups optionally substituted with one or more (preferably one to three) halogen atoms;
(14) sulfamoyl groups which may be mono- or di-substituted with C16 alkyl groups optionally substituted with one or more (preferably one to three) halogen atoms;
(15) carboxy groups;
(16) hydroxy group;
(17) C 1.6 alkoxy groups which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms, (b) carboxy groups, (c) C 1.6 alkoxy groups, and (d) C 1.6 alkoxy-carbonyl groups;
(18) C2_6 alkenyloxy groups (such as ethenyloxy) which may be substituted with one or more (preferably one to three) halogen atoms;
(19) C3_10 cycloalkyloxy groups (such as cyclohexyloxy);
(20)C7-13 aralkyloxy groups (such as benzyloxy) which may be substituted with one or more (preferably one to three) halogen atoms;
(21) C6_14 aryloxy groups (such as phenyloxy and naphthyloxy);
(22) C 1.6 alkyl-carbonyloxy groups (such as acetyloxy and tert-butylcarbonyloxy);
[0026]
(23) mercapto groups;
(24)C 1-6alkylthio groups (such as methylthio and ethylthio) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms, and (b) C6_14 aryl groups;
(25) C6_14 arylthio groups (such as phenylthio and naphthylthio);
(26) aromatic heterocyclic thio groups (such as tetrazolylthio) which may be substituted with one or more (preferably one to three) C1_6 alkyl groups;
(27) sulfo groups;
(28) cyano group;
(29) azide groups;
(30) nitro groups;
(31) nitroso groups;
(32) halogen atoms;
(33) C1_6 alkylsulfinyl groups (such as methylsulfinyl);
(34) oxo group;
(35)C3-1 Ocycloalkyl-C1_6 alkyloxy groups (such as cyclopropylmethyloxy);
(36)C 1-3 alkylenedioxy groups;
(37) aromatic heterocyclic-carbonylthio groups (such as indolylcarbonylthio) which may be substituted with one or more (preferably one to three) amino group [the amino group may be mono- or di-substituted with substituents selected from C1_6 alkyl groups and aromatic heterocyclic-sulfonyl groups (such as thienylsulfonyl)];
(38) formyl groups;
[0024]
The C3_10 cycloalkyl groups, C3_10 cycloalkenyl groups, C4_10 cycloalkadienyl groups, C6_14 aryl groups, C7_13 aralkyl groups, C8_13 arylalkenyl groups, and cycloalkyl-C1_6 alkyl groups given above as examples of "hydrocarbon groups"
may have one or more (preferably one to three) substituents in substitutable positions.
Examples of such substituents include:
(1) C3_10 cycloalkyl groups (such as cyclopropyl and cyclohexyl);
(2) C6.14 aryl groups (such as phenyl and naphthyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, and (d) halogen atoms;
(3) aromatic heterocyclic groups (such as thienyl, furyl, pyridyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, tetrazolyl, oxadiazolyl, pyrazinyl, quinolyl, and indolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, and (d) halogen atoms;
(4) non-aromatic heterocyclic groups (such as tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, dioxolyl, dioxolanyl, 1,3-dihydro-2-benzofuranyl, thiazolidinyl, and thiazolinyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C 1.6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, (d) C 1.6 alkyl-carbonyl groups, (e) C 1.6 alkyl-sulfonyl groups, (f) oxo group, and (g) halogen atoms;
(5) amino group which may be mono- or di-substituted with substituents selected from (a) C 1.6 alkyl groups, (b) C1_6 alkyl-carbonyl groups, (c) C1_6 alkoxy-carbonyl groups, (d) C6_14 aryl-carbonyl groups (such as benzoyl), (e) C7_13 aralkyl-carbonyl groups (such as benzylcarbonyl and phenethylcarbonyl), (f) carbamoyl groups (such as carbamoyl, methylcarbamoyl, benzylcarbamoyl, and dimethylcarbamoyl) which may be mono- or di-substituted with substituents selected from C1_6 alkyl groups, C6_14 aryl groups, and C7_13 aralkyl groups;
(g) C1_6 alkylsulfonyl groups (such as methylsulfonyl, ethylsulfonyl, and isopropylsulfonyl), (h) C6_14 arylsulfonyl groups (such as benzenesulfonyl, toluenesulfonyl, 1-naphthalenesulfonyl, and 2-naphthalenesulfonyl), and (i) C7_13 aralkylsulfonyl groups (such as benzylsulfonyl);
(6) amidino group;
[0025]
(7) C1_6 alkyl-carbonyl groups which may be substituted with one or more (preferably one to three) halogen atoms;
(8) C1_6 alkoxy-carbonyl groups which may be substituted with one or more (preferably one to three) halogen atoms;
(9) aromatic heterocyclic-carbonyl groups (such as thienylcarbonyl and indolylcarbonyl) which may be substituted with one or more (preferably one to three) amino groups (the amino groups may be mono- or di-substituted with substituents selected from C1.6 alkyl groups and aromatic heterocyclic-sulfonyl groups (such as thienylsulfonyl));
(10) non-aromatic heterocyclic-carbonyl groups (such as morpholinylcarbonyl and pyrrolidinocarbonyl);
(11) C1_6 alkylsulfonyl groups (such as methylsulfonyl and ethylsulfonyl) which may be substituted with one or more (preferably one to three) halogen atoms;
(12) carbamoyl groups which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) C6_14 aryl groups (such as phenyl), (c) C7_13 aralkyl groups (such as benzyl), and (d) aromatic heterocyclic-C1_6 alkyl groups (such as furfuryl);
(13) thiocarbamoyl groups which may be mono- or di-substituted with C1_6 alkyl groups optionally substituted with one or more (preferably one to three) halogen atoms;
(14) sulfamoyl groups which may be mono- or di-substituted with C16 alkyl groups optionally substituted with one or more (preferably one to three) halogen atoms;
(15) carboxy groups;
(16) hydroxy group;
(17) C 1.6 alkoxy groups which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms, (b) carboxy groups, (c) C 1.6 alkoxy groups, and (d) C 1.6 alkoxy-carbonyl groups;
(18) C2_6 alkenyloxy groups (such as ethenyloxy) which may be substituted with one or more (preferably one to three) halogen atoms;
(19) C3_10 cycloalkyloxy groups (such as cyclohexyloxy);
(20)C7-13 aralkyloxy groups (such as benzyloxy) which may be substituted with one or more (preferably one to three) halogen atoms;
(21) C6_14 aryloxy groups (such as phenyloxy and naphthyloxy);
(22) C 1.6 alkyl-carbonyloxy groups (such as acetyloxy and tert-butylcarbonyloxy);
[0026]
(23) mercapto groups;
(24)C 1-6alkylthio groups (such as methylthio and ethylthio) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms, and (b) C6_14 aryl groups;
(25) C6_14 arylthio groups (such as phenylthio and naphthylthio);
(26) aromatic heterocyclic thio groups (such as tetrazolylthio) which may be substituted with one or more (preferably one to three) C1_6 alkyl groups;
(27) sulfo groups;
(28) cyano group;
(29) azide groups;
(30) nitro groups;
(31) nitroso groups;
(32) halogen atoms;
(33) C1_6 alkylsulfinyl groups (such as methylsulfinyl);
(34) oxo group;
(35)C3-1 Ocycloalkyl-C1_6 alkyloxy groups (such as cyclopropylmethyloxy);
(36)C 1-3 alkylenedioxy groups;
(37) aromatic heterocyclic-carbonylthio groups (such as indolylcarbonylthio) which may be substituted with one or more (preferably one to three) amino group [the amino group may be mono- or di-substituted with substituents selected from C1_6 alkyl groups and aromatic heterocyclic-sulfonyl groups (such as thienylsulfonyl)];
(38) formyl groups;
(39) aromatic heterocyclic-oxo groups (such as pyrimidyloxy and pyrazinyloxy);
[0027]
[0027]
(40) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms, (b) carboxy groups, (c) hydroxy group, (d) C1_6 alkoxy groups which may be substituted with one or more (preferably one to three) substituents selected from carboxy groups and C1_6 alkoxy-carbonyl groups, (e) C1_6 alkoxy-carbonyl groups, (f) C1_6 alkyl-carbonyloxy groups (such as acetyloxy and tert-butylcarbonyloxy), (g) carbamoyl groups which may be mono- or di-substituted with substituents selected from C1.6 alkyl, C1_6 alkylsulfonyl groups, and amino group, (h) aromatic heterocyclic groups (such as thienyl, tetrazolyl, and imidazolyl) which may be substituted with one or more (preferably one to three) C1_6 alkyl groups, (i) non-aromatic heterocyclic groups (such as tetrahydrofuranyl, piperidino, piperazinyl, morpholinyl, dihydrooxadiazolyl, and hexahydropyrazinooxazinyl (such as hexahydropyrazino [2,1 -c] [ 1,4] oxazinyl)) which may be substituted with one to three substituents selected from C 1.6 alkyl-carbonyl groups and oxo group, (j) amino group which may be mono- or di-substituted with C1_6 alkyl groups (the C1_6 alkyl groups may be substituted with one or more (preferably one to three) substituents selected from non-aromatic heterocyclic groups (such as morpholinyl), C1_6 alkoxy groups, and C1_6 alkylsulfonyl groups), (k) C1_6 alkylsulfonyl groups which may be substituted with one or more (preferably one to three) carboxy groups, (1) C1_6 alkylthio groups which may be substituted with one or more (preferably one to three) substituents selected from carboxy groups, C16 alkoxy-carbonyl groups, hydroxy group, and carbamoyl groups, (m) phosphono groups which may be mono- or di-substituted with C 1.6 alkyl groups, (n) non-aromatic heterocyclic-carbonyl groups (such as morpholinylcarbonyl), (o) cyano group, and (p) C6_14 aryloxy groups which may be substituted with one to three substituents selected from carboxy groups and C1_6 alkoxy-carbonyl groups;
(41) C2_6 alkenyl groups (such as ethenyl and 1-propenyl) which may be substituted with one to three substituents selected from (a) halogen atoms, (b) carboxy groups, (c) C1_6 alkoxy-carbonyl groups, and (d) carbamoyl groups; and (42)C7-13 aralkyl groups (such as benzyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) C1_6 alkyl groups which may be substituted with one or more (preferably one to three) halogen atoms, (b) hydroxy group, (c) C1_6 alkoxy groups, and (d) halogen atoms.
[0028]
Unless otherwise noted, examples of the "heterocyclic groups" (and "heterocyclic-in substituents) of the "optionally substituted heterocyclic groups" used herein include five- to twelve-membered (preferably five- to eight-membered) aromatic heterocyclic groups (heteroaryl groups) or saturated or unsaturated non-aromatic heterocyclic groups (aliphatic heterocyclic groups) having one or more (preferably one to four, and even more preferably one or two) hetero atoms selected from oxygen atom, optionally oxidized sulfur atoms, and nitrogen atom or the like (preferably oxygen atom, sulfur atom, and nitrogen atom or the like) as the atoms (ring atoms) forming the ring system.
Unless otherwise noted, examples of the "five- to ten-membered heterocyclic groups" or "five-to ten-membered heterocyclic-" in substituents used herein include such "heterocyclic groups" that have five to ten members.
Unless otherwise noted, examples of the "five- to six-membered heterocycles"
or "five-to six-membered heterocyclic-" in substituents used herein include such "heterocyclic groups" that have five to six members.
[0029]
Unless otherwise noted, examples of the "aromatic heterocyclic groups" (and "aromatic heterocyclic-" in substituents) used herein are five- to twelve-membered (preferably five- to eight-membered) and have one or more (preferably one to four, and more preferably one or two) hetero atoms selected from oxygen atom, optionally oxidized sulfur atoms, and nitrogen atom or the like (preferably oxygen atom, sulfur atom, and nitrogen atom or the like) as the atoms (ring atoms) forming the ring system.
Examples thereof include monocyclic aromatic heterocyclic groups (examples include five- or six-membered monocyclic aromatic heterocyclic groups such as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl) and fused aromatic heterocyclic groups (examples include eight- to twelve-membered fused aromatic heterocyclic groups such as benzofuranyl, isobenzofuranyl, benzothienyl, indolyl, isoindolyl, 1 H-indazolyl, benzindazolyl, benzoxazolyl, 1,2-benzoisoxazolyl, benzothiazolyl, benzopyranyl, 1,2-benzoisothiazolyl, 1H-benzotriazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxazolinyl, phthalazinyl, naphthyridinyl, purinyl, pteridinyl, carbazolyl, a-carbolinyl, [3-carbolinyl, y-carbolinyl, acridinyl, phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiinyl, thianthrenyl, phenanthridinyl, phenanthrolinyl, indolizinyl, pyrrolo[I,2-b]pyridazinyl, pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[1,5-a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrimidinyl, 1,2,4-triazolo[4,3-a]pyridyl and 1,2,4-triazolo[4,3-b]pyridazinyl.
Preferred examples of fused aromatic heterocyclic groups include heterocycles in which a five- or six-membered monocyclic aromatic heterocyclic group noted above is condensed with a benzene ring, or heterocycles in which two of the same or different five- or six-membered monocyclic aromatic heterocyclic groups noted above are condensed.
[0030]
Unless otherwise noted, examples of the "non-aromatic heterocyclic groups (aliphatic heterocyclic groups)" (and "non-aromatic heterocyclic-" in substituents) used herein are five- to twelve-membered (preferably five- to eight-membered) and have one or more (preferably one to four, and even more preferably one or two) hetero atoms selected from oxygen atom, optionally oxidized sulfur atoms, and nitrogen atom or the like (preferably oxygen atom, sulfur atom, and nitrogen atom or the like) as the atoms (ring atoms) forming the ring system. Examples thereof include three- to eight-membered (preferably five- or six-membered) saturated or unsaturated (preferably saturated) non-aromatic heterocyclic groups (aliphatic heterocyclic groups) such as oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperidyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, piperazinyl, and dihydro-1,2,4-oxadiazolyl.
Such "heterocyclic groups" and "five- or six-membered heterocyclic groups" may have one or more (preferably one to three) substituents in substitutable positions.
Examples of such substituents include the substituents given as examples for "C3_ to cycloalkyl groups, C3.10 cycloalkenyl groups, C4.10 cycloalkadienyl groups, C6_14 aryl groups, C7.13 aralkyl groups, C8_13 arylalkenyl groups, and C3_10 cycloalkyl-C1_6 alkyl groups" noted above.
[0031]
Unless otherwise noted, examples of such "substituents" for "optionally substituted amino group" include the substituents given as examples for "C3-10 cycloalkyl groups, C3_10 cycloalkenyl groups, C4_10 cycloalkadienyl groups, C6_14 aryl groups, C7_13 aralkyl groups, C8_13 arylalkenyl groups, and C3_10 cycloalkyl-C1_6 alkyl groups" noted above. The "amino groups" may have one or two such substituents in substitutable positions (that is, may be mono- or di-substituted).
[0032]
Unless otherwise noted, examples of the "acyl groups" used herein include optionally substituted hydrocarbon-carbonyl groups, optionally substituted heterocyclic-carbonyl groups, optionally substituted hydrocarbon-sulfonyl groups, and optionally substituted heterocyclic-sulfonyl groups.
Examples of the "optionally substituted hydrocarbon (groups)" in the "optionally substituted hydrocarbon-carbonyl groups" and "optionally substituted hydrocarbon-sulfonyl groups" include the groups given as examples of "optionally substituted C 1.14 hydrocarbon groups" above.
[0033]
The symbols in formula (I) above will be described.
[0034]
In formula (I), A represents -(CH2)õ-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-.
Here, Ra represents a hydrogen atom, halogen atom, optionally halogenated C1_6 alkyl group, or optionally halogenated C1_6 alkoxy group.
A is preferably -CO-NH- or -NH-CO-.
[0035]
In formula (I), B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-Rb, optionally substituted C1_14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group (preferably an optionally substituted five- or six-membered heterocyclic group), optionally substituted amino group, or acyl group.
Here, Rb represents a hydrogen atom, halogen atom, optionally halogenated C1_6 alkyl group, or optionally halogenated C 1.6 alkoxy group.
B is preferably (1) a hydrogen atom, (2) a C1_6 alkyl group (such as methyl, ethyl, n-propyl, or i-propyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as bromine and fluorine atoms), (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with one or more substituents (preferably one to three) selected from optionally hydroxy-substituted C1_6 alkyl groups (such as methyl and hydroxymethyl), C6_lo aryls (such as phenyl), C1_6 alkyl-carbonyls (such as acetyl), C1_6 alkoxy-carbonyls (such as tert-butoxycarbonyl), and carbamoyl groups, (e) C6_10 aryl groups (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as chlorine atom), hydroxy group, and amino group, (f) C1_6 alkylsulfanyl groups (such as methylsulfanyl), (g) C1_6 alkylsulfinyl groups (such as methylsulfinyl), (h) C1_6 alkylsulfonyl groups (such as methylsulfonyl), (i) C1_6 alkoxy groups (such as methoxy, ethoxy, and isopropoxy), (j) C6-1o aryloxy groups (such as phenoxy), (k) C7_13 aralkyloxy groups (such as benzyloxy), (1) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, pyrazolyl, imidazolyl, tetrazolyl, furyl, tetrahydrofuryl, thienyl, piperidyl, piperazinyl, tetrahydropyranyl, pyridyl, morpholinyl, pyrazinyl, tetrahydroquinolinyl, and benzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from C 1.6 alkyl groups (such as methyl and isopropyl), C16 alkyl-carbonyl groups (such as acetyl), and oxo group, and (m) carbamoyl groups, (3) a C2_6 alkenyl group (such as vinyl) which may be substituted with a five-or six-membered heterocyclic group (such as imidazolyl, furyl, and pyridyl), (4) a C3_10 cycloalkyl group (such as cyclopropyl), (5) a C6_10 aryl group (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) hydroxy group, (b) cyano group, (c) C1_6 alkoxy groups (such as methoxy), (d) mono- or di-C1_6 alkyl-amino (such as dimethylamino), and (e) C1_6 alkyl-carbonylamino (such as acetylamino), (6) an amino group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups (such as methyl and dimethylaminoethyl) which may be substituted with mono- or di-C1_6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, thiazole, thiazolidinyl, tetrahydrofuryl, pyridyl, morpholinyl, quinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as fluorine atom) and oxo group, or (7) a five- to ten-membered heterocyclic groups (such as pyrazolyl, piperidyl, imidazolyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furazanyl, piperidyl, pyridyl, tetrahydropyranyl, pyridazinyl, tetrahydroindolyl, isoindolyl, indazolyl, dihydrobenzofuranyl, benzothiophenyl, tetrahydroquinolinyl, and tetrahydrobenzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as fluorine atom), (b) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups (such as dimethylamino), (c) C1_6 alkoxy groups (such as methoxy), (d) C1_6 alkyl-carbonyl groups (such as acetyl), (e) C 1.6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), and (f) carbamoyl.
[0036]
B is also preferably:
(1) a hydrogen atom, (2) a C1_6 alkyl group (such as methyl, ethyl, n-propyl, or i-propyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as bromine and fluorine atoms), (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C 1.6 alkyl groups (such as methyl and hydroxyethyl), C6_10 aryls (such as phenyl), C1_6 alkoxy-carbonyls (such as tert-butoxycarbonyl), and C1_6 alkyl-carbonyls (such as acetyl), and carbamoyl groups, (e) C6_10 aryl groups (such as phenyl) which may be substituted with one to three substituents selected from halogen atoms (such as chlorine atom), hydroxy group, and mono- or di-C1_6 alkylamino groups, (f) C1_6 alkylsulfanyl groups (such as methylsulfanyl), (g) C1_6 alkylsulfinyl groups (such as methylsulfinyl), (h) C 1.6 alkoxy groups (such as methoxy, ethoxy, and isopropoxy), (i) C6_10 aryloxy groups (such as phenoxy), (j) C7_13 aralkyloxy groups (such as benzyloxy), (k) five- to ten-membered (preferably five- or six-membered) heterocyclic groups (such as pyrrolidinyl, pyrazolyl, imidazolyl, tetrazolyl, furyl, tetrahydrofuryl, thienyl, piperidyl, piperazinyl, tetrahydropyranyl, pyridyl, morpholinyl, pyrazinyl, tetrahydroquinolinyl, and benzoisoxazolyl) which may be substituted with one or more substituents selected from C1_6 alkyl groups (such as methyl and isopropyl), C1_6 alkyl-carbonyl groups (such as acetyl), and oxo group, and (1) carbamoyl, (3) a C2_6 alkenyl group (such as vinyl) which may be substituted with a five-or six-membered heterocyclic group (such as imidazolyl, furyl, and pyridyl), (4) a C3_10 cycloalkyl group (such as cyclopropyl) which may be substituted with a C1_6 alkoxy group (such as methoxy), (5) a C6-10 aryl group (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) hydroxy group, (b) cyano group, (c) C16 alkoxy groups (such as methoxy), (d) mono- or di-C1_6 alkyl-amino (such as dimethylamino), and (e) C1_6 alkyl-carbonylamino (such as acetylamino), (6) an amino group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups (such as methyl and dimethylaminoethyl) which may be substituted with mono- or di-C1_6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, thiazole, thiazolidinyl, tetrahydrofuryl, pyridyl, morpholinyl, quinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as fluorine atom) and oxo group, or (7) a five- to ten-membered heterocyclic groups (such as pyrazolyl, piperidyl, imidazolyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furazanyl, piperidyl, pyridyl, tetrahydropyranyl, pyridazinyl, tetrahydroindolyl, isoindolyl, indazolyl, dihydrobenzofuranyl, benzothiophenyl, tetrahydroquinolinyl, and tetrahydrobenzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as fluorine atom), (b) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups (such as dimethylamino), (c) C 1.6 alkoxy groups (such as methoxy), (d) C1_6 alkyl-carbonyl groups (such as acetyl), (e) C1_6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), (f) carbamoyl, (g) five- or six-membered heterocyclic groups (such as morpholinyl), and (h) oxo.
[0037]
In formula (I), X1, X2, X3, and X4 represent the same or different -CR"= or -N=.
Here, R" represents a hydrogen atom, halogen atom, optionally halogenated C1_6 alkyl group, or optionally halogenated C1_6 alkoxy group.
One or two of X1, X2, X3, and X4 are preferably -N=.
The moiety represented by the following in formula (I) is N N
or N
[0038]
In formula (I), Y is -0-, -S-, -S(O)-, -S(O)2-, or -NR''-.
Here, RI represents a hydrogen atom, halogen atom, optionally halogenated C1_6 alkyl group, or optionally halogenated C1_6 alkoxy group. RY is preferably a hydrogen atom.
Y is preferably -0-, -S-, or -NRY- (where RY is a hydrogen atom or C 1.6 alkyl group), more preferably -0-, -S-, or -NH-, and even more preferably -0-.
[0039]
In formula (I), Z is a bond, methylene, or ethylene (dimethylene). -Y-Z- is preferably not -NRY-(CH2)2-.
[0040]
In formula (I), Arl is a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more (preferably one to three) substituents selected from the same or different halogen atoms, optionally halogenated C
1.6 alkyl groups, and optionally halogenated C1-6 alkoxy groups.
[0041]
Examples of such "five- to ten-membered aromatic rings" include:
(1) C6_10 aromatic carbon rings (such as benzene and naphthalene), (2) five- or six-membered monocyclic aromatic heterocycles (including five-membered rings having one to four hetero atoms selected from nitrogen, oxygen, and sulfur atoms, such as thiophene, furan, oxazole, isoxazole, isothiazole, imidazole, pyrazole, triazole, and tetrazole; or six-membered rings having one to four hetero atoms selected from nitrogen, oxygen, and sulfur atoms other than carbon atoms, such as pyridine, pyrimidine, triazine, pyridazine, and pyrazine), and (3) seven- to ten-membered bicyclic aromatic heterocycles (including heterocycles in which a five- to six-membered monocyclic aromatic heterocycle noted above is condensed with a benzene ring, such as benzofuran, isobenzofuran, indole, isoindole, indazole, quinoline, and isoquinoline; or heterocycles in which two of the same or different five- or six-membered nitrogen-containing monocyclic aromatic heterocycles noted above are condensed, such as indolizine and naphthyridine).
The "five- to ten-membered aromatic ring" is preferably benzene, for example.
The "five- to ten-membered aromatic ring" is preferably not substituted or has one to three (more preferably one) of the substituents noted above. The substituents are preferably a halogen atom such as fluorine, for example.
[0042]
In formula (I), Ar 2 is a five- or six-membered aromatic ring which may be substituted with one or more substituents selected from the same or different halogen atoms, optionally halogenated C 1.6 alkyl groups, and optionally halogenated C1 .6 alkoxy groups, and may be condensed with an optionally substituted five- or six-membered ring.
[0028]
Unless otherwise noted, examples of the "heterocyclic groups" (and "heterocyclic-in substituents) of the "optionally substituted heterocyclic groups" used herein include five- to twelve-membered (preferably five- to eight-membered) aromatic heterocyclic groups (heteroaryl groups) or saturated or unsaturated non-aromatic heterocyclic groups (aliphatic heterocyclic groups) having one or more (preferably one to four, and even more preferably one or two) hetero atoms selected from oxygen atom, optionally oxidized sulfur atoms, and nitrogen atom or the like (preferably oxygen atom, sulfur atom, and nitrogen atom or the like) as the atoms (ring atoms) forming the ring system.
Unless otherwise noted, examples of the "five- to ten-membered heterocyclic groups" or "five-to ten-membered heterocyclic-" in substituents used herein include such "heterocyclic groups" that have five to ten members.
Unless otherwise noted, examples of the "five- to six-membered heterocycles"
or "five-to six-membered heterocyclic-" in substituents used herein include such "heterocyclic groups" that have five to six members.
[0029]
Unless otherwise noted, examples of the "aromatic heterocyclic groups" (and "aromatic heterocyclic-" in substituents) used herein are five- to twelve-membered (preferably five- to eight-membered) and have one or more (preferably one to four, and more preferably one or two) hetero atoms selected from oxygen atom, optionally oxidized sulfur atoms, and nitrogen atom or the like (preferably oxygen atom, sulfur atom, and nitrogen atom or the like) as the atoms (ring atoms) forming the ring system.
Examples thereof include monocyclic aromatic heterocyclic groups (examples include five- or six-membered monocyclic aromatic heterocyclic groups such as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl) and fused aromatic heterocyclic groups (examples include eight- to twelve-membered fused aromatic heterocyclic groups such as benzofuranyl, isobenzofuranyl, benzothienyl, indolyl, isoindolyl, 1 H-indazolyl, benzindazolyl, benzoxazolyl, 1,2-benzoisoxazolyl, benzothiazolyl, benzopyranyl, 1,2-benzoisothiazolyl, 1H-benzotriazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxazolinyl, phthalazinyl, naphthyridinyl, purinyl, pteridinyl, carbazolyl, a-carbolinyl, [3-carbolinyl, y-carbolinyl, acridinyl, phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiinyl, thianthrenyl, phenanthridinyl, phenanthrolinyl, indolizinyl, pyrrolo[I,2-b]pyridazinyl, pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[1,5-a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrimidinyl, 1,2,4-triazolo[4,3-a]pyridyl and 1,2,4-triazolo[4,3-b]pyridazinyl.
Preferred examples of fused aromatic heterocyclic groups include heterocycles in which a five- or six-membered monocyclic aromatic heterocyclic group noted above is condensed with a benzene ring, or heterocycles in which two of the same or different five- or six-membered monocyclic aromatic heterocyclic groups noted above are condensed.
[0030]
Unless otherwise noted, examples of the "non-aromatic heterocyclic groups (aliphatic heterocyclic groups)" (and "non-aromatic heterocyclic-" in substituents) used herein are five- to twelve-membered (preferably five- to eight-membered) and have one or more (preferably one to four, and even more preferably one or two) hetero atoms selected from oxygen atom, optionally oxidized sulfur atoms, and nitrogen atom or the like (preferably oxygen atom, sulfur atom, and nitrogen atom or the like) as the atoms (ring atoms) forming the ring system. Examples thereof include three- to eight-membered (preferably five- or six-membered) saturated or unsaturated (preferably saturated) non-aromatic heterocyclic groups (aliphatic heterocyclic groups) such as oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperidyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, piperazinyl, and dihydro-1,2,4-oxadiazolyl.
Such "heterocyclic groups" and "five- or six-membered heterocyclic groups" may have one or more (preferably one to three) substituents in substitutable positions.
Examples of such substituents include the substituents given as examples for "C3_ to cycloalkyl groups, C3.10 cycloalkenyl groups, C4.10 cycloalkadienyl groups, C6_14 aryl groups, C7.13 aralkyl groups, C8_13 arylalkenyl groups, and C3_10 cycloalkyl-C1_6 alkyl groups" noted above.
[0031]
Unless otherwise noted, examples of such "substituents" for "optionally substituted amino group" include the substituents given as examples for "C3-10 cycloalkyl groups, C3_10 cycloalkenyl groups, C4_10 cycloalkadienyl groups, C6_14 aryl groups, C7_13 aralkyl groups, C8_13 arylalkenyl groups, and C3_10 cycloalkyl-C1_6 alkyl groups" noted above. The "amino groups" may have one or two such substituents in substitutable positions (that is, may be mono- or di-substituted).
[0032]
Unless otherwise noted, examples of the "acyl groups" used herein include optionally substituted hydrocarbon-carbonyl groups, optionally substituted heterocyclic-carbonyl groups, optionally substituted hydrocarbon-sulfonyl groups, and optionally substituted heterocyclic-sulfonyl groups.
Examples of the "optionally substituted hydrocarbon (groups)" in the "optionally substituted hydrocarbon-carbonyl groups" and "optionally substituted hydrocarbon-sulfonyl groups" include the groups given as examples of "optionally substituted C 1.14 hydrocarbon groups" above.
[0033]
The symbols in formula (I) above will be described.
[0034]
In formula (I), A represents -(CH2)õ-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-.
Here, Ra represents a hydrogen atom, halogen atom, optionally halogenated C1_6 alkyl group, or optionally halogenated C1_6 alkoxy group.
A is preferably -CO-NH- or -NH-CO-.
[0035]
In formula (I), B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-Rb, -S-Rb, -S(O)-Rb, optionally substituted C1_14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group (preferably an optionally substituted five- or six-membered heterocyclic group), optionally substituted amino group, or acyl group.
Here, Rb represents a hydrogen atom, halogen atom, optionally halogenated C1_6 alkyl group, or optionally halogenated C 1.6 alkoxy group.
B is preferably (1) a hydrogen atom, (2) a C1_6 alkyl group (such as methyl, ethyl, n-propyl, or i-propyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as bromine and fluorine atoms), (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with one or more substituents (preferably one to three) selected from optionally hydroxy-substituted C1_6 alkyl groups (such as methyl and hydroxymethyl), C6_lo aryls (such as phenyl), C1_6 alkyl-carbonyls (such as acetyl), C1_6 alkoxy-carbonyls (such as tert-butoxycarbonyl), and carbamoyl groups, (e) C6_10 aryl groups (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as chlorine atom), hydroxy group, and amino group, (f) C1_6 alkylsulfanyl groups (such as methylsulfanyl), (g) C1_6 alkylsulfinyl groups (such as methylsulfinyl), (h) C1_6 alkylsulfonyl groups (such as methylsulfonyl), (i) C1_6 alkoxy groups (such as methoxy, ethoxy, and isopropoxy), (j) C6-1o aryloxy groups (such as phenoxy), (k) C7_13 aralkyloxy groups (such as benzyloxy), (1) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, pyrazolyl, imidazolyl, tetrazolyl, furyl, tetrahydrofuryl, thienyl, piperidyl, piperazinyl, tetrahydropyranyl, pyridyl, morpholinyl, pyrazinyl, tetrahydroquinolinyl, and benzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from C 1.6 alkyl groups (such as methyl and isopropyl), C16 alkyl-carbonyl groups (such as acetyl), and oxo group, and (m) carbamoyl groups, (3) a C2_6 alkenyl group (such as vinyl) which may be substituted with a five-or six-membered heterocyclic group (such as imidazolyl, furyl, and pyridyl), (4) a C3_10 cycloalkyl group (such as cyclopropyl), (5) a C6_10 aryl group (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) hydroxy group, (b) cyano group, (c) C1_6 alkoxy groups (such as methoxy), (d) mono- or di-C1_6 alkyl-amino (such as dimethylamino), and (e) C1_6 alkyl-carbonylamino (such as acetylamino), (6) an amino group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups (such as methyl and dimethylaminoethyl) which may be substituted with mono- or di-C1_6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, thiazole, thiazolidinyl, tetrahydrofuryl, pyridyl, morpholinyl, quinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as fluorine atom) and oxo group, or (7) a five- to ten-membered heterocyclic groups (such as pyrazolyl, piperidyl, imidazolyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furazanyl, piperidyl, pyridyl, tetrahydropyranyl, pyridazinyl, tetrahydroindolyl, isoindolyl, indazolyl, dihydrobenzofuranyl, benzothiophenyl, tetrahydroquinolinyl, and tetrahydrobenzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as fluorine atom), (b) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups (such as dimethylamino), (c) C1_6 alkoxy groups (such as methoxy), (d) C1_6 alkyl-carbonyl groups (such as acetyl), (e) C 1.6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), and (f) carbamoyl.
[0036]
B is also preferably:
(1) a hydrogen atom, (2) a C1_6 alkyl group (such as methyl, ethyl, n-propyl, or i-propyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as bromine and fluorine atoms), (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C 1.6 alkyl groups (such as methyl and hydroxyethyl), C6_10 aryls (such as phenyl), C1_6 alkoxy-carbonyls (such as tert-butoxycarbonyl), and C1_6 alkyl-carbonyls (such as acetyl), and carbamoyl groups, (e) C6_10 aryl groups (such as phenyl) which may be substituted with one to three substituents selected from halogen atoms (such as chlorine atom), hydroxy group, and mono- or di-C1_6 alkylamino groups, (f) C1_6 alkylsulfanyl groups (such as methylsulfanyl), (g) C1_6 alkylsulfinyl groups (such as methylsulfinyl), (h) C 1.6 alkoxy groups (such as methoxy, ethoxy, and isopropoxy), (i) C6_10 aryloxy groups (such as phenoxy), (j) C7_13 aralkyloxy groups (such as benzyloxy), (k) five- to ten-membered (preferably five- or six-membered) heterocyclic groups (such as pyrrolidinyl, pyrazolyl, imidazolyl, tetrazolyl, furyl, tetrahydrofuryl, thienyl, piperidyl, piperazinyl, tetrahydropyranyl, pyridyl, morpholinyl, pyrazinyl, tetrahydroquinolinyl, and benzoisoxazolyl) which may be substituted with one or more substituents selected from C1_6 alkyl groups (such as methyl and isopropyl), C1_6 alkyl-carbonyl groups (such as acetyl), and oxo group, and (1) carbamoyl, (3) a C2_6 alkenyl group (such as vinyl) which may be substituted with a five-or six-membered heterocyclic group (such as imidazolyl, furyl, and pyridyl), (4) a C3_10 cycloalkyl group (such as cyclopropyl) which may be substituted with a C1_6 alkoxy group (such as methoxy), (5) a C6-10 aryl group (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) hydroxy group, (b) cyano group, (c) C16 alkoxy groups (such as methoxy), (d) mono- or di-C1_6 alkyl-amino (such as dimethylamino), and (e) C1_6 alkyl-carbonylamino (such as acetylamino), (6) an amino group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups (such as methyl and dimethylaminoethyl) which may be substituted with mono- or di-C1_6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, thiazole, thiazolidinyl, tetrahydrofuryl, pyridyl, morpholinyl, quinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as fluorine atom) and oxo group, or (7) a five- to ten-membered heterocyclic groups (such as pyrazolyl, piperidyl, imidazolyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furazanyl, piperidyl, pyridyl, tetrahydropyranyl, pyridazinyl, tetrahydroindolyl, isoindolyl, indazolyl, dihydrobenzofuranyl, benzothiophenyl, tetrahydroquinolinyl, and tetrahydrobenzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as fluorine atom), (b) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups (such as dimethylamino), (c) C 1.6 alkoxy groups (such as methoxy), (d) C1_6 alkyl-carbonyl groups (such as acetyl), (e) C1_6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), (f) carbamoyl, (g) five- or six-membered heterocyclic groups (such as morpholinyl), and (h) oxo.
[0037]
In formula (I), X1, X2, X3, and X4 represent the same or different -CR"= or -N=.
Here, R" represents a hydrogen atom, halogen atom, optionally halogenated C1_6 alkyl group, or optionally halogenated C1_6 alkoxy group.
One or two of X1, X2, X3, and X4 are preferably -N=.
The moiety represented by the following in formula (I) is N N
or N
[0038]
In formula (I), Y is -0-, -S-, -S(O)-, -S(O)2-, or -NR''-.
Here, RI represents a hydrogen atom, halogen atom, optionally halogenated C1_6 alkyl group, or optionally halogenated C1_6 alkoxy group. RY is preferably a hydrogen atom.
Y is preferably -0-, -S-, or -NRY- (where RY is a hydrogen atom or C 1.6 alkyl group), more preferably -0-, -S-, or -NH-, and even more preferably -0-.
[0039]
In formula (I), Z is a bond, methylene, or ethylene (dimethylene). -Y-Z- is preferably not -NRY-(CH2)2-.
[0040]
In formula (I), Arl is a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more (preferably one to three) substituents selected from the same or different halogen atoms, optionally halogenated C
1.6 alkyl groups, and optionally halogenated C1-6 alkoxy groups.
[0041]
Examples of such "five- to ten-membered aromatic rings" include:
(1) C6_10 aromatic carbon rings (such as benzene and naphthalene), (2) five- or six-membered monocyclic aromatic heterocycles (including five-membered rings having one to four hetero atoms selected from nitrogen, oxygen, and sulfur atoms, such as thiophene, furan, oxazole, isoxazole, isothiazole, imidazole, pyrazole, triazole, and tetrazole; or six-membered rings having one to four hetero atoms selected from nitrogen, oxygen, and sulfur atoms other than carbon atoms, such as pyridine, pyrimidine, triazine, pyridazine, and pyrazine), and (3) seven- to ten-membered bicyclic aromatic heterocycles (including heterocycles in which a five- to six-membered monocyclic aromatic heterocycle noted above is condensed with a benzene ring, such as benzofuran, isobenzofuran, indole, isoindole, indazole, quinoline, and isoquinoline; or heterocycles in which two of the same or different five- or six-membered nitrogen-containing monocyclic aromatic heterocycles noted above are condensed, such as indolizine and naphthyridine).
The "five- to ten-membered aromatic ring" is preferably benzene, for example.
The "five- to ten-membered aromatic ring" is preferably not substituted or has one to three (more preferably one) of the substituents noted above. The substituents are preferably a halogen atom such as fluorine, for example.
[0042]
In formula (I), Ar 2 is a five- or six-membered aromatic ring which may be substituted with one or more substituents selected from the same or different halogen atoms, optionally halogenated C 1.6 alkyl groups, and optionally halogenated C1 .6 alkoxy groups, and may be condensed with an optionally substituted five- or six-membered ring.
[0043]
Preferred examples of "halogen atoms" as the substituent include chlorine and fluorine atoms.
Preferred examples of an "optionally halogenated C i _6 alkyl group" as the substituent include trifluoromethyl.
Preferred examples of an "optionally halogenated C _6 alkoxy" as the substituent include methoxy.
Examples of such "five- or six-membered aromatic rings" include:
(1) benzene, and (2) five- or six-membered monocyclic aromatic heterocycles (including five-membered rings having one to four hetero atoms selected from nitrogen, oxygen, and sulfur atoms, such as thiophene, furan, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, and tetrazole; or six-membered rings having one to four hetero atoms selected from nitrogen, oxygen, and sulfur atoms other than carbon atoms, such as pyridine, pyrimidine, triazine, pyridazine, and pyrazine).
Preferred examples of the "five- or six-membered aromatic ring" include furan, thiophene, benzene, and pyridine.
The "five- or six-membered aromatic ring" is preferably not substituted or has one to three (more preferably one or two) of the substituents noted above.
Examples of "optionally substituted five- or six-membered rings" with which the above "five- or six-membered aromatic ring" may be condensed include five- or six-membered saturated or unsaturated carbon rings or heterocycles (such as cyclopentene and pyrrole). The "five- or six-membered ring" may have one to three substituents, and examples of such substituents include ones that are the same as the substituents for the "optionally substituted five- or six-membered heterocyclic groups."
Preferred examples of "halogen atoms" as the substituent include chlorine and fluorine atoms.
Preferred examples of an "optionally halogenated C i _6 alkyl group" as the substituent include trifluoromethyl.
Preferred examples of an "optionally halogenated C _6 alkoxy" as the substituent include methoxy.
Examples of such "five- or six-membered aromatic rings" include:
(1) benzene, and (2) five- or six-membered monocyclic aromatic heterocycles (including five-membered rings having one to four hetero atoms selected from nitrogen, oxygen, and sulfur atoms, such as thiophene, furan, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, and tetrazole; or six-membered rings having one to four hetero atoms selected from nitrogen, oxygen, and sulfur atoms other than carbon atoms, such as pyridine, pyrimidine, triazine, pyridazine, and pyrazine).
Preferred examples of the "five- or six-membered aromatic ring" include furan, thiophene, benzene, and pyridine.
The "five- or six-membered aromatic ring" is preferably not substituted or has one to three (more preferably one or two) of the substituents noted above.
Examples of "optionally substituted five- or six-membered rings" with which the above "five- or six-membered aromatic ring" may be condensed include five- or six-membered saturated or unsaturated carbon rings or heterocycles (such as cyclopentene and pyrrole). The "five- or six-membered ring" may have one to three substituents, and examples of such substituents include ones that are the same as the substituents for the "optionally substituted five- or six-membered heterocyclic groups."
[0044]
Compound (I) is preferably a compound in which A is -CO-NH- or -NH-CO-;
B is (1) a hydrogen atom, (2) a C1_6 alkyl group (such as methyl, ethyl, n-propyl, or i-propyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as bromine and fluorine atoms), (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C1_6 alkyls (such as methyl and hydroxymethyl), C6.10 aryls (such as phenyl), C1_6 alkoxy-carbonyls (such as tert-butoxycarbonyl), and C1_6 alkyl-carbonyls (such as acetyl), and carbamoyl groups, (e) C6_10 aryl groups (such as phenyl) which may be substituted with one to three substituents selected from halogen atoms (such as chlorine atom), hydroxy group, and amino group, (f) C1_6 alkylsulfanyl groups (such as methylsulfanyl), (g) C1_6 alkylsulfinyl groups (such as methylsulfinyl), (h) C1_6 alkoxy groups (such as methoxy, ethoxy, and isopropoxy), (i) C6_10 aryloxy groups (such as phenoxy), (j) C7_13 aralkyloxy groups (such as benzyloxy), (k) five- to ten-membered (preferably five- or six-membered) heterocyclic groups (such as pyrrolidinyl, pyrazolyl, imidazolyl, tetrazolyl, furyl, tetrahydrofuryl, thienyl, piperidyl, piperazinyl, piperazinyl, tetrahydropyranyl, pyridyl, morpholinyl, pyrazinyl, tetrahydroquinolinyl, and benzoisoxazolyl) which may be substituted with one or more substituents selected from C1_6 alkyl groups (such as methyl and isopropyl), C1_6 alkyl-carbonyl groups (such as acetyl), and oxo group, and (1) carbamoyl, (3) a C2_6 alkenyl group (such as vinyl) which may be substituted with a five-or six-membered heterocyclic group(s) (such as imidazolyl, furyl, and pyridyl), (4) a C3_1 o cycloalkyl group (such as cyclopropyl), (5) a C6_10 aryl group (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) hydroxy group, (b) cyano group, (c) C16 alkoxy groups (such as methoxy), (d) mono- or di-C1_6 alkyl-amino (such as dimethylamino), and (e) C1_6 alkyl-carbonyl amino (such as acetylamino), (6) an amino group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups (such as methyl and dimethylaminoethyl) which may be substituted with mono- or di-C1_6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, thiazole, thiazolidinyl, tetrahydrofuryl, pyridyl, morpholinyl, quinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as fluorine atom) and oxo group, or (7) a five- to ten-membered heterocyclic groups (such as pyrazolyl, piperidyl, imidazolyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furazanyl, piperidyl, pyridyl, tetrahydropyranyl, pyridazinyl, tetrahydroindolyl, isoindolyl, indazolyl, dihydrobenzofuranyl, benzothiophenyl, tetrahydroquinolinyl, and tetrahydrobenzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as fluorine atom), (b) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups (such as dimethylamino), (c) C,.6 alkoxy groups (such as methoxy), (d) C1_6 alkyl-carbonyl groups (such as acetyl), (e) C1_6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), and (f) carbamoyl;
X', X2, X3, and X4 are the same or different -CR"= or -N=, and one or two of X', X2, X3, and X4 are -N=;
Y is -0-;
Ar' is a benzene ring or indole ring which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms and optionally halogenated C 1.6 alkyl groups;
Ar 2 is a five-or six-membered aromatic ring (such as furan, thiophene, benzene, and pyridine) which may be substituted with one or more (preferably one to three) substituents selected from the same or different halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with a five- or six-membered ring (such as cyclopentene and pyrrole); and Rx is a hydrogen atom or optionally halogenated C1_6 alkyl group (such as trifluoromethyl).
Compound (I) is preferably a compound in which A is -CO-NH- or -NH-CO-;
B is (1) a hydrogen atom, (2) a C1_6 alkyl group (such as methyl, ethyl, n-propyl, or i-propyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as bromine and fluorine atoms), (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C1_6 alkyls (such as methyl and hydroxymethyl), C6.10 aryls (such as phenyl), C1_6 alkoxy-carbonyls (such as tert-butoxycarbonyl), and C1_6 alkyl-carbonyls (such as acetyl), and carbamoyl groups, (e) C6_10 aryl groups (such as phenyl) which may be substituted with one to three substituents selected from halogen atoms (such as chlorine atom), hydroxy group, and amino group, (f) C1_6 alkylsulfanyl groups (such as methylsulfanyl), (g) C1_6 alkylsulfinyl groups (such as methylsulfinyl), (h) C1_6 alkoxy groups (such as methoxy, ethoxy, and isopropoxy), (i) C6_10 aryloxy groups (such as phenoxy), (j) C7_13 aralkyloxy groups (such as benzyloxy), (k) five- to ten-membered (preferably five- or six-membered) heterocyclic groups (such as pyrrolidinyl, pyrazolyl, imidazolyl, tetrazolyl, furyl, tetrahydrofuryl, thienyl, piperidyl, piperazinyl, piperazinyl, tetrahydropyranyl, pyridyl, morpholinyl, pyrazinyl, tetrahydroquinolinyl, and benzoisoxazolyl) which may be substituted with one or more substituents selected from C1_6 alkyl groups (such as methyl and isopropyl), C1_6 alkyl-carbonyl groups (such as acetyl), and oxo group, and (1) carbamoyl, (3) a C2_6 alkenyl group (such as vinyl) which may be substituted with a five-or six-membered heterocyclic group(s) (such as imidazolyl, furyl, and pyridyl), (4) a C3_1 o cycloalkyl group (such as cyclopropyl), (5) a C6_10 aryl group (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) hydroxy group, (b) cyano group, (c) C16 alkoxy groups (such as methoxy), (d) mono- or di-C1_6 alkyl-amino (such as dimethylamino), and (e) C1_6 alkyl-carbonyl amino (such as acetylamino), (6) an amino group which may be mono- or di-substituted with substituents selected from (a) C1_6 alkyl groups (such as methyl and dimethylaminoethyl) which may be substituted with mono- or di-C1_6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, thiazole, thiazolidinyl, tetrahydrofuryl, pyridyl, morpholinyl, quinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as fluorine atom) and oxo group, or (7) a five- to ten-membered heterocyclic groups (such as pyrazolyl, piperidyl, imidazolyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furazanyl, piperidyl, pyridyl, tetrahydropyranyl, pyridazinyl, tetrahydroindolyl, isoindolyl, indazolyl, dihydrobenzofuranyl, benzothiophenyl, tetrahydroquinolinyl, and tetrahydrobenzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as fluorine atom), (b) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups (such as dimethylamino), (c) C,.6 alkoxy groups (such as methoxy), (d) C1_6 alkyl-carbonyl groups (such as acetyl), (e) C1_6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), and (f) carbamoyl;
X', X2, X3, and X4 are the same or different -CR"= or -N=, and one or two of X', X2, X3, and X4 are -N=;
Y is -0-;
Ar' is a benzene ring or indole ring which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms and optionally halogenated C 1.6 alkyl groups;
Ar 2 is a five-or six-membered aromatic ring (such as furan, thiophene, benzene, and pyridine) which may be substituted with one or more (preferably one to three) substituents selected from the same or different halogen atoms, optionally halogenated C1_6 alkyl groups, and optionally halogenated C1_6 alkoxy groups, and which may be condensed with a five- or six-membered ring (such as cyclopentene and pyrrole); and Rx is a hydrogen atom or optionally halogenated C1_6 alkyl group (such as trifluoromethyl).
[0045]
Compound (I) is also preferably a compound in which A is -CO-NH- or -NH-CO-;
B is preferably:
(1) a hydrogen atom, (2) a C1_6 alkyl group (such as methyl, ethyl, n-propyl, or i-propyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as bromine and fluorine atoms), (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C 1.6 alkyl groups (such as methyl and hydroxyethyl), C6_10 aryls (such as phenyl), C1_6 alkoxy-carbonyls (such as tert-butoxycarbonyl), and C1_6 alkyl-carbonyls (such as acetyl), and carbamoyl groups, (e) C6_10 aryl groups (such as phenyl) which may be substituted with one to three substituents selected from halogen atoms (such as chlorine atom), hydroxy group, and mono- or di-C1_6 alkylamino groups, (f) C1_6 alkylsulfanyl groups (such as methylsulfanyl), (g) C1_6 alkylsulfinyl groups (such as methylsulfinyl), (h) CI.6 alkoxy groups (such as methoxy, ethoxy, and isopropoxy), (i) C6_10 aryloxy groups (such as phenoxy), (j) C7_13 aralkyloxy groups (such as benzyloxy), (k) five- to ten-membered (preferably five- or six-membered) heterocyclic groups (such as pyrrolidinyl, pyrazolyl, imidazolyl, tetrazolyl, furyl, tetrahydrofuryl, thienyl, piperidyl, piperazinyl, tetrahydropyranyl, pyridyl, morpholinyl, pyrazinyl, tetrahydroquinolinyl, and benzoisoxazolyl) which may be substituted with one or more substituents selected from C1_6 alkyl groups (such as methyl and isopropyl), C1_6 alkyl-carbonyl groups (such as acetyl), and oxo group, and (1) carbamoyl, (3) a C2_6 alkenyl group (such as vinyl) which may be substituted with a five-or six-membered heterocyclic group (such as imidazolyl, furyl, and pyridyl), (4) a C3_lo cycloalkyl group (such as cyclopropyl) which may be substituted with a C1_6 alkoxy group (such as methoxy), (5) a C6_lo aryl group (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) hydroxy group, (b) cyano group, (c) C1_6 alkoxy groups (such as methoxy), (d) mono- or di-C1_6 alkyl-amino (such as dimethylamino), and (e) C1.6 alkyl-carbonylamino (such as acetylamino), (6) an amino group which may be mono- or di-substituted with substituents selected from (a) C 1.6 alkyl groups (such as methyl and dimethylaminoethyl) which may be substituted with mono- or di-C1_6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, thiazole, thiazolidinyl, tetrahydrofuryl, pyridyl, morpholinyl, quinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as fluorine atom) and oxo group, or (7) a five- to ten-membered heterocyclic groups (such as pyrazolyl, piperidyl, imidazolyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furazanyl, piperidyl, pyridyl, tetrahydropyranyl, pyridazinyl, tetrahydroindolyl, isoindolyl, indazolyl, dihydrobenzofuranyl, benzothiophenyl, tetrahydroquinolinyl, and tetrahydrobenzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as fluorine atom), (b) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups (such as dimethylamino), (c) C1_6 alkoxy groups (such as methoxy), (d) C1_6 alkyl-carbonyl groups (such as acetyl), (e) C1_6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), and (f) carbamoyl, (g) five- or six-membered heterocyclic groups (such as morpholinyl), and (h) oxo;
X1, X2, X3, and X4 are the same or different -CR'= or -N=, and one or two of X1, X2, X3, and X4 are -N=;
Y is -0-, -S-, or -NH-;
Arl is a benzene ring or indole ring which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms and optionally halogenated C1_6 alkyl groups;
Ar 2 is a five-or six-membered aromatic ring (such as furan, thiophene, benzene, and pyridine) which may be substituted with one or more (preferably one to three) substituents selected from the same or different halogen atoms, optionally halogenated C16 alkyl groups, and optionally halogenated C 1.6 alkoxy groups, and which may be condensed with a five- or six-membered ring (such as cyclopentene and pyrrole); and R" is a hydrogen atom or optionally halogenated C1_6 alkyl group (such as trifluoromethyl).
Compound (I) is also preferably a compound in which A is -CO-NH- or -NH-CO-;
B is preferably:
(1) a hydrogen atom, (2) a C1_6 alkyl group (such as methyl, ethyl, n-propyl, or i-propyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as bromine and fluorine atoms), (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C 1.6 alkyl groups (such as methyl and hydroxyethyl), C6_10 aryls (such as phenyl), C1_6 alkoxy-carbonyls (such as tert-butoxycarbonyl), and C1_6 alkyl-carbonyls (such as acetyl), and carbamoyl groups, (e) C6_10 aryl groups (such as phenyl) which may be substituted with one to three substituents selected from halogen atoms (such as chlorine atom), hydroxy group, and mono- or di-C1_6 alkylamino groups, (f) C1_6 alkylsulfanyl groups (such as methylsulfanyl), (g) C1_6 alkylsulfinyl groups (such as methylsulfinyl), (h) CI.6 alkoxy groups (such as methoxy, ethoxy, and isopropoxy), (i) C6_10 aryloxy groups (such as phenoxy), (j) C7_13 aralkyloxy groups (such as benzyloxy), (k) five- to ten-membered (preferably five- or six-membered) heterocyclic groups (such as pyrrolidinyl, pyrazolyl, imidazolyl, tetrazolyl, furyl, tetrahydrofuryl, thienyl, piperidyl, piperazinyl, tetrahydropyranyl, pyridyl, morpholinyl, pyrazinyl, tetrahydroquinolinyl, and benzoisoxazolyl) which may be substituted with one or more substituents selected from C1_6 alkyl groups (such as methyl and isopropyl), C1_6 alkyl-carbonyl groups (such as acetyl), and oxo group, and (1) carbamoyl, (3) a C2_6 alkenyl group (such as vinyl) which may be substituted with a five-or six-membered heterocyclic group (such as imidazolyl, furyl, and pyridyl), (4) a C3_lo cycloalkyl group (such as cyclopropyl) which may be substituted with a C1_6 alkoxy group (such as methoxy), (5) a C6_lo aryl group (such as phenyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) hydroxy group, (b) cyano group, (c) C1_6 alkoxy groups (such as methoxy), (d) mono- or di-C1_6 alkyl-amino (such as dimethylamino), and (e) C1.6 alkyl-carbonylamino (such as acetylamino), (6) an amino group which may be mono- or di-substituted with substituents selected from (a) C 1.6 alkyl groups (such as methyl and dimethylaminoethyl) which may be substituted with mono- or di-C1_6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups (such as pyrrolidinyl, thiazole, thiazolidinyl, tetrahydrofuryl, pyridyl, morpholinyl, quinolinyl) which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms (such as fluorine atom) and oxo group, or (7) a five- to ten-membered heterocyclic groups (such as pyrazolyl, piperidyl, imidazolyl, furyl, tetrahydrofuryl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furazanyl, piperidyl, pyridyl, tetrahydropyranyl, pyridazinyl, tetrahydroindolyl, isoindolyl, indazolyl, dihydrobenzofuranyl, benzothiophenyl, tetrahydroquinolinyl, and tetrahydrobenzoisoxazolyl) which may be substituted with one or more (preferably one to three) substituents selected from (a) halogen atoms (such as fluorine atom), (b) C1_6 alkyl groups (such as methyl and isopropyl) which may be substituted with one or more (preferably one to three) substituents selected from hydroxy group and mono- or di-C1_6 alkylamino groups (such as dimethylamino), (c) C1_6 alkoxy groups (such as methoxy), (d) C1_6 alkyl-carbonyl groups (such as acetyl), (e) C1_6 alkoxy-carbonyl groups (such as tert-butoxycarbonyl), and (f) carbamoyl, (g) five- or six-membered heterocyclic groups (such as morpholinyl), and (h) oxo;
X1, X2, X3, and X4 are the same or different -CR'= or -N=, and one or two of X1, X2, X3, and X4 are -N=;
Y is -0-, -S-, or -NH-;
Arl is a benzene ring or indole ring which may be substituted with one or more (preferably one to three) substituents selected from halogen atoms and optionally halogenated C1_6 alkyl groups;
Ar 2 is a five-or six-membered aromatic ring (such as furan, thiophene, benzene, and pyridine) which may be substituted with one or more (preferably one to three) substituents selected from the same or different halogen atoms, optionally halogenated C16 alkyl groups, and optionally halogenated C 1.6 alkoxy groups, and which may be condensed with a five- or six-membered ring (such as cyclopentene and pyrrole); and R" is a hydrogen atom or optionally halogenated C1_6 alkyl group (such as trifluoromethyl).
[0046]
Compound (I) is, in particular, preferably 4-amino-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride (Working Example 33), N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3,N3-dimethyl-(3-alaninamide hydrochloride (Working Example 30), 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin-1-ylethyl)benzamide (Working Example 39), N-(2-hydroxyethyl)-3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzamide (Working Example 65), N-(2-hydroxyethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide (Working Example 69), 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide (Working Example 87), N-(2-aminoethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide hydrochloride (Working Example 81), 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide (Working Example 85), 3-(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide (Working Example 101), N-(2-pyrrolidin-l-ylethyl)-3-[2-({2-[3-(trifluoromethyl)phenyl]ethyl }
amino)pyrimidin-4-yl]benzamide (Working Example 146), N-cyclopropyl-3-{6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl} benzamide (Working Example 168), N-(3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)acetamide (Working Example 234), 3 -(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(pyridin-3 -ylmethyl)benzamide (Working Example 195), 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-(methylsulfinyl)ethyl)benzamide (Working Example 96), and 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide (Working Example 104).
Compound (I) is, in particular, preferably 4-amino-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride (Working Example 33), N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3,N3-dimethyl-(3-alaninamide hydrochloride (Working Example 30), 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin-1-ylethyl)benzamide (Working Example 39), N-(2-hydroxyethyl)-3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzamide (Working Example 65), N-(2-hydroxyethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide (Working Example 69), 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide (Working Example 87), N-(2-aminoethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide hydrochloride (Working Example 81), 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide (Working Example 85), 3-(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide (Working Example 101), N-(2-pyrrolidin-l-ylethyl)-3-[2-({2-[3-(trifluoromethyl)phenyl]ethyl }
amino)pyrimidin-4-yl]benzamide (Working Example 146), N-cyclopropyl-3-{6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl} benzamide (Working Example 168), N-(3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)acetamide (Working Example 234), 3 -(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(pyridin-3 -ylmethyl)benzamide (Working Example 195), 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-(methylsulfinyl)ethyl)benzamide (Working Example 96), and 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide (Working Example 104).
[0047]
Examples of salts for when compound (I) is in the form of a salt include salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids.
Preferable examples of salts with inorganic bases include salts with alkali metals such as sodium and potassium salts; salts with alkaline earth metals such as calcium and magnesium salts; aluminum salts; and ammonium salts.
Preferable examples of salts with organic bases include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, and N,N-dibenzylethylenediamine.
Preferable examples of salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, and phosphoric acid.
Preferable examples of salts with organic acids include salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
Preferable examples of salts with basic amino acids include salts with arginine, lysine, and ornithine.
Preferable examples of salts with acidic amino acids include salts with aspartic acid and glutamic acid.
Examples of salts for when compound (I) is in the form of a salt include salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids.
Preferable examples of salts with inorganic bases include salts with alkali metals such as sodium and potassium salts; salts with alkaline earth metals such as calcium and magnesium salts; aluminum salts; and ammonium salts.
Preferable examples of salts with organic bases include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, and N,N-dibenzylethylenediamine.
Preferable examples of salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, and phosphoric acid.
Preferable examples of salts with organic acids include salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
Preferable examples of salts with basic amino acids include salts with arginine, lysine, and ornithine.
Preferable examples of salts with acidic amino acids include salts with aspartic acid and glutamic acid.
[0048]
A prodrug of compound (I) is a compound that is converted to compound (I) by a reaction involving an enzyme, gastric acid, or the like under the physiological conditions in the body; that is, a compound that is converted to compound (I) by enzymatic oxidation, reduction, hydrolysis, or the like, or a compound that is converted to compound (I) by hydrolysis or the like involving gastric acid or the like.
Examples of prodrugs of compound (I) include compounds in which an amino group of compound (I) is acylated, alkylated, or phosphorylated (such as compounds in which an amino group of compound (I) is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo- 1,3-dioxolen-4-yl) methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated, or tert-butylated); compounds in which a hydroxy group of compound (I) is acylated, alkylated, phosphorylated, or borated (such as compounds in which a hydroxy group of compound (I) is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, or dimethylaminomethylcarbonylated); compounds in which a carboxyl group of compound (I) is esterified or amidated (such as compounds in which a carboxyl group of compound (I) is ethyl esterified, phenyl esterified, carboxymethyl esterified, dimethylaminomethyl esterified, pivaloyloxymethyl esterified, ethoxycarbonyloxyethyl esterified, phthalidyl esterified, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl esterified, cyclohexyloxycarbonylethyl esterified, or methylamidated). These compounds can be produced from compound (I) by a method that is well known per se.
A prodrug of compound (I) may also be a compound that is converted to compound (I) under physiological conditions as described in Development of Pharmaceutical Products, Vol. 7, Molecular Design, pp. 163-198, Hirokawa Shoten (1990).
Compound (I) may also be labeled with an isotope (such as 3H, ' 4C, 35S, and ' 25I) or the like.
Compound (I) may furthermore be an anhydride, a hydrate, or a solvate.
A prodrug of compound (I) is a compound that is converted to compound (I) by a reaction involving an enzyme, gastric acid, or the like under the physiological conditions in the body; that is, a compound that is converted to compound (I) by enzymatic oxidation, reduction, hydrolysis, or the like, or a compound that is converted to compound (I) by hydrolysis or the like involving gastric acid or the like.
Examples of prodrugs of compound (I) include compounds in which an amino group of compound (I) is acylated, alkylated, or phosphorylated (such as compounds in which an amino group of compound (I) is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo- 1,3-dioxolen-4-yl) methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated, or tert-butylated); compounds in which a hydroxy group of compound (I) is acylated, alkylated, phosphorylated, or borated (such as compounds in which a hydroxy group of compound (I) is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, or dimethylaminomethylcarbonylated); compounds in which a carboxyl group of compound (I) is esterified or amidated (such as compounds in which a carboxyl group of compound (I) is ethyl esterified, phenyl esterified, carboxymethyl esterified, dimethylaminomethyl esterified, pivaloyloxymethyl esterified, ethoxycarbonyloxyethyl esterified, phthalidyl esterified, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl esterified, cyclohexyloxycarbonylethyl esterified, or methylamidated). These compounds can be produced from compound (I) by a method that is well known per se.
A prodrug of compound (I) may also be a compound that is converted to compound (I) under physiological conditions as described in Development of Pharmaceutical Products, Vol. 7, Molecular Design, pp. 163-198, Hirokawa Shoten (1990).
Compound (I) may also be labeled with an isotope (such as 3H, ' 4C, 35S, and ' 25I) or the like.
Compound (I) may furthermore be an anhydride, a hydrate, or a solvate.
[0049]
Methods for producing compound (I) will be described. Compound (I) can be produced by reaction formulas 1 through 10 below or a method based thereon.
The compounds in the reaction formulas may also be in the form of salts. Examples of such salts include the same ones noted above for salts of compound (I).
[Reaction Formula 1]
B
(CH2)õ COL A
Art Art RaNHB
X1 X4 (III) 1 4 XXY,Z A X211 XY,Z 2 Ar (Ila) (I) (In the formula, L' represents a leaving group, and the other symbols are synonymous with the above.) Compound (I) can be produced by reacting compound (Ila) and compound (III) in the presence of a base or acid as needed.
Compound (III) is commercially available, and can be produced according to a method that is well known per se or a method based thereon.
Examples of the "leaving group" represented by L' include hydroxy group, halogen atoms (such as fluorine, chlorine, bromine, or iodine), optionally halogenated C1_5 alkylsulfonyloxy groups (such as methanesulfonyloxy, ethanesulfonyloxy, or trichloromethanesulfonyloxy), optionally substituted C6_,0 arylsulfonyloxy groups, optionally substituted phenyloxy groups, and optionally substituted benzothiazol-2-yl thio groups.
Examples of "optionally substituted C6_10 arylsulfonyloxy groups" include C6-arylsulfonyloxy groups (such as phenylsulfonyloxy and naphthylsulfonyloxy) which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include phenylsulfonyloxy, m-nitrophenylsulfonyloxy, and p-toluenesulfonyloxy.
Examples of "optionally substituted phenyloxy groups" include phenyloxy groups which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C 1.6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include phenyloxy and 4-nitrophenoxy.
Examples of optionally substituted benzothiazol-2-yl groups include benzothiazol-2-yl groups which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include benzothiazol-2-yl.
Compound (III) is used in an amount of about 1 to 10 mol, and preferably about I
to 2 mol, per mol compound (Ila).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N-methylpiperidine, N-methylpyrroli dine, and N-methylmorpholine; alkali metal hydrides such as sodium hydride and potassium hydride; metal amides such as sodium amide, lithium diisopropylamide, and lithium hexamethyldisilazide; and metal alkoxides such as sodium methoxide, sodium ethoxide, and potassium tributoxide.
The "base" is normally used in an amount of about 0.1 to 10 equivalents, and preferably 0.8 to 2 equivalents, relative to compound (Ila).
Examples of "acids" include methanesulfonic acid, p-toluenesulfonic acid, and camphorsulfonic acid.
The "acid" is normally used in an amount of about 0.1 to 10 equivalents, and preferably 0.8 to 3 equivalents, relative to compound (Ila).
It is advantageous to carry out the reaction without a solvent or with a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress: water; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; hydrocarbons such as benzene, toluene, cyclohexane, and hexane;
amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; sulfoxides such as dimethyl sulfoxide; and nitrogen-containing aromatic hydrocarbons such as pyridine, lutidine, and quinoline.
The reaction temperature is generally in the range of about -40 to 150 C, and preferably 0 to 100 C.
The reaction time is generally in the range of 5 minutes to 24 hours, and preferably minutes to 5 hours.
When L1 is OH, compound (IIa) may be reacted with compound (III) in the presence of an appropriate condensation agent as an alternative method.
Compound (III) is generally used in an amount of about 0.8 to about 10 mol, and preferably about 0.8 to about 2 mol, per mol compound (IIa).
Examples of "condensation agents" include N,N'-carbodiimides such as N,N'-dicyclohexyl carbodiimide and I -ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC); azolides such as N,N'-carbonylimidazole; 2-halogenopyridinium salts such as 2-chloro-l-methyl pyridinium iodide and 2-fluoro-l-methyl pyridinium iodide; and other compounds such as N-ethoxycarbonyl-2-ethoxy- 1,2-dihydroquinoline, diethyl cyanophosphate, phosphorus oxychloride, and acetic anhydride.
The "condensation agent" is generally used in an amount of about 0.8 to about mol, and preferably about 1 to about 3 mol, per mol compound (IIa).
The reaction may also be carried out in the presence of a base as needed.
Examples of "bases" include basic salts such as potassium acetate and sodium acetate;
and tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyl dimethylamine, 4-dimethylaminopyridine, N-methylpiperidine, N-methylpyrrolidine, and N-methylmorpholine. The reaction may also be carried out in the presence of a condensation accelerator such as 1-hydroxy-1 H-benzotriazole (HOBt) monohydrate as needed.
The "base" is generally used in an amount of about 0.5 to about 5 mol, and preferably about 2 to about 3 mol, per mol compound (IIa).
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such a solvent include the following solvents or mixtures thereof:
alcohols such as methanol, ethanol, and propanol; hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxy ethane; amides such as N,N-dimethyl formamide, N,N-dimethyl acetamide, hexamethyl phosphoric triamide, and 1-methyl pyrrolidin-2-one; sulfoxides such as dimethyl sulfoxide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and acid anhydrides such as acetic anhydride.
The reaction time is generally about 10 min to about 48 hours, and preferably about 30 min to about 24 hours.
The reaction temperature is generally in the range of about -20 to about 150 C, and preferably about 0 to about 100 C.
The reaction time can be shortened using a microwave reactor or the like.
The compound (I) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
Methods for producing compound (I) will be described. Compound (I) can be produced by reaction formulas 1 through 10 below or a method based thereon.
The compounds in the reaction formulas may also be in the form of salts. Examples of such salts include the same ones noted above for salts of compound (I).
[Reaction Formula 1]
B
(CH2)õ COL A
Art Art RaNHB
X1 X4 (III) 1 4 XXY,Z A X211 XY,Z 2 Ar (Ila) (I) (In the formula, L' represents a leaving group, and the other symbols are synonymous with the above.) Compound (I) can be produced by reacting compound (Ila) and compound (III) in the presence of a base or acid as needed.
Compound (III) is commercially available, and can be produced according to a method that is well known per se or a method based thereon.
Examples of the "leaving group" represented by L' include hydroxy group, halogen atoms (such as fluorine, chlorine, bromine, or iodine), optionally halogenated C1_5 alkylsulfonyloxy groups (such as methanesulfonyloxy, ethanesulfonyloxy, or trichloromethanesulfonyloxy), optionally substituted C6_,0 arylsulfonyloxy groups, optionally substituted phenyloxy groups, and optionally substituted benzothiazol-2-yl thio groups.
Examples of "optionally substituted C6_10 arylsulfonyloxy groups" include C6-arylsulfonyloxy groups (such as phenylsulfonyloxy and naphthylsulfonyloxy) which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include phenylsulfonyloxy, m-nitrophenylsulfonyloxy, and p-toluenesulfonyloxy.
Examples of "optionally substituted phenyloxy groups" include phenyloxy groups which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C 1.6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include phenyloxy and 4-nitrophenoxy.
Examples of optionally substituted benzothiazol-2-yl groups include benzothiazol-2-yl groups which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include benzothiazol-2-yl.
Compound (III) is used in an amount of about 1 to 10 mol, and preferably about I
to 2 mol, per mol compound (Ila).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N-methylpiperidine, N-methylpyrroli dine, and N-methylmorpholine; alkali metal hydrides such as sodium hydride and potassium hydride; metal amides such as sodium amide, lithium diisopropylamide, and lithium hexamethyldisilazide; and metal alkoxides such as sodium methoxide, sodium ethoxide, and potassium tributoxide.
The "base" is normally used in an amount of about 0.1 to 10 equivalents, and preferably 0.8 to 2 equivalents, relative to compound (Ila).
Examples of "acids" include methanesulfonic acid, p-toluenesulfonic acid, and camphorsulfonic acid.
The "acid" is normally used in an amount of about 0.1 to 10 equivalents, and preferably 0.8 to 3 equivalents, relative to compound (Ila).
It is advantageous to carry out the reaction without a solvent or with a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress: water; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; hydrocarbons such as benzene, toluene, cyclohexane, and hexane;
amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; sulfoxides such as dimethyl sulfoxide; and nitrogen-containing aromatic hydrocarbons such as pyridine, lutidine, and quinoline.
The reaction temperature is generally in the range of about -40 to 150 C, and preferably 0 to 100 C.
The reaction time is generally in the range of 5 minutes to 24 hours, and preferably minutes to 5 hours.
When L1 is OH, compound (IIa) may be reacted with compound (III) in the presence of an appropriate condensation agent as an alternative method.
Compound (III) is generally used in an amount of about 0.8 to about 10 mol, and preferably about 0.8 to about 2 mol, per mol compound (IIa).
Examples of "condensation agents" include N,N'-carbodiimides such as N,N'-dicyclohexyl carbodiimide and I -ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC); azolides such as N,N'-carbonylimidazole; 2-halogenopyridinium salts such as 2-chloro-l-methyl pyridinium iodide and 2-fluoro-l-methyl pyridinium iodide; and other compounds such as N-ethoxycarbonyl-2-ethoxy- 1,2-dihydroquinoline, diethyl cyanophosphate, phosphorus oxychloride, and acetic anhydride.
The "condensation agent" is generally used in an amount of about 0.8 to about mol, and preferably about 1 to about 3 mol, per mol compound (IIa).
The reaction may also be carried out in the presence of a base as needed.
Examples of "bases" include basic salts such as potassium acetate and sodium acetate;
and tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyl dimethylamine, 4-dimethylaminopyridine, N-methylpiperidine, N-methylpyrrolidine, and N-methylmorpholine. The reaction may also be carried out in the presence of a condensation accelerator such as 1-hydroxy-1 H-benzotriazole (HOBt) monohydrate as needed.
The "base" is generally used in an amount of about 0.5 to about 5 mol, and preferably about 2 to about 3 mol, per mol compound (IIa).
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such a solvent include the following solvents or mixtures thereof:
alcohols such as methanol, ethanol, and propanol; hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxy ethane; amides such as N,N-dimethyl formamide, N,N-dimethyl acetamide, hexamethyl phosphoric triamide, and 1-methyl pyrrolidin-2-one; sulfoxides such as dimethyl sulfoxide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and acid anhydrides such as acetic anhydride.
The reaction time is generally about 10 min to about 48 hours, and preferably about 30 min to about 24 hours.
The reaction temperature is generally in the range of about -20 to about 150 C, and preferably about 0 to about 100 C.
The reaction time can be shortened using a microwave reactor or the like.
The compound (I) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[0050]
[Reaction Formula 2]
B
NHRa A
Arl (IVa) (IVb) N) Art X1 ~X4 BCOL2 or (BCO)20 or B'NCO X1 ~Xa XZ X3~Y Z ' X?X3~_ Y"Z
" A~ Ar (IIb) (I) (In the formula, L2 represents a leaving group, B' represents a group derived by the removal of an amino group from B when B is an optionally substituted amino group, and the other symbols are synonymous with the above.) Compound (I) can be produced by allowing compound (IIb) to react with compound (IVa), compound (IVb), or compound (V) in the presence of a base or acid as needed.
Compound (IVa), compound (IVb), or compound (V) is commercially available, and can be produced according to a method that is well known per se or a method based thereon.
Examples of the "leaving group" represented by L2 include hydroxy group, halogen atoms (such as fluorine, chlorine, bromine, or iodine), optionally halogenated C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), optionally halogenated C1_5 alkylsulfonyloxy groups (such as methanesulfonyloxy, ethanesulfonyloxy, or trichloromethanesulfonyloxy), optionally substituted C6_10 arylsulfonyloxy groups, optionally substituted phenyloxy groups, and optionally substituted benzothiazol-2-yl thio groups.
Examples of "optionally substituted C6_10 arylsulfonyloxy groups" include C6-arylsulfonyloxy groups (such as phenylsulfonyloxy and naphthylsulfonyloxy) which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include phenylsulfonyloxy, m-nitrophenylsulfonyloxy, and p-toluenesulfonyloxy.
Examples of "optionally substituted phenyloxy groups" include phenyloxy groups which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include phenyloxy and 4-nitrophenoxy.
Examples of optionally substituted benzothiazol-2-ylthio groups include benzothiazol-2-ylthio groups which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro;
specific examples thereof include benzothiazol-2-ylthio.
Compound (IVa), compound (IVb), or compound (V) is used in an amount of about 1 to 10 mol, and preferably about 1 to 2 mol, per mol compound (IIb).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N-methylpiperidine, N-methylpyrrolidine, and N-methylmorpholine; alkali metal hydrides such as sodium hydride and potassium hydride; metal amides such as sodium amide, lithium diisopropylamide, and lithium hexamethyldisilazide; and metal alkoxides such as sodium methoxide, sodium ethoxide, and potassium tributoxide.
The "base" is normally used in an amount of about 0.1 to 10 equivalents, and preferably 0.8 to 2 equivalents, relative to compound (Ilb).
Examples of "acids" include methanesulfonic acid, p-toluenesulfonic acid, and camphorsulfonic acid.
The "acid" is normally used in an amount of about 0.1 to 10 equivalents, and preferably 0.8 to 3 equivalents, relative to compound (IIb).
It is advantageous to carry out the reaction without a solvent or with a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress: water; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; hydrocarbons such as benzene, toluene, cyclohexane, and hexane;
amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; sulfoxides such as dimethyl sulfoxide; and nitrogen-containing aromatic hydrocarbons such as pyridine, lutidine, and quinoline.
The reaction temperature is generally in the range of about -40 to 150 C, and preferably 0 to 100 C.
The reaction time is generally in the range of 5 minutes to 24 hours, and preferably minutes to 5 hours.
Compound (II) may be reacted with BCOOH in the presence of an appropriate condensation agent as an alternative method.
BCOOH is generally used in an amount of about 0.8 to about 10 mol, and preferably about 0.8 to about 2 mol, per mol compound (IIb).
Examples of "condensation agents" include N,N'-carbodiimides such as N,N'-dicyclohexyl carbodiimide and 1 -ethyl -3 -(3 -dimethylaminopropyl)carbodiimi de hydrochloride (WSC); azolides such as N,N'-carbonylimidazole; 2-halogenopyridinium salts such as 2-chloro-l-methyl pyridinium iodide and 2-fluoro-l-methyl pyridinium iodide; and other compounds such as N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, diethyl cyanophosphate, phosphorus oxychloride, and acetic anhydride.
The "condensation agent" is generally used in an amount of about 0.8 to about mol, and preferably about I to about 3 mol, per mol compound (IIb).
The reaction may also be carried out in the presence of a base as needed.
Examples of "bases" include basic salts such as such as potassium acetate and sodium acetate; and tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyl dimethylamine, 4-dimethylaminopyridine, N-methylpiperidine, N-methylpyrroli dine, and N-methylmorpholine. The reaction may also be carried out in the presence of a condensation accelerator such as 1-hydroxy-IH-benzotriazole (HOBt) monohydrate as needed.
The "base" is generally used in an amount of about 0.5 to about 5 mol, and preferably about 2 to about 3 mol, per mol compound (IIb).
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such a solvent include the following solvents or mixtures thereof:
alcohols such as methanol, ethanol, and propanol; hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxy ethane; amides such as N,N-dimethyl formamide, N,N-dimethyl acetamide, hexamethyl phosphoric triamide, and 1-methyl pyrrolidin-2-one; sulfoxides such as dimethyl sulfoxide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and acid anhydrides such as acetic anhydride.
The reaction time is generally about 10 min to about 48 hours, and preferably about 30 min to about 24 hours.
The reaction temperature is generally in the range of about -20 to about 150 C, and preferably about 0 to about 100 C.
The reaction time can be shortened using a microwave reactor or the like.
The compound (I) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[0051]
[Reaction Formula 3]
Compounds (I) in which B is -NHB' can also be produced by the process represented in the following reaction formula. In other words, compound (IIb) can be 2,2,2-trichloroethoxycarbonylated with 2,2,2-trichloroethyl chloroformate to synthesize compound (F), which can then be reacted with compound (VI) to obtain compound (I).
NHRa H B
Ar' N B'NH2 A
CC13CH2OCOCI ?yOCH2CCI3 Ar X 2 X3JY,Z Art X2-, XY.Z
Are (IIb) V) (I) (In the formula the symbols are synonymous with the above.) Compound (1') can be produced from compound (IIb) by the same method for producing compound (I) from compound (IIb) in reaction formula 2.
Compound (I) can be produced by reacting compound (I') with compound (VI) under basic conditions in a solvent that does not affect the reaction.
[Reaction Formula 2]
B
NHRa A
Arl (IVa) (IVb) N) Art X1 ~X4 BCOL2 or (BCO)20 or B'NCO X1 ~Xa XZ X3~Y Z ' X?X3~_ Y"Z
" A~ Ar (IIb) (I) (In the formula, L2 represents a leaving group, B' represents a group derived by the removal of an amino group from B when B is an optionally substituted amino group, and the other symbols are synonymous with the above.) Compound (I) can be produced by allowing compound (IIb) to react with compound (IVa), compound (IVb), or compound (V) in the presence of a base or acid as needed.
Compound (IVa), compound (IVb), or compound (V) is commercially available, and can be produced according to a method that is well known per se or a method based thereon.
Examples of the "leaving group" represented by L2 include hydroxy group, halogen atoms (such as fluorine, chlorine, bromine, or iodine), optionally halogenated C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), optionally halogenated C1_5 alkylsulfonyloxy groups (such as methanesulfonyloxy, ethanesulfonyloxy, or trichloromethanesulfonyloxy), optionally substituted C6_10 arylsulfonyloxy groups, optionally substituted phenyloxy groups, and optionally substituted benzothiazol-2-yl thio groups.
Examples of "optionally substituted C6_10 arylsulfonyloxy groups" include C6-arylsulfonyloxy groups (such as phenylsulfonyloxy and naphthylsulfonyloxy) which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include phenylsulfonyloxy, m-nitrophenylsulfonyloxy, and p-toluenesulfonyloxy.
Examples of "optionally substituted phenyloxy groups" include phenyloxy groups which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro; specific examples thereof include phenyloxy and 4-nitrophenoxy.
Examples of optionally substituted benzothiazol-2-ylthio groups include benzothiazol-2-ylthio groups which may have one to three substituents selected from C1_6 alkyls (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl), C1_6 alkoxy groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy), and nitro;
specific examples thereof include benzothiazol-2-ylthio.
Compound (IVa), compound (IVb), or compound (V) is used in an amount of about 1 to 10 mol, and preferably about 1 to 2 mol, per mol compound (IIb).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N-methylpiperidine, N-methylpyrrolidine, and N-methylmorpholine; alkali metal hydrides such as sodium hydride and potassium hydride; metal amides such as sodium amide, lithium diisopropylamide, and lithium hexamethyldisilazide; and metal alkoxides such as sodium methoxide, sodium ethoxide, and potassium tributoxide.
The "base" is normally used in an amount of about 0.1 to 10 equivalents, and preferably 0.8 to 2 equivalents, relative to compound (Ilb).
Examples of "acids" include methanesulfonic acid, p-toluenesulfonic acid, and camphorsulfonic acid.
The "acid" is normally used in an amount of about 0.1 to 10 equivalents, and preferably 0.8 to 3 equivalents, relative to compound (IIb).
It is advantageous to carry out the reaction without a solvent or with a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress: water; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; hydrocarbons such as benzene, toluene, cyclohexane, and hexane;
amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; sulfoxides such as dimethyl sulfoxide; and nitrogen-containing aromatic hydrocarbons such as pyridine, lutidine, and quinoline.
The reaction temperature is generally in the range of about -40 to 150 C, and preferably 0 to 100 C.
The reaction time is generally in the range of 5 minutes to 24 hours, and preferably minutes to 5 hours.
Compound (II) may be reacted with BCOOH in the presence of an appropriate condensation agent as an alternative method.
BCOOH is generally used in an amount of about 0.8 to about 10 mol, and preferably about 0.8 to about 2 mol, per mol compound (IIb).
Examples of "condensation agents" include N,N'-carbodiimides such as N,N'-dicyclohexyl carbodiimide and 1 -ethyl -3 -(3 -dimethylaminopropyl)carbodiimi de hydrochloride (WSC); azolides such as N,N'-carbonylimidazole; 2-halogenopyridinium salts such as 2-chloro-l-methyl pyridinium iodide and 2-fluoro-l-methyl pyridinium iodide; and other compounds such as N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, diethyl cyanophosphate, phosphorus oxychloride, and acetic anhydride.
The "condensation agent" is generally used in an amount of about 0.8 to about mol, and preferably about I to about 3 mol, per mol compound (IIb).
The reaction may also be carried out in the presence of a base as needed.
Examples of "bases" include basic salts such as such as potassium acetate and sodium acetate; and tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyl dimethylamine, 4-dimethylaminopyridine, N-methylpiperidine, N-methylpyrroli dine, and N-methylmorpholine. The reaction may also be carried out in the presence of a condensation accelerator such as 1-hydroxy-IH-benzotriazole (HOBt) monohydrate as needed.
The "base" is generally used in an amount of about 0.5 to about 5 mol, and preferably about 2 to about 3 mol, per mol compound (IIb).
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such a solvent include the following solvents or mixtures thereof:
alcohols such as methanol, ethanol, and propanol; hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxy ethane; amides such as N,N-dimethyl formamide, N,N-dimethyl acetamide, hexamethyl phosphoric triamide, and 1-methyl pyrrolidin-2-one; sulfoxides such as dimethyl sulfoxide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and acid anhydrides such as acetic anhydride.
The reaction time is generally about 10 min to about 48 hours, and preferably about 30 min to about 24 hours.
The reaction temperature is generally in the range of about -20 to about 150 C, and preferably about 0 to about 100 C.
The reaction time can be shortened using a microwave reactor or the like.
The compound (I) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[0051]
[Reaction Formula 3]
Compounds (I) in which B is -NHB' can also be produced by the process represented in the following reaction formula. In other words, compound (IIb) can be 2,2,2-trichloroethoxycarbonylated with 2,2,2-trichloroethyl chloroformate to synthesize compound (F), which can then be reacted with compound (VI) to obtain compound (I).
NHRa H B
Ar' N B'NH2 A
CC13CH2OCOCI ?yOCH2CCI3 Ar X 2 X3JY,Z Art X2-, XY.Z
Are (IIb) V) (I) (In the formula the symbols are synonymous with the above.) Compound (1') can be produced from compound (IIb) by the same method for producing compound (I) from compound (IIb) in reaction formula 2.
Compound (I) can be produced by reacting compound (I') with compound (VI) under basic conditions in a solvent that does not affect the reaction.
Compound (VI) is commercially available, and can also be produced according to a method that is well known per se or a method based thereon.
Compound (VI) is generally used in an amount of about 2 to 10 mol, and preferably about 2 to 5 mol, per mol compound (I').
Examples of the "base" include pyridine, triethylamine, diisopropylethylamine, potassium carbonate, sodium carbonate, sodium hydride, and potassium hydride.
The "base" is generally used in an amount of about 2 to 10 mol, and preferably about 2 to 5 mol, per mol compound (I').
Examples of solvents that do not affect the reaction include: ethers such as tetrahydrofuran; halogenated hydrocarbons such as chloroform; aromatic hydrocarbons such as toluene; amides such as N,N-dimethyl formamide; and sulfoxides such as dimethyl sulfoxide. These solvents may be used in the form of mixtures of two or more in suitable proportions.
The reaction temperature is generally in the range of about -50 to 200 C.
The reaction time is generally in the range of about 0.5 minutes to about 36 hours.
The compound (I) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[0052]
[Reaction Formula 4]
Compound (I) can be produced by the method represented in the following reaction formula, that is, Suzuki coupling.
B
I B
A
A
Art Art B(OR)2(VI1) X1~X4 1 4 X X2X3' Y-Z X2X3~Y.Z
Are Arz (Ilc) (I) (In the formula, L3 represents a leaving group, and the other symbols are synonymous with the above.) Compound (IIc) is reacted with a boronic acid (VII) such as a substituted boronic acid or substituted boronic ester in a solvent under basic conditions in the presence of a transition metal catalyst.
Compound (VII) can be procured in the form of a commercially available product, and can also be produced according to a method that is well known per se or a method based thereon.
Examples of the "leaving group" represented by L3 include halogen atoms (such as chlorine, bromine, and iodine), and optionally halogenated C1_5 alkylsulfonyloxy groups (such as trifluoromethanesulfonyloxy).
The "boronic acid" is generally used in an amount of about 0.5 to about 10 mol, and preferably about 0.9 to about 3 mol, per mol compound (IIc).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, and N-methylmorpholine; and metal alkoxides such as sodium methoxide, sodium ethoxide, sodium, tributoxide, and potassium tributoxide.
Examples of "transition metal catalysts" include palladium catalysts such as palladium acetate, palladium chloride, tetrakis(triphenylphosphine)palladium, 1,1-bis-(diphenylphosphino)ferrocene dichloropalladium, and dichlorobis(triphenylphosphine)palladium. The transition metal catalyst is generally used in an amount of about 0.001 to about 3 mol, and preferably about 0.02 to about 0.2 mol, per mol compound (IIc).
Examples of solvent include the following solvents or mixtures thereof: ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, and propanol;
hydrocarbons such as benzene, toluene, carbon disulfide, cyclohexane, and hexane; amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane;
nitriles such as acetonitrile and propionitrile; sulfoxides such as dimethyl sulfoxide; and water.
The reaction temperature is generally in the range of 0 to 250 C, and preferably 50 to 150 C. The reaction time is generally about 5 min to about 48 hours, and preferably about 30 min to about 24 hours.
The reaction time can be shortened using a microwave reactor or the like.
The product can be used as is, in the form of the reaction solution or in the form of a crude product, in subsequent reactions, but can be isolated from the reaction mixture by a conventional method and easily purified by a common separation technique (such as recrystallization, distillation, or chromatography).
[0053]
[Reaction Formula 5]
B B
A A
Art YH'Z Are Art (VIII) XI
4 1 " 4 X1 , X X
X X3LL3 X2IXY Z Are (lid) (I) (In the formula, the symbols are synonymous with the above.) Compound (I) can be produced by reacting compound (IId) and compound (VIII) in the presence of a base as needed. A copper catalyst such as copper or a copper salt may also be used as needed. Alternatively, the compound can also be produced by the Buchwald cross-coupling reaction.
[0054]
Compound (VIII) can be easily procured in the form of a commercially available product, and can also be produced according to a method that is well known per se or a method based thereon.
Compound (VI) is generally used in an amount of about 2 to 10 mol, and preferably about 2 to 5 mol, per mol compound (I').
Examples of the "base" include pyridine, triethylamine, diisopropylethylamine, potassium carbonate, sodium carbonate, sodium hydride, and potassium hydride.
The "base" is generally used in an amount of about 2 to 10 mol, and preferably about 2 to 5 mol, per mol compound (I').
Examples of solvents that do not affect the reaction include: ethers such as tetrahydrofuran; halogenated hydrocarbons such as chloroform; aromatic hydrocarbons such as toluene; amides such as N,N-dimethyl formamide; and sulfoxides such as dimethyl sulfoxide. These solvents may be used in the form of mixtures of two or more in suitable proportions.
The reaction temperature is generally in the range of about -50 to 200 C.
The reaction time is generally in the range of about 0.5 minutes to about 36 hours.
The compound (I) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[0052]
[Reaction Formula 4]
Compound (I) can be produced by the method represented in the following reaction formula, that is, Suzuki coupling.
B
I B
A
A
Art Art B(OR)2(VI1) X1~X4 1 4 X X2X3' Y-Z X2X3~Y.Z
Are Arz (Ilc) (I) (In the formula, L3 represents a leaving group, and the other symbols are synonymous with the above.) Compound (IIc) is reacted with a boronic acid (VII) such as a substituted boronic acid or substituted boronic ester in a solvent under basic conditions in the presence of a transition metal catalyst.
Compound (VII) can be procured in the form of a commercially available product, and can also be produced according to a method that is well known per se or a method based thereon.
Examples of the "leaving group" represented by L3 include halogen atoms (such as chlorine, bromine, and iodine), and optionally halogenated C1_5 alkylsulfonyloxy groups (such as trifluoromethanesulfonyloxy).
The "boronic acid" is generally used in an amount of about 0.5 to about 10 mol, and preferably about 0.9 to about 3 mol, per mol compound (IIc).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, and N-methylmorpholine; and metal alkoxides such as sodium methoxide, sodium ethoxide, sodium, tributoxide, and potassium tributoxide.
Examples of "transition metal catalysts" include palladium catalysts such as palladium acetate, palladium chloride, tetrakis(triphenylphosphine)palladium, 1,1-bis-(diphenylphosphino)ferrocene dichloropalladium, and dichlorobis(triphenylphosphine)palladium. The transition metal catalyst is generally used in an amount of about 0.001 to about 3 mol, and preferably about 0.02 to about 0.2 mol, per mol compound (IIc).
Examples of solvent include the following solvents or mixtures thereof: ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, and propanol;
hydrocarbons such as benzene, toluene, carbon disulfide, cyclohexane, and hexane; amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane;
nitriles such as acetonitrile and propionitrile; sulfoxides such as dimethyl sulfoxide; and water.
The reaction temperature is generally in the range of 0 to 250 C, and preferably 50 to 150 C. The reaction time is generally about 5 min to about 48 hours, and preferably about 30 min to about 24 hours.
The reaction time can be shortened using a microwave reactor or the like.
The product can be used as is, in the form of the reaction solution or in the form of a crude product, in subsequent reactions, but can be isolated from the reaction mixture by a conventional method and easily purified by a common separation technique (such as recrystallization, distillation, or chromatography).
[0053]
[Reaction Formula 5]
B B
A A
Art YH'Z Are Art (VIII) XI
4 1 " 4 X1 , X X
X X3LL3 X2IXY Z Are (lid) (I) (In the formula, the symbols are synonymous with the above.) Compound (I) can be produced by reacting compound (IId) and compound (VIII) in the presence of a base as needed. A copper catalyst such as copper or a copper salt may also be used as needed. Alternatively, the compound can also be produced by the Buchwald cross-coupling reaction.
[0054]
Compound (VIII) can be easily procured in the form of a commercially available product, and can also be produced according to a method that is well known per se or a method based thereon.
[0055]
Compound (VIII) is generally used in an amount of about 0.8 to about 10 mol, and preferably about 1 to about 5 mol, per mol compound (IId).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, and N-methylmorpholine; alkali metal hydrides such as sodium hydride and potassium hydride; metal amides such as sodium amide, lithium diisopropylamide, and lithium hexamethyldisilazide; and metal alkoxides such as sodium methoxide, sodium ethoxide, sodium tributoxide, and potassium tributoxide.
The "base" is generally used in an amount of about 0.8 to about 10 mol, and preferably about 1 to about 5 mol, per mol compound (Ild).
Compound (VIII) is generally used in an amount of about 0.8 to about 10 mol, and preferably about 1 to about 5 mol, per mol compound (IId).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, and N-methylmorpholine; alkali metal hydrides such as sodium hydride and potassium hydride; metal amides such as sodium amide, lithium diisopropylamide, and lithium hexamethyldisilazide; and metal alkoxides such as sodium methoxide, sodium ethoxide, sodium tributoxide, and potassium tributoxide.
The "base" is generally used in an amount of about 0.8 to about 10 mol, and preferably about 1 to about 5 mol, per mol compound (Ild).
[0056]
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress:
alcohols such as methanol, ethanol, and propanol; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; hydrocarbons such as benzene, toluene, cyclohexane, and hexane; amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and sulfoxides such as dimethyl sulfoxide.
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress:
alcohols such as methanol, ethanol, and propanol; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; hydrocarbons such as benzene, toluene, cyclohexane, and hexane; amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and sulfoxides such as dimethyl sulfoxide.
[0057]
Examples of "copper catalysts" include copper, copper halides (such as CuI, CuBr, and CuCI), and copper oxide (CuO).
The "copper catalyst" is generally used in an amount of about 0.1 to about 10 mol, and preferably about 0.5 to about 2 mol, per mol compound (IId).
Examples of "copper catalysts" include copper, copper halides (such as CuI, CuBr, and CuCI), and copper oxide (CuO).
The "copper catalyst" is generally used in an amount of about 0.1 to about 10 mol, and preferably about 0.5 to about 2 mol, per mol compound (IId).
[0058]
Examples of palladium catalysts for when compound (I) is synthesized by the Buchwald reaction include palladium acetate, palladium chloride, tetrakis(triphenylphosphine)palladium, bis(dibenzylideneacetone)palladium, and tris(dibenzylideneacetone)palladium, and examples of "ligands" include phosphines, preferably trialkylphosphines, triarylphosphines, and trialkoxyphosphines.
Examples of palladium catalysts for when compound (I) is synthesized by the Buchwald reaction include palladium acetate, palladium chloride, tetrakis(triphenylphosphine)palladium, bis(dibenzylideneacetone)palladium, and tris(dibenzylideneacetone)palladium, and examples of "ligands" include phosphines, preferably trialkylphosphines, triarylphosphines, and trialkoxyphosphines.
[0059]
The palladium catalyst is generally used in an amount of about 0.001 to about mol, and preferably about 0.01 to about 0.5 mol, per mol compound (IId). The "phosphine" is generally used in an amount of about 0.001 to about 10 mol, and preferably about 0.01 to about 1 mol, per mol compound (IId).
The palladium catalyst is generally used in an amount of about 0.001 to about mol, and preferably about 0.01 to about 0.5 mol, per mol compound (IId). The "phosphine" is generally used in an amount of about 0.001 to about 10 mol, and preferably about 0.01 to about 1 mol, per mol compound (IId).
[0060]
The reaction time is generally about 30 min to about 72 hours, and preferably about 1 hour to about 48 hours.
The reaction temperature is generally in the range of about -20 to about 200 C, and preferably about 0 to about 150 C.
The reaction time is generally about 30 min to about 72 hours, and preferably about 1 hour to about 48 hours.
The reaction temperature is generally in the range of about -20 to about 200 C, and preferably about 0 to about 150 C.
[0061]
The reaction time can be shortened using a microwave reactor or the like.
The reaction time can be shortened using a microwave reactor or the like.
[0062]
The product can be used as is, in the form of a reaction solution or in the form of a crude product, in subsequent reactions, but can be isolated from the reaction mixture by a conventional method and easily purified by a common separation technique (such as recrystallization, distillation, or chromatography).
The product can be used as is, in the form of a reaction solution or in the form of a crude product, in subsequent reactions, but can be isolated from the reaction mixture by a conventional method and easily purified by a common separation technique (such as recrystallization, distillation, or chromatography).
[0063]
[Reaction Formula 6]
B B
I
A A
Art L4"Z Are Art (IX) X1 x4 X1 Xa it X2\X3l yH X21X3~Y,Z Art (Ile) (1) Compound (I) can be produced by reacting compound (Ile) and compound (IX) in the presence of a base as needed.
Examples of the "leaving group" represented by L4 include hydroxy group, halogen atoms (such as fluorine, chlorine, bromine, and iodine), optionally halogenated C1_5 alkylsulfonyloxy groups (such as methanesulfonyloxy, ethanesulfonyloxy, and trichloromethanesulfonyloxy), and C6_10 arylsulfonyloxy groups which may have substituents. Examples of "optionally substituted C6_10 arylsulfonyloxy groups" include C6_10 arylsulfonyloxy groups (such as phenylsulfonyloxy and naphthylsulfonyloxy) which may have one to three substituents selected from C1-6 alkyl groups, C I-6 alkoxy groups, and nitro; specific examples thereof include phenylsulfonyloxy, m-nitrophenylsulfonyloxy, and p-toluenesulfonyloxy.
Compound (IX) is generally used in an amount of about 1.0 to 5.0 mol, and preferably about 1.0 to 2.0 mol, per mol compound (Ile).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperi dine, N-methylpyrrolidine, and N-methylmorpholine; alkali metal hydrides such as sodium hydride and potassium hydride; metal amides such as sodium amide, lithium diisopropylamide, and lithium hexamethyldisilazide; and metal alkoxides such as sodium methoxide, sodium ethoxide, and potassium tributoxide. The base is generally used in an amount of about 1.0 to 5.0 mol, and preferably about 1.0 to 2.0 mol, per mol compound (Ile).
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress:
alcohols such as methanol, ethanol, and propanol; ethers such as diethyl ether, tetrahydrofuran, dioxane, and 1,2-dimethoxyethane; hydrocarbons such as benzene, toluene, cyclohexane, and hexane; amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and sulfoxides such as dimethyl sulfoxide.
The reaction time is generally in the range of 30 minutes to 48 hours, and preferably 1 hour to 24 hours. The reaction temperature is generally in the range of -20 to 200 C, and preferably 0 to 150 C.
The Mitsunobu reaction (Synthesis, 1981, pages 1-27) can be used instead of the above reaction.
In this reaction, compound (Ile) is reacted with compound (IX) in which L4 is OH
in the presence of an azodicarboxylate (such as diethyl azodicarboxylate) and a phosphine (such as triphenylphosphine or tributylphosphine).
Compound (IX) in which L4 is OH is generally used in an amount of about 1.0 to 5.0 mol, and preferably about 1.0 to 2.0 mol, per mol compound (Ile).
The "azodicarboxylate" and "phosphine" are each generally used in an amount of about 1.0 to 5.0 mol, and preferably about 1.0 to 2.0 mol, per mol compound (Ile).
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress:
ethers such as diethyl ether, tetrahydrofuran, dioxane, and 1,2-dimethoxyethane;
hydrocarbons such as benzene, toluene, cyclohexane, and hexane; amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and sulfoxides such as dimethyl sulfoxide.
The reaction time is generally in the range of 5 minutes to 48 hours, and preferably 30 minutes to 24 hours. The reaction temperature is generally in the range of -20 to 200 C, and preferably 0 to 100 C.
[Reaction Formula 6]
B B
I
A A
Art L4"Z Are Art (IX) X1 x4 X1 Xa it X2\X3l yH X21X3~Y,Z Art (Ile) (1) Compound (I) can be produced by reacting compound (Ile) and compound (IX) in the presence of a base as needed.
Examples of the "leaving group" represented by L4 include hydroxy group, halogen atoms (such as fluorine, chlorine, bromine, and iodine), optionally halogenated C1_5 alkylsulfonyloxy groups (such as methanesulfonyloxy, ethanesulfonyloxy, and trichloromethanesulfonyloxy), and C6_10 arylsulfonyloxy groups which may have substituents. Examples of "optionally substituted C6_10 arylsulfonyloxy groups" include C6_10 arylsulfonyloxy groups (such as phenylsulfonyloxy and naphthylsulfonyloxy) which may have one to three substituents selected from C1-6 alkyl groups, C I-6 alkoxy groups, and nitro; specific examples thereof include phenylsulfonyloxy, m-nitrophenylsulfonyloxy, and p-toluenesulfonyloxy.
Compound (IX) is generally used in an amount of about 1.0 to 5.0 mol, and preferably about 1.0 to 2.0 mol, per mol compound (Ile).
Examples of "bases" include basic salts such as sodium carbonate, potassium carbonate, cesium carbonate, and sodium bicarbonate; aromatic amines such as pyridine and lutidine; tertiary amines such as triethylamine, tripropylamine, tributylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperi dine, N-methylpyrrolidine, and N-methylmorpholine; alkali metal hydrides such as sodium hydride and potassium hydride; metal amides such as sodium amide, lithium diisopropylamide, and lithium hexamethyldisilazide; and metal alkoxides such as sodium methoxide, sodium ethoxide, and potassium tributoxide. The base is generally used in an amount of about 1.0 to 5.0 mol, and preferably about 1.0 to 2.0 mol, per mol compound (Ile).
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress:
alcohols such as methanol, ethanol, and propanol; ethers such as diethyl ether, tetrahydrofuran, dioxane, and 1,2-dimethoxyethane; hydrocarbons such as benzene, toluene, cyclohexane, and hexane; amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and sulfoxides such as dimethyl sulfoxide.
The reaction time is generally in the range of 30 minutes to 48 hours, and preferably 1 hour to 24 hours. The reaction temperature is generally in the range of -20 to 200 C, and preferably 0 to 150 C.
The Mitsunobu reaction (Synthesis, 1981, pages 1-27) can be used instead of the above reaction.
In this reaction, compound (Ile) is reacted with compound (IX) in which L4 is OH
in the presence of an azodicarboxylate (such as diethyl azodicarboxylate) and a phosphine (such as triphenylphosphine or tributylphosphine).
Compound (IX) in which L4 is OH is generally used in an amount of about 1.0 to 5.0 mol, and preferably about 1.0 to 2.0 mol, per mol compound (Ile).
The "azodicarboxylate" and "phosphine" are each generally used in an amount of about 1.0 to 5.0 mol, and preferably about 1.0 to 2.0 mol, per mol compound (Ile).
It is advantageous to carry out the reaction using a solvent that is inert to the reaction. Examples of such solvents include, but are not particularly limited to, the following solvents or mixtures thereof, as long as the reaction can progress:
ethers such as diethyl ether, tetrahydrofuran, dioxane, and 1,2-dimethoxyethane;
hydrocarbons such as benzene, toluene, cyclohexane, and hexane; amides such as N,N-dimethyl formamide and N,N-dimethyl acetamide; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; nitriles such as acetonitrile and propionitrile; and sulfoxides such as dimethyl sulfoxide.
The reaction time is generally in the range of 5 minutes to 48 hours, and preferably 30 minutes to 24 hours. The reaction temperature is generally in the range of -20 to 200 C, and preferably 0 to 100 C.
[0064]
[Reaction Formula 7]
X1 ~Xa La Z Arz X ~X3 YH (IX) (X) L3 (CH2),COL' XXa YH'Z Are L3 Are X X3 L3 (VIII) X.IX4 B(OR)2 2 (XII) (XI) X ~XY,Z Arz (11c) (CH2),COL' L3 (CH2),COL' XXa Are (CH2)nCOL Z XAre YH 2 t' XX3 L3 B(OR)2 (XII) (VIII) X ~X3jlY,Z Arz Xi , Xa (XI) z 1I
X X3" \L3 (Ila) (XhIIa) La,Z Arz (CH2)nCOL' OL3 ~1J(CH2)nCOL1 Are X1-Xa B(OR)2 NO X1 X4 X X3i- YH 2 X X3il YH
(X) (XhIlb) Compound (Ile) can be produced from compound (X) by the same method for producing compound (I) from compound (Ile) in reaction formula 6, or from compound (XI) by the same method for producing compound (I) from compound (IId) in reaction formula 5.
Compound (XIIIa) can be produced from compound (XI) by the same method for producing compound (I) from compound (Ile) in reaction formula 4.
Compound (XIIIb) can be produced from compound (X) by the same method for producing compound (1) from compound (Ile) in reaction formula 4.
Compound (IIa) can be produced from compound (Ile) by the same method for producing compound (I) from compound (IIc) in reaction formula 4, from compound (XIIIa) by the same method for producing compound (I) from compound (IId) in reaction formula 5, or from compound (XIIIb) by the same method for producing compound (I) from compound (Ile) in reaction formula 6.
[Reaction Formula 7]
X1 ~Xa La Z Arz X ~X3 YH (IX) (X) L3 (CH2),COL' XXa YH'Z Are L3 Are X X3 L3 (VIII) X.IX4 B(OR)2 2 (XII) (XI) X ~XY,Z Arz (11c) (CH2),COL' L3 (CH2),COL' XXa Are (CH2)nCOL Z XAre YH 2 t' XX3 L3 B(OR)2 (XII) (VIII) X ~X3jlY,Z Arz Xi , Xa (XI) z 1I
X X3" \L3 (Ila) (XhIIa) La,Z Arz (CH2)nCOL' OL3 ~1J(CH2)nCOL1 Are X1-Xa B(OR)2 NO X1 X4 X X3i- YH 2 X X3il YH
(X) (XhIlb) Compound (Ile) can be produced from compound (X) by the same method for producing compound (I) from compound (Ile) in reaction formula 6, or from compound (XI) by the same method for producing compound (I) from compound (IId) in reaction formula 5.
Compound (XIIIa) can be produced from compound (XI) by the same method for producing compound (I) from compound (Ile) in reaction formula 4.
Compound (XIIIb) can be produced from compound (X) by the same method for producing compound (1) from compound (Ile) in reaction formula 4.
Compound (IIa) can be produced from compound (Ile) by the same method for producing compound (I) from compound (IIc) in reaction formula 4, from compound (XIIIa) by the same method for producing compound (I) from compound (IId) in reaction formula 5, or from compound (XIIIb) by the same method for producing compound (I) from compound (Ile) in reaction formula 6.
[0065]
The compound (IIa) or (IIc) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[Reaction Formula 8]
3 NHRa Art X1X4 B(OR)2 XX1' Z Are (XIV) , NHRa Ar (IIc) X1 ' X4 3 NHRa XX3~Y.Z Are Ar1 NHRa L Art Xi X4 B(OR)2 (XIV) YH,Z A~ (Ilb) x2"X3 L3 X1 X III) (XI) X X3"\L3 (XV) Compound (XV) can be produced from compound (XI) by the same method for producing compound (I) from compound (llc) in reaction formula 4.
Compound (Ilb) can be produced from compound (IIc) by the same method for producing compound (I) from compound (IIc) in reaction formula 4, or from compound (XV) by the same method for producing compound (I) from compound (IId) in reaction formula 5.
The compound (IIa) or (IIc) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[Reaction Formula 8]
3 NHRa Art X1X4 B(OR)2 XX1' Z Are (XIV) , NHRa Ar (IIc) X1 ' X4 3 NHRa XX3~Y.Z Are Ar1 NHRa L Art Xi X4 B(OR)2 (XIV) YH,Z A~ (Ilb) x2"X3 L3 X1 X III) (XI) X X3"\L3 (XV) Compound (XV) can be produced from compound (XI) by the same method for producing compound (I) from compound (llc) in reaction formula 4.
Compound (Ilb) can be produced from compound (IIc) by the same method for producing compound (I) from compound (IIc) in reaction formula 4, or from compound (XV) by the same method for producing compound (I) from compound (IId) in reaction formula 5.
[0066]
The compound (IIb) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[Reaction Formula 9]
B
B I
i A
L3 A T X1 X4 Are XZ~X3~YH B(OR)2(VII) Xii x (X) (lie) Compound (Ile) can be produced from compound (X) by the same method for producing compound (I) from compound (Ile) in reaction formula 4.
The compound (Ile) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[Reaction Formula 10]
B B
X1 X4 Art T"
X 2X3" . B(OR)2(Vil) XX4 (Xl) X 2XS~~ L 3 (lid) Compound (IId) can be produced from compound (XI) by the same method for producing compound (I) from compound (IIc) in reaction formula 4.
The compound (IId) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
The compound (IIb) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[Reaction Formula 9]
B
B I
i A
L3 A T X1 X4 Are XZ~X3~YH B(OR)2(VII) Xii x (X) (lie) Compound (Ile) can be produced from compound (X) by the same method for producing compound (I) from compound (Ile) in reaction formula 4.
The compound (Ile) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[Reaction Formula 10]
B B
X1 X4 Art T"
X 2X3" . B(OR)2(Vil) XX4 (Xl) X 2XS~~ L 3 (lid) Compound (IId) can be produced from compound (XI) by the same method for producing compound (I) from compound (IIc) in reaction formula 4.
The compound (IId) thus obtained can be isolated from the reaction mixture by a conventional method, and can be isolated and purified by a well-known technique of separation and purification such as concentration, vacuum concentration, solvent extraction, crystallization, recrystallization, transfer dissolution, or chromatography.
[0067]
When isomerization has occurred, configurational isomers (E and Z isomers) of compound (I) can be isolated and purified by a conventional technique of separation such as extraction, recrystallization, distillation, or chromatography to produce a pure compound. The isomerization of double bonds can be allowed to progress to obtain the corresponding pure isomers through the use of heat, acid catalysts, transition metal complexes, metal catalysts, radical catalysts, exposure to light, strongly basic catalysts, or the like according to the method in the New Course in Experimental Chemistry 14 (Ed. by The Chemical Society of Japan), pages 251-253 and Course in Experimental Chemistry 19, 4`h Edition (Ed. by The Chemical Society of Japan), pages 273-274, or methods based thereon.
Stereoisomers of compound (I) may also be produced, depending on the type of substituent, but such isomers are encompassed by the present invention, both individually and in combination.
Compound (I) may or may not be in the form of a hydrate.
In either case, compound (I) can be synthesized through the following additional reactions as needed, either individually or in any combination: deprotection, acylation, alkylation, hydrogenation, oxidation, reduction, carbon chain extension, and substituent replacement.
Target substances that are obtained in free form as a result of the above reactions can be converted to salts by a conventional method, and those that are obtained in the form of salts can also be converted to the free form or another salt by a conventional method. The compound (I) thus obtained can be isolated and purified from the reaction mixture by a well-known technique such as transfer dissolution, concentration, solvent extraction, fractional distillation, crystallization, recrystallization, or chromatography.
When compound (I) is in the form of a configurational isomer, diastereoisomer, conformer, or the like, it can also be isolated by the above separation and purification techniques as needed. When compound (I) is in the form of a racemic mixture, it can be separated into the d and I forms by a common technique of optical resolution.
When isomerization has occurred, configurational isomers (E and Z isomers) of compound (I) can be isolated and purified by a conventional technique of separation such as extraction, recrystallization, distillation, or chromatography to produce a pure compound. The isomerization of double bonds can be allowed to progress to obtain the corresponding pure isomers through the use of heat, acid catalysts, transition metal complexes, metal catalysts, radical catalysts, exposure to light, strongly basic catalysts, or the like according to the method in the New Course in Experimental Chemistry 14 (Ed. by The Chemical Society of Japan), pages 251-253 and Course in Experimental Chemistry 19, 4`h Edition (Ed. by The Chemical Society of Japan), pages 273-274, or methods based thereon.
Stereoisomers of compound (I) may also be produced, depending on the type of substituent, but such isomers are encompassed by the present invention, both individually and in combination.
Compound (I) may or may not be in the form of a hydrate.
In either case, compound (I) can be synthesized through the following additional reactions as needed, either individually or in any combination: deprotection, acylation, alkylation, hydrogenation, oxidation, reduction, carbon chain extension, and substituent replacement.
Target substances that are obtained in free form as a result of the above reactions can be converted to salts by a conventional method, and those that are obtained in the form of salts can also be converted to the free form or another salt by a conventional method. The compound (I) thus obtained can be isolated and purified from the reaction mixture by a well-known technique such as transfer dissolution, concentration, solvent extraction, fractional distillation, crystallization, recrystallization, or chromatography.
When compound (I) is in the form of a configurational isomer, diastereoisomer, conformer, or the like, it can also be isolated by the above separation and purification techniques as needed. When compound (I) is in the form of a racemic mixture, it can be separated into the d and I forms by a common technique of optical resolution.
[0068]
Compound (I) has excellent GPR52 agonist activity, and can be used as an agent for preventing or treating various diseases in mammals (such as humans, cows, horses, dogs, cats, monkeys, mice, and rats, but particularly humans). The compound of the present invention has low toxicity (such as acute toxicity, chronic toxicity, cardiac toxicity, carcinogenicity, or genotoxicity) and few side effects.
Compound (I) has excellent GPR52 agonist activity, and can be used as an agent for preventing or treating various diseases in mammals (such as humans, cows, horses, dogs, cats, monkeys, mice, and rats, but particularly humans). The compound of the present invention has low toxicity (such as acute toxicity, chronic toxicity, cardiac toxicity, carcinogenicity, or genotoxicity) and few side effects.
[0069]
Compound (I) or a prodrug thereof (hereinafter, also simply referred to as compound of the invention) can be used as a pharmaceutical agent for preventing or treating schizophrenia.
The compound of the present invention has excellent GPR52 agonist activity and is useful for the prevention or treatment of diseases in mammals (including humans, mice, rats, rabbits, dogs, cats, cows, horses, swine, and monkeys) such as mental disorders (including schizophrenia, depression, anxiety, bipolar disorders or PTSD, anxiety neuroses, and obsessive-compulsive neuroses), neurodegenerative diseases (such as Alzheimer's disease, mild cognitive impairment (MCI), Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, spinocerebellar degeneration, multiple sclerosis (MS), and Pick disease). The compound of the present invention is particularly useful for improving symptoms of schizophrenia, including (1) positive symptoms such as delusion and hallucination, (2) negative symptoms such as hypesthesia, social withdrawal, and diminished motivation/loss of concentration, and (3) cognitive dysfunction.
Compound (I) or a prodrug thereof (hereinafter, also simply referred to as compound of the invention) can be used as a pharmaceutical agent for preventing or treating schizophrenia.
The compound of the present invention has excellent GPR52 agonist activity and is useful for the prevention or treatment of diseases in mammals (including humans, mice, rats, rabbits, dogs, cats, cows, horses, swine, and monkeys) such as mental disorders (including schizophrenia, depression, anxiety, bipolar disorders or PTSD, anxiety neuroses, and obsessive-compulsive neuroses), neurodegenerative diseases (such as Alzheimer's disease, mild cognitive impairment (MCI), Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, spinocerebellar degeneration, multiple sclerosis (MS), and Pick disease). The compound of the present invention is particularly useful for improving symptoms of schizophrenia, including (1) positive symptoms such as delusion and hallucination, (2) negative symptoms such as hypesthesia, social withdrawal, and diminished motivation/loss of concentration, and (3) cognitive dysfunction.
[0070]
The compound of the present invention has low toxicity (such as acute toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiac toxicity, drug interactions, and carcinogenicity), and can therefore be safely administered, as such or while mixed with a pharmaceutically acceptable carrier or the like, in the form of the pharmaceutical composition of the present invention to mammals (such as humans, mice, rats, rabbits, dogs, cats, cows, horses, swine, and monkeys), and can be used as an agent for preventing or treating the diseases.
The compound of the present invention has low toxicity (such as acute toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiac toxicity, drug interactions, and carcinogenicity), and can therefore be safely administered, as such or while mixed with a pharmaceutically acceptable carrier or the like, in the form of the pharmaceutical composition of the present invention to mammals (such as humans, mice, rats, rabbits, dogs, cats, cows, horses, swine, and monkeys), and can be used as an agent for preventing or treating the diseases.
[0071]
A variety of organic or inorganic substances commonly used as formulation materials may be used as the pharmaceutically acceptable carrier herein, and may be compounded in the form of excipients, lubricants, binders, and disintegrants in solid formulations, and in the form of solvents, dissolution aids, suspending agents, isotonizing agents, buffers, and soothing agents or the like in liquid formulations.
Additives such as preservatives, antioxidants, colorants, and sweeteners can also be used as needed.
A variety of organic or inorganic substances commonly used as formulation materials may be used as the pharmaceutically acceptable carrier herein, and may be compounded in the form of excipients, lubricants, binders, and disintegrants in solid formulations, and in the form of solvents, dissolution aids, suspending agents, isotonizing agents, buffers, and soothing agents or the like in liquid formulations.
Additives such as preservatives, antioxidants, colorants, and sweeteners can also be used as needed.
[0072]
Preferred examples of excipients include lactose, sucrose, D-mannitol, D-sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, gum arabic, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminometasilicate.
Preferred examples of lubricants lubricant include magnesium stearate, calcium stearate, talc, and colloidal silica.
Preferred examples of excipients include lactose, sucrose, D-mannitol, D-sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, gum arabic, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminometasilicate.
Preferred examples of lubricants lubricant include magnesium stearate, calcium stearate, talc, and colloidal silica.
[0073]
Preferred examples of binders include pregelatinized starch, saccharose, gelatin, gum arabic, methylcellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and polyvinyl pyrrolidone.
Preferred examples of binders include pregelatinized starch, saccharose, gelatin, gum arabic, methylcellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and polyvinyl pyrrolidone.
[0074]
Preferred examples of disintegrants include lactose, sucrose, starch, carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, sodium carboxymethyl starch, light anhydrous silicic acid, and low-substituted hydroxypropylcellulose.
Preferred examples of disintegrants include lactose, sucrose, starch, carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, sodium carboxymethyl starch, light anhydrous silicic acid, and low-substituted hydroxypropylcellulose.
[0075]
Preferred examples of solvents include water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, and cottonseed oil.
Preferred examples of solvents include water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, and cottonseed oil.
[0076]
Preferred examples of dissolution aids include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, and sodium acetate.
Preferred examples of dissolution aids include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, and sodium acetate.
[0077]
Preferred examples of suspending agents include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerol monostearate;
hydrophilic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methylcellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, and hydroxypropyl cellulose; and polysorbates and polyoxyethylene hydrogenated castor oil.
Preferred examples of suspending agents include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerol monostearate;
hydrophilic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methylcellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, and hydroxypropyl cellulose; and polysorbates and polyoxyethylene hydrogenated castor oil.
[0078]
Preferred examples of isotonizing agents include sodium chloride, glycerin, D-mannitol, D-sorbitol, and glucose.
Preferred examples of buffers include phosphate, acetate, carbonate, and citrate buffers.
Preferred examples of soothing agents include benzyl alcohol.
Preferred examples of preservatives include p-hydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, and sorbic acid.
Preferred examples of antioxidants include sulfites and ascorbates.
Preferred examples of isotonizing agents include sodium chloride, glycerin, D-mannitol, D-sorbitol, and glucose.
Preferred examples of buffers include phosphate, acetate, carbonate, and citrate buffers.
Preferred examples of soothing agents include benzyl alcohol.
Preferred examples of preservatives include p-hydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, and sorbic acid.
Preferred examples of antioxidants include sulfites and ascorbates.
[0079]
Preferred examples of colorants include water-soluble edible tar pigments (including food coloring such as Food Color Red Nos. 2 and 3, Food Color Yellow Nos.
4 and 5, and Food Color Blue Nos. 1 and 2), water-insoluble lake pigments (including aluminum salts of the aforementioned water-soluble edible tar pigments), and natural pigments (such as a-carotene, chlorophyll, and red oxide).
Preferred examples of sweeteners include saccharin sodium, dipotassium glycyrrhizinate, aspartame, and stevia.
Preferred examples of colorants include water-soluble edible tar pigments (including food coloring such as Food Color Red Nos. 2 and 3, Food Color Yellow Nos.
4 and 5, and Food Color Blue Nos. 1 and 2), water-insoluble lake pigments (including aluminum salts of the aforementioned water-soluble edible tar pigments), and natural pigments (such as a-carotene, chlorophyll, and red oxide).
Preferred examples of sweeteners include saccharin sodium, dipotassium glycyrrhizinate, aspartame, and stevia.
[0080]
Examples of dosage forms for the aforementioned pharmaceutical composition include oral agents such as tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, and orally disintegrable tablets), capsules (including soft capsules and micro capsules), granules, powders, troches, syrups, emulsions, suspensions, and films (such as orally disintegrable films); and parenteral agents such as injections (including subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, and drip infusions), topical agents (such as transdermal formulations and ointments), suppositories (such as rectal suppositories and vaginal suppositories), pellets, nasal agents, pulmonary formulations (inhalants), and ophthalmic solutions. These can be can be safely administered orally or parenterally (such as locally, rectally, or intravenously).
These formulations may also be controlled-release formulations such as rapid-release formulations and sustained-release formulations (such as sustained-release microcapsules).
Examples of dosage forms for the aforementioned pharmaceutical composition include oral agents such as tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, and orally disintegrable tablets), capsules (including soft capsules and micro capsules), granules, powders, troches, syrups, emulsions, suspensions, and films (such as orally disintegrable films); and parenteral agents such as injections (including subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, and drip infusions), topical agents (such as transdermal formulations and ointments), suppositories (such as rectal suppositories and vaginal suppositories), pellets, nasal agents, pulmonary formulations (inhalants), and ophthalmic solutions. These can be can be safely administered orally or parenterally (such as locally, rectally, or intravenously).
These formulations may also be controlled-release formulations such as rapid-release formulations and sustained-release formulations (such as sustained-release microcapsules).
[0081]
The pharmaceutical composition of the present invention can be produced by a method commonly used in the technical field of drug formulations, such as the methods described in the Japan Pharmacopoeia. Specific methods for producing formulations are described below.
The content of the compound of the present invention in the pharmaceutical composition of the present invention will vary depending on the dosage form, the dose of the compound of the present invention, and the like, but is in the range of about 0.01 to 100% by weight, for example.
The pharmaceutical composition of the present invention can be produced by a method commonly used in the technical field of drug formulations, such as the methods described in the Japan Pharmacopoeia. Specific methods for producing formulations are described below.
The content of the compound of the present invention in the pharmaceutical composition of the present invention will vary depending on the dosage form, the dose of the compound of the present invention, and the like, but is in the range of about 0.01 to 100% by weight, for example.
[0082]
The dosage of the compound of the present invention will vary depending on the subject of treatment, route of administration, treated disease, symptoms, and the like, but when given orally to adults patients with schizophrenia, for example, the normal single dose is about 0.1 to about 20 mg/kg body weight, preferably about 0.2 to about mg/kg body weight, and even more preferably about 0.5 to about 10 mg/kg, at a time, and is preferably given once or several times a day.
The dosage of the compound of the present invention will vary depending on the subject of treatment, route of administration, treated disease, symptoms, and the like, but when given orally to adults patients with schizophrenia, for example, the normal single dose is about 0.1 to about 20 mg/kg body weight, preferably about 0.2 to about mg/kg body weight, and even more preferably about 0.5 to about 10 mg/kg, at a time, and is preferably given once or several times a day.
[0083]
The compound of the present invention may be used in combination with other active ingredients. Examples of such active ingredients include:
atypical antipsychotic agents (such as clozapine, olanzapine, risperidone, aripiprazole, iloperidone, asenapine, ziprasidone, quetiapine, and zotepine);
typical antipsychotic agents (such as haloperidol and chlorpromazine);
selective serotonin reuptake inhibitors (such as paroxetine, sertraline, fluvoxamine, and fluoxetine), selective serotonin-noradrenaline reuptake inhibitors (such as milnacipran and venlafaxine), and selective noradrenaline-dopamine reuptake inhibitors (e.g., bupropion);
tetracyclic antidepressants (such as amoxapine and clomipramine);
tricyclic antidepressants (such as imipramine and amitriptyline);
other antidepressant agents (such as NS-2359, Lu AA21004, and DOV21947);
a7-nicotinic receptor partial modulators (such as SSR-180711 and PNU-120596);
NK2 antagonists;
NK3 antagonists;
glycine transporter 1 inhibitors (such as ALX5407 and SSR504734);
metabolic glutamate receptor modulators (such as CDPPB and MPEP);
anxiolytics [benzodiazepine-based agents (such as diazepam and etizolam) and serotonin 5-HT]A agonists (such as tandospirone)];
sleep inducing agents [benzodiazepine-based agents (e.g.., estazolam and triazolam);
non-benzodiazepine-based agents (such as zolpidem), and melatonin receptor agonists (such as ramelteon)];
0-amyloid vaccines;
0-amyloid-degrading enzymes and the like;
brain function activators (such as aniracetam and nicergoline);
anti-Parkinson agents [such as dopamine receptor agonists (including L-DOPA, bromocriptine, pergolide, talipexole, pramipexole, cabergoline, and amantadine), mono-amine oxidase (MAO) inhibitors (such as deprenyl, selegiline, remacemide, and riluzole), anticholinergic agents (such as trihexyphenidyl and biperiden); and COMT
inhibitors (such as entacapone)];
therapeutic agents for amyotrophic lateral sclerosis (including neurotrophic factors and riluzole);
antihyperlipidemic drugs such as cholesterol-lowering drugs [statins (such as pravastatin sodium, atorvastatin, simvastatin, and rosuvastatin), fibrates (such as clofibrate), and squalene synthase inhibitors];
therapeutic agents for abnormal behaviors/wandering symptoms associated with dementia (such as sedatives and anxiolytics);
apoptosis inhibitors (such as CPI-1189, IDN-6556, and CEP-1347);
neuronal differentiation/regeneration accelerators (such as leteprinim and xaliproden (SR-57746-A), and SB-216763);
antihypertensive agents;
therapeutic agents for diabetes mellitus;
nonsteroidal anti-inflammatory agents (such as meloxicam, tenoxicam, indomethacin, ibuprofen, celecoxib, rofecoxib, aspirin, and indomethacin);
disease-modifying anti-rheumatic drugs (DMARDs);
anticytokine agents (such as TNF inhibitors and MAP kinase inhibitors);
steroid agents (such as dexamethasone, hexestrol, and cortisone acetate); sex hormones or the derivatives thereof (such as progesterone, estradiol, and estradiol benzoate);
parathyroid hormone (PTH); and calcium receptor blockers (hereinafter, also simply referred to as concomitant drugs).
The compound of the present invention can in particular preferably be used in combination with various drugs having action on the central nervous system and drugs for the treatment of diseases that tend to develop with schizophrenia (such as drugs for the treatment of diabetes).
The compound of the present invention can in particular preferably be used in combination with various active ingredients having no action on GPR52.
The time of administration of the compound of the present invention and concomitant drugs is not limited, and they may be given at the same or different times to the subjects of treatment. The compound of the present invention and a concomitant drug may furthermore be given in the form of two formulations containing their respective active ingredients or in the form of a single formulation containing both active ingredients.
The aforementioned concomitant drugs may be used in combinations of two or more in suitable proportions.
The dosage of concomitant drugs can be suitably selected based on the clinically used dose. The compounding ratio of the compound of the present invention and concomitant drugs can be suitably selected depending on the subject of treatment, route of administration, disease being treated, symptoms, combination, and the like.
When the subject of treatment is human, for example, the concomitant drug may be used in an amount of 0.01 to 100 parts by weigh per part by weight of the compound of the present invention.
When the compound of the present invention is used in combination with a concomitant drug, the amounts of the respective drugs can be reduced to within a safe range in consideration of their counter-effects.
[Working Examples]
The compound of the present invention may be used in combination with other active ingredients. Examples of such active ingredients include:
atypical antipsychotic agents (such as clozapine, olanzapine, risperidone, aripiprazole, iloperidone, asenapine, ziprasidone, quetiapine, and zotepine);
typical antipsychotic agents (such as haloperidol and chlorpromazine);
selective serotonin reuptake inhibitors (such as paroxetine, sertraline, fluvoxamine, and fluoxetine), selective serotonin-noradrenaline reuptake inhibitors (such as milnacipran and venlafaxine), and selective noradrenaline-dopamine reuptake inhibitors (e.g., bupropion);
tetracyclic antidepressants (such as amoxapine and clomipramine);
tricyclic antidepressants (such as imipramine and amitriptyline);
other antidepressant agents (such as NS-2359, Lu AA21004, and DOV21947);
a7-nicotinic receptor partial modulators (such as SSR-180711 and PNU-120596);
NK2 antagonists;
NK3 antagonists;
glycine transporter 1 inhibitors (such as ALX5407 and SSR504734);
metabolic glutamate receptor modulators (such as CDPPB and MPEP);
anxiolytics [benzodiazepine-based agents (such as diazepam and etizolam) and serotonin 5-HT]A agonists (such as tandospirone)];
sleep inducing agents [benzodiazepine-based agents (e.g.., estazolam and triazolam);
non-benzodiazepine-based agents (such as zolpidem), and melatonin receptor agonists (such as ramelteon)];
0-amyloid vaccines;
0-amyloid-degrading enzymes and the like;
brain function activators (such as aniracetam and nicergoline);
anti-Parkinson agents [such as dopamine receptor agonists (including L-DOPA, bromocriptine, pergolide, talipexole, pramipexole, cabergoline, and amantadine), mono-amine oxidase (MAO) inhibitors (such as deprenyl, selegiline, remacemide, and riluzole), anticholinergic agents (such as trihexyphenidyl and biperiden); and COMT
inhibitors (such as entacapone)];
therapeutic agents for amyotrophic lateral sclerosis (including neurotrophic factors and riluzole);
antihyperlipidemic drugs such as cholesterol-lowering drugs [statins (such as pravastatin sodium, atorvastatin, simvastatin, and rosuvastatin), fibrates (such as clofibrate), and squalene synthase inhibitors];
therapeutic agents for abnormal behaviors/wandering symptoms associated with dementia (such as sedatives and anxiolytics);
apoptosis inhibitors (such as CPI-1189, IDN-6556, and CEP-1347);
neuronal differentiation/regeneration accelerators (such as leteprinim and xaliproden (SR-57746-A), and SB-216763);
antihypertensive agents;
therapeutic agents for diabetes mellitus;
nonsteroidal anti-inflammatory agents (such as meloxicam, tenoxicam, indomethacin, ibuprofen, celecoxib, rofecoxib, aspirin, and indomethacin);
disease-modifying anti-rheumatic drugs (DMARDs);
anticytokine agents (such as TNF inhibitors and MAP kinase inhibitors);
steroid agents (such as dexamethasone, hexestrol, and cortisone acetate); sex hormones or the derivatives thereof (such as progesterone, estradiol, and estradiol benzoate);
parathyroid hormone (PTH); and calcium receptor blockers (hereinafter, also simply referred to as concomitant drugs).
The compound of the present invention can in particular preferably be used in combination with various drugs having action on the central nervous system and drugs for the treatment of diseases that tend to develop with schizophrenia (such as drugs for the treatment of diabetes).
The compound of the present invention can in particular preferably be used in combination with various active ingredients having no action on GPR52.
The time of administration of the compound of the present invention and concomitant drugs is not limited, and they may be given at the same or different times to the subjects of treatment. The compound of the present invention and a concomitant drug may furthermore be given in the form of two formulations containing their respective active ingredients or in the form of a single formulation containing both active ingredients.
The aforementioned concomitant drugs may be used in combinations of two or more in suitable proportions.
The dosage of concomitant drugs can be suitably selected based on the clinically used dose. The compounding ratio of the compound of the present invention and concomitant drugs can be suitably selected depending on the subject of treatment, route of administration, disease being treated, symptoms, combination, and the like.
When the subject of treatment is human, for example, the concomitant drug may be used in an amount of 0.01 to 100 parts by weigh per part by weight of the compound of the present invention.
When the compound of the present invention is used in combination with a concomitant drug, the amounts of the respective drugs can be reduced to within a safe range in consideration of their counter-effects.
[Working Examples]
[0084]
The present invention will be illustrated in further detail by the following reference examples, working examples, preparation example, and test example, but these examples, which are merely embodiments, do not limit the present invention and may be modified without departing from the scope of the invention.
In the following reference examples and working examples, "room temperature"
ordinarily indicates a temperature from about 10 C to about 35 C. Percentages for yield indicate mol/mol% and percentages for solvent used in chromatography indicate percent by volume, but otherwise indicate percent by weight. Broad peaks such as OH
and NH
protons that could not be confirmed in the proton NMR spectra are not included in the data.
Other abbreviations used in this document are defined below.
s: singlet d: doublet dd: doublet of doublets dt: doublet of triplets t: triplet tt: triplet of triplets td: triplet of doublets q: quartet septet m: multiplet br: broad J: coupling constant Hz: Hertz CDC13 : deuterated chloroform DMSO-d6 : deuterated dimethyl sulfoxide H-NMR: proton nuclear magnetic resonance HPLC: high performance liquid chromatography THF: tetrahydrofuran DMF: N,N-dimethyl formamide DMSO: dimethyl sulfoxide NMP: N-methyl pyrrolidone HOBt: 1-hydroxybenzotriazole WSC: 1-ethyl -3-(3-dimethylaminopropyl)carbodiimide hydrochloride HATU: 2-(7-aza-1 H-benzotriazol-l -yl)-1,1,3,3-tetramethyluronium hexafluorophosphate DMTMM: 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride n-hydrate DBU: 1,8-diazabicyclo[5.4.0]-7-undecene LC-MS: liquid chromatography-mass spectrometry ESI: electrospray ionization [0085]
Reference Example 1 2-Chloro-4-(3-nitrophenyl)pyrimidine 3-Nitrophenylboronic acid (2.2 g, 13.2 mmol), tetrakis(triphenylphosphine)palladium (0.77 g, 0.67 mmol), and 2 N sodium carbonate aqueous solution (8 mL) were added to a dimethoxyethane (100 mL) solution of 2,4-dichloropyrimi dine (2.0 g, 13.4 mmol), and the mixture was heated to reflux for 13 hours in an argon atmosphere. Ethyl acetate was added to the reaction solution, and the solution was washed with water and with saturated brine, dried, and concentrated. The residue was purified by silica gel column chromatography (THF) and then recrystallized from ethyl acetate to give 1.2 g of the titled compound (yield: 39%).
1 H-NMR (CDC13) 8 : 7.72 - 7.77 (2H, m), 8.39 - 8.43 (1H, m), 8.47 - 8.51 (1H, m), 8.77 (1 H, d, J = 5.1 Hz), 8.93 (1 H, t, J = 2.1 Hz).
The present invention will be illustrated in further detail by the following reference examples, working examples, preparation example, and test example, but these examples, which are merely embodiments, do not limit the present invention and may be modified without departing from the scope of the invention.
In the following reference examples and working examples, "room temperature"
ordinarily indicates a temperature from about 10 C to about 35 C. Percentages for yield indicate mol/mol% and percentages for solvent used in chromatography indicate percent by volume, but otherwise indicate percent by weight. Broad peaks such as OH
and NH
protons that could not be confirmed in the proton NMR spectra are not included in the data.
Other abbreviations used in this document are defined below.
s: singlet d: doublet dd: doublet of doublets dt: doublet of triplets t: triplet tt: triplet of triplets td: triplet of doublets q: quartet septet m: multiplet br: broad J: coupling constant Hz: Hertz CDC13 : deuterated chloroform DMSO-d6 : deuterated dimethyl sulfoxide H-NMR: proton nuclear magnetic resonance HPLC: high performance liquid chromatography THF: tetrahydrofuran DMF: N,N-dimethyl formamide DMSO: dimethyl sulfoxide NMP: N-methyl pyrrolidone HOBt: 1-hydroxybenzotriazole WSC: 1-ethyl -3-(3-dimethylaminopropyl)carbodiimide hydrochloride HATU: 2-(7-aza-1 H-benzotriazol-l -yl)-1,1,3,3-tetramethyluronium hexafluorophosphate DMTMM: 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride n-hydrate DBU: 1,8-diazabicyclo[5.4.0]-7-undecene LC-MS: liquid chromatography-mass spectrometry ESI: electrospray ionization [0085]
Reference Example 1 2-Chloro-4-(3-nitrophenyl)pyrimidine 3-Nitrophenylboronic acid (2.2 g, 13.2 mmol), tetrakis(triphenylphosphine)palladium (0.77 g, 0.67 mmol), and 2 N sodium carbonate aqueous solution (8 mL) were added to a dimethoxyethane (100 mL) solution of 2,4-dichloropyrimi dine (2.0 g, 13.4 mmol), and the mixture was heated to reflux for 13 hours in an argon atmosphere. Ethyl acetate was added to the reaction solution, and the solution was washed with water and with saturated brine, dried, and concentrated. The residue was purified by silica gel column chromatography (THF) and then recrystallized from ethyl acetate to give 1.2 g of the titled compound (yield: 39%).
1 H-NMR (CDC13) 8 : 7.72 - 7.77 (2H, m), 8.39 - 8.43 (1H, m), 8.47 - 8.51 (1H, m), 8.77 (1 H, d, J = 5.1 Hz), 8.93 (1 H, t, J = 2.1 Hz).
[0086]
Reference Example 2 (4-(3 -Nitrophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine 2-(3,4-Dimethoxyphenyl)ethylamine (1.3 g, 7.2 mmol) and ethyl diisopropylamine (1.7 mL, 9.5 mmol) were added to an n-butanol (15 mL) solution of 2-chloro-4-(3-nitrophenyl)pyrimidine (1.1 g, 4.7 mmol) synthesized in Reference Example 1, and the mixture was heated for 30 min to 130 C while irradiated with microwaves. The reaction solution was dissolved in ethyl acetate, and the solution was washed with water and with saturated brine, dried, and was concentrated. The residue was purified by silica gel column chromatography (ethyl acetate) and recrystallized from ethyl acetate-hexane to give 1.5 g of the titled compound (yield: 84%).
1 H-NMR (CDC13) 8 : 2.93 (2H, t, J = 6.9 Hz), 3.75 - 3.82 (2H, m), 3.87 (3H, s), 3.88 (3 H, s), 5.30 (1 H, br t, J = 5.7 Hz), 6.78 (111, s), 6.84 (2H, d, J = 0.6 Hz), 7.03 (1 H, d, J
= 5.4 Hz), 7.65 (1 H, t, J = 8.1 Hz), 8.30 - 8.37 (2H, m), 8.41 (1H, d, J =
5.1 Hz), 8.92 (1H, br s).
Reference Example 2 (4-(3 -Nitrophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine 2-(3,4-Dimethoxyphenyl)ethylamine (1.3 g, 7.2 mmol) and ethyl diisopropylamine (1.7 mL, 9.5 mmol) were added to an n-butanol (15 mL) solution of 2-chloro-4-(3-nitrophenyl)pyrimidine (1.1 g, 4.7 mmol) synthesized in Reference Example 1, and the mixture was heated for 30 min to 130 C while irradiated with microwaves. The reaction solution was dissolved in ethyl acetate, and the solution was washed with water and with saturated brine, dried, and was concentrated. The residue was purified by silica gel column chromatography (ethyl acetate) and recrystallized from ethyl acetate-hexane to give 1.5 g of the titled compound (yield: 84%).
1 H-NMR (CDC13) 8 : 2.93 (2H, t, J = 6.9 Hz), 3.75 - 3.82 (2H, m), 3.87 (3H, s), 3.88 (3 H, s), 5.30 (1 H, br t, J = 5.7 Hz), 6.78 (111, s), 6.84 (2H, d, J = 0.6 Hz), 7.03 (1 H, d, J
= 5.4 Hz), 7.65 (1 H, t, J = 8.1 Hz), 8.30 - 8.37 (2H, m), 8.41 (1H, d, J =
5.1 Hz), 8.92 (1H, br s).
[0087]
Reference Example 3 4-(3 -Aminophenyl)-N-(2-(3 ,4-dimethoxyphenyl) ethyl)pyrimidine-2-amine 10%-Palladium carbon (0.13 g) was added to a THF-ethanol (1:1, 40 mL) solution of (4-(3-nitrophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine (1.3 g, 3.4 mmol) synthesized in Reference Example 2, and the mixture was stirred for 1 day at room temperature in a hydrogen atmosphere at ordinary pressure. The reaction solution was filtered and concentrated. The residue was purified by basic silica gel column chromatography (hexane-ethyl acetate = 10:0 to 0:10) and was recrystallized from ethyl acetate-hexane to give 1.2 g (quantitative) of the titled- compound.
'H-NMR (CDC13) 6 : 2.91 (2H, t, J = 6.9 Hz), 3.72 - 3.82 (4H, m), 3.87 (6H, s), 5.21 (1 H, br t, J = 5.7 Hz), 6.78-6.84 (4H, m), 6.93 (1 H, d, J = 5.1 Hz), 7.22-7.27 (1 H, m), 7.36- 7.39 (2H, m), 8.31 (1H, d, J = 5.1 Hz).
Reference Example 3 4-(3 -Aminophenyl)-N-(2-(3 ,4-dimethoxyphenyl) ethyl)pyrimidine-2-amine 10%-Palladium carbon (0.13 g) was added to a THF-ethanol (1:1, 40 mL) solution of (4-(3-nitrophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine (1.3 g, 3.4 mmol) synthesized in Reference Example 2, and the mixture was stirred for 1 day at room temperature in a hydrogen atmosphere at ordinary pressure. The reaction solution was filtered and concentrated. The residue was purified by basic silica gel column chromatography (hexane-ethyl acetate = 10:0 to 0:10) and was recrystallized from ethyl acetate-hexane to give 1.2 g (quantitative) of the titled- compound.
'H-NMR (CDC13) 6 : 2.91 (2H, t, J = 6.9 Hz), 3.72 - 3.82 (4H, m), 3.87 (6H, s), 5.21 (1 H, br t, J = 5.7 Hz), 6.78-6.84 (4H, m), 6.93 (1 H, d, J = 5.1 Hz), 7.22-7.27 (1 H, m), 7.36- 7.39 (2H, m), 8.31 (1H, d, J = 5.1 Hz).
[0088]
Reference Example 4 Ethyl 3 -(2-chloropyrimidin-4-yl)benzoate The titled compound was obtained from 2,4-dichloropyrimidine and 3-ethoxycarbonylphenylboronic acid in the same manner as in Reference Example 1.
Yield: 58%.
'H-NMR (CDC13 ) 6 : 1.44(3H,t,J=7.2Hz),4.45(2H,q,J=7.2Hz),7.62(1H,t,J
7.5 Hz), 7.74 (1H, d, J = 5.1 Hz), 8.20-8.24 (1H, m), 8.33 - 8.37 (1H, m), 8.69 - 8.70 (2H, m).
Reference Example 4 Ethyl 3 -(2-chloropyrimidin-4-yl)benzoate The titled compound was obtained from 2,4-dichloropyrimidine and 3-ethoxycarbonylphenylboronic acid in the same manner as in Reference Example 1.
Yield: 58%.
'H-NMR (CDC13 ) 6 : 1.44(3H,t,J=7.2Hz),4.45(2H,q,J=7.2Hz),7.62(1H,t,J
7.5 Hz), 7.74 (1H, d, J = 5.1 Hz), 8.20-8.24 (1H, m), 8.33 - 8.37 (1H, m), 8.69 - 8.70 (2H, m).
[0089]
Reference Example 5 Ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoate The titled compound was obtained from ethyl 3-(2-chloropyrimidin-4-yl)benzoate synthesized in Reference Example 4 and 2-(3,4-dimethoxyphenyl)ethylamine in the same manner as in Reference Example 2. Yield: 78%.
'H-NMR (CDC13) 6: 1.42(3H,t,J=7.2Hz),2.92(2H,t,J=6.9Hz),3.78(2H,q,J
6.9 Hz), 3.87 (6H, s), 4.42 (2H, q, J = 7.2 Hz), 5.26 (1H, t, J = 5.4 Hz), 6.78 - 6.83 (3H, m), 7.03 (1 H, d, J = 5.1 Hz),7.55(1H,t,J=7.8Hz),8.13-8.16(1H,m),8.26(1H, brd, J = 7.5 Hz), 8.3 7 (1 H, d, J = 5.1 Hz), 8.67 (1 H, s).
Reference Example 5 Ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoate The titled compound was obtained from ethyl 3-(2-chloropyrimidin-4-yl)benzoate synthesized in Reference Example 4 and 2-(3,4-dimethoxyphenyl)ethylamine in the same manner as in Reference Example 2. Yield: 78%.
'H-NMR (CDC13) 6: 1.42(3H,t,J=7.2Hz),2.92(2H,t,J=6.9Hz),3.78(2H,q,J
6.9 Hz), 3.87 (6H, s), 4.42 (2H, q, J = 7.2 Hz), 5.26 (1H, t, J = 5.4 Hz), 6.78 - 6.83 (3H, m), 7.03 (1 H, d, J = 5.1 Hz),7.55(1H,t,J=7.8Hz),8.13-8.16(1H,m),8.26(1H, brd, J = 7.5 Hz), 8.3 7 (1 H, d, J = 5.1 Hz), 8.67 (1 H, s).
[0090]
Reference Example 6 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid Lithium hydroxide monohydrate (296 mg, 7.1 mmol) was added to a THF-ethanol-water (1:1:1, 60 ml) solution of ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoate (1.9 g, 4.7 mmol) synthesized in Reference Example 5, and the mixture was stirred for 20 min at room temperature. The reaction solution was concentrated at reduced pressure and was made acidic with the addition of diluted hydrochloric acid, aqueous ammonia and saturated ammonium chloride aqueous solution were then added, and the product was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried, and concentrated, and the residue was recrystallized from ethyl acetate-diisopropyl ether to give 1.5 g of the titled compound (yield: 84%).
' H-NMR (DMSO-d6) 8 : 2.96 (2H, t, J = 7.2 Hz), 3.83 - 3.86 (8H, m), 6.79 -6.88 (4H, m), 7.06 (1 H, d, J = 5.4 Hz), 7.60 (1 H, t, J = 7.8 Hz), 8.22 - 8.33 (3H, m), 8.78 (111, s).
Reference Example 6 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid Lithium hydroxide monohydrate (296 mg, 7.1 mmol) was added to a THF-ethanol-water (1:1:1, 60 ml) solution of ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoate (1.9 g, 4.7 mmol) synthesized in Reference Example 5, and the mixture was stirred for 20 min at room temperature. The reaction solution was concentrated at reduced pressure and was made acidic with the addition of diluted hydrochloric acid, aqueous ammonia and saturated ammonium chloride aqueous solution were then added, and the product was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried, and concentrated, and the residue was recrystallized from ethyl acetate-diisopropyl ether to give 1.5 g of the titled compound (yield: 84%).
' H-NMR (DMSO-d6) 8 : 2.96 (2H, t, J = 7.2 Hz), 3.83 - 3.86 (8H, m), 6.79 -6.88 (4H, m), 7.06 (1 H, d, J = 5.4 Hz), 7.60 (1 H, t, J = 7.8 Hz), 8.22 - 8.33 (3H, m), 8.78 (111, s).
[0091]
Reference Example 7 2-Chloro-6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine A tetrahydrofuran (30 mL) solution of 6-chloropyridin-2-ol (1.0 g, 7.72 mmol), (3,4-dimethoxyphenyl)ethanol (1.55 g, 8.44 mmol), triphenylphosphine (2.23 g, 8.44 mmol), and diethyl azodicarboxylate (1.61 g, 8.44 mmol) was stirred for 1 hour at room temperature. The reaction mixture was concentrated at reduced pressure, and the residue was chromatographed on a silica gel column (hexane-ethyl acetate 80:20) to give 1.76 g of the titled compound (yield: 78%). Oily substance.
'H-NMR (CDC13) 6 : 3.01 (2H, t, J = 6.9 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.49 (21-1, t, J
= 6.9 Hz), 6.60 - 6.89 (5H, m), 7.45- 7.92 (1H, m).
Reference Example 7 2-Chloro-6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine A tetrahydrofuran (30 mL) solution of 6-chloropyridin-2-ol (1.0 g, 7.72 mmol), (3,4-dimethoxyphenyl)ethanol (1.55 g, 8.44 mmol), triphenylphosphine (2.23 g, 8.44 mmol), and diethyl azodicarboxylate (1.61 g, 8.44 mmol) was stirred for 1 hour at room temperature. The reaction mixture was concentrated at reduced pressure, and the residue was chromatographed on a silica gel column (hexane-ethyl acetate 80:20) to give 1.76 g of the titled compound (yield: 78%). Oily substance.
'H-NMR (CDC13) 6 : 3.01 (2H, t, J = 6.9 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.49 (21-1, t, J
= 6.9 Hz), 6.60 - 6.89 (5H, m), 7.45- 7.92 (1H, m).
[0092]
Reference Example 8 4-(2-(3 -Bromophenoxy) ethyl)-1,2 -dimethoxybenzene The titled compound was obtained using 3-bromophenol in the same manner as in Reference Example 7. Yield: 56%. Oily substance.
' H-NMR (CDC13) 6 : 3.03 (2H, t, J = 6.9 Hz), 3.86 (3H, s), 3.87 (3H, s), 4.12 (2H, t, J
= 6.9 Hz), 6.78 - 6.85 (4H, m), 7.02 - 7.16 (3H, m).
Reference Example 8 4-(2-(3 -Bromophenoxy) ethyl)-1,2 -dimethoxybenzene The titled compound was obtained using 3-bromophenol in the same manner as in Reference Example 7. Yield: 56%. Oily substance.
' H-NMR (CDC13) 6 : 3.03 (2H, t, J = 6.9 Hz), 3.86 (3H, s), 3.87 (3H, s), 4.12 (2H, t, J
= 6.9 Hz), 6.78 - 6.85 (4H, m), 7.02 - 7.16 (3H, m).
[0093]
Reference Example 9 2-Chloro-6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridine The titled compound was obtained using 2-(3-(trifluoromethyl)phenyl)ethanol in the same manner as in Reference Example 7. Yield: 83%. Oily substance.
H-NMR (CDC13) 6 : 3.13 (2H, t, J = 6.9 Hz), 4.52 (2H, t, J = 6.9 Hz), 6.62 (1H, t, J =
8.4 Hz), 6.88 (1H, t, J = 7.5 Hz), 7.38 - 7.53 (5H, m).
Reference Example 9 2-Chloro-6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridine The titled compound was obtained using 2-(3-(trifluoromethyl)phenyl)ethanol in the same manner as in Reference Example 7. Yield: 83%. Oily substance.
H-NMR (CDC13) 6 : 3.13 (2H, t, J = 6.9 Hz), 4.52 (2H, t, J = 6.9 Hz), 6.62 (1H, t, J =
8.4 Hz), 6.88 (1H, t, J = 7.5 Hz), 7.38 - 7.53 (5H, m).
[0094]
Reference Example 10 2-Chloro-6-(2-(3-fluorophenyl)ethoxy)pyridine The titled compound was obtained using 2-(3-fluorophenyl)ethanol in the same manner as in Reference Example 7. Yield: 78%. Oily substance.
H-NMR(CDC13)6:3.06(2H,t,J=6.9Hz),4.50(2H,t, J = 6.9Hz),6.62(1H,d,J=
8.1 Hz), 6.84 - 7.06 (4H, m), 7.20 - 7.29 (1 H, m), 7.48 (1 H, dd, J = 8.4, 7.5 Hz).
Reference Example 10 2-Chloro-6-(2-(3-fluorophenyl)ethoxy)pyridine The titled compound was obtained using 2-(3-fluorophenyl)ethanol in the same manner as in Reference Example 7. Yield: 78%. Oily substance.
H-NMR(CDC13)6:3.06(2H,t,J=6.9Hz),4.50(2H,t, J = 6.9Hz),6.62(1H,d,J=
8.1 Hz), 6.84 - 7.06 (4H, m), 7.20 - 7.29 (1 H, m), 7.48 (1 H, dd, J = 8.4, 7.5 Hz).
[0095]
Reference Example 11 2-Chloro-6-(2-(3-methylphenyl)ethoxy)pyridine The titled compound was obtained using 2-(3-methylphenyl)ethanol in the same manner as in Reference Example 7. Yield: 97%. Oily substance.
H-NMR (CDC13) 6: 2.33 (3H, s), 3.03 (2H, t, J = 7.2 Hz), 4.49 (2H, t, J = 7.2 Hz), 6.62 (1 H, d, J = 8.1 Hz), 6.86 (1 H, d, J = 7.5 Hz), 7.00-7.20 (4H, m), 7.47 (1 H, t, J = 8.1 Hz).
Reference Example 11 2-Chloro-6-(2-(3-methylphenyl)ethoxy)pyridine The titled compound was obtained using 2-(3-methylphenyl)ethanol in the same manner as in Reference Example 7. Yield: 97%. Oily substance.
H-NMR (CDC13) 6: 2.33 (3H, s), 3.03 (2H, t, J = 7.2 Hz), 4.49 (2H, t, J = 7.2 Hz), 6.62 (1 H, d, J = 8.1 Hz), 6.86 (1 H, d, J = 7.5 Hz), 7.00-7.20 (4H, m), 7.47 (1 H, t, J = 8.1 Hz).
[0096]
Reference Example 12 2-Chloro-6-(2-(2,4-dichlorophenyl)ethoxy)pyridine The titled compound was obtained using 2-(2,4-dichlorophenyl)ethanol in the same manner as in Reference Example 7. Yield: 67%. Oily substance.
'H-NMR (CDC13) 6: 3.18 (2H, t, J = 6.9Hz),4.50(2H,t,J=6.9Hz),6.61 (1H,d,J=
8.1 Hz), 6.88 (I H, d, J = 7.5 Hz), 7.17 (1 H, dd, J = 8.4, 2.1 Hz), 7.22 (1 H, s), 7.37 (1 H, t, J = 2.1 Hz), 7.49 (1 H, t, J = 7.8 Hz).
Reference Example 12 2-Chloro-6-(2-(2,4-dichlorophenyl)ethoxy)pyridine The titled compound was obtained using 2-(2,4-dichlorophenyl)ethanol in the same manner as in Reference Example 7. Yield: 67%. Oily substance.
'H-NMR (CDC13) 6: 3.18 (2H, t, J = 6.9Hz),4.50(2H,t,J=6.9Hz),6.61 (1H,d,J=
8.1 Hz), 6.88 (I H, d, J = 7.5 Hz), 7.17 (1 H, dd, J = 8.4, 2.1 Hz), 7.22 (1 H, s), 7.37 (1 H, t, J = 2.1 Hz), 7.49 (1 H, t, J = 7.8 Hz).
[0097]
Reference Example 13 2-Chloro-6-(2-(3-methoxyphenyl)ethoxy)pyridine The titled compound was obtained using 2-(3-methoxyphenyl)ethanol in the same manner as in Reference Example 7. Yield: 67%. Oily substance.
'H-NMR (CDC13) 6 : 3.05 (2H, t, J = 6.9 Hz), 3.80 (3H, s), 4.50 (2H, t, J =
6.9 Hz), 6.62 (1 H, d, J = 8.1 Hz), 6.74 - 6.89 (4H, m), 7.21 (1 H, t, J = 8.1 Hz), 7.47 (1 H, t, J =
7.5 Hz).
Reference Example 13 2-Chloro-6-(2-(3-methoxyphenyl)ethoxy)pyridine The titled compound was obtained using 2-(3-methoxyphenyl)ethanol in the same manner as in Reference Example 7. Yield: 67%. Oily substance.
'H-NMR (CDC13) 6 : 3.05 (2H, t, J = 6.9 Hz), 3.80 (3H, s), 4.50 (2H, t, J =
6.9 Hz), 6.62 (1 H, d, J = 8.1 Hz), 6.74 - 6.89 (4H, m), 7.21 (1 H, t, J = 8.1 Hz), 7.47 (1 H, t, J =
7.5 Hz).
[0098]
Reference Example 14 2-Chloro-6-(2-((2,4-dichlorobenzyl)oxy)pyridine The titled compound was obtained using (2,4-dichlorophenyl)methanol in the same manner as in Reference Example 7. Yield: 51 %. Oily substance.
' H-NMR (CDC13) 6 : 5.42 (2H, s), 6.72 (1 H, d, J = 8.1 Hz), 6.93 (1 H, d, J =
7.5 Hz), 7.22 - 7.2 8 (1 H, m), 7.41 (1 H, d, J = 2.7 Hz), 7.47 (1 H, d, J =
8.4Hz),7.54(1H,t,J=
7.8 Hz).
Reference Example 14 2-Chloro-6-(2-((2,4-dichlorobenzyl)oxy)pyridine The titled compound was obtained using (2,4-dichlorophenyl)methanol in the same manner as in Reference Example 7. Yield: 51 %. Oily substance.
' H-NMR (CDC13) 6 : 5.42 (2H, s), 6.72 (1 H, d, J = 8.1 Hz), 6.93 (1 H, d, J =
7.5 Hz), 7.22 - 7.2 8 (1 H, m), 7.41 (1 H, d, J = 2.7 Hz), 7.47 (1 H, d, J =
8.4Hz),7.54(1H,t,J=
7.8 Hz).
[0099]
Reference Example 15 3-Chloro-5-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine The titled compound was obtained using 5-chloropyridin-3-ol in the same manner as in Reference Example 7. Yield: 78%. Melting point: 101 - 102 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.06 (2H, t, J = 6.9 Hz), 3.87 (3H, s), 3.88 (3H, s), 4.19 (2H, t, J
= 6.9 Hz), 6.77 - 6.82 (3H, m), 7.16- 7.20 (1 H, m), 8.15-8.20 (2H, m).
Reference Example 15 3-Chloro-5-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine The titled compound was obtained using 5-chloropyridin-3-ol in the same manner as in Reference Example 7. Yield: 78%. Melting point: 101 - 102 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.06 (2H, t, J = 6.9 Hz), 3.87 (3H, s), 3.88 (3H, s), 4.19 (2H, t, J
= 6.9 Hz), 6.77 - 6.82 (3H, m), 7.16- 7.20 (1 H, m), 8.15-8.20 (2H, m).
[0100]
Reference Example 16 2-Chloro-4-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine A DMF (10 mL) suspension of 2-chloro-4-nitropyridine (1.10 g, 6.31 mmol) and 2-(3,4-dimethoxyphenyl)ethanol (1.23 g, 6.75 mmol) was added at 0 C to a DMF
(30 mL) suspension of sodium hydride (60% liquid paraffin dispersion, 504 mg, 12.6 mmol), and the mixture was stirred for 1 hour at room temperature. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined extract was washed with water, dried over magnesium sulfate, and then concentrated at reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate 1:1) to give 1.87 g of the titled compound (yield:
quantitative). Melting point: 116 - 117 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 3.05 (2H, t, J = 6.9 Hz), 3.87 (3H, s), 3.88 (3H, s), 4.19 (2H, t, J
= 6.9 Hz), 6.70 - 6.83 (5H, m), 8.17 (1H, d, J = 5.7 Hz).
Reference Example 16 2-Chloro-4-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine A DMF (10 mL) suspension of 2-chloro-4-nitropyridine (1.10 g, 6.31 mmol) and 2-(3,4-dimethoxyphenyl)ethanol (1.23 g, 6.75 mmol) was added at 0 C to a DMF
(30 mL) suspension of sodium hydride (60% liquid paraffin dispersion, 504 mg, 12.6 mmol), and the mixture was stirred for 1 hour at room temperature. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined extract was washed with water, dried over magnesium sulfate, and then concentrated at reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate 1:1) to give 1.87 g of the titled compound (yield:
quantitative). Melting point: 116 - 117 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 3.05 (2H, t, J = 6.9 Hz), 3.87 (3H, s), 3.88 (3H, s), 4.19 (2H, t, J
= 6.9 Hz), 6.70 - 6.83 (5H, m), 8.17 (1H, d, J = 5.7 Hz).
[0101]
Reference Example 17 2-(2-(3,4-Dimethoxyphenyl)ethoxy)-4-iodopyridine Sodium hydride (60% liquid paraffin dispersion, 358 mg, 8.96 mmol) was added at 0 C to a DMF (3 mL) solution of 2-fluoro-4-iodopyridine (1.0 g, 4.48 mmol) and 2-(3,4-dimethoxyphenyl)ethanol (0.9 g, 5.0 mmol), and the mixture was stirred for 16 hours at room temperature. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined extract was washed with water, dried over magnesium sulfate, and then concentrated at reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate 1:1) to give 0.88 g of the titled compound (yield: 51%). Oily substance.
'H-NMR (CDC13) 6 : 3.00 (2H, t, J = 6.9 Hz), 3.86 (3H, s), 3.87 (3H, s), 4.46 (2H, t, J
= 6.9 Hz), 6.77 - 6.80 (3H, m), 7.13 - 7.21 (2H, m), 7.79 (1H, d, J = 5.4 Hz).
Reference Example 17 2-(2-(3,4-Dimethoxyphenyl)ethoxy)-4-iodopyridine Sodium hydride (60% liquid paraffin dispersion, 358 mg, 8.96 mmol) was added at 0 C to a DMF (3 mL) solution of 2-fluoro-4-iodopyridine (1.0 g, 4.48 mmol) and 2-(3,4-dimethoxyphenyl)ethanol (0.9 g, 5.0 mmol), and the mixture was stirred for 16 hours at room temperature. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined extract was washed with water, dried over magnesium sulfate, and then concentrated at reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate 1:1) to give 0.88 g of the titled compound (yield: 51%). Oily substance.
'H-NMR (CDC13) 6 : 3.00 (2H, t, J = 6.9 Hz), 3.86 (3H, s), 3.87 (3H, s), 4.46 (2H, t, J
= 6.9 Hz), 6.77 - 6.80 (3H, m), 7.13 - 7.21 (2H, m), 7.79 (1H, d, J = 5.4 Hz).
[0102]
Reference Example 18 2-(2-(3,4-Dimethoxyphenyl)ethoxy)-6-(3-nitrophenyl)pyridine The titled compound was obtained using 2-chloro-6-(2-(3,4-dimethoxyphenyl)ethoxy)pyri dine obtained in Reference Example 7 in the same manner as in Reference Example 2. Yield: 92%.
'H-NMR (CDC13) 6 : 3.10 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.64 (2H, t, J
= 7.2 Hz), 6.75 (1 H, d, J = 8.1 Hz), 6.83 - 6.91 (31-1, m), 7.39 (1 H, d, J =
7.5 Hz), 7.60 (1H, t, J = 7.5 Hz), 7.67 (1H, t, J = 7.5 Hz), 8.19 - 8.24 (1H, m), 8.30 -8.36 (1H, m), 8.88 (1 H, s).
Reference Example 18 2-(2-(3,4-Dimethoxyphenyl)ethoxy)-6-(3-nitrophenyl)pyridine The titled compound was obtained using 2-chloro-6-(2-(3,4-dimethoxyphenyl)ethoxy)pyri dine obtained in Reference Example 7 in the same manner as in Reference Example 2. Yield: 92%.
'H-NMR (CDC13) 6 : 3.10 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.64 (2H, t, J
= 7.2 Hz), 6.75 (1 H, d, J = 8.1 Hz), 6.83 - 6.91 (31-1, m), 7.39 (1 H, d, J =
7.5 Hz), 7.60 (1H, t, J = 7.5 Hz), 7.67 (1H, t, J = 7.5 Hz), 8.19 - 8.24 (1H, m), 8.30 -8.36 (1H, m), 8.88 (1 H, s).
[0103]
Reference Example 19 3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)aniline The titled compound was obtained using 2-(2-(3,4-dimethoxyphenyl)ethoxy)-6-(3-nitrophenyl)pyridine obtained in Reference Example 18 in the same manner as in Reference Example 3. Yield: 80%. Melting point: 103 - 104 C.
'H-NMR (CDC13) 8 : 3.08 (2H, t, J = 7.2 Hz), 3.74 (2H, br s), 3.86 (3H, s), 3.87 (3H, s), 4.61(2H, t, J = 7.2 Hz), 6.67 (111, d, J = 7.8 Hz), 6.67-6.72 (1 H, m), 6.79 - 6.87 (311, m), 7.17 - 7.29 (2H, m), 7.35 - 7.58 (2H, m), 7.51 (1H, t, J = 7.5 Hz).
Reference Example 19 3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)aniline The titled compound was obtained using 2-(2-(3,4-dimethoxyphenyl)ethoxy)-6-(3-nitrophenyl)pyridine obtained in Reference Example 18 in the same manner as in Reference Example 3. Yield: 80%. Melting point: 103 - 104 C.
'H-NMR (CDC13) 8 : 3.08 (2H, t, J = 7.2 Hz), 3.74 (2H, br s), 3.86 (3H, s), 3.87 (3H, s), 4.61(2H, t, J = 7.2 Hz), 6.67 (111, d, J = 7.8 Hz), 6.67-6.72 (1 H, m), 6.79 - 6.87 (311, m), 7.17 - 7.29 (2H, m), 7.35 - 7.58 (2H, m), 7.51 (1H, t, J = 7.5 Hz).
[0104]
Reference Example 20 Ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoate and ethyl 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoate Sodium hydride (60% liquid paraffin dispersion, 324 mg, 8.12 mmol) was added at 0 C to a DMF (50 mL) solution of 2,4-dichloropyrimidine (1.0 g, 6.71 mmol) and 2-(3,4-dimethoxyphenyl)ethanol (1.35 g, 7.38 mmol), and the mixture was stirred for 3 hours at 60 C. Water was added to the reaction solution, and the product was extracted with ethyl acetate. An ether mixture (1.06 g) was obtained. A 2 N sodium carbonate aqueous solution (20 mL)-1,2-dimethoxyethane (20 mL) mixture of tetrakis(triphenylphosphine)palladium (0) (125 mg, 0.11 mmol), (3-(ethoxycarbonyl)phenyl)boronic acid (837 mg, 4.32 mmol), and the above mixture was reacted for 16 hours at 90 C in a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, then dried over anhydrous sodium sulfate, and then concentrated at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 1:1) to give 840 mg (yield: 31%) of ethyl 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoate and 240 mg (yield: 9%) of ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoate.
Ethyl 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoate Melting point: 101 - 102 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.41 (3H, t, J = 7.2 Hz), 3.10 (2H, t, J = 7.2 Hz), 3.86(3H, s), 3.88 (3H, s), 4.42 (2H, q, J = 7.2 Hz), 4.71 (2H, t, J = 7.2 Hz), 6.64 (1H, d, J = 5.4 Hz), 6.79-6.90(3H,m),7.54(1H,t,J=7.5Hz),8.15(1H, d, J = 7.5Hz),8.52(1H,d,J=
5.7 Hz), 8:60 (1 H, d, J = 8.1 Hz), 9.07 (1 H, s).
Ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoate Melting point: 94 - 95 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.42 (3H, t, J = 7.2 Hz), 3.14 (2H, t, J = 6.9 Hz), 3.86(3H, s), 3.88 (3H, s), 4.42 (2H, q, J = 7.2 Hz), 4.66 (2H, t, J = 6.9 Hz), 6.79 - 6.90 (3H, m), 7.41 (1H,d,J=5.1 Hz),7.56(1H,t,J=7.8Hz),8.17(1H,d,J=7.8Hz),8.32(1H,d,J=
7.8 Hz), 8.5 7 (1 H, d, J = 5.1 Hz), 8.69 (1 H, s).
Reference Example 20 Ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoate and ethyl 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoate Sodium hydride (60% liquid paraffin dispersion, 324 mg, 8.12 mmol) was added at 0 C to a DMF (50 mL) solution of 2,4-dichloropyrimidine (1.0 g, 6.71 mmol) and 2-(3,4-dimethoxyphenyl)ethanol (1.35 g, 7.38 mmol), and the mixture was stirred for 3 hours at 60 C. Water was added to the reaction solution, and the product was extracted with ethyl acetate. An ether mixture (1.06 g) was obtained. A 2 N sodium carbonate aqueous solution (20 mL)-1,2-dimethoxyethane (20 mL) mixture of tetrakis(triphenylphosphine)palladium (0) (125 mg, 0.11 mmol), (3-(ethoxycarbonyl)phenyl)boronic acid (837 mg, 4.32 mmol), and the above mixture was reacted for 16 hours at 90 C in a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, then dried over anhydrous sodium sulfate, and then concentrated at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 1:1) to give 840 mg (yield: 31%) of ethyl 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoate and 240 mg (yield: 9%) of ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoate.
Ethyl 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoate Melting point: 101 - 102 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.41 (3H, t, J = 7.2 Hz), 3.10 (2H, t, J = 7.2 Hz), 3.86(3H, s), 3.88 (3H, s), 4.42 (2H, q, J = 7.2 Hz), 4.71 (2H, t, J = 7.2 Hz), 6.64 (1H, d, J = 5.4 Hz), 6.79-6.90(3H,m),7.54(1H,t,J=7.5Hz),8.15(1H, d, J = 7.5Hz),8.52(1H,d,J=
5.7 Hz), 8:60 (1 H, d, J = 8.1 Hz), 9.07 (1 H, s).
Ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoate Melting point: 94 - 95 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.42 (3H, t, J = 7.2 Hz), 3.14 (2H, t, J = 6.9 Hz), 3.86(3H, s), 3.88 (3H, s), 4.42 (2H, q, J = 7.2 Hz), 4.66 (2H, t, J = 6.9 Hz), 6.79 - 6.90 (3H, m), 7.41 (1H,d,J=5.1 Hz),7.56(1H,t,J=7.8Hz),8.17(1H,d,J=7.8Hz),8.32(1H,d,J=
7.8 Hz), 8.5 7 (1 H, d, J = 5.1 Hz), 8.69 (1 H, s).
[0105]
Reference Example 21 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoic acid 1 N sodium hydroxide aqueous solution (5 mL, 5 mmol) was added at room temperature to an ethanol (30 mL) solution of ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoate (240 mg, 0.588 mmol) obtained in Reference Example 20, and the mixture was stirred for 2 hours at 60 C and then concentrated at reduced pressure. Water and hydrochloric acid were added to the reaction solution to make the aqueous layer acidic, and the product was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, and then dried over anhydrous sodium sulfate. The solvent was distilled off at reduced pressure, and the resulting residue was crystallized from ethyl acetate-hexane to give 200 mg of the titled compound (yield: 89%). Melting point: 171 - 172 C (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 :3.15 (2H, t, J = 6.9 Hz), 3.85(3H, s), 3.89 (3H, s), 4.68 (2H, t, J =
6.9 Hz), 6.80 - 6.92 (3 H, m), 7.43 (1 H, d, J = 5.4 Hz), 7.62 (1 H, t, J =
7.8 Hz), 8.25 (1H,d,J=7.8Hz),8.38(1H,d,J=7.8Hz),8.62(1H,d, J = 5.4 Hz), 8.79 (1 H, s), IH
unconfirmed.
Reference Example 21 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoic acid 1 N sodium hydroxide aqueous solution (5 mL, 5 mmol) was added at room temperature to an ethanol (30 mL) solution of ethyl 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoate (240 mg, 0.588 mmol) obtained in Reference Example 20, and the mixture was stirred for 2 hours at 60 C and then concentrated at reduced pressure. Water and hydrochloric acid were added to the reaction solution to make the aqueous layer acidic, and the product was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, and then dried over anhydrous sodium sulfate. The solvent was distilled off at reduced pressure, and the resulting residue was crystallized from ethyl acetate-hexane to give 200 mg of the titled compound (yield: 89%). Melting point: 171 - 172 C (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 :3.15 (2H, t, J = 6.9 Hz), 3.85(3H, s), 3.89 (3H, s), 4.68 (2H, t, J =
6.9 Hz), 6.80 - 6.92 (3 H, m), 7.43 (1 H, d, J = 5.4 Hz), 7.62 (1 H, t, J =
7.8 Hz), 8.25 (1H,d,J=7.8Hz),8.38(1H,d,J=7.8Hz),8.62(1H,d, J = 5.4 Hz), 8.79 (1 H, s), IH
unconfirmed.
[0106]
Reference Example 22 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoic acid The titled compound was obtained using ethyl 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoate obtained in Reference Example 20 in the same manner as in Reference Example 21. Yield: 84%. Melting point: 193 -194 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 3.12 (2H, t, J = 7.2 Hz), 3.87(3H, s), 3.89 (3H, s), 4.74 (2H, t, J =
7.2 Hz), 6.69 (1 H, d, J = 5.7 Hz), 6.82 - 6.90 (3H, m), 7.59 (1 H, t, J = 7.8 Hz), 8.23 (1 H, d, J = 7.5 Hz), 8.63 (1 H, d, J = 5.7 Hz), 8.66 (1 H, d, J = 8.1 Hz), 9.26 (1 H, s), 1 H
unconfirmed.
Reference Example 22 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoic acid The titled compound was obtained using ethyl 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoate obtained in Reference Example 20 in the same manner as in Reference Example 21. Yield: 84%. Melting point: 193 -194 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 3.12 (2H, t, J = 7.2 Hz), 3.87(3H, s), 3.89 (3H, s), 4.74 (2H, t, J =
7.2 Hz), 6.69 (1 H, d, J = 5.7 Hz), 6.82 - 6.90 (3H, m), 7.59 (1 H, t, J = 7.8 Hz), 8.23 (1 H, d, J = 7.5 Hz), 8.63 (1 H, d, J = 5.7 Hz), 8.66 (1 H, d, J = 8.1 Hz), 9.26 (1 H, s), 1 H
unconfirmed.
[0107]
Reference Example 23 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid A mixture of 2-chloro-6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine (1.76 g, 5.99 mmol) obtained in Reference Example 7, (3-(ethoxycarbonyl)phenyl)boronic acid (1.28 g, 6.59 mmol), and tetrakis(triphenylphosphine)palladium (0) (207 mg, 0.18 mmol) in 2 N sodium carbonate aqueous solution (20 mL)-1,2-dimethoxyethane (20 mL) was reacted for 16 hours at 90 C in a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, then dried over anhydrous sodium sulfate, and then concentrated at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 2:3) to give 1.36 g of ethyl 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoate. 1 N sodium hydroxide aqueous solution (10 mL, 10 mmol) was added at room temperature to an ethanol (50 mL) solution of this compound, and the mixture was stirred for 2 hours at 60 C and was then concentrated at reduced pressure. Water and hydrochloric acid were added to the reaction solution to make the aqueous layer acidic, and the product was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, and then dried over anhydrous sodium sulfate. The solvent was distilled off at reduced pressure, and the resulting residue was crystallized from ethyl acetate-hexane to give 820 mg of the titled compound (yield: 36%). Melting point: 147 - 148 C.
' H-NMR (CDC13) 6 : 3.11 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.66 (2H, t, J
= 7.2 Hz), 6.72 (1 H, d, J = 8.1 Hz), 6.82 - 6.91 (3H, m), 7.41 (1 H, d, J =
7.5 Hz), 7.57 (1H,t;J=7.5Hz),7.66(1H,t,J=7.5Hz),8.14(1H,dd,J=7.5, 1.2 Hz). 8.3 0 (1 H, d, J
= 6.6 Hz), 8.76 (1 H, s), 1 H unconfirmed.
Reference Example 23 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid A mixture of 2-chloro-6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine (1.76 g, 5.99 mmol) obtained in Reference Example 7, (3-(ethoxycarbonyl)phenyl)boronic acid (1.28 g, 6.59 mmol), and tetrakis(triphenylphosphine)palladium (0) (207 mg, 0.18 mmol) in 2 N sodium carbonate aqueous solution (20 mL)-1,2-dimethoxyethane (20 mL) was reacted for 16 hours at 90 C in a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, then dried over anhydrous sodium sulfate, and then concentrated at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 2:3) to give 1.36 g of ethyl 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoate. 1 N sodium hydroxide aqueous solution (10 mL, 10 mmol) was added at room temperature to an ethanol (50 mL) solution of this compound, and the mixture was stirred for 2 hours at 60 C and was then concentrated at reduced pressure. Water and hydrochloric acid were added to the reaction solution to make the aqueous layer acidic, and the product was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, and then dried over anhydrous sodium sulfate. The solvent was distilled off at reduced pressure, and the resulting residue was crystallized from ethyl acetate-hexane to give 820 mg of the titled compound (yield: 36%). Melting point: 147 - 148 C.
' H-NMR (CDC13) 6 : 3.11 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.66 (2H, t, J
= 7.2 Hz), 6.72 (1 H, d, J = 8.1 Hz), 6.82 - 6.91 (3H, m), 7.41 (1 H, d, J =
7.5 Hz), 7.57 (1H,t;J=7.5Hz),7.66(1H,t,J=7.5Hz),8.14(1H,dd,J=7.5, 1.2 Hz). 8.3 0 (1 H, d, J
= 6.6 Hz), 8.76 (1 H, s), 1 H unconfirmed.
[0108]
Reference Example 24 3'-(2-(3,4-dimethoxyphenyl)ethoxy)biphenyl-3-carboxylic acid The titled compound was obtained using 4-(2-(3-bromophenoxy)ethyl)-1,2-dimethoxybenzene obtained in Reference Example 8 was used in the same manner as in Reference Example 23. Yield: 62%. Melting point: 100 - 102 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 3.08 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.89 (3H, s), 4.23 (2H, t, J
= 7.2 Hz), 6.79 - 7.00 (41-1, m), 7.05 - 7.25 (2H, m), 7.37 (1H, t, J = 8.1 Hz), 7.53 (21-1, t, J = 7.5 Hz), 7.82 (1 H, dd, J = 7.5, 1.2 Hz), 8.06 - 8.12 (1 H, m), 8.53 (1 H, m).
Reference Example 24 3'-(2-(3,4-dimethoxyphenyl)ethoxy)biphenyl-3-carboxylic acid The titled compound was obtained using 4-(2-(3-bromophenoxy)ethyl)-1,2-dimethoxybenzene obtained in Reference Example 8 was used in the same manner as in Reference Example 23. Yield: 62%. Melting point: 100 - 102 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 3.08 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.89 (3H, s), 4.23 (2H, t, J
= 7.2 Hz), 6.79 - 7.00 (41-1, m), 7.05 - 7.25 (2H, m), 7.37 (1H, t, J = 8.1 Hz), 7.53 (21-1, t, J = 7.5 Hz), 7.82 (1 H, dd, J = 7.5, 1.2 Hz), 8.06 - 8.12 (1 H, m), 8.53 (1 H, m).
[0109]
Reference Example 25 3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridine obtained in Reference Example 9 in the same manner as in Reference Example 23. Yield: 45%. Melting point: 135 - 136 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 3.21 (2H,t,J=6.9Hz),4.69(21-1,t,J=6.9Hz),6.71 (1H,d,J=
8.4 Hz), 7.40 - 7.72 (7H, m), 8.14 (1 H, d, J = 7.5 Hz), 8.29 (1 H, d, J = 8.4 Hz), 8.75 (I H, s), I H unconfirmed.
Reference Example 25 3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridine obtained in Reference Example 9 in the same manner as in Reference Example 23. Yield: 45%. Melting point: 135 - 136 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 3.21 (2H,t,J=6.9Hz),4.69(21-1,t,J=6.9Hz),6.71 (1H,d,J=
8.4 Hz), 7.40 - 7.72 (7H, m), 8.14 (1 H, d, J = 7.5 Hz), 8.29 (1 H, d, J = 8.4 Hz), 8.75 (I H, s), I H unconfirmed.
[0110]
Reference Example 26 3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(3-fluorophenyl)ethoxy)pyridine obtained in Reference Example 10 in the same manner as in Reference Example 23. Yield: 46%. Melting point: 142 - 143 C. (Ethyl acetate-hexane).
HNMR(CDC13)6:3.16(2H,t,J=6.9Hz),4.67(2H,t,J=6.9Hz),6.72(1H,d,J
7.8 Hz), 6.88 - 6.96 (1 H, m), 7.05 (1 H, d, J = 10.2 Hz), 7.12 (1 H, d, J =
7.8 Hz), 7.23 -7.32(1H,m),7.41 (1H,d,J=7.2Hz),7.57(11-1,t,J=7.8Hz),7.66(1H,t,J=7.5Hz), 8.14 (1 H, d, J = 7.8 Hz), 8.29 (1 H, d, J = 8.1 Hz), 8.76 (1 H, s), 1 H
unconfirmed.
Reference Example 26 3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(3-fluorophenyl)ethoxy)pyridine obtained in Reference Example 10 in the same manner as in Reference Example 23. Yield: 46%. Melting point: 142 - 143 C. (Ethyl acetate-hexane).
HNMR(CDC13)6:3.16(2H,t,J=6.9Hz),4.67(2H,t,J=6.9Hz),6.72(1H,d,J
7.8 Hz), 6.88 - 6.96 (1 H, m), 7.05 (1 H, d, J = 10.2 Hz), 7.12 (1 H, d, J =
7.8 Hz), 7.23 -7.32(1H,m),7.41 (1H,d,J=7.2Hz),7.57(11-1,t,J=7.8Hz),7.66(1H,t,J=7.5Hz), 8.14 (1 H, d, J = 7.8 Hz), 8.29 (1 H, d, J = 8.1 Hz), 8.76 (1 H, s), 1 H
unconfirmed.
[0111]
Reference Example 27 3-(6-(2-(3-methylphenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(3-methylphenyl)ethoxy)pyridine obtained in Reference Example 11 in the same manner as in Reference Example 23. Yield: 27%. Melting point: 125 - 126 C. (Ethyl acetate-hexane).
H-NMR (CDC13) 6 : 2.35 (3H, s), 3.13 (2H, t, J = 7.2 Hz), 4.66 (2H, t, J = 7.2 Hz), 6.72 (1 H, d, J = 8.1 Hz),7.05(1H,d,J=6.3Hz),7.14-7.25(3H,m),7.40(1H,d,J=
7.8 Hz), 7.5 7 (1 H, t, J = 8.1 Hz), 7.66 (1 H, t, J = 7.5 Hz), 8.14 (1 H, d, J = 7.5 Hz), 8.3 2 (1 H, d, J = 7.8 Hz), 8.76 (1 H, s), 1 H unconfirmed.
Reference Example 27 3-(6-(2-(3-methylphenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(3-methylphenyl)ethoxy)pyridine obtained in Reference Example 11 in the same manner as in Reference Example 23. Yield: 27%. Melting point: 125 - 126 C. (Ethyl acetate-hexane).
H-NMR (CDC13) 6 : 2.35 (3H, s), 3.13 (2H, t, J = 7.2 Hz), 4.66 (2H, t, J = 7.2 Hz), 6.72 (1 H, d, J = 8.1 Hz),7.05(1H,d,J=6.3Hz),7.14-7.25(3H,m),7.40(1H,d,J=
7.8 Hz), 7.5 7 (1 H, t, J = 8.1 Hz), 7.66 (1 H, t, J = 7.5 Hz), 8.14 (1 H, d, J = 7.5 Hz), 8.3 2 (1 H, d, J = 7.8 Hz), 8.76 (1 H, s), 1 H unconfirmed.
[0112]
Reference Example 28 3-(6-(2-(2,4-dichlorophenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(2,4-dichlorophenyl)ethoxy)pyridine obtained in Reference Example 12 in the same manner as in Reference Example 23. Yield: 40%. Melting point: 199 - 200 C. (Ethyl acetate-hexane).
H-NMR (CDC13) 6 : 3.27 (2H, t, J = 6.9 Hz), 4.68 (2H, t, J = 6.9 Hz), 6.70 (1H, d, J =
8.1 Hz), 7.18 - 7.26 (1 H, m), 7.30- 7.43 (3H, m), 7.57 (1 H, t, J = 7.8 Hz), 7.66 (1 H, t, J
= 7.8 Hz), 8.15 (1 H, d, J = 7.8 Hz), 8.29 (1 H, d, J = 7.8 Hz), 8.77 (1 H, s), 1 H
unconfirmed.
Reference Example 28 3-(6-(2-(2,4-dichlorophenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(2,4-dichlorophenyl)ethoxy)pyridine obtained in Reference Example 12 in the same manner as in Reference Example 23. Yield: 40%. Melting point: 199 - 200 C. (Ethyl acetate-hexane).
H-NMR (CDC13) 6 : 3.27 (2H, t, J = 6.9 Hz), 4.68 (2H, t, J = 6.9 Hz), 6.70 (1H, d, J =
8.1 Hz), 7.18 - 7.26 (1 H, m), 7.30- 7.43 (3H, m), 7.57 (1 H, t, J = 7.8 Hz), 7.66 (1 H, t, J
= 7.8 Hz), 8.15 (1 H, d, J = 7.8 Hz), 8.29 (1 H, d, J = 7.8 Hz), 8.77 (1 H, s), 1 H
unconfirmed.
[0113]
Reference Example 29 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(3-methoxyphenyl)ethoxy)pyridine obtained in Reference Example 13 in the same manner as in Reference Example 23. Yield: 40%. Melting point: 156 - 157 C. (Ethyl acetate-hexane).
'H-NMR (CDC13)8 : 3.14(2H,t,J=7.2Hz),3.80(3H,s),4.67(2H,t,J=7.2Hz), 6.72 (1 H, d, J = 7.2 Hz), 6.75 - 6.90 (1 H, m), 6.87 - 6.90 (1 H, m), 6.94 (1 H, t, J = 7.8 Hz), 7.25 (1 H, t, J = 7.8 Hz), 7.40 (1 H, d, J = 7.5 Hz), 7.57 (1 H, t, J =
7.8 Hz), 7.65 (1 H, t, J = 7.5 Hz), 8.10 - 8.16 (1 H, m), 8.28 - 8.33 (1 H, m), 8.75 (1 H, t, J = 1.5 Hz), 1 H unconfirmed.
Reference Example 29 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-(3-methoxyphenyl)ethoxy)pyridine obtained in Reference Example 13 in the same manner as in Reference Example 23. Yield: 40%. Melting point: 156 - 157 C. (Ethyl acetate-hexane).
'H-NMR (CDC13)8 : 3.14(2H,t,J=7.2Hz),3.80(3H,s),4.67(2H,t,J=7.2Hz), 6.72 (1 H, d, J = 7.2 Hz), 6.75 - 6.90 (1 H, m), 6.87 - 6.90 (1 H, m), 6.94 (1 H, t, J = 7.8 Hz), 7.25 (1 H, t, J = 7.8 Hz), 7.40 (1 H, d, J = 7.5 Hz), 7.57 (1 H, t, J =
7.8 Hz), 7.65 (1 H, t, J = 7.5 Hz), 8.10 - 8.16 (1 H, m), 8.28 - 8.33 (1 H, m), 8.75 (1 H, t, J = 1.5 Hz), 1 H unconfirmed.
[0114]
Reference Example 30 3-(6-((2,4-dichlorobenzyl)oxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-((2,4-dichlorobenzyl)oxy)pyridine obtained in Reference Example 14 in the same manner as in Reference Example 23. Yield: 49%. Melting point: 186 - 187 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) b : 5.60 (2H, s), 6.82 (1H, d, J = 8.4 Hz), 7.22 - 7.27 (1H, m), 7.42 -7.61(4H,m),7.71(1H,d,J=8.1Hz),8.14(1H,t, J = 7.8 Hz), 8.2 8 (1 H, d, J = 8.1 Hz).8.71 (1 H, t, J = 1.8 Hz), 1 H unconfirmed.
Reference Example 30 3-(6-((2,4-dichlorobenzyl)oxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-6-(2-((2,4-dichlorobenzyl)oxy)pyridine obtained in Reference Example 14 in the same manner as in Reference Example 23. Yield: 49%. Melting point: 186 - 187 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) b : 5.60 (2H, s), 6.82 (1H, d, J = 8.4 Hz), 7.22 - 7.27 (1H, m), 7.42 -7.61(4H,m),7.71(1H,d,J=8.1Hz),8.14(1H,t, J = 7.8 Hz), 8.2 8 (1 H, d, J = 8.1 Hz).8.71 (1 H, t, J = 1.8 Hz), 1 H unconfirmed.
[0115]
Reference Example 31 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-4-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine obtained in Reference Example 16 in the same manner as in Reference Example 23. Yield: 67%. Melting point: 194 - 195 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) S : 3.11 (2H, t, J = 6.9 Hz), 3.87(3H, s), 3.90 (3H, s), 4.31 (2H, t, J =
6.9 Hz), 6.70 -6.90 (4H, m), 7.29 (1 H, d, J = 2.4 Hz), 7.56 (1 H, t, J = 7.5 Hz), 8.04 (1 H, d, J = 7.8 Hz), 8.19 (1 H, d, J = 7.5 Hz).8.81 (1 H, d, J = 6.0 Hz), 9.01 (1 H, s), I H
=unconfirmed.
Reference Example 31 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using 2-chloro-4-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine obtained in Reference Example 16 in the same manner as in Reference Example 23. Yield: 67%. Melting point: 194 - 195 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) S : 3.11 (2H, t, J = 6.9 Hz), 3.87(3H, s), 3.90 (3H, s), 4.31 (2H, t, J =
6.9 Hz), 6.70 -6.90 (4H, m), 7.29 (1 H, d, J = 2.4 Hz), 7.56 (1 H, t, J = 7.5 Hz), 8.04 (1 H, d, J = 7.8 Hz), 8.19 (1 H, d, J = 7.5 Hz).8.81 (1 H, d, J = 6.0 Hz), 9.01 (1 H, s), I H
=unconfirmed.
[0116]
Reference Example 32 3-(5-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-3-yl)benzoic acid The titled compound was obtained using 3-chloro-5-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine obtained in Reference Example 15 in the same manner as in Reference Example 23. Yield: 47%. Melting point: 181 - 182 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.11 (2H, t, J = 6.6 Hz), 3.86(3H, s), 3.89 (3H, s), 4.31 (2H, t, J =
6.6 Hz), 6.81 - 6.85 (3 H, m), 7.47 (1 H, s), 7.58 (1 H, t, J = 7.8 Hz), 7.79 (1 H, d, J = 7.2 Hz), 8.16 (1 H, d, J = 7.8 Hz), 8.3 7 (1 H, s), 8.41 (1 H, s), 8.5 7 (1 H, s), 1 H unconfirmed.
Reference Example 32 3-(5-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-3-yl)benzoic acid The titled compound was obtained using 3-chloro-5-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine obtained in Reference Example 15 in the same manner as in Reference Example 23. Yield: 47%. Melting point: 181 - 182 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.11 (2H, t, J = 6.6 Hz), 3.86(3H, s), 3.89 (3H, s), 4.31 (2H, t, J =
6.6 Hz), 6.81 - 6.85 (3 H, m), 7.47 (1 H, s), 7.58 (1 H, t, J = 7.8 Hz), 7.79 (1 H, d, J = 7.2 Hz), 8.16 (1 H, d, J = 7.8 Hz), 8.3 7 (1 H, s), 8.41 (1 H, s), 8.5 7 (1 H, s), 1 H unconfirmed.
[0117]
Reference Example 33 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-4-yl)benzoic acid The titled compound was obtained using 2-(2-(3,4-dimethoxyphenyl)ethoxy)-4-iodopyridine obtained in Reference Example 17 in the same manner as in Reference Example 23. Yield: 58%. Melting point: 148 - 149 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) S : 3.08 (2H, t, J = 6.9 Hz), 3.86(3H, s), 3.88 (3H, s), 4.57 (2H, t, J =
6.9 Hz), 6.80 - 6.87 (3H, m), 6.99 (1 H, s), 7.14 (1 H, dd, J = 5.4, 1.8 Hz), 7.59 (1 H, t, J
= 7.8 Hz), 7.85 (1 H, dd, J = 5.4, 1.8 Hz), 8.17 (1 H, dd, J = 7.8, 1.2 Hz), 8.24 (1 H, d, J =
5.1 Hz), 8.36 (1 H, s), 1 H unconfirmed.
Reference Example 33 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-4-yl)benzoic acid The titled compound was obtained using 2-(2-(3,4-dimethoxyphenyl)ethoxy)-4-iodopyridine obtained in Reference Example 17 in the same manner as in Reference Example 23. Yield: 58%. Melting point: 148 - 149 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) S : 3.08 (2H, t, J = 6.9 Hz), 3.86(3H, s), 3.88 (3H, s), 4.57 (2H, t, J =
6.9 Hz), 6.80 - 6.87 (3H, m), 6.99 (1 H, s), 7.14 (1 H, dd, J = 5.4, 1.8 Hz), 7.59 (1 H, t, J
= 7.8 Hz), 7.85 (1 H, dd, J = 5.4, 1.8 Hz), 8.17 (1 H, dd, J = 7.8, 1.2 Hz), 8.24 (1 H, d, J =
5.1 Hz), 8.36 (1 H, s), 1 H unconfirmed.
[0118]
Reference Example 34 Methyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoate A DMF (138 mL) mixture of 2,4-dichlorophenol (5.0 g, 30.7 mmol), 2,6-dichloropyridine (4.1 g, 27.9 mmol), and potassium carbonate (4.2 g, 30.7 mmol) was added at room temperature, the mixture was stirred for 16 hours at 30 C, cold water (300 mL) was then poured in, and the product was extracted with ethyl acetate.
The organic layer was washed with saturated brine and dried over sodium sulfate.
The solvent was distilled off at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 3:7) to give a crude product of 2-chloro-6-(2,4-dichlorophenoxy)pyridine. A 2 N sodium carbonate aqueous solution (20 mL)-1,2-dimethoxyethane (20 mL) mixture of the above compound (3.9 g), (3-(methoxycarbonyl)phenyl)boronic acid (2.8 g, 15.6 mmol), and tetrakis(triphenylphosphine)palladium (0) (492 mg, 0.43 mmol) was reacted for hours at 90 C in a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, then dried over anhydrous sodium sulfate, and then concentrated at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 2:3) to give 2.4 g of the titled compound (yield 23%).
Melting point: 112 - 113 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.93 (3H, s), 6.93 (1H, d, J = 8.4 Hz), 7.21 - 7.33 (2H, m), 7.45 (I H, t, J = 7.8 Hz), 7.51 (1H,d,J=2.4Hz),7.55(1H,t,J=7.5Hz),7.80(1H,t,J=7.5 Hz), 8.01 (2H, dt, J = 7.5, 1.5 Hz), 8.48 (1 H, t, J = 1.5 Hz).
Reference Example 34 Methyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoate A DMF (138 mL) mixture of 2,4-dichlorophenol (5.0 g, 30.7 mmol), 2,6-dichloropyridine (4.1 g, 27.9 mmol), and potassium carbonate (4.2 g, 30.7 mmol) was added at room temperature, the mixture was stirred for 16 hours at 30 C, cold water (300 mL) was then poured in, and the product was extracted with ethyl acetate.
The organic layer was washed with saturated brine and dried over sodium sulfate.
The solvent was distilled off at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 3:7) to give a crude product of 2-chloro-6-(2,4-dichlorophenoxy)pyridine. A 2 N sodium carbonate aqueous solution (20 mL)-1,2-dimethoxyethane (20 mL) mixture of the above compound (3.9 g), (3-(methoxycarbonyl)phenyl)boronic acid (2.8 g, 15.6 mmol), and tetrakis(triphenylphosphine)palladium (0) (492 mg, 0.43 mmol) was reacted for hours at 90 C in a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, then dried over anhydrous sodium sulfate, and then concentrated at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 2:3) to give 2.4 g of the titled compound (yield 23%).
Melting point: 112 - 113 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.93 (3H, s), 6.93 (1H, d, J = 8.4 Hz), 7.21 - 7.33 (2H, m), 7.45 (I H, t, J = 7.8 Hz), 7.51 (1H,d,J=2.4Hz),7.55(1H,t,J=7.5Hz),7.80(1H,t,J=7.5 Hz), 8.01 (2H, dt, J = 7.5, 1.5 Hz), 8.48 (1 H, t, J = 1.5 Hz).
[0119]
Reference Example 35 Methyl 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoate The titled compound was obtained using 3,5-dichlorophenol in the same manner as in Reference Example 34. Yield: 38%. Melting point: 125 - 126 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.94 (3H, s), 6.90 (1H, d, J = 7.8 Hz), 7.18 (2H, d, J =
1.8 Hz), 7.22 (1 H, d, J = 1.8 Hz), 7.50 (1 H, t, J = 7.8 Hz), 7.60 (1 H, d, J = 7.8 Hz), 7.82 (1 H, t, J
= 7.8 Hz), 8.03-8.12 (2H, m), 8.55 (1H, s).
Reference Example 35 Methyl 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoate The titled compound was obtained using 3,5-dichlorophenol in the same manner as in Reference Example 34. Yield: 38%. Melting point: 125 - 126 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.94 (3H, s), 6.90 (1H, d, J = 7.8 Hz), 7.18 (2H, d, J =
1.8 Hz), 7.22 (1 H, d, J = 1.8 Hz), 7.50 (1 H, t, J = 7.8 Hz), 7.60 (1 H, d, J = 7.8 Hz), 7.82 (1 H, t, J
= 7.8 Hz), 8.03-8.12 (2H, m), 8.55 (1H, s).
[0120]
Reference Example 36 Methyl 3-(6-(2,3-dichlorophenoxy)pyridin-2-yl)benzoate The titled compound was obtained using 2,3-dichlorophenol in the same manner as in Reference Example 34. Yield: 28%. Melting point: 105 - 106 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) S : 3.93 (3H, s), 6.93 (1H, d, J = 8.1 Hz), 7.23- 7.30 (2H, m), 7.38 (1 H, dd, J = 7.5, 1.8 Hz), 7.44 (1 H, t, J = 7.8 Hz), 7.55 (1 H, d, J = 7.8 Hz), 7.80 (1 H, t, J
= 7.8 Hz), 7.97-8.03 (2H, m), 8.55 (1 H, t, J = 1.5 Hz).
Reference Example 36 Methyl 3-(6-(2,3-dichlorophenoxy)pyridin-2-yl)benzoate The titled compound was obtained using 2,3-dichlorophenol in the same manner as in Reference Example 34. Yield: 28%. Melting point: 105 - 106 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) S : 3.93 (3H, s), 6.93 (1H, d, J = 8.1 Hz), 7.23- 7.30 (2H, m), 7.38 (1 H, dd, J = 7.5, 1.8 Hz), 7.44 (1 H, t, J = 7.8 Hz), 7.55 (1 H, d, J = 7.8 Hz), 7.80 (1 H, t, J
= 7.8 Hz), 7.97-8.03 (2H, m), 8.55 (1 H, t, J = 1.5 Hz).
[0121]
Reference Example 37 Methyl 3-(6-(3,4-dichlorophenoxy)pyridin-2-yl)benzoate The titled compound was obtained using 3,4-dichlorophenol in the same manner as in Reference Example 34. Yield: 16%. Melting point: 133 - 134 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.94 (3H, s), 6.89 (1 H, d, J= 7.8 Hz), 7.11 (1H,dd,J=8.7,3.0 Hz), 7.40 (1 H, d, J = 3.0 Hz), 7.45- 7.53 (2H, m), 7.58 (1 H, d, J = 7.2 Hz), 7.80 (1 H, t, J
= 7.8 Hz), 8.01 - 8.10 (2H, m), 8.53 (1 H, s).
Reference Example 37 Methyl 3-(6-(3,4-dichlorophenoxy)pyridin-2-yl)benzoate The titled compound was obtained using 3,4-dichlorophenol in the same manner as in Reference Example 34. Yield: 16%. Melting point: 133 - 134 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 3.94 (3H, s), 6.89 (1 H, d, J= 7.8 Hz), 7.11 (1H,dd,J=8.7,3.0 Hz), 7.40 (1 H, d, J = 3.0 Hz), 7.45- 7.53 (2H, m), 7.58 (1 H, d, J = 7.2 Hz), 7.80 (1 H, t, J
= 7.8 Hz), 8.01 - 8.10 (2H, m), 8.53 (1 H, s).
[0122]
Reference Example 38 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using methyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoate obtained in Reference Example 32 in the same manner as in Reference Example 21. Yield: 78%. Melting point: 244 - 245 C.
(Ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6 :7.11 (1H, d, J = 8.1 Hz), 7.42- 7.59 (3H, m), 7.72- 7.82 (2H, m), 7.91 - 8.07 (3H, m), 8.38 (1 H, s), 1 H unconfirmed.
Reference Example 38 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using methyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoate obtained in Reference Example 32 in the same manner as in Reference Example 21. Yield: 78%. Melting point: 244 - 245 C.
(Ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6 :7.11 (1H, d, J = 8.1 Hz), 7.42- 7.59 (3H, m), 7.72- 7.82 (2H, m), 7.91 - 8.07 (3H, m), 8.38 (1 H, s), 1 H unconfirmed.
[0123]
Reference Example 39 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using methyl 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoate obtained in Reference Example 33 in the same manner as in Reference Example 21. Yield: 77%. Melting point: 234 - 235 C.
(Ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6 : 7.10 (1 H, d, J = 8.1 Hz), 7.41 (2H, d, J = 1.8 Hz), 7.49 (1 H, d, J = 1.8 Hz), 7.58 (1 H, t, J = 7.8 Hz), 7.85 (114, d, J = 7.8 Hz), 7.96 (1 H, d, J = 8.1 Hz), 8.01 (1 H, t, J = 8.1 Hz), 8.13 (1 H, d, J = 8.1 Hz), 8.46 (1 H, s), 13.0 (1 H, br s).
Reference Example 39 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using methyl 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoate obtained in Reference Example 33 in the same manner as in Reference Example 21. Yield: 77%. Melting point: 234 - 235 C.
(Ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6 : 7.10 (1 H, d, J = 8.1 Hz), 7.41 (2H, d, J = 1.8 Hz), 7.49 (1 H, d, J = 1.8 Hz), 7.58 (1 H, t, J = 7.8 Hz), 7.85 (114, d, J = 7.8 Hz), 7.96 (1 H, d, J = 8.1 Hz), 8.01 (1 H, t, J = 8.1 Hz), 8.13 (1 H, d, J = 8.1 Hz), 8.46 (1 H, s), 13.0 (1 H, br s).
[0124]
Reference Example 40 3-(6-(2,3-dichlorophenoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using methyl 3-(6-(2,3-dichlorophenoxy)pyridin-2-yl)benzoate obtained in Reference Example 34 in the same manner as in Reference Example 21. Yield: 90%. Melting point: 216 - 217 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 6.94 (114, d, J = 7.8 Hz), 7.20 - 7.31 (2H, m), 7.39 (1 H, dd, J =
7.5, 1.2 Hz), 7.48 (1 H, t, J = 7.8 Hz), 7.57 (1 H, d, J = 7.8 Hz), 7.82 (1 H, t, J = 7.8 Hz), 8.07 (2H, t, J = 7.8 Hz), 8.55 (1 H, s), 1 H unconfirmed.
Reference Example 40 3-(6-(2,3-dichlorophenoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using methyl 3-(6-(2,3-dichlorophenoxy)pyridin-2-yl)benzoate obtained in Reference Example 34 in the same manner as in Reference Example 21. Yield: 90%. Melting point: 216 - 217 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 6.94 (114, d, J = 7.8 Hz), 7.20 - 7.31 (2H, m), 7.39 (1 H, dd, J =
7.5, 1.2 Hz), 7.48 (1 H, t, J = 7.8 Hz), 7.57 (1 H, d, J = 7.8 Hz), 7.82 (1 H, t, J = 7.8 Hz), 8.07 (2H, t, J = 7.8 Hz), 8.55 (1 H, s), 1 H unconfirmed.
[0125]
Reference Example 41 3-(6-(3,4-Dichlorophenoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using methyl 3-(6-(3,4-dichlorophenoxy)pyridin-2-yl)benzoate obtained in Reference Example 35 in the same manner as in Reference Example 21. Yield: 91%. Melting point: 230 - 231 C.
(Ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6 : 7.09 (1 H, d, J = 8.1 Hz), 7.29 (1 H, dd, J = 8.7, 2.7 Hz), 7.5 8 (lH,t,J=7.8Hz),7.64(1H,d,J=2.7Hz),7.70(1H,t,J=9.0Hz),7.83(1H,d,J=
7.8 Hz), 7.93-8.04 (2H, m), 8.13 (1 H, d, J = 7.8 Hz), 8.46 (1 H, s), 1 H
unconfirmed.
Reference Example 41 3-(6-(3,4-Dichlorophenoxy)pyridin-2-yl)benzoic acid The titled compound was obtained using methyl 3-(6-(3,4-dichlorophenoxy)pyridin-2-yl)benzoate obtained in Reference Example 35 in the same manner as in Reference Example 21. Yield: 91%. Melting point: 230 - 231 C.
(Ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6 : 7.09 (1 H, d, J = 8.1 Hz), 7.29 (1 H, dd, J = 8.7, 2.7 Hz), 7.5 8 (lH,t,J=7.8Hz),7.64(1H,d,J=2.7Hz),7.70(1H,t,J=9.0Hz),7.83(1H,d,J=
7.8 Hz), 7.93-8.04 (2H, m), 8.13 (1 H, d, J = 7.8 Hz), 8.46 (1 H, s), 1 H
unconfirmed.
[0126]
Reference Example 42 3 -Bromo-N-(2-cyanoethyl)benzamide WSC (5.73 g, 29.9 mmol) and HOBt (4.04 g, 29.9 mmol) were added to a DMF
(25 mL) solution of 3-bromobenzoic acid (5.00 g, 24.9 mmol) and 3-aminopropanenitrile (2.21 mL, 29.9 mmol), and the mixture was stirred for 15 hours at room temperature. The addition of saturated aqueous sodium bicarbonate to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. Diethyl ether was added to the residue, and the crystals were filtered off to give 5.66 g of the titled compound (yield: 90%). Melting point: 100 -101 C (ethyl acetate).
1 H-NMR (CDC13 ):6 2.76 (2H, t, J = 6.2 Hz), 3.71 (2H, q, J = 6.2 Hz), 6.82 (1H, br s), 7.32 (1H, t, J = 7.9 Hz), 7.58- 7.74 (2H, m), 7.94 (1H, t, J = 1.8 Hz).
Reference Example 42 3 -Bromo-N-(2-cyanoethyl)benzamide WSC (5.73 g, 29.9 mmol) and HOBt (4.04 g, 29.9 mmol) were added to a DMF
(25 mL) solution of 3-bromobenzoic acid (5.00 g, 24.9 mmol) and 3-aminopropanenitrile (2.21 mL, 29.9 mmol), and the mixture was stirred for 15 hours at room temperature. The addition of saturated aqueous sodium bicarbonate to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. Diethyl ether was added to the residue, and the crystals were filtered off to give 5.66 g of the titled compound (yield: 90%). Melting point: 100 -101 C (ethyl acetate).
1 H-NMR (CDC13 ):6 2.76 (2H, t, J = 6.2 Hz), 3.71 (2H, q, J = 6.2 Hz), 6.82 (1H, br s), 7.32 (1H, t, J = 7.9 Hz), 7.58- 7.74 (2H, m), 7.94 (1H, t, J = 1.8 Hz).
[0127]
Reference Example 43 N-(2-Cyanoethyl)-3 -(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (1, 1 -Bis(diphenylphosphino)ferrocene)dichloropalladium (II) complex with dichloromethane (327 mg, 0.40 mmol) was added to a mixture of 3-bromo-N-(2-cyanoethyl)benzamide (2.00 g, 7.90 mmol) obtained in Working Example 42, bis(pinacolato)diboron (2.41 g, 9.48 mmol), potassium acetate (930 mg, 9.48 mmol), and DMSO (45 mL), and the mixture was heated and stirred for 15 hours at 90 C.
The reaction solution was poured into ethyl acetate and was washed with 1 M
magnesium sulfate aqueous solution and saturated brine. The solution was then dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure.
The residue was purified by silica gel column chromatography to give 1.60 g of the titled compound (yield: 67%) in the form of an oily substance.
1 H-NMR (DMSO- d6 ):6 1.36 (12H, s), 2.72-2.80 (2H, m), 3.71 (2H, q, J = 6.4 Hz), 6.8 5 (1 H, br s), 7.46 (1 H, t, J = 7.6 Hz), 7.96 (2H, dd, J = 7.6, 1.9 Hz), 8.12 (1 H, s).
Reference Example 43 N-(2-Cyanoethyl)-3 -(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (1, 1 -Bis(diphenylphosphino)ferrocene)dichloropalladium (II) complex with dichloromethane (327 mg, 0.40 mmol) was added to a mixture of 3-bromo-N-(2-cyanoethyl)benzamide (2.00 g, 7.90 mmol) obtained in Working Example 42, bis(pinacolato)diboron (2.41 g, 9.48 mmol), potassium acetate (930 mg, 9.48 mmol), and DMSO (45 mL), and the mixture was heated and stirred for 15 hours at 90 C.
The reaction solution was poured into ethyl acetate and was washed with 1 M
magnesium sulfate aqueous solution and saturated brine. The solution was then dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure.
The residue was purified by silica gel column chromatography to give 1.60 g of the titled compound (yield: 67%) in the form of an oily substance.
1 H-NMR (DMSO- d6 ):6 1.36 (12H, s), 2.72-2.80 (2H, m), 3.71 (2H, q, J = 6.4 Hz), 6.8 5 (1 H, br s), 7.46 (1 H, t, J = 7.6 Hz), 7.96 (2H, dd, J = 7.6, 1.9 Hz), 8.12 (1 H, s).
[0128]
Reference Example 44 2-Chloro-6-(2,4-dimethylphenoxy)pyridine 2,4-dimethylphenol (0.326 mL, 2.70 mmol) was added to a mixture of 2,6-dichloropyridine (400 mg, 2.70 mmol) and potassium carbonate (373 mg, 2.70 mmol), and the mixture was heated and stirred for 6 hours at 130 C. The addition of water to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography to give 510 mg of the titled compound (yield: 81 %) in the form of an oily substance.
' H-NMR (CDC13 ):8 2.14 (3H, s), 2.33 (3H, s), 6.59 (1 H, d, J = 8.1 Hz), 6.90 - 6.95 (1 H, m), 6.98 (1 H, d, J = 7.5 Hz), 7.00 - 7.04 (1 H, m), 7.07 (1 H, s), 7.5 6 (1 H, t, J = 7.8 Hz).
Reference Example 44 2-Chloro-6-(2,4-dimethylphenoxy)pyridine 2,4-dimethylphenol (0.326 mL, 2.70 mmol) was added to a mixture of 2,6-dichloropyridine (400 mg, 2.70 mmol) and potassium carbonate (373 mg, 2.70 mmol), and the mixture was heated and stirred for 6 hours at 130 C. The addition of water to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography to give 510 mg of the titled compound (yield: 81 %) in the form of an oily substance.
' H-NMR (CDC13 ):8 2.14 (3H, s), 2.33 (3H, s), 6.59 (1 H, d, J = 8.1 Hz), 6.90 - 6.95 (1 H, m), 6.98 (1 H, d, J = 7.5 Hz), 7.00 - 7.04 (1 H, m), 7.07 (1 H, s), 7.5 6 (1 H, t, J = 7.8 Hz).
[0129]
Reference Example 45 2-Chloro-6-(2,4-difluorophenoxy)pyridine The titled compound was synthesized using 2,4-difluorophenol in the same manner as in Reference Example 44. Yield: 93%.
'H-NMR (CDC13 ):S 6.84 - 6.99 (3H, m), 7.04 (1 H, d, J = 7.6 Hz), 7.14-7.24 (1 H, m), 7.61 -7.68(1H,m) [0130]
Reference Example 46 2-Chloro-6-(4-chlorophenoxy)pyridine The titled compound was synthesized using 4-chlorophenol in the same manner as in Reference Example 44. Yield: 96%.
'H-NMR (CDC13 ):6 6.79 (1 H, d, J = 8.1 Hz), 7.05 (1 H, d, J = 7.5 Hz), 7.07-7.13 (2H, m), 7.32- 7.40 (2H, m), 7.63 (1 H, t, J = 7.8 Hz).
Reference Example 45 2-Chloro-6-(2,4-difluorophenoxy)pyridine The titled compound was synthesized using 2,4-difluorophenol in the same manner as in Reference Example 44. Yield: 93%.
'H-NMR (CDC13 ):S 6.84 - 6.99 (3H, m), 7.04 (1 H, d, J = 7.6 Hz), 7.14-7.24 (1 H, m), 7.61 -7.68(1H,m) [0130]
Reference Example 46 2-Chloro-6-(4-chlorophenoxy)pyridine The titled compound was synthesized using 4-chlorophenol in the same manner as in Reference Example 44. Yield: 96%.
'H-NMR (CDC13 ):6 6.79 (1 H, d, J = 8.1 Hz), 7.05 (1 H, d, J = 7.5 Hz), 7.07-7.13 (2H, m), 7.32- 7.40 (2H, m), 7.63 (1 H, t, J = 7.8 Hz).
[0131]
Reference Example 47 2-Chloro-6-(3 -chlorophenoxy)pyridine The titled compound was synthesized using 3-chlorophenol in the same manner as in Reference Example 44. Yield: 90%.
1 H-NMR (CDC13 ):S 6.80 (1H, d, J = 8.1 Hz), 7.01 - 7.11 (2H, m), 7.14-7.24 (2H, m), 7.32 (1 H, t, J = 8.1 Hz), 7.65 (1 H, t, J = 7.8 Hz).
Reference Example 47 2-Chloro-6-(3 -chlorophenoxy)pyridine The titled compound was synthesized using 3-chlorophenol in the same manner as in Reference Example 44. Yield: 90%.
1 H-NMR (CDC13 ):S 6.80 (1H, d, J = 8.1 Hz), 7.01 - 7.11 (2H, m), 7.14-7.24 (2H, m), 7.32 (1 H, t, J = 8.1 Hz), 7.65 (1 H, t, J = 7.8 Hz).
[0132]
Reference Example 48 2-Chloro-6-(2-chlorophenoxy)pyridine The titled compound was synthesized using 2-chlorophenol in the same manner as in Reference Example 44. Yield: 97%.
1 H-NMR (CDC13 ):6 6.80 (1 H, d, J = 8.0 Hz), 7.03 (1 H, d, J = 7.6 Hz), 7.15 -7.24 (2H, m), 7.27 - 7.35 (1H, m), 7.46 (1H, dd, J = 7.8, 1.3 Hz), 7.63 (1H, t, J = 8.0 Hz) [0133]
Reference Example 49 2-Chloro-6-(3 -methoxyphenoxy)pyridine The titled compound was synthesized using 2-chlorophenol in the same manner as in Reference Example 44. Yield: 75%.
1 H-NMR (CDC13 ):S 3.80 (3H, s), 6.67 - 6.80 (4H, m), 7.03 (1H, d, J = 7.6 Hz), 7.25 -7.33 (1H,m),7.61 (1 H, t, J = 8. 0 Hz).
Reference Example 48 2-Chloro-6-(2-chlorophenoxy)pyridine The titled compound was synthesized using 2-chlorophenol in the same manner as in Reference Example 44. Yield: 97%.
1 H-NMR (CDC13 ):6 6.80 (1 H, d, J = 8.0 Hz), 7.03 (1 H, d, J = 7.6 Hz), 7.15 -7.24 (2H, m), 7.27 - 7.35 (1H, m), 7.46 (1H, dd, J = 7.8, 1.3 Hz), 7.63 (1H, t, J = 8.0 Hz) [0133]
Reference Example 49 2-Chloro-6-(3 -methoxyphenoxy)pyridine The titled compound was synthesized using 2-chlorophenol in the same manner as in Reference Example 44. Yield: 75%.
1 H-NMR (CDC13 ):S 3.80 (3H, s), 6.67 - 6.80 (4H, m), 7.03 (1H, d, J = 7.6 Hz), 7.25 -7.33 (1H,m),7.61 (1 H, t, J = 8. 0 Hz).
[0134]
Reference Example 50 2-Chloro-6-(cyclohexyloxy)pyridine After all of a toluene solution of diethyl azodicarboxylate (2.2 mol/l, 2.10 mL, 4.63 mmol) had been added in the form of drops at 0 C to a THE (10 mL) solution of 6-chloropyridin-2-ol (500 mg, 3.86 mmol), cyclohexanol (0.449 mL, 4.25 mmol), and triphenylphosphine (1.1 lg, 4.25 mmol), the mixture was stirred for 15 hours at room temperature. The solvent was distilled off at reduced pressure, and he residue was purified by silica gel column chromatography to give 225 mg of the titled compound (yield: 28%) in the form of an oily substance.
'H-NMR (CDC13 ):S 1.20 - 1.66 (6H, m), 1.71 - 1.85 (2H, m), 1.93 - 2.05 (2H, m), 4.95 - 5.08 (1 H, m), 6.59 (114, dd, J = 8.2, 0.7 Hz), 6.83 (1 H, d, J = 7.5 Hz), 7.42- 7.52 (1H, m).
Reference Example 50 2-Chloro-6-(cyclohexyloxy)pyridine After all of a toluene solution of diethyl azodicarboxylate (2.2 mol/l, 2.10 mL, 4.63 mmol) had been added in the form of drops at 0 C to a THE (10 mL) solution of 6-chloropyridin-2-ol (500 mg, 3.86 mmol), cyclohexanol (0.449 mL, 4.25 mmol), and triphenylphosphine (1.1 lg, 4.25 mmol), the mixture was stirred for 15 hours at room temperature. The solvent was distilled off at reduced pressure, and he residue was purified by silica gel column chromatography to give 225 mg of the titled compound (yield: 28%) in the form of an oily substance.
'H-NMR (CDC13 ):S 1.20 - 1.66 (6H, m), 1.71 - 1.85 (2H, m), 1.93 - 2.05 (2H, m), 4.95 - 5.08 (1 H, m), 6.59 (114, dd, J = 8.2, 0.7 Hz), 6.83 (1 H, d, J = 7.5 Hz), 7.42- 7.52 (1H, m).
[0135]
Reference Example 51 5-((6-chloropyridin-2-yl)oxy)-1 H-indole The titled compound was synthesized using 1 H-indol-5-ol in the same manner as in Reference Example 44. Yield: 26%. Melting point: 117 - 118 C (ethyl acetate).
' H-NMR (CDC13 ):S 6.53 (1H, t, J = 2.7 Hz), 6.64 (11-1, d, J = 8.3 Hz), 6.93-7.02 (2H, m), 7.22- 7.28 (1H, m), 7.37 (1H, d, J = 5.7 Hz), 7.39 (1H, s), 7.54 (1H, t, J
= 8.0 Hz), 8.31 (1 H, br s).
Reference Example 51 5-((6-chloropyridin-2-yl)oxy)-1 H-indole The titled compound was synthesized using 1 H-indol-5-ol in the same manner as in Reference Example 44. Yield: 26%. Melting point: 117 - 118 C (ethyl acetate).
' H-NMR (CDC13 ):S 6.53 (1H, t, J = 2.7 Hz), 6.64 (11-1, d, J = 8.3 Hz), 6.93-7.02 (2H, m), 7.22- 7.28 (1H, m), 7.37 (1H, d, J = 5.7 Hz), 7.39 (1H, s), 7.54 (1H, t, J
= 8.0 Hz), 8.31 (1 H, br s).
[0136]
Reference Example 52 2-Chloro-6-(2,3-dihydro-1 H-inden-5-yloxy)pyridine The titled compound was synthesized using indan-5-ol in the same manner as in Reference Example 44. Yield: 83%.
' H-NMR (CDC13 ):8 2.03-2.17 (2H, m), 2.84-2.97 (4H, m), 6.69 (1H, d, J = 8.3 Hz), 6.88 (1 H, dd, J = 8.0, 2.3 Hz), 6.94- 7.04 (2H, m), 7.21 (1 H, d, J = 8.0 Hz), 7.53- 7.65 (1H, m).
Reference Example 52 2-Chloro-6-(2,3-dihydro-1 H-inden-5-yloxy)pyridine The titled compound was synthesized using indan-5-ol in the same manner as in Reference Example 44. Yield: 83%.
' H-NMR (CDC13 ):8 2.03-2.17 (2H, m), 2.84-2.97 (4H, m), 6.69 (1H, d, J = 8.3 Hz), 6.88 (1 H, dd, J = 8.0, 2.3 Hz), 6.94- 7.04 (2H, m), 7.21 (1 H, d, J = 8.0 Hz), 7.53- 7.65 (1H, m).
[0137]
Reference Example 53 1-(3-((6-Chloropyridin-2-yl)oxy)phenyl)ethanone The titled compound was synthesized using 1-(3-hydroxyphenyl)ethanone in the same manner as in Reference Example 44. Yield: 80%. Melting point: 82 - 83 C
(ethyl acetate).
' H-NMR (CDC13 ):8 2.61 (3H, s), 6.83 (1 H, d, J = 8.1 Hz), 7.07 (1 H, d, J =
7.2 Hz), 7.33-7.40(1H,m),7.50(1H,t,J=7.9Hz),7.66(1H,t,J=7.9Hz),7.71 - 7.74(1H, m), 7.78- 7.84 (1 H, m).
Reference Example 53 1-(3-((6-Chloropyridin-2-yl)oxy)phenyl)ethanone The titled compound was synthesized using 1-(3-hydroxyphenyl)ethanone in the same manner as in Reference Example 44. Yield: 80%. Melting point: 82 - 83 C
(ethyl acetate).
' H-NMR (CDC13 ):8 2.61 (3H, s), 6.83 (1 H, d, J = 8.1 Hz), 7.07 (1 H, d, J =
7.2 Hz), 7.33-7.40(1H,m),7.50(1H,t,J=7.9Hz),7.66(1H,t,J=7.9Hz),7.71 - 7.74(1H, m), 7.78- 7.84 (1 H, m).
[0138]
Reference Example 54 3-((6-chloropyridin-2-yl)oxy)-N,N-dimethylaniline The titled compound was synthesized using 3-(dimethylamino)phenol in the same manner as in Reference Example 42. Yield: 43%. Melting point: 71 - 72 C (ethyl acetate).
' H-NMR (CDC13 ):8 2.95 (6H, s), 6.43-6.50 (2H, m), 6.54-6.60 (1H, m), 6.68 (1H, d, J
= 8.3 Hz), 7.01 (1 H, d, J = 7.5 Hz), 7.19- 7.27 (1 H, m), 7.53- 7.60 (111, m).
Reference Example 54 3-((6-chloropyridin-2-yl)oxy)-N,N-dimethylaniline The titled compound was synthesized using 3-(dimethylamino)phenol in the same manner as in Reference Example 42. Yield: 43%. Melting point: 71 - 72 C (ethyl acetate).
' H-NMR (CDC13 ):8 2.95 (6H, s), 6.43-6.50 (2H, m), 6.54-6.60 (1H, m), 6.68 (1H, d, J
= 8.3 Hz), 7.01 (1 H, d, J = 7.5 Hz), 7.19- 7.27 (1 H, m), 7.53- 7.60 (111, m).
[0139]
Reference Example 55 2-Chloro-6-((5-chloropyridin-3-yl)oxy)pyridine The titled compound was synthesized using 5-chloropyridin-3-ol in the same manner as in Reference Example 44. Yield: 67%. Melting point: 46 - 47 C (ethyl acetate).
'H-NMR(CDC13): 6 6.92 (1 H, d, J = 8.1 Hz), 7.11 (1H,d,J=7.5Hz),7.58(1H,t,J=
2.3 Hz), 7.70 (1 H, t, J = 7.8 Hz), 8.41 (1 H, d, J = 2.4 Hz), 8.44 (1 H, d, J
= 2.1 Hz).
Reference Example 55 2-Chloro-6-((5-chloropyridin-3-yl)oxy)pyridine The titled compound was synthesized using 5-chloropyridin-3-ol in the same manner as in Reference Example 44. Yield: 67%. Melting point: 46 - 47 C (ethyl acetate).
'H-NMR(CDC13): 6 6.92 (1 H, d, J = 8.1 Hz), 7.11 (1H,d,J=7.5Hz),7.58(1H,t,J=
2.3 Hz), 7.70 (1 H, t, J = 7.8 Hz), 8.41 (1 H, d, J = 2.4 Hz), 8.44 (1 H, d, J
= 2.1 Hz).
[0140]
Reference Example 56 2-Chloro-6-(2,5-dichlorophenoxy)pyridine The titled compound was synthesized using 2,5-dichlorophenol in the same manner as in Reference Example 44. Yield: 81 %. Melting point: 82 - 84 C
(ethyl acetate).
'H-NMR(CDC13):66.87(1H,d,J=8.1 Hz), 7.07 (1 H, d, J = 7.7 Hz), 7.14- 7.20 (1 H, m), 7.23 (114, d, J = 2.4 Hz), 7.39 (1 H, d, J = 8.7 Hz), 7.63- 7.70 (1 H, m).
Reference Example 56 2-Chloro-6-(2,5-dichlorophenoxy)pyridine The titled compound was synthesized using 2,5-dichlorophenol in the same manner as in Reference Example 44. Yield: 81 %. Melting point: 82 - 84 C
(ethyl acetate).
'H-NMR(CDC13):66.87(1H,d,J=8.1 Hz), 7.07 (1 H, d, J = 7.7 Hz), 7.14- 7.20 (1 H, m), 7.23 (114, d, J = 2.4 Hz), 7.39 (1 H, d, J = 8.7 Hz), 7.63- 7.70 (1 H, m).
[0141]
Reference Example 57 2-Chloro-6-(2,4-dichlorophenoxy)pyridine A DMF (45 mL) solution of 2,6-dichloropyridine (3.00 g, 20.3 mmol), 2,4-dichlorophenol (3.47 g, 21.3 mmol), and potassium carbonate (3.08 g, 22.3 mmol) was stirred at 120 C over night. Water was poured into the reaction solution, and the F
product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give 5.10 g of the titled compound (yield 92%) in the form of an oily substance.
'H-NMR(CDC13) 6: 6.86 (1 H, d, J = 8.1 Hz),7.04(1H,d,J=7.5Hz),7.12 - 7.18 (1H,m),7.23 - 7.31 (1H,m),7.47(1H,d,J=2.4Hz ),7.61 - 7.68(1H,m).
Reference Example 57 2-Chloro-6-(2,4-dichlorophenoxy)pyridine A DMF (45 mL) solution of 2,6-dichloropyridine (3.00 g, 20.3 mmol), 2,4-dichlorophenol (3.47 g, 21.3 mmol), and potassium carbonate (3.08 g, 22.3 mmol) was stirred at 120 C over night. Water was poured into the reaction solution, and the F
product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give 5.10 g of the titled compound (yield 92%) in the form of an oily substance.
'H-NMR(CDC13) 6: 6.86 (1 H, d, J = 8.1 Hz),7.04(1H,d,J=7.5Hz),7.12 - 7.18 (1H,m),7.23 - 7.31 (1H,m),7.47(1H,d,J=2.4Hz ),7.61 - 7.68(1H,m).
[0142]
Reference Example 58 2-Chloro-6-((2,4-dichlorophenyl)thio)pyridine A DMF (30 mL) solution of 2,4-dichloropyridine (2.00 g, 13.5 mmol), 2,4-dichlorothiophenol (1.76 mL, 14.2 mmol), and potassium carbonate (2.05 g, 14.9 mmol) was stirred at 120 C for 5 hours. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give 1.68 g of the titled compound (yield 43%) in the form of an oily substance.
'H-NMR (CDC13) 6: 6.73 - 6.80 (1 H, m), 7.03 - 7.10 (1 H, m), 7.28 - 7.34 (1 H, m), 7.40 - 7.49 (1 H, m), 7.54 - 7.66 (2H, m).
Reference Example 58 2-Chloro-6-((2,4-dichlorophenyl)thio)pyridine A DMF (30 mL) solution of 2,4-dichloropyridine (2.00 g, 13.5 mmol), 2,4-dichlorothiophenol (1.76 mL, 14.2 mmol), and potassium carbonate (2.05 g, 14.9 mmol) was stirred at 120 C for 5 hours. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give 1.68 g of the titled compound (yield 43%) in the form of an oily substance.
'H-NMR (CDC13) 6: 6.73 - 6.80 (1 H, m), 7.03 - 7.10 (1 H, m), 7.28 - 7.34 (1 H, m), 7.40 - 7.49 (1 H, m), 7.54 - 7.66 (2H, m).
[0143]
Reference Example 59 2-Chloro-6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridine The titled compound was obtained in the form of an oily substance using 2,6-dichloro-4-(trifluoromethyl)pyridine in the same manner as in Reference Example 1.
Yield: 82%.
'H-NMR (CDC13) 6: 7.07 - 7.20 (2H, m), 7.22 - 7.36 (2H, m), 7.50 (1H, d, J =
2.4 Hz).
Reference Example 59 2-Chloro-6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridine The titled compound was obtained in the form of an oily substance using 2,6-dichloro-4-(trifluoromethyl)pyridine in the same manner as in Reference Example 1.
Yield: 82%.
'H-NMR (CDC13) 6: 7.07 - 7.20 (2H, m), 7.22 - 7.36 (2H, m), 7.50 (1H, d, J =
2.4 Hz).
[0144]
Reference Example 60 2,2,2-Trichloroethyl (6-fluoropyridin-3-yl)carbamate 2,2,2-Trichloroethyl chlorocarbonate (0.406 mL, 2.95 mmol) was added in the form of drops at 0 C to a THE (10 mL) solution of 6-fluoropyridin-3-amine (300 mg, 2.68 mmol) and triethylamine (0.213 mL, 2.95 mmol), and the mixture was then stirred for 1 hour at 0 C. The addition of water to the reaction solution was followed by extraction with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. Hexane was added to the resulting crystals, which were filtered off to give 710 mg of the titled compound (yield:
92%). Melting point: 114 - 115 C (ethyl acetate).
'H-NMR (CDC13 ):8 4.84 (2H, s), 6.96 (1 H, dd, J = 8.9, 3.2 Hz), 7.05 (1 H, br s), 8.08 (1 H, br s), 8.19 (1 H, s).
Reference Example 60 2,2,2-Trichloroethyl (6-fluoropyridin-3-yl)carbamate 2,2,2-Trichloroethyl chlorocarbonate (0.406 mL, 2.95 mmol) was added in the form of drops at 0 C to a THE (10 mL) solution of 6-fluoropyridin-3-amine (300 mg, 2.68 mmol) and triethylamine (0.213 mL, 2.95 mmol), and the mixture was then stirred for 1 hour at 0 C. The addition of water to the reaction solution was followed by extraction with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. Hexane was added to the resulting crystals, which were filtered off to give 710 mg of the titled compound (yield:
92%). Melting point: 114 - 115 C (ethyl acetate).
'H-NMR (CDC13 ):8 4.84 (2H, s), 6.96 (1 H, dd, J = 8.9, 3.2 Hz), 7.05 (1 H, br s), 8.08 (1 H, br s), 8.19 (1 H, s).
[0145]
Reference Example 61 Ethyl 3-bromo-5-fluorobenzoate An ethanol (40 mL) solution of 3-bromo-5-fluorobenzoic acid (2.00 g, 9.13 mmol) and concentrated sulfuric acid(2.0 ml) was heated to reflux over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure to give 1.89 g of the titled compound (yield: 84%) in the form of an oily substance.
'H-NMR (CDC13) 6:1.40 (3H, t, J = 7.2 Hz), 4.39 (2H, q, J = 7.2 Hz), 7.40 -7.47 (1H, m), 7.64 - 7.70 (1 H, m), 7.96 - 8.00 (1 H, m).
Reference Example 61 Ethyl 3-bromo-5-fluorobenzoate An ethanol (40 mL) solution of 3-bromo-5-fluorobenzoic acid (2.00 g, 9.13 mmol) and concentrated sulfuric acid(2.0 ml) was heated to reflux over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure to give 1.89 g of the titled compound (yield: 84%) in the form of an oily substance.
'H-NMR (CDC13) 6:1.40 (3H, t, J = 7.2 Hz), 4.39 (2H, q, J = 7.2 Hz), 7.40 -7.47 (1H, m), 7.64 - 7.70 (1 H, m), 7.96 - 8.00 (1 H, m).
[0146]
Reference Example 62 Ethyl 3-bromo-4-fluorobenzoate The titled compound was obtained in the form of an oily substance using 3-bromo-4-fluorobenzoic acid in the same manner as in Reference Example 61. Yield:
88%.
'H-NMR (CDC13) b: 1.40 (3H, t, J = 7.2 Hz), 4.38 (2H, q, J = 7.2 Hz), 7.13 -7.21 (1H, m), 7.94 - 8.04 (1 H, m), 8.26 (1 H, dd, J = 7.2, 2.1 Hz).
r [0147]
Reference Example 63 Ethyl 3-bromo-2-fluorobenzoate The titled compound was obtained in the form of an oily substance using 3-bromo-2-fluorobenzoic acid in the same manner as in Reference Example 61. Yield: 91 %.
'H-NMR (CDC13) 8: 1.36 - 1.44 (3H, m), 4.36 - 4.46 (2H, m), 7.05 - 7.14 (111, m), 7.69 - 7.77 (1 H, m), 7.83 - 7.91 (1 H, m).
Reference Example 62 Ethyl 3-bromo-4-fluorobenzoate The titled compound was obtained in the form of an oily substance using 3-bromo-4-fluorobenzoic acid in the same manner as in Reference Example 61. Yield:
88%.
'H-NMR (CDC13) b: 1.40 (3H, t, J = 7.2 Hz), 4.38 (2H, q, J = 7.2 Hz), 7.13 -7.21 (1H, m), 7.94 - 8.04 (1 H, m), 8.26 (1 H, dd, J = 7.2, 2.1 Hz).
r [0147]
Reference Example 63 Ethyl 3-bromo-2-fluorobenzoate The titled compound was obtained in the form of an oily substance using 3-bromo-2-fluorobenzoic acid in the same manner as in Reference Example 61. Yield: 91 %.
'H-NMR (CDC13) 8: 1.36 - 1.44 (3H, m), 4.36 - 4.46 (2H, m), 7.05 - 7.14 (111, m), 7.69 - 7.77 (1 H, m), 7.83 - 7.91 (1 H, m).
[0148]
Reference Example 64 Ethyl 5-bromo-2-fluorobenzoate The titled compound was obtained in the form of an oily substance using 5-bromo-2-fluorobenzoic acid in the same manner as in Reference Example 61. Yield:
92%.
' H-NMR (CDC13) S: 1.40 (3H, t, J = 7.2 Hz), 4.40 (2H, q, J = 7.2 Hz), 7.04 (1H, dd, J
= 10.2, 8.9 Hz), 7.56 - 7.64 (1 H, m), 8.05 (1 H, dd, J = 8.9, 2.6 Hz).
Reference Example 64 Ethyl 5-bromo-2-fluorobenzoate The titled compound was obtained in the form of an oily substance using 5-bromo-2-fluorobenzoic acid in the same manner as in Reference Example 61. Yield:
92%.
' H-NMR (CDC13) S: 1.40 (3H, t, J = 7.2 Hz), 4.40 (2H, q, J = 7.2 Hz), 7.04 (1H, dd, J
= 10.2, 8.9 Hz), 7.56 - 7.64 (1 H, m), 8.05 (1 H, dd, J = 8.9, 2.6 Hz).
[0149]
Reference Example 65 Methyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate The titled compound was obtained in solid form using methyl 3-bromo-4-methylbenzoate acid in the same manner as in Reference Example 43.
Yield: 65%.
' H-NMR (CDC13) S: 1.35 (12H, s), 2.58 (31-1, s), 3.90 (3H, s), 7.23 (1H, d, J
= 7.9 Hz), 7.97 (1 H, dd, J = 7.9, 2.0 Hz ), 8.40 (1 H, d, J = 2.0 Hz).
Reference Example 65 Methyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate The titled compound was obtained in solid form using methyl 3-bromo-4-methylbenzoate acid in the same manner as in Reference Example 43.
Yield: 65%.
' H-NMR (CDC13) S: 1.35 (12H, s), 2.58 (31-1, s), 3.90 (3H, s), 7.23 (1H, d, J
= 7.9 Hz), 7.97 (1 H, dd, J = 7.9, 2.0 Hz ), 8.40 (1 H, d, J = 2.0 Hz).
[0150]
Reference Example 66 Ethyl 3-(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)benzoate Tetrakis(triphenylphosphine)palladium (0) (802 mg, 0.694 mmol) was added at room temperature in a nitrogen atmosphere to a 1,2-dimethoxyethane (35 mL) solution of 2-chloro-6-((2,4-dichlorophenyl)thio)pyridine (1.68 g, 5.78 mmol) obtained in Reference Example 58, (3-(ethoxycarbonyl)-phenyl)boronic acid (1.35 g, 6.94 mmol), and 2 N sodium carbonate aqueous solution (11.6 mL), and the mixture was stirred at 100 C over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give 1.13 g of the titled compound (yield 48%) in solid form.
1 H-NMR (CDC13) 8: 1.36 - 1.46 (3H, m), 4.42 (2H, q, J = 7.2 Hz), 6.91 - 6.99 (1H, m), 7.28 - 7.36 (2H, m), 7.44 - 7.76 (4H, m), 8.01 - 8.14 (2H, m), 8.50 - 8.56 (1H, m).
Reference Example 66 Ethyl 3-(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)benzoate Tetrakis(triphenylphosphine)palladium (0) (802 mg, 0.694 mmol) was added at room temperature in a nitrogen atmosphere to a 1,2-dimethoxyethane (35 mL) solution of 2-chloro-6-((2,4-dichlorophenyl)thio)pyridine (1.68 g, 5.78 mmol) obtained in Reference Example 58, (3-(ethoxycarbonyl)-phenyl)boronic acid (1.35 g, 6.94 mmol), and 2 N sodium carbonate aqueous solution (11.6 mL), and the mixture was stirred at 100 C over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give 1.13 g of the titled compound (yield 48%) in solid form.
1 H-NMR (CDC13) 8: 1.36 - 1.46 (3H, m), 4.42 (2H, q, J = 7.2 Hz), 6.91 - 6.99 (1H, m), 7.28 - 7.36 (2H, m), 7.44 - 7.76 (4H, m), 8.01 - 8.14 (2H, m), 8.50 - 8.56 (1H, m).
[0151]
Reference Example 67 Methyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoate The titled compound was obtained in solid form using 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 9 and methyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate obtained in Reference Example 65 in the same manner as in Reference Example 66. Yield: 82%.
1 H-NMR (CDCI3) 6: 2.24 (3H, s), 3.90 (3H, s), 6.97 (1H, d, J = 8.3 Hz), 7.13 -7.27 (4H, m), 7.45 (1 H, d, J = 2.4 Hz), 7.81 (1 H, t, J = 7.9 Hz), 7.89 (1 H, dd, J = 7.9, 1.7 Hz), 8.02 (1 H, d, J = 1.7 Hz).
Reference Example 67 Methyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoate The titled compound was obtained in solid form using 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 9 and methyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate obtained in Reference Example 65 in the same manner as in Reference Example 66. Yield: 82%.
1 H-NMR (CDCI3) 6: 2.24 (3H, s), 3.90 (3H, s), 6.97 (1H, d, J = 8.3 Hz), 7.13 -7.27 (4H, m), 7.45 (1 H, d, J = 2.4 Hz), 7.81 (1 H, t, J = 7.9 Hz), 7.89 (1 H, dd, J = 7.9, 1.7 Hz), 8.02 (1 H, d, J = 1.7 Hz).
[0152]
Reference Example 68 Ethyl 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoate The titled compound was obtained in the form of an oily substance using 2-chloro-6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridine obtained in Reference Example 59 in the same manner as in Reference Example 66. Yield: 75%.
1 H-NMR (CDC13) 8: 1.42 (3H, t, J = 7.2 Hz), 4.41 (2H, q, J = 7.2 Hz), 7.17 -7.27 (2H, m), 7.31 - 7.37 (1 H, m), 7.44 - 7.55 (2H, m), 7.72 (111, s), 7.95 - 8.01 (1H, m), 8.05 -8.11 (1 H, m), 8.46 - 8.48 (1 H, m).
Reference Example 68 Ethyl 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoate The titled compound was obtained in the form of an oily substance using 2-chloro-6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridine obtained in Reference Example 59 in the same manner as in Reference Example 66. Yield: 75%.
1 H-NMR (CDC13) 8: 1.42 (3H, t, J = 7.2 Hz), 4.41 (2H, q, J = 7.2 Hz), 7.17 -7.27 (2H, m), 7.31 - 7.37 (1 H, m), 7.44 - 7.55 (2H, m), 7.72 (111, s), 7.95 - 8.01 (1H, m), 8.05 -8.11 (1 H, m), 8.46 - 8.48 (1 H, m).
[0153]
Reference Example 69 Ethyl 3 -(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5 -fluorobenzoate A DMF (25 mL) solution of ethyl 3-bromo-5-fluorobenzoate (1.89 g, 7.65 mmol) obtained in Reference Example 61, bispinacolatodiboron (2.33 g, 9.18 mmol), 1,1-bis-(diphenylphosphino)-ferrocene palladium dichloride (312 mg, 0.382 mmol), and potassium acetate (2.25 g, 22.9 mmol) was stirred over night at 80 C in a nitrogen atmosphere. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate, and concentrated at reduced pressure through a small amount of silica gel to give ethyl 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate in the form of a crude product. Tetrakis(triphenylphosphine)palladium (0) (606 mg, 0.525 mmol) was added at room temperature in a nitrogen atmosphere to a 1,2-dimethoxyethane (24 mL) solution of the above compound (1.93 g), 2-chloro-6-(2,4-dichlorophenoxy)pyridine (1.20 g, 4.37 mmol) obtained in Reference Example 9, and 2 N sodium carbonate aqueous solution (8.7 mL), and the mixture was stirred at over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:19) to give 1.28 g of the titled compound (yield 72%) in solid form.
1 H-NMR (CDC13) 8: 1.37 - 1.44 (3H, m), 4.35 - 4.44 (2H, m), 6.98 (1H, d, J =
8.1 Hz), 7.20 - 7.28 (1H, m), 7.29 - 7.36 (1H, m), 7.49 - 7.57 (2H, m), 7.65 - 7.73 (2H, m), 7.82 (1H, t, J = 8.1 Hz), 8.25 - 8.31 (1H, m).
Reference Example 69 Ethyl 3 -(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5 -fluorobenzoate A DMF (25 mL) solution of ethyl 3-bromo-5-fluorobenzoate (1.89 g, 7.65 mmol) obtained in Reference Example 61, bispinacolatodiboron (2.33 g, 9.18 mmol), 1,1-bis-(diphenylphosphino)-ferrocene palladium dichloride (312 mg, 0.382 mmol), and potassium acetate (2.25 g, 22.9 mmol) was stirred over night at 80 C in a nitrogen atmosphere. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate, and concentrated at reduced pressure through a small amount of silica gel to give ethyl 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate in the form of a crude product. Tetrakis(triphenylphosphine)palladium (0) (606 mg, 0.525 mmol) was added at room temperature in a nitrogen atmosphere to a 1,2-dimethoxyethane (24 mL) solution of the above compound (1.93 g), 2-chloro-6-(2,4-dichlorophenoxy)pyridine (1.20 g, 4.37 mmol) obtained in Reference Example 9, and 2 N sodium carbonate aqueous solution (8.7 mL), and the mixture was stirred at over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:19) to give 1.28 g of the titled compound (yield 72%) in solid form.
1 H-NMR (CDC13) 8: 1.37 - 1.44 (3H, m), 4.35 - 4.44 (2H, m), 6.98 (1H, d, J =
8.1 Hz), 7.20 - 7.28 (1H, m), 7.29 - 7.36 (1H, m), 7.49 - 7.57 (2H, m), 7.65 - 7.73 (2H, m), 7.82 (1H, t, J = 8.1 Hz), 8.25 - 8.31 (1H, m).
[0154]
Reference Example 70 Ethyl 3 -(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoate The titled compound was obtained in the form of an oily substance using ethyl bromo-4-fluorobenzoate obtained in Reference Example 62 and 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 9 in the same manner as in Reference Example 69. Yield: 14%.
1 H-NMR (CDC13) 6: 1.39 (3H, t, J = 7.0 Hz), 4.36 (2H, q, J = 7.0 Hz), 6.95 -7.02 (1H, m), 7.11 - 7.19 (1H, m), 7.22 - 7.34 (2H, m), 7.51 (1H, d, J = 2.3 Hz), 7.58 -7.64 (1H, m), 7.81 (1 H, t, J = 7.8 Hz), 7.9 8 - 8.05 (1 H, m), 8.44 (1 H, dd, J = 7.7, 2.3 Hz).
Reference Example 70 Ethyl 3 -(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoate The titled compound was obtained in the form of an oily substance using ethyl bromo-4-fluorobenzoate obtained in Reference Example 62 and 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 9 in the same manner as in Reference Example 69. Yield: 14%.
1 H-NMR (CDC13) 6: 1.39 (3H, t, J = 7.0 Hz), 4.36 (2H, q, J = 7.0 Hz), 6.95 -7.02 (1H, m), 7.11 - 7.19 (1H, m), 7.22 - 7.34 (2H, m), 7.51 (1H, d, J = 2.3 Hz), 7.58 -7.64 (1H, m), 7.81 (1 H, t, J = 7.8 Hz), 7.9 8 - 8.05 (1 H, m), 8.44 (1 H, dd, J = 7.7, 2.3 Hz).
[0155]
Reference Example 71 Ethyl 3 -(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoate The titled compound was obtained in the form of an oily substance using ethyl bromo-2-fluorobenzoate obtained in Reference Example 63 and 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 9 in the same manner as in Reference Example 69. Yield: 16%.
1 H-NMR (CDC13) 8: 1.40 (3H, t, J = 7.2 Hz), 4.40 (2H, q, J = 7.2 Hz), 6.96 (1H, d, J =
8.3 Hz), 7.15 - 7.25 (2H, m), 7.26 - 7.31 (111, m), 7.50 (114, d, J = 2.3 Hz), 7.63 (1 H, dd, J = 7.6, 2.3 Hz), 7.80 (1H, t, J = 8.3 Hz), 7.84 - 7.93 (2H, m).
Reference Example 71 Ethyl 3 -(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoate The titled compound was obtained in the form of an oily substance using ethyl bromo-2-fluorobenzoate obtained in Reference Example 63 and 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 9 in the same manner as in Reference Example 69. Yield: 16%.
1 H-NMR (CDC13) 8: 1.40 (3H, t, J = 7.2 Hz), 4.40 (2H, q, J = 7.2 Hz), 6.96 (1H, d, J =
8.3 Hz), 7.15 - 7.25 (2H, m), 7.26 - 7.31 (111, m), 7.50 (114, d, J = 2.3 Hz), 7.63 (1 H, dd, J = 7.6, 2.3 Hz), 7.80 (1H, t, J = 8.3 Hz), 7.84 - 7.93 (2H, m).
[0156]
Reference Example 72 Ethyl 5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoate The titled compound was obtained in the form of an oily substance using ethyl bromo-2-fluorobenzoate obtained in Reference Example 64 and 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 9 in the same manner as in Reference Example 69. Yield: 28%.
1 H-NMR (CDC13) 6:1.37 - 1.45 (3H, m), 4.34 - 4.47 (2H, m), 6.93 (1H, d, J =
8.3 Hz), 7.07 - 7.37 (3H, m), 7.45 - 7.54 (2H, m), 7.80 (1H, t, J = 7.8 Hz), 7.91 -8.00 (1H, m), 8.34 - 8.41 (1 H, m).
Reference Example 72 Ethyl 5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoate The titled compound was obtained in the form of an oily substance using ethyl bromo-2-fluorobenzoate obtained in Reference Example 64 and 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 9 in the same manner as in Reference Example 69. Yield: 28%.
1 H-NMR (CDC13) 6:1.37 - 1.45 (3H, m), 4.34 - 4.47 (2H, m), 6.93 (1H, d, J =
8.3 Hz), 7.07 - 7.37 (3H, m), 7.45 - 7.54 (2H, m), 7.80 (1H, t, J = 7.8 Hz), 7.91 -8.00 (1H, m), 8.34 - 8.41 (1 H, m).
[0157]
Reference Example 73 Ethyl 6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxylate The titled compound was obtained in the form of an oily substance using ethyl bromonicotinate and 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 59 in the same manner as in Reference Example 69. Yield: 42%.
' H-NMR (CDC13) 6:1.38 - 1.47 (3H, m), 4.43 (2H, q, J = 7.1 Hz), 7.02 (1H, d, J = 8.1 Hz), 7.19 - 7.37 (2H, m), 7.43 - 7.61 (2H, m), 7.81 - 7.89 (1H, m), 8.65 (1H, t, J = 2.2 Hz), 9.18 (2H, d, J = 2.2 Hz).
Reference Example 73 Ethyl 6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxylate The titled compound was obtained in the form of an oily substance using ethyl bromonicotinate and 2-chloro-6-(2,4-dichlorophenoxy)pyridine obtained in Reference Example 59 in the same manner as in Reference Example 69. Yield: 42%.
' H-NMR (CDC13) 6:1.38 - 1.47 (3H, m), 4.43 (2H, q, J = 7.1 Hz), 7.02 (1H, d, J = 8.1 Hz), 7.19 - 7.37 (2H, m), 7.43 - 7.61 (2H, m), 7.81 - 7.89 (1H, m), 8.65 (1H, t, J = 2.2 Hz), 9.18 (2H, d, J = 2.2 Hz).
[0158]
Reference Example 74 Methyl 1-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-1 H-indole-5-carboxylate Sodium hydride (148 mg, 3.69 mmol) was added in a nitrogen atmosphere to a DMF (5 mL) solution of methyl 1H-indole-5-carboxylate (647 mg, 3.69 mmol), the mixture was stirred for 15 min at room temperature, and a DMF (5 ml) solution of 2,4-dichloropyrimidine (500 mg, 3.36 mmol) was then added in the form of drops, and the mixture was stirred for 1 hour at room temperature. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give methyl 1-(2-chloropyrimidin-4-yl)-1 H-indole-5-carboxylate in the form of a crude product. An n-butanol (2.8 mL) solution of the above compound (240 mg), 3,4-dimethoxyphenethylamine (0.283 ml, 1.67 mmol), and N-ethyl diisopropylamine (0.292 ml, 1.67 mmol) was stirred for 3 hours at 130 C.
Water was poured into the reaction solution, and the product was extracted with ethyl acetate.
The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:1) to give 157 mg of the titled compound (yield 11%) in solid form.
'H-NMR (CDC13) 6: 2.94 (2H, t, J = 7.0 Hz), 3.79 (2H, q, J = 7.0 Hz), 3.86 (3H, s), 3.87 (3H, s), 3.95 (3H, s), 5.31 (1 H, br s), 6.69 (1 H, d, J = 5.7 Hz), 6.75 -6.84 (4H, m), 7.75 (1 H, d, J = 3.6 Hz), 8.00 (1 H, dd, J = 8.9, 1.5 Hz), 8.29 - 8.39 (2H, m), 8.51 (1 H, d, J = 8.8 Hz).
Reference Example 74 Methyl 1-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-1 H-indole-5-carboxylate Sodium hydride (148 mg, 3.69 mmol) was added in a nitrogen atmosphere to a DMF (5 mL) solution of methyl 1H-indole-5-carboxylate (647 mg, 3.69 mmol), the mixture was stirred for 15 min at room temperature, and a DMF (5 ml) solution of 2,4-dichloropyrimidine (500 mg, 3.36 mmol) was then added in the form of drops, and the mixture was stirred for 1 hour at room temperature. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give methyl 1-(2-chloropyrimidin-4-yl)-1 H-indole-5-carboxylate in the form of a crude product. An n-butanol (2.8 mL) solution of the above compound (240 mg), 3,4-dimethoxyphenethylamine (0.283 ml, 1.67 mmol), and N-ethyl diisopropylamine (0.292 ml, 1.67 mmol) was stirred for 3 hours at 130 C.
Water was poured into the reaction solution, and the product was extracted with ethyl acetate.
The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:1) to give 157 mg of the titled compound (yield 11%) in solid form.
'H-NMR (CDC13) 6: 2.94 (2H, t, J = 7.0 Hz), 3.79 (2H, q, J = 7.0 Hz), 3.86 (3H, s), 3.87 (3H, s), 3.95 (3H, s), 5.31 (1 H, br s), 6.69 (1 H, d, J = 5.7 Hz), 6.75 -6.84 (4H, m), 7.75 (1 H, d, J = 3.6 Hz), 8.00 (1 H, dd, J = 8.9, 1.5 Hz), 8.29 - 8.39 (2H, m), 8.51 (1 H, d, J = 8.8 Hz).
[0159]
Reference Example 75 Ethyl 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzoate A toluene (20 mL) solution of 2,4-dichloropyridine (1.00 g, 6.71 mmol), 2,4-dichloroaniline (1.20 g, 7.38 mmol), sodium tert-butoxide (968 mg, 10.1 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyl xanthene (233 mg, 0.403 mmol), and tris(dibenzylideneacetone)dipalladium (0) (123 mg, 0.134 mmol) was stirred at over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:19) to give 6-chloro-N-(2,4-dichlorophenyl)pyridine-2-amine in the form of a crude product.
Tetrakis(triphenylphosphine)palladium (0) (862 mg, 0.746 mmol) was added at room temperature in a nitrogen atmosphere to a 1,2-dimethoxyethane (35 mL) solution of the above compound (1.71 g), (3-(ethoxycarbonyl)-phenyl)boronic acid (1.33 g, 6.84 mmol), and 2 N sodium carbonate aqueous solution (12.4 mL), and the mixture was stirred at 100 C over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give 1.41 g of the titled compound (yield 54%) in solid form.
'H-NMR (CDC13) S: 1.44 (3H, t, J = 7.2 Hz), 4.43 (2H, q, J = 7.2 Hz), 6.78 (1H, d, J =
8.1 Hz), 6.92 (1 H, s), 7.24 - 7.31 (1 H, m), 7.34 - 7.43 (2H, m), 7.51 - 7.58 (1 H, m), 7.66 (1 H, t, J = 8.1 Hz), 8.05 - 8.12 (1 H, m), 8.18 - 8.24 (1 H, m), 8.39 (1 H, t, J = 8.1 Hz), 8.67 (1 H, t, J = 1.7 Hz).
Reference Example 75 Ethyl 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzoate A toluene (20 mL) solution of 2,4-dichloropyridine (1.00 g, 6.71 mmol), 2,4-dichloroaniline (1.20 g, 7.38 mmol), sodium tert-butoxide (968 mg, 10.1 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyl xanthene (233 mg, 0.403 mmol), and tris(dibenzylideneacetone)dipalladium (0) (123 mg, 0.134 mmol) was stirred at over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:19) to give 6-chloro-N-(2,4-dichlorophenyl)pyridine-2-amine in the form of a crude product.
Tetrakis(triphenylphosphine)palladium (0) (862 mg, 0.746 mmol) was added at room temperature in a nitrogen atmosphere to a 1,2-dimethoxyethane (35 mL) solution of the above compound (1.71 g), (3-(ethoxycarbonyl)-phenyl)boronic acid (1.33 g, 6.84 mmol), and 2 N sodium carbonate aqueous solution (12.4 mL), and the mixture was stirred at 100 C over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:9) to give 1.41 g of the titled compound (yield 54%) in solid form.
'H-NMR (CDC13) S: 1.44 (3H, t, J = 7.2 Hz), 4.43 (2H, q, J = 7.2 Hz), 6.78 (1H, d, J =
8.1 Hz), 6.92 (1 H, s), 7.24 - 7.31 (1 H, m), 7.34 - 7.43 (2H, m), 7.51 - 7.58 (1 H, m), 7.66 (1 H, t, J = 8.1 Hz), 8.05 - 8.12 (1 H, m), 8.18 - 8.24 (1 H, m), 8.39 (1 H, t, J = 8.1 Hz), 8.67 (1 H, t, J = 1.7 Hz).
[0160]
Reference Example 76 Ethyl 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoate A DMF (15 mL) solution of 2,6-dichloro-3-(trifluoromethyl)pyridine (1.00 g, 4.63 mmol), 2,4-dichlorophenol (792 mg, 4.86 mmol), and potassium carbonate (704 mg, 5.09 mmol) was stirred at 120 C for 3 hours. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:99) to give 2-chloro-6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridine in the form of a crude product.
Tetrakis(triphenylphosphine)palladium (0) (474 mg, 0.410 mmol) was added at room temperature in a nitrogen atmosphere to a 1,2-dimethoxyethane (20 mL) solution of the above compound (1.17 g), (3-(ethoxycarbonyl)-phenyl)boronic acid (729 mg, 3.76 mmol), and 2 N sodium carbonate aqueous solution (6.8 mL), and the mixture was stirred at 100 C over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:19) to give 788 mg of the titled compound (yield 51 %) in the form of an oily substance.
'H-NMR(CDC13) 6: 1.39(3H,t,J=7.1 Hz),4.28(2H,q,J=7.1 Hz),7.04(1H,d,J=
8.5 Hz), 7.14 - 7.20 (1 H, m), 7.22 - 7.29 (1 H, m), 7.41 - 7.50 (2H, m), 7.56 - 7.64 (1 H, m), 8.04 - 8.14 (3H, m).
Reference Example 76 Ethyl 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoate A DMF (15 mL) solution of 2,6-dichloro-3-(trifluoromethyl)pyridine (1.00 g, 4.63 mmol), 2,4-dichlorophenol (792 mg, 4.86 mmol), and potassium carbonate (704 mg, 5.09 mmol) was stirred at 120 C for 3 hours. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:99) to give 2-chloro-6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridine in the form of a crude product.
Tetrakis(triphenylphosphine)palladium (0) (474 mg, 0.410 mmol) was added at room temperature in a nitrogen atmosphere to a 1,2-dimethoxyethane (20 mL) solution of the above compound (1.17 g), (3-(ethoxycarbonyl)-phenyl)boronic acid (729 mg, 3.76 mmol), and 2 N sodium carbonate aqueous solution (6.8 mL), and the mixture was stirred at 100 C over night. Water was poured into the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:19) to give 788 mg of the titled compound (yield 51 %) in the form of an oily substance.
'H-NMR(CDC13) 6: 1.39(3H,t,J=7.1 Hz),4.28(2H,q,J=7.1 Hz),7.04(1H,d,J=
8.5 Hz), 7.14 - 7.20 (1 H, m), 7.22 - 7.29 (1 H, m), 7.41 - 7.50 (2H, m), 7.56 - 7.64 (1 H, m), 8.04 - 8.14 (3H, m).
[0161]
Reference Example 77 3-(6-((2,4-Dichlorophenyl)thio)pyridin-2-yl)benzoic acid 1 N sodium hydroxide aqueous solution (5.6 mL) was added at room temperature to a tetrahydrofuran (14 mL)-methanol (7 mL) solution of ethyl 3-(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)benzoate (1.13 g, 2.79 mmol) obtained in Reference Example 66, and the mixture was stirred over night. Water was poured into the reaction solution, the pH was adjusted to between 2 and 3 with 1 N hydrochloric acid aqueous solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. Diethyl ether was added to the residue, and 708 mg of the titled compound (yield 67%) was filtered off in solid form.
' H-NMR (DMSO-d6) S: 7.12 (1H, dd, J = 6.6, 1.9 Hz), 7.51 - 7.62 (2H, m), 7.76 - 7.90 (3H, m), 7.95 - 8.10 (2H, m), 8.16 (1 H, d, J = 7.7 Hz), 8.47 - 8.52 (1 H, m).
Reference Example 77 3-(6-((2,4-Dichlorophenyl)thio)pyridin-2-yl)benzoic acid 1 N sodium hydroxide aqueous solution (5.6 mL) was added at room temperature to a tetrahydrofuran (14 mL)-methanol (7 mL) solution of ethyl 3-(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)benzoate (1.13 g, 2.79 mmol) obtained in Reference Example 66, and the mixture was stirred over night. Water was poured into the reaction solution, the pH was adjusted to between 2 and 3 with 1 N hydrochloric acid aqueous solution, and the product was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was distilled off at reduced pressure. Diethyl ether was added to the residue, and 708 mg of the titled compound (yield 67%) was filtered off in solid form.
' H-NMR (DMSO-d6) S: 7.12 (1H, dd, J = 6.6, 1.9 Hz), 7.51 - 7.62 (2H, m), 7.76 - 7.90 (3H, m), 7.95 - 8.10 (2H, m), 8.16 (1 H, d, J = 7.7 Hz), 8.47 - 8.52 (1 H, m).
[0162]
Reference Example 78 1-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-1 H-indole-5-carboxylic acid The titled compound was obtained in solid form using methyl 1-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-1 H-indole-5-carboxylate obtained in Reference Example 74 in the same manner as in Reference Example 77. Yield:
90%.
'H-NMR (DMSO-d6) 6: 2.85 - 2.98 (2H, m), 3.63 - 3.82 (8H, m), 6.77 - 7.09 (4H, m), 7.30 (1 H, d, J = 6.2 Hz), 7.90 (1 H, dd, J = 8.9, 1.5 Hz), 8.26 - 8.33 (2H, m), 8.36 - 8.49 (1H, m), 8.55 - 8.76 (1H, m), 8.81 - 9.04 (1H, m).
Reference Example 78 1-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-1 H-indole-5-carboxylic acid The titled compound was obtained in solid form using methyl 1-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-1 H-indole-5-carboxylate obtained in Reference Example 74 in the same manner as in Reference Example 77. Yield:
90%.
'H-NMR (DMSO-d6) 6: 2.85 - 2.98 (2H, m), 3.63 - 3.82 (8H, m), 6.77 - 7.09 (4H, m), 7.30 (1 H, d, J = 6.2 Hz), 7.90 (1 H, dd, J = 8.9, 1.5 Hz), 8.26 - 8.33 (2H, m), 8.36 - 8.49 (1H, m), 8.55 - 8.76 (1H, m), 8.81 - 9.04 (1H, m).
[0163]
Reference Example 79 3-(6-((2,4-Dichlorophenyl)amino)pyridin-2-yl)benzoic acid The titled compound was obtained in solid form using ethyl 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzoate obtained in Reference Example 75 in the same manner as in Reference Example 77. Yield: 90%.
'H-NMR (DMSO-d6) 6: 7.04 (1H, d, J = 8.1 Hz), 7.37 (1H, dd, J = 8.9, 2.4 Hz), 7.47 (1 H, d, J = 7.3 Hz), 7.55 - 7.65 (2H, m), 7.73 (1 H, t, J = 8.1 Hz), 7.92 -7.99 (1 H, m), 8.23 (1 H, d, J = 8.9 Hz ), 8.60 (1 H, t, J = 1. 6 Hz), 8.67 (1 H, s).
Reference Example 79 3-(6-((2,4-Dichlorophenyl)amino)pyridin-2-yl)benzoic acid The titled compound was obtained in solid form using ethyl 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzoate obtained in Reference Example 75 in the same manner as in Reference Example 77. Yield: 90%.
'H-NMR (DMSO-d6) 6: 7.04 (1H, d, J = 8.1 Hz), 7.37 (1H, dd, J = 8.9, 2.4 Hz), 7.47 (1 H, d, J = 7.3 Hz), 7.55 - 7.65 (2H, m), 7.73 (1 H, t, J = 8.1 Hz), 7.92 -7.99 (1 H, m), 8.23 (1 H, d, J = 8.9 Hz ), 8.60 (1 H, t, J = 1. 6 Hz), 8.67 (1 H, s).
[0164]
Reference Example 80 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoic acid The titled compound was obtained in solid form using methyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoate obtained in Reference Example 67 in the same manner as in Reference Example 77. Yield: 76%.
' H-NMR (DMSO-d6) 6: 2.17 (3H, s), 7.18 (1H, d, J = 8.1 Hz), 7.32 - 7.43 (3H, m), 7.44 - 7.51 (1 H, m), 7.76 (1 H, t, J = 2.4 Hz), 7.79 - 7.89 (2H, m), 7.97 -8.05 (1 H, m).
Reference Example 80 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoic acid The titled compound was obtained in solid form using methyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoate obtained in Reference Example 67 in the same manner as in Reference Example 77. Yield: 76%.
' H-NMR (DMSO-d6) 6: 2.17 (3H, s), 7.18 (1H, d, J = 8.1 Hz), 7.32 - 7.43 (3H, m), 7.44 - 7.51 (1 H, m), 7.76 (1 H, t, J = 2.4 Hz), 7.79 - 7.89 (2H, m), 7.97 -8.05 (1 H, m).
[0165]
Reference Example 81 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-5-fluorobenzoic acid The titled compound was obtained in. solid form using ethyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5-fluorobenzoate obtained in Reference Example 69 in the same manner as in Reference Example 77. Yield: 85%.
'H-NMR (DMSO-d6) 6: 7.17 (1H, d, J = 8.1 Hz), 7.43 - 7.58 (2H, m), 7.62 - 7.71 (1H, m), 7.83 (1 H, d, J = 2.4 Hz), 7.85 - 7.91 (2H, m), 8.03 (1 H, t, J = 8.1 Hz), 8.21 - 8.28 (1H, m).
Reference Example 81 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-5-fluorobenzoic acid The titled compound was obtained in. solid form using ethyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5-fluorobenzoate obtained in Reference Example 69 in the same manner as in Reference Example 77. Yield: 85%.
'H-NMR (DMSO-d6) 6: 7.17 (1H, d, J = 8.1 Hz), 7.43 - 7.58 (2H, m), 7.62 - 7.71 (1H, m), 7.83 (1 H, d, J = 2.4 Hz), 7.85 - 7.91 (2H, m), 8.03 (1 H, t, J = 8.1 Hz), 8.21 - 8.28 (1H, m).
[0166]
Reference Example 82 3 -(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoic acid The titled compound was obtained in solid form using ethyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoate obtained in Reference Example 70 in the same manner as in Reference Example 77. Yield: 82%.
' H-NMR (DMSO-d6) 6: 7.18 (1H, d, J = 8.1 Hz), 7.37 - 7.53 (3H, m), 7.63 (1H, dd, J =
7.3, 1.9 Hz), 7.78 (1 H, d, J = 1.9 Hz), 7.94 - 8.07 (2H, m), 8.24 (1 H, dd, J
= 7.3, 1.9 Hz).
Reference Example 82 3 -(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoic acid The titled compound was obtained in solid form using ethyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoate obtained in Reference Example 70 in the same manner as in Reference Example 77. Yield: 82%.
' H-NMR (DMSO-d6) 6: 7.18 (1H, d, J = 8.1 Hz), 7.37 - 7.53 (3H, m), 7.63 (1H, dd, J =
7.3, 1.9 Hz), 7.78 (1 H, d, J = 1.9 Hz), 7.94 - 8.07 (2H, m), 8.24 (1 H, dd, J
= 7.3, 1.9 Hz).
[0167]
Reference Example 83 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid The titled compound was obtained in solid form using ethyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoate obtained in Reference Example 71 in the same manner as in Reference Example 77. Yield: 85%.
' H-NMR (DMSO-d6) 6: 7.19 (1 H, d, J = 8.1 Hz), 7.34 (1 H, t, J = 7.7 Hz), 7.42 - 7.53 (2H, m), 7.59 (1 H, dd, J = 7.7, 2.2 Hz), 7.68 - 7.76 (1 H, m), 7.80 (1 H, d, J = 2.2 Hz), 7.82 - 7.90 (1 H, m), 8.03 (1 H, t, J = 7.7 Hz).
Reference Example 83 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid The titled compound was obtained in solid form using ethyl 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoate obtained in Reference Example 71 in the same manner as in Reference Example 77. Yield: 85%.
' H-NMR (DMSO-d6) 6: 7.19 (1 H, d, J = 8.1 Hz), 7.34 (1 H, t, J = 7.7 Hz), 7.42 - 7.53 (2H, m), 7.59 (1 H, dd, J = 7.7, 2.2 Hz), 7.68 - 7.76 (1 H, m), 7.80 (1 H, d, J = 2.2 Hz), 7.82 - 7.90 (1 H, m), 8.03 (1 H, t, J = 7.7 Hz).
[0168]
Reference Example 84 5-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid The titled compound was obtained in solid form using ethyl 5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoate obtained in Reference Example 72 in the same manner as in Reference Example 77. Yield: 83%.
1 H-NMR (DMSO-d6) 6: 7.11 (1 H, d, J = 8.1 Hz), 7.34 - 7.48 (2H, m), 7.49 -7.55 (1 H, m), 7.75 - 7.82 (2H, m), 7.96 - 8.11 (2H, m), 8.31 (1H, dd, J = 7.2, 2.4 Hz).
Reference Example 84 5-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid The titled compound was obtained in solid form using ethyl 5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoate obtained in Reference Example 72 in the same manner as in Reference Example 77. Yield: 83%.
1 H-NMR (DMSO-d6) 6: 7.11 (1 H, d, J = 8.1 Hz), 7.34 - 7.48 (2H, m), 7.49 -7.55 (1 H, m), 7.75 - 7.82 (2H, m), 7.96 - 8.11 (2H, m), 8.31 (1H, dd, J = 7.2, 2.4 Hz).
[0169]
Reference Example 85 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoic acid The titled compound was obtained in solid form using ethyl 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoate obtained in Reference Example 76 in the same manner as in Reference Example 77. Yield: 93%.
' H-NMR (DMSO-d6) 6: 7.35 - 7.42 (1H, m), 7.45 - 7.53 (2H, m), 7.54 - 7.62 (2H, m), 7.78 (1 H, d, J = 1.3 Hz), 7.93 (1 H, s), 7.97 - 8.04 (11J, m), 8.40 (1 H, d, J = 8.7 Hz).
Reference Example 85 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoic acid The titled compound was obtained in solid form using ethyl 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoate obtained in Reference Example 76 in the same manner as in Reference Example 77. Yield: 93%.
' H-NMR (DMSO-d6) 6: 7.35 - 7.42 (1H, m), 7.45 - 7.53 (2H, m), 7.54 - 7.62 (2H, m), 7.78 (1 H, d, J = 1.3 Hz), 7.93 (1 H, s), 7.97 - 8.04 (11J, m), 8.40 (1 H, d, J = 8.7 Hz).
[0170]
Reference Example 86 6-(2,4-Dichlorophenoxy)-2,3'-bipyridine- 5'-carboxylic acid The titled compound was obtained in solid form using ethyl 6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxylate obtained in Reference Example 73 in the same manner as in Reference Example 77. Yield: 34%.
' H-NMR (DMSO-d6) 6: 7.20 (1H, d, J = 7.7 Hz), 7.41 - 7.58 (2H, m), 7.80 -7.97 (2H, m), 8.05 (1 H, t J = 7.7 Hz), 8.59 (1 H, t, J = 2.1 Hz), 9.05 (1 H, d, J = 1.9 Hz), 9.20 (1 H, d, J = 1.9 Hz).
Reference Example 86 6-(2,4-Dichlorophenoxy)-2,3'-bipyridine- 5'-carboxylic acid The titled compound was obtained in solid form using ethyl 6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxylate obtained in Reference Example 73 in the same manner as in Reference Example 77. Yield: 34%.
' H-NMR (DMSO-d6) 6: 7.20 (1H, d, J = 7.7 Hz), 7.41 - 7.58 (2H, m), 7.80 -7.97 (2H, m), 8.05 (1 H, t J = 7.7 Hz), 8.59 (1 H, t, J = 2.1 Hz), 9.05 (1 H, d, J = 1.9 Hz), 9.20 (1 H, d, J = 1.9 Hz).
[0171]
Reference Example 87 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoic acid The titled compound was obtained in solid form using ethyl 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoate obtained in Reference Example 68 in the same manner as in Reference Example 77. Yield: 55%.
' H-NMR (DMSO-d6) S: 7.50 - 7.63 (4H, m), 7.85 (1H, dd, J = 2.0, 0.8 Hz), 7.96 - 8.02 (1 H, m), 8.13 - 8.20 (2H, m), 8.43 (1 H, t, J = 1.5 Hz).
Reference Example 87 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoic acid The titled compound was obtained in solid form using ethyl 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoate obtained in Reference Example 68 in the same manner as in Reference Example 77. Yield: 55%.
' H-NMR (DMSO-d6) S: 7.50 - 7.63 (4H, m), 7.85 (1H, dd, J = 2.0, 0.8 Hz), 7.96 - 8.02 (1 H, m), 8.13 - 8.20 (2H, m), 8.43 (1 H, t, J = 1.5 Hz).
[0172]
Reference Example 88 6-Bromo-N-(2,4-dichlorobenzyl)pyridine-2-amine A DMF (15 mL) solution of 2,6-dibromopyridine (2.37 g, 10.0 mmol), triphenylphosphine (524 mg, 2.00 mmol), bis(triphenylphosphine)palladium (II) dichloride (140 mg, 0.20 mmol), and potassium carbonate (3.04 g, 22.0 mmol) was stirred for 10 min at room temperature in a nitrogen atmosphere, 2,4-dichlorobenzylamine (1.76 g, 10.0 mmol) was then added, and the mixture was reacted for 23 hours at 110 C. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated at reduced pressure, and the residue was purified by NH silica gel column chromatography (hexane-ethyl acetate 10:0 -* 9:1), and was crystallized from hexane-ethyl acetate and purified to give 903 mg of the titled compound (yield: 27%).
' H-NMR (CDC13) 6: 4.55 (2H, d, J = 6.3 Hz), 5.12 (1 H, br.s.), 6.23 (1 H, d, J = 8.2 Hz), 6.76 (1 H, d, J = 7.4 Hz), 7.14 - 7.28 (2H, m), 7.33 - 7.42 (2H, m) [0173]
Reference Example 89 6-Bromo-N-{2-[3-(trifluoromethyl)phenyl]ethyl }pyridine-2-amine The titled compound was obtained using 2,6-dibromopyridine and 2-[3-(trifluoromethyl)phenyl]ethanamine in the same manner as in Reference Example 88.' H-NMR (CDC13) 6:2.98 (2H, t, J = 7.0 Hz), 3.52 - 3.63 (2H, m), 4.61 (1 H, br.s.), 6.28 (1H, d, J = 7.7 Hz), 6.74 (1H, d, J = 7.4 Hz), 7.20 - 7.30 (1H, m), 7.38 -7.54 (4H, m) [0174]
Reference Example 90 Ethyl 3- { 6-[(2,4-dichlorobenzyl)amino]pyridin-2-yl } benzoate The titled compound was obtained using 6-bromo-N-(2,4-dichlorobenzyl)pyridine-amine obtained in Reference Example 88 and (3-(ethoxycarbonyl)-phenyl)boronic acid in the same manner as in Reference Example 66.1 H-NMR (CDC13) 6: 1.42 (3H, t, J =
7.0 Hz), 4.42 (2H, q, J = 7.1 Hz), 4.68 (2H, d, J = 6.3 Hz), 5.09 (1H, t, J =
6.0 Hz), 6.34 (1 H, d, J = 8.2 Hz), 7.13 (1 H, d, J = 7.4 Hz), 7.19 (1 H, dd, J = 8.2, 1.9 Hz), 7.40 (1 H, d, J = 2.2 Hz), 7.43 - 7.55 (3H, m), 8.05 (1H, dt, J = 7.7, 1.5 Hz), 8.15 (1H, dd, J = 7.6, 1.5 Hz), 8.63 (1 H, t, J = 1.5 Hz) [0175]
Reference Example 91 Ethyl 3- [6-({ 2- [3-(trifluoromethyl)phenyl] ethyl } amino)pyridin-2-yl]benzoate The titled compound was obtained using 6-bromo-N-{2-[3-(trifluoromethyl)phenyl]ethyl}pyridine-2-amine obtained in Reference Example 89 and (3-(ethoxycarbonyl)-phenyl)boronic acid in the same manner as in Reference Example 66.' H-NMR (CDC13) 6 : 1.41 (31-1, t, J = 7.1 Hz), 3.05 (21-1, t, J = 7.1 Hz), 3.63 - 3.78 (2H, m), 4.41 (2H, q, J = 7.1 Hz), 4.64 (1 H, t, J = 5.8 Hz), 6.36 (1 H, d, J
= 8.2 Hz), 7.12 (1 H, d, J = 7.4 Hz), 7.3 7 - 7.5 5 (61-1, m), 8.05 (1 H, dt, J = 8.2, 1.1 Hz), 8.21 (1 H, ddd, J
= 7.8, 1.6, 1.5 Hz), 8.64 (1 H, t, J = 1.8 Hz) [0176]
Reference Example 92 3-{6-[(2,4-Dichlorobenzyl)amino]pyridin-2-yl}benzoic acid The titled compound was obtained in solid form using ethyl 3-{6-[(2,4-dichlorobenzyl)amino]pyridin-2-yl)benzoate obtained in Reference Example 90 in the same manner as in Reference Example 77.' H-NMR (DMSO-d6) 8: 4.60 (21-1, d, J =
5.8 Hz), 6.54 (1 H, d, J = 8.2 Hz), 7.12 (1 H, d, J = 7.4 Hz), 7.35 (2H, dd, J =
8.4, 2.1 Hz), 7.41 - 7.55 (3H, m), 7.57 (1 H, d, J = 1.9 Hz), 7.89 (1 H, dd, J = 7.7, 1.1 Hz), 8.11 (1 H, d, J = 6.6 Hz), 8.49 (1 H, d, J = 1.4 Hz), 12.95 (1 H, br.s.) [0177]
Reference Example 93 3- [6-( { 2- [3 -(Trifluoromethyl)phenyl] ethyl } amino)pyridin-2-yljbenzoic acid The titled compound was obtained in solid form using ethyl 3-[6-({2-[3-(trifluoromethyl)phenyl] ethyl }amino)pyridin-2-yl)benzoate obtained in Reference Example 91 in the same manner as in Reference Example 66.1 H-NMR (CDC13) 6:
3.15 (2H, t, J = 7.3 Hz), 3.66 (2H, t, J = 7.4 Hz), 6.47 (1 H, d, J = 8.5 Hz), 7.03 (1 H, d, J =
7.1 Hz), 7.36 - 7.66 (6H, m), 7.96 (1 H, d, J = 7.7 Hz), 8.21 (1 H, d, J = 7.7 Hz), 9.12 (1 H, s) [0178]
Working Example 1 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)acetamide Acetic anhydride (45 L, 0.48 mmol) was added to a pyridine (3 mL) solution of (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine (0.15 g, 0.43 mmol) synthesized in Reference Example 3, and the mixture was stirred for 90 min at room temperature. Ethyl acetate was added to the reaction solution, the solution was washed with water and with saturated brine, and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate 10:0 - 0:10) and was recrystallized from ethyl acetate-hexane to give 0.11 g (yield 65%) of the titled compound in the form of crystals.
Melting point: 146 - 148 C.
'H-NMR (CDC13) 6: 2.21 (3H, s), 2.91 (2H, t, J = 6.9 Hz), 3.73-3.79 (2H, m), 3.86 (6H, s), 5.20 (1 H, br t, J = 6.0 Hz), 6.78-6.81 (3H, m), 6.96 (1 H, d, J =
5.4 Hz), 7.37 (1 H, br s), 7.42 (1 H, t, J = 8.1 Hz), 7.72- 7.75 (2H, m), 8.08 (1 H, br s), 8.58 (1 H, d, J =
5.1 Hz).
Reference Example 88 6-Bromo-N-(2,4-dichlorobenzyl)pyridine-2-amine A DMF (15 mL) solution of 2,6-dibromopyridine (2.37 g, 10.0 mmol), triphenylphosphine (524 mg, 2.00 mmol), bis(triphenylphosphine)palladium (II) dichloride (140 mg, 0.20 mmol), and potassium carbonate (3.04 g, 22.0 mmol) was stirred for 10 min at room temperature in a nitrogen atmosphere, 2,4-dichlorobenzylamine (1.76 g, 10.0 mmol) was then added, and the mixture was reacted for 23 hours at 110 C. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated at reduced pressure, and the residue was purified by NH silica gel column chromatography (hexane-ethyl acetate 10:0 -* 9:1), and was crystallized from hexane-ethyl acetate and purified to give 903 mg of the titled compound (yield: 27%).
' H-NMR (CDC13) 6: 4.55 (2H, d, J = 6.3 Hz), 5.12 (1 H, br.s.), 6.23 (1 H, d, J = 8.2 Hz), 6.76 (1 H, d, J = 7.4 Hz), 7.14 - 7.28 (2H, m), 7.33 - 7.42 (2H, m) [0173]
Reference Example 89 6-Bromo-N-{2-[3-(trifluoromethyl)phenyl]ethyl }pyridine-2-amine The titled compound was obtained using 2,6-dibromopyridine and 2-[3-(trifluoromethyl)phenyl]ethanamine in the same manner as in Reference Example 88.' H-NMR (CDC13) 6:2.98 (2H, t, J = 7.0 Hz), 3.52 - 3.63 (2H, m), 4.61 (1 H, br.s.), 6.28 (1H, d, J = 7.7 Hz), 6.74 (1H, d, J = 7.4 Hz), 7.20 - 7.30 (1H, m), 7.38 -7.54 (4H, m) [0174]
Reference Example 90 Ethyl 3- { 6-[(2,4-dichlorobenzyl)amino]pyridin-2-yl } benzoate The titled compound was obtained using 6-bromo-N-(2,4-dichlorobenzyl)pyridine-amine obtained in Reference Example 88 and (3-(ethoxycarbonyl)-phenyl)boronic acid in the same manner as in Reference Example 66.1 H-NMR (CDC13) 6: 1.42 (3H, t, J =
7.0 Hz), 4.42 (2H, q, J = 7.1 Hz), 4.68 (2H, d, J = 6.3 Hz), 5.09 (1H, t, J =
6.0 Hz), 6.34 (1 H, d, J = 8.2 Hz), 7.13 (1 H, d, J = 7.4 Hz), 7.19 (1 H, dd, J = 8.2, 1.9 Hz), 7.40 (1 H, d, J = 2.2 Hz), 7.43 - 7.55 (3H, m), 8.05 (1H, dt, J = 7.7, 1.5 Hz), 8.15 (1H, dd, J = 7.6, 1.5 Hz), 8.63 (1 H, t, J = 1.5 Hz) [0175]
Reference Example 91 Ethyl 3- [6-({ 2- [3-(trifluoromethyl)phenyl] ethyl } amino)pyridin-2-yl]benzoate The titled compound was obtained using 6-bromo-N-{2-[3-(trifluoromethyl)phenyl]ethyl}pyridine-2-amine obtained in Reference Example 89 and (3-(ethoxycarbonyl)-phenyl)boronic acid in the same manner as in Reference Example 66.' H-NMR (CDC13) 6 : 1.41 (31-1, t, J = 7.1 Hz), 3.05 (21-1, t, J = 7.1 Hz), 3.63 - 3.78 (2H, m), 4.41 (2H, q, J = 7.1 Hz), 4.64 (1 H, t, J = 5.8 Hz), 6.36 (1 H, d, J
= 8.2 Hz), 7.12 (1 H, d, J = 7.4 Hz), 7.3 7 - 7.5 5 (61-1, m), 8.05 (1 H, dt, J = 8.2, 1.1 Hz), 8.21 (1 H, ddd, J
= 7.8, 1.6, 1.5 Hz), 8.64 (1 H, t, J = 1.8 Hz) [0176]
Reference Example 92 3-{6-[(2,4-Dichlorobenzyl)amino]pyridin-2-yl}benzoic acid The titled compound was obtained in solid form using ethyl 3-{6-[(2,4-dichlorobenzyl)amino]pyridin-2-yl)benzoate obtained in Reference Example 90 in the same manner as in Reference Example 77.' H-NMR (DMSO-d6) 8: 4.60 (21-1, d, J =
5.8 Hz), 6.54 (1 H, d, J = 8.2 Hz), 7.12 (1 H, d, J = 7.4 Hz), 7.35 (2H, dd, J =
8.4, 2.1 Hz), 7.41 - 7.55 (3H, m), 7.57 (1 H, d, J = 1.9 Hz), 7.89 (1 H, dd, J = 7.7, 1.1 Hz), 8.11 (1 H, d, J = 6.6 Hz), 8.49 (1 H, d, J = 1.4 Hz), 12.95 (1 H, br.s.) [0177]
Reference Example 93 3- [6-( { 2- [3 -(Trifluoromethyl)phenyl] ethyl } amino)pyridin-2-yljbenzoic acid The titled compound was obtained in solid form using ethyl 3-[6-({2-[3-(trifluoromethyl)phenyl] ethyl }amino)pyridin-2-yl)benzoate obtained in Reference Example 91 in the same manner as in Reference Example 66.1 H-NMR (CDC13) 6:
3.15 (2H, t, J = 7.3 Hz), 3.66 (2H, t, J = 7.4 Hz), 6.47 (1 H, d, J = 8.5 Hz), 7.03 (1 H, d, J =
7.1 Hz), 7.36 - 7.66 (6H, m), 7.96 (1 H, d, J = 7.7 Hz), 8.21 (1 H, d, J = 7.7 Hz), 9.12 (1 H, s) [0178]
Working Example 1 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)acetamide Acetic anhydride (45 L, 0.48 mmol) was added to a pyridine (3 mL) solution of (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine (0.15 g, 0.43 mmol) synthesized in Reference Example 3, and the mixture was stirred for 90 min at room temperature. Ethyl acetate was added to the reaction solution, the solution was washed with water and with saturated brine, and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate 10:0 - 0:10) and was recrystallized from ethyl acetate-hexane to give 0.11 g (yield 65%) of the titled compound in the form of crystals.
Melting point: 146 - 148 C.
'H-NMR (CDC13) 6: 2.21 (3H, s), 2.91 (2H, t, J = 6.9 Hz), 3.73-3.79 (2H, m), 3.86 (6H, s), 5.20 (1 H, br t, J = 6.0 Hz), 6.78-6.81 (3H, m), 6.96 (1 H, d, J =
5.4 Hz), 7.37 (1 H, br s), 7.42 (1 H, t, J = 8.1 Hz), 7.72- 7.75 (2H, m), 8.08 (1 H, br s), 8.58 (1 H, d, J =
5.1 Hz).
[0179]
Working Example 2 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)-2-methoxyacetamide Methoxyacetic acid (46 mg, 0.51 mmol), WSC (99 mg, 0.52 mmol), and HOBt (70 mg, 0.52 mmol) were added to a DMF (3 mL) solution of (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine (0.15 g, 0.43 mmol) synthesized in Reference Example 3, and the mixture was stirred for 16 hours at room temperature.
Ethyl acetate was added to the reaction solution, the solution was washed with water and with saturated brine, and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate 10:0 -> 0:10) and was recrystallized from ethyl acetate-hexane to give 0.14 g (yield 77%) of the titled compound in the form of crystals. Melting point: 140 - 141 C.
'H-NMR (CDC13) 6: 2.92 (2H, t, J = 6.9 Hz), 3.53 (3H, s), 3.74-3.80 (2H, m), 3.87 (6H, s), 4.05 (2H,s), 5.22 (111, br t, J = 5.7 Hz), 6.78 (1 H, s), 6.82 (2H, s), 6.98 (1 H, d, J
= 5.1 Hz), 7.44 (1H, d, J = 8.1 Hz), 7.76- 7.80 (2H, m), 8.19 (1H, br s), 8.33-8.36 (2H, m).
Working Example 2 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)-2-methoxyacetamide Methoxyacetic acid (46 mg, 0.51 mmol), WSC (99 mg, 0.52 mmol), and HOBt (70 mg, 0.52 mmol) were added to a DMF (3 mL) solution of (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine (0.15 g, 0.43 mmol) synthesized in Reference Example 3, and the mixture was stirred for 16 hours at room temperature.
Ethyl acetate was added to the reaction solution, the solution was washed with water and with saturated brine, and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate 10:0 -> 0:10) and was recrystallized from ethyl acetate-hexane to give 0.14 g (yield 77%) of the titled compound in the form of crystals. Melting point: 140 - 141 C.
'H-NMR (CDC13) 6: 2.92 (2H, t, J = 6.9 Hz), 3.53 (3H, s), 3.74-3.80 (2H, m), 3.87 (6H, s), 4.05 (2H,s), 5.22 (111, br t, J = 5.7 Hz), 6.78 (1 H, s), 6.82 (2H, s), 6.98 (1 H, d, J
= 5.1 Hz), 7.44 (1H, d, J = 8.1 Hz), 7.76- 7.80 (2H, m), 8.19 (1H, br s), 8.33-8.36 (2H, m).
[0180]
Working Example 3 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)benzamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and benzoic acid in the same manner as in Working Example 2. Yield: 64%.
Melting point: 168 - 170 C (ethyl acetate-hexane).
' H-NMR (CDC13) 8: 2.92 (2H, t, J = 6.9 Hz), 3.74-3.81 (2H, m), 3.85 (6H, s), 5.21 (1 H, br t), 6.79-6.81 (311, m), 7.01 (1 H, d, J = 5.1 Hz), 7.46- 7.61 (4H, m), 7.79- 7.92 (5H, m), 8.26 (1H, s), 8.35 (1H, d, J = 5.1 Hz).
Working Example 3 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)benzamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and benzoic acid in the same manner as in Working Example 2. Yield: 64%.
Melting point: 168 - 170 C (ethyl acetate-hexane).
' H-NMR (CDC13) 8: 2.92 (2H, t, J = 6.9 Hz), 3.74-3.81 (2H, m), 3.85 (6H, s), 5.21 (1 H, br t), 6.79-6.81 (311, m), 7.01 (1 H, d, J = 5.1 Hz), 7.46- 7.61 (4H, m), 7.79- 7.92 (5H, m), 8.26 (1H, s), 8.35 (1H, d, J = 5.1 Hz).
[0181]
Working Example 4 Tert-butyl ((3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenylcarbamoyl)methyl)carbamate ester The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and N-Boc-glycine in the same manner as in Working Example 2. Yield: 76%.
1 H-NMR (CDC13) 6: 1.49 (9H, s), 2.91 (2H, t, J = 6.6 Hz), 3.73-3.78 (2H, m), 3.68 (6H, s), 3.96 (2H, d, J = 6.0 Hz), 5.21 - 5.23 (2H, m), 6.78-6.82 (3H, m), 6.96 (1 H, d, J
= 5.4 Hz), 7.42 (1 H, t, J = 8.1 Hz), 7.70 (1 H, d, J = 7.8 Hz), 7.77 (1 H, d, J = 7.8 Hz), 8.12 (1 H, s), 8.19 (1 H, br s), 8.3 3 (1 H, d, J = 5.1 Hz).
Working Example 4 Tert-butyl ((3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenylcarbamoyl)methyl)carbamate ester The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and N-Boc-glycine in the same manner as in Working Example 2. Yield: 76%.
1 H-NMR (CDC13) 6: 1.49 (9H, s), 2.91 (2H, t, J = 6.6 Hz), 3.73-3.78 (2H, m), 3.68 (6H, s), 3.96 (2H, d, J = 6.0 Hz), 5.21 - 5.23 (2H, m), 6.78-6.82 (3H, m), 6.96 (1 H, d, J
= 5.4 Hz), 7.42 (1 H, t, J = 8.1 Hz), 7.70 (1 H, d, J = 7.8 Hz), 7.77 (1 H, d, J = 7.8 Hz), 8.12 (1 H, s), 8.19 (1 H, br s), 8.3 3 (1 H, d, J = 5.1 Hz).
[0182]
Working Example 5 N-(3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-2-methylpropanamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and iso-butyric anhydride in the same manner as in Working Example 1. Yield: 81%.
Melting point: 146 - 147 C (ethyl acetate-hexane).
I H-NMR (CDC13) 6: 1.28 (6H, d, J = 6.6 Hz), 2.54 (1H, m), 2.91 (2H, t, J =
6.9 Hz), 3.76 (2H, td, J = 5.4, 6.9 Hz), 3.86 (6H, s), 5.21 (1H, t, J = 5.4 Hz), 6.78-6.82 (3H, m), 6.97 (1 H, d, J = 5.4 Hz), 7.32 (1 H, br s), 7.41 (1 H, t, J = 7.8 Hz), 7.72-7.74 (2H, m), 8.15 (1H, s), 8.33 (1H, d, J = 5.1 Hz).
Working Example 5 N-(3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-2-methylpropanamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and iso-butyric anhydride in the same manner as in Working Example 1. Yield: 81%.
Melting point: 146 - 147 C (ethyl acetate-hexane).
I H-NMR (CDC13) 6: 1.28 (6H, d, J = 6.6 Hz), 2.54 (1H, m), 2.91 (2H, t, J =
6.9 Hz), 3.76 (2H, td, J = 5.4, 6.9 Hz), 3.86 (6H, s), 5.21 (1H, t, J = 5.4 Hz), 6.78-6.82 (3H, m), 6.97 (1 H, d, J = 5.4 Hz), 7.32 (1 H, br s), 7.41 (1 H, t, J = 7.8 Hz), 7.72-7.74 (2H, m), 8.15 (1H, s), 8.33 (1H, d, J = 5.1 Hz).
[0183]
Working Example 6 2-Amino-N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)acetamide hydrochloride 4 N hydrogen chloride-ethyl acetate solution (2 mL) was added to an ethyl acetate mL) solution of tert-butyl ((3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-yl)phenylcarbamoyl)methyl)carbamate ester (200 mg, 0.39 mmol) synthesized in Working Example 4, and the mixture was stirred for 16 hours at room temperature. The precipitated crystals were filtered off and washed with ethyl acetate to give 188 mg of the titled compound (yield: quantitative). Melting point: 224 - 226 C.
I H-NMR (DMSO-d6) 6 : 2.87 (2H, t, J = 6.9 Hz), 3.69 (6H, s), 3.73 (2H, s), 3.82-3.86 (2H, m), 6.79-6.91 (3H, m), 7.28 (1H, br s), 7.54 (1H, d, J = 8.1 Hz), 7.88 (2H, br s), 8.31 (4H, br), 8.45 (2H, d, J = 5.7 Hz), 11.07 (1H, s).
Working Example 6 2-Amino-N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)acetamide hydrochloride 4 N hydrogen chloride-ethyl acetate solution (2 mL) was added to an ethyl acetate mL) solution of tert-butyl ((3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-yl)phenylcarbamoyl)methyl)carbamate ester (200 mg, 0.39 mmol) synthesized in Working Example 4, and the mixture was stirred for 16 hours at room temperature. The precipitated crystals were filtered off and washed with ethyl acetate to give 188 mg of the titled compound (yield: quantitative). Melting point: 224 - 226 C.
I H-NMR (DMSO-d6) 6 : 2.87 (2H, t, J = 6.9 Hz), 3.69 (6H, s), 3.73 (2H, s), 3.82-3.86 (2H, m), 6.79-6.91 (3H, m), 7.28 (1H, br s), 7.54 (1H, d, J = 8.1 Hz), 7.88 (2H, br s), 8.31 (4H, br), 8.45 (2H, d, J = 5.7 Hz), 11.07 (1H, s).
[0184]
Working Example 7 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and tetrahydrofuran-3-carboxylic acid in the same manner as in Working Example 2.
Yield:
76%. Melting point: 146 - 147 C (ethyl acetate-hexane).
1 H-NMR (CDC13) 6 : 2.29 (2H, q, J = 7.2 Hz), 2.91 (2H, t, J = 6.9 Hz), 3.06 (1H, m), 3.73-4.15 (6H, m), 3.86 (6H, s), 5.24 (1 H, t, J = 5.7 Hz), 6.78-6.84 (3H, m), 6.97 (1 H, d, J = 5.4 Hz), 7.42 (1 H, t, J = 7.8 Hz), 7.63 (1 H, br s), 7.71 - 7.77 (2H, m), 8.12 (1 H, s), 8.3 3 (1 H, d, J = 5.4 Hz).
Working Example 7 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)tetrahydrofuran-3-carboxamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and tetrahydrofuran-3-carboxylic acid in the same manner as in Working Example 2.
Yield:
76%. Melting point: 146 - 147 C (ethyl acetate-hexane).
1 H-NMR (CDC13) 6 : 2.29 (2H, q, J = 7.2 Hz), 2.91 (2H, t, J = 6.9 Hz), 3.06 (1H, m), 3.73-4.15 (6H, m), 3.86 (6H, s), 5.24 (1 H, t, J = 5.7 Hz), 6.78-6.84 (3H, m), 6.97 (1 H, d, J = 5.4 Hz), 7.42 (1 H, t, J = 7.8 Hz), 7.63 (1 H, br s), 7.71 - 7.77 (2H, m), 8.12 (1 H, s), 8.3 3 (1 H, d, J = 5.4 Hz).
[0185]
Working Example 8 Tert-butyl (4-((3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-4-oxobutyl)carbamate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 4-(tert-butoxycarbonylamino)butyric acid in the same manner as in Working Example 2.
Yield:
79%. Melting point: 154 - 157 C (ethyl acetate-hexane).
'H-NMR (CDC13) 6: 1.47 (9H, s), 1.86-1.94 (2H, m), 2.42 (2H, t, J = 6.6 Hz), 2.91 (2H, t, J = 6.6 Hz), 3.25-3.31 (2H, m), 3.77 (2H, q, J = 6.3 Hz), 3.87 (6H, s), 4.75 (1H, br t), 5.20 (1 H, br), 6.78-6.81 (3H, m), 6.98 (1 H, d, J = 5.1 Hz), 7.42 (1 H, t, J = 7.8 Hz), 7.76- 7.78 (2H, m), 8.28-8.30 (2H, m), 8.91 (114, br s).
Working Example 8 Tert-butyl (4-((3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-4-oxobutyl)carbamate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 4-(tert-butoxycarbonylamino)butyric acid in the same manner as in Working Example 2.
Yield:
79%. Melting point: 154 - 157 C (ethyl acetate-hexane).
'H-NMR (CDC13) 6: 1.47 (9H, s), 1.86-1.94 (2H, m), 2.42 (2H, t, J = 6.6 Hz), 2.91 (2H, t, J = 6.6 Hz), 3.25-3.31 (2H, m), 3.77 (2H, q, J = 6.3 Hz), 3.87 (6H, s), 4.75 (1H, br t), 5.20 (1 H, br), 6.78-6.81 (3H, m), 6.98 (1 H, d, J = 5.1 Hz), 7.42 (1 H, t, J = 7.8 Hz), 7.76- 7.78 (2H, m), 8.28-8.30 (2H, m), 8.91 (114, br s).
[0186]
Working Example 9 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)pentanamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and valeric anhydride in the same manner as in Working Example 1. Yield: 73%. Melting point:
136 - 137 C (ethanol-hexane).
' H-NMR (CDC13) S : 0.96 (3H, t, J = 7.2 Hz), 1.39-1.47 (2H, m), 1.69-1.79 (2H, m), 2.40 (2H, t, J = 7.5 Hz), 2.91 (2H, t, J = 6.9 Hz), 3.73-3.80 (2H, m), 3.87 (6H, s), 5.17 (1 H, t, J = 5.7 Hz), 6.78-6.82 (3 H, m), 6.98 (1 H, d, J = 5.1 Hz), 7.24-7.26 (1 H, m), 7.42 (1 H, t, J = 7.8 Hz), 7.73 (2H, br s), 8.12 (1 H, s), 8.3 3 (1 H, d, J = 5.1 Hz).
Working Example 9 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)pentanamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and valeric anhydride in the same manner as in Working Example 1. Yield: 73%. Melting point:
136 - 137 C (ethanol-hexane).
' H-NMR (CDC13) S : 0.96 (3H, t, J = 7.2 Hz), 1.39-1.47 (2H, m), 1.69-1.79 (2H, m), 2.40 (2H, t, J = 7.5 Hz), 2.91 (2H, t, J = 6.9 Hz), 3.73-3.80 (2H, m), 3.87 (6H, s), 5.17 (1 H, t, J = 5.7 Hz), 6.78-6.82 (3 H, m), 6.98 (1 H, d, J = 5.1 Hz), 7.24-7.26 (1 H, m), 7.42 (1 H, t, J = 7.8 Hz), 7.73 (2H, br s), 8.12 (1 H, s), 8.3 3 (1 H, d, J = 5.1 Hz).
[0187]
Working Example 10 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)-3-phenylpropionamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 3-phenylpropionic acid in the same manner as in Working Example 2. Yield: 77%.
Melting point: 155 - 156 C (ethanol-hexane).
'H-NMR (CDC13) 6 : 2.69 (2H, t, J = 7.8 Hz), 2.90 (2H, t, J = 6.9 Hz), 3.08 (2H, t, J =
7.8 Hz), 3.72-3.79 (2H, m), 3.85 (3H, s), 3.86 (3H, s), 5.19 (1H, t, J = 5.7 Hz), 6.78-6.81 (3H, m), 6.95 (1 H, d, J = 5.1 Hz), 7.18- 7.33 (6H, m), 7.40 (1 H, t, J =
7.8 Hz), 7.65 (1 H, d, J = 8.1 Hz), 7.74 (1 H, d, J = 7.8 Hz), 8.03 (1 H, s), 8.32 (1 H, d, J = 2.1 Hz).
Working Example 10 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)-3-phenylpropionamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 3-phenylpropionic acid in the same manner as in Working Example 2. Yield: 77%.
Melting point: 155 - 156 C (ethanol-hexane).
'H-NMR (CDC13) 6 : 2.69 (2H, t, J = 7.8 Hz), 2.90 (2H, t, J = 6.9 Hz), 3.08 (2H, t, J =
7.8 Hz), 3.72-3.79 (2H, m), 3.85 (3H, s), 3.86 (3H, s), 5.19 (1H, t, J = 5.7 Hz), 6.78-6.81 (3H, m), 6.95 (1 H, d, J = 5.1 Hz), 7.18- 7.33 (6H, m), 7.40 (1 H, t, J =
7.8 Hz), 7.65 (1 H, d, J = 8.1 Hz), 7.74 (1 H, d, J = 7.8 Hz), 8.03 (1 H, s), 8.32 (1 H, d, J = 2.1 Hz).
[0188]
Working Example 11 2-Acetylamino-N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)acetamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and N-acetylglycine in the same manner as in Working Example 2. Yield: 45%. Melting point: 177 - 178 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6) 8: 1.87 (3H, s), 2.82 (2H, t, J = 7.5 Hz), 3.55-3.58 (2H, m), 3.71 (3H, s), 3.72 (3H, s), 3.89 (2H, d, J = 6.0 Hz), 6.78 (1H, d, J = 8.1 Hz), 6.85-6.88 (2H, m), 7.02 (1 H, d, J = 5.1 Hz), 7.23 (1 H, t, J = 5.1 Hz), 7.44 (1 H, t, J =
7.8 Hz), 7.70 -7.76 (2H, m), 8.23 (1H, t, J = 6.0 Hz), 8.33-8.36 (2H, m), 10.12 (1H, s).
Working Example 11 2-Acetylamino-N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)acetamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and N-acetylglycine in the same manner as in Working Example 2. Yield: 45%. Melting point: 177 - 178 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6) 8: 1.87 (3H, s), 2.82 (2H, t, J = 7.5 Hz), 3.55-3.58 (2H, m), 3.71 (3H, s), 3.72 (3H, s), 3.89 (2H, d, J = 6.0 Hz), 6.78 (1H, d, J = 8.1 Hz), 6.85-6.88 (2H, m), 7.02 (1 H, d, J = 5.1 Hz), 7.23 (1 H, t, J = 5.1 Hz), 7.44 (1 H, t, J =
7.8 Hz), 7.70 -7.76 (2H, m), 8.23 (1H, t, J = 6.0 Hz), 8.33-8.36 (2H, m), 10.12 (1H, s).
[0189]
Working Example 12 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)-3-methoxybenzamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 3-methoxybenzoic acid in the same manner as in Working Example 2. Yield: 80%.
Melting point: 142 - 143 C (ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 2.92 (2H, t, J = 7.2 Hz), 3.74-3.81 (2H, m), 3.85 (6H, s), 3.88 (3H, s), 5.30 (1H, br t), 6.78-6.81 (3H, m), 7.01 (114, d, J = 5.1 Hz), 7.08-7.12 (1H, m), 7.37-7.50 (4H, m), 7.78-7.87 (21-1, m), 8.97 (1 H, s), 8.26 (1 H, s), 8.34 (1 H, d, J = 5.4 Hz).
Working Example 12 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)-3-methoxybenzamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 3-methoxybenzoic acid in the same manner as in Working Example 2. Yield: 80%.
Melting point: 142 - 143 C (ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 2.92 (2H, t, J = 7.2 Hz), 3.74-3.81 (2H, m), 3.85 (6H, s), 3.88 (3H, s), 5.30 (1H, br t), 6.78-6.81 (3H, m), 7.01 (114, d, J = 5.1 Hz), 7.08-7.12 (1H, m), 7.37-7.50 (4H, m), 7.78-7.87 (21-1, m), 8.97 (1 H, s), 8.26 (1 H, s), 8.34 (1 H, d, J = 5.4 Hz).
[0190]
Working Example 13 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-3-furamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 3-furancarboxylic acid in the same manner as in Working Example 2. Yield: 79%.
Melting point: 151 - 152 C (ethyl acetate-hexane).
' H-NMR (CDC13) 6: 2.91 (2H, t, J = 6.9 Hz), 3.75-3.77 (2H, m), 3.84 (6H, s), 5.39 (1H, br s), 6.77-6.80 (4H, m), 6.95 (1H, d, J = 5.4 Hz), 7.41 - 7.50 (2H, m), 7.75- 7.85 (3H, m), 8.09 (1 H, s), 8.15 (1 H, t, J = 1.8 Hz), 8.32 (1 H, d, J = 5.4 Hz).
Working Example 13 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-3-furamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 3-furancarboxylic acid in the same manner as in Working Example 2. Yield: 79%.
Melting point: 151 - 152 C (ethyl acetate-hexane).
' H-NMR (CDC13) 6: 2.91 (2H, t, J = 6.9 Hz), 3.75-3.77 (2H, m), 3.84 (6H, s), 5.39 (1H, br s), 6.77-6.80 (4H, m), 6.95 (1H, d, J = 5.4 Hz), 7.41 - 7.50 (2H, m), 7.75- 7.85 (3H, m), 8.09 (1 H, s), 8.15 (1 H, t, J = 1.8 Hz), 8.32 (1 H, d, J = 5.4 Hz).
[0191]
Working Example 14 Tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-3-oxopropyl)carbamate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and N-Boc-(3-alanine in the same manner as in Working Example 2. Yield: 85%. Melting point:
141 C (ethyl acetate-hexane).
' H-NMR (CDCI3) 6 : 1.44 (9H, s), 2.64 (2H, t, J = 5.7 Hz), 2.91 (2H, t, J =
6.9 Hz), 3.52 (2H, q, J = 6.3 Hz), 3.77 (2H, q, J = 6.6 Hz), 3.86 (6H, s), 5.19-5.23 (2H, m), 6.78-6.82 (3H, m), 6.96 (1 H, d, J = 5.4 Hz), 7.42 (1 H, t, J = 8.1 Hz), 7.70 -7.78 (3H, m), 8.15 (1H, s), 8.33 (1H, d, J = 5.1 Hz).
Working Example 14 Tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-3-oxopropyl)carbamate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and N-Boc-(3-alanine in the same manner as in Working Example 2. Yield: 85%. Melting point:
141 C (ethyl acetate-hexane).
' H-NMR (CDCI3) 6 : 1.44 (9H, s), 2.64 (2H, t, J = 5.7 Hz), 2.91 (2H, t, J =
6.9 Hz), 3.52 (2H, q, J = 6.3 Hz), 3.77 (2H, q, J = 6.6 Hz), 3.86 (6H, s), 5.19-5.23 (2H, m), 6.78-6.82 (3H, m), 6.96 (1 H, d, J = 5.4 Hz), 7.42 (1 H, t, J = 8.1 Hz), 7.70 -7.78 (3H, m), 8.15 (1H, s), 8.33 (1H, d, J = 5.1 Hz).
[0192]
Working Example 15 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-(3-alaninamide hydrochloride The titled compound was obtained from tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-3-oxopropyl)carbamate synthesized in Working Example 14 in the same manner as in Working Example 6.
Yield: 98%. Melting point: 136 - 138 C (methanol-ethyl acetate).
'H-NMR (DMSO-d6) 6 : 2.73-2.88 (4H, m), 3.07-3.13 (2H, m), 3.64-3.73 (8H, m), 6.79-6.89 (3H, m), 7.22 (1 H, br s), 7.50 (1 H, t, J = 7.8 Hz), 7.82 (2H, br s), 7.97 (4H, br s), 8.42-8.46 (2H, m), 10.53 (1H, s).
Working Example 15 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-(3-alaninamide hydrochloride The titled compound was obtained from tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-3-oxopropyl)carbamate synthesized in Working Example 14 in the same manner as in Working Example 6.
Yield: 98%. Melting point: 136 - 138 C (methanol-ethyl acetate).
'H-NMR (DMSO-d6) 6 : 2.73-2.88 (4H, m), 3.07-3.13 (2H, m), 3.64-3.73 (8H, m), 6.79-6.89 (3H, m), 7.22 (1 H, br s), 7.50 (1 H, t, J = 7.8 Hz), 7.82 (2H, br s), 7.97 (4H, br s), 8.42-8.46 (2H, m), 10.53 (1H, s).
[0193]
Working Example 16 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)-4-dimethylaminobutyramide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and N,N-dimethyl-4-aminobutyric acid in the same manner as in Working Example 2.
Yield:
72%. Melting point: 121 - 123 C (ethyl acetate-diisopropyl ether).
'H-NMR (CDC13) 6: 1.86-1.92 (2H, m), 2.32 (6H, s), 2.43-2.55 (4H, m), 2.90 (2H, t, J
= 6.9 Hz), 3.72-3.79 (2H, m), 3.86 (6H, s), 5.23 (1 H, t, J = 5.7 Hz), 6.77-6.81 (3H, m), 6.97 (1 H, d, J = 5.1 Hz), 7.40 (1 H, t, J = 7.8 Hz), 7.72 (2H, d, J = 7.5 Hz), 8.17 (1 H, s), 8.32 (1 H, d, J = 5.1 Hz), 10.14 (1 H, s).
Working Example 16 N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)-4-dimethylaminobutyramide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and N,N-dimethyl-4-aminobutyric acid in the same manner as in Working Example 2.
Yield:
72%. Melting point: 121 - 123 C (ethyl acetate-diisopropyl ether).
'H-NMR (CDC13) 6: 1.86-1.92 (2H, m), 2.32 (6H, s), 2.43-2.55 (4H, m), 2.90 (2H, t, J
= 6.9 Hz), 3.72-3.79 (2H, m), 3.86 (6H, s), 5.23 (1 H, t, J = 5.7 Hz), 6.77-6.81 (3H, m), 6.97 (1 H, d, J = 5.1 Hz), 7.40 (1 H, t, J = 7.8 Hz), 7.72 (2H, d, J = 7.5 Hz), 8.17 (1 H, s), 8.32 (1 H, d, J = 5.1 Hz), 10.14 (1 H, s).
[0194]
Working Example 17 Tert-butyl (5-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-5-oxopentyl)carbamate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 5-(tert-butoxycarbonylamino)valeric acid in the same manner as in Working Example 2.
Yield:
73%. Melting point: 143 - 144 C (ethyl acetate-diisopropyl ether).
' H-NMR (CDC13) 6: 1.43 (9H, s), 1.53-1.60 (2H, m), 1.73-1.83 (2H, m), 2.43 (2H, t, J
= 7.2 Hz), 2.91 (2H, t, J = 6.6 Hz), 3.16-3.20 (2H, brq), 3.76 (21-1, q, J =
6.9 Hz), 3.89 (6H, s), 4.67 (1 H, br s), 5.29 (1 H, t, J = 5.7 Hz), 6.78-6.82 (3 H, m), 6.97 (1 H, d, J = 5.1 Hz), 7.41 (IH, t, J = 7.8 Hz), 7.71 -7.76(3H,m),7.16(1H,s),8.33(1H,d,J=5.4Hz).
Working Example 17 Tert-butyl (5-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-5-oxopentyl)carbamate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 5-(tert-butoxycarbonylamino)valeric acid in the same manner as in Working Example 2.
Yield:
73%. Melting point: 143 - 144 C (ethyl acetate-diisopropyl ether).
' H-NMR (CDC13) 6: 1.43 (9H, s), 1.53-1.60 (2H, m), 1.73-1.83 (2H, m), 2.43 (2H, t, J
= 7.2 Hz), 2.91 (2H, t, J = 6.6 Hz), 3.16-3.20 (2H, brq), 3.76 (21-1, q, J =
6.9 Hz), 3.89 (6H, s), 4.67 (1 H, br s), 5.29 (1 H, t, J = 5.7 Hz), 6.78-6.82 (3 H, m), 6.97 (1 H, d, J = 5.1 Hz), 7.41 (IH, t, J = 7.8 Hz), 7.71 -7.76(3H,m),7.16(1H,s),8.33(1H,d,J=5.4Hz).
[0195]
Working Example 18 4-Bromo-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 4-bromobutyric acid in the same manner as in Working Example 2. Yield: 17%.
Melting point: 191 - 193 C (ethyl acetate-hexane).
' H-NMR (CDC13) 6: 2.18-2.26 (21-1, m), 2.60 (21-1, t, J = 7.2 Hz), 2.90 (21-1, t, J = 6.9 Hz), 3.68 (21-1, t, J = 6.0 Hz), 3.73-3.79 (21-1, m), 3.86 (6H, s), 5.28 (1H, t, J = 5.4 Hz), 6.78-6.81 (3H, m), 6.96 (1H, d, J = 5.4 Hz), 7.39-7.48 (2H, m), 7.71 - 7.76 (2H, s), 8.12 (1H, s), 8.32 (1H, d, J = 5.1 Hz).
Working Example 18 4-Bromo-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 4-bromobutyric acid in the same manner as in Working Example 2. Yield: 17%.
Melting point: 191 - 193 C (ethyl acetate-hexane).
' H-NMR (CDC13) 6: 2.18-2.26 (21-1, m), 2.60 (21-1, t, J = 7.2 Hz), 2.90 (21-1, t, J = 6.9 Hz), 3.68 (21-1, t, J = 6.0 Hz), 3.73-3.79 (21-1, m), 3.86 (6H, s), 5.28 (1H, t, J = 5.4 Hz), 6.78-6.81 (3H, m), 6.96 (1H, d, J = 5.4 Hz), 7.39-7.48 (2H, m), 7.71 - 7.76 (2H, s), 8.12 (1H, s), 8.32 (1H, d, J = 5.1 Hz).
[0196]
Working Example 19 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-4-pyrrolidin- l -yl butanamide Pyrrolidine (1 mL) was added to an N-methyl pyrrolidone (10 mL) solution of 4-bromo-N-(3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide synthesized in Working Example 18 (200 mg, 0.4 mmol), and the mixture was heated to 80 C for 16 hours. Ethyl acetate was added to the reaction solution, and the solution was washed with water and with saturated brine, dried, and concentrated. The residue was purified by basic silica gel column chromatography (ethyl acetate -> ethyl acetate-methanol 95:5) and recrystallized from ethyl acetate-diisopropyl ether to give 118 mg of the titled compound (yield 60%). Melting point:
121 - 122 C.
' H-NMR (CDC13) 6: 1.84-1.96 (6H, m), 2.52-2.65 (8H, m), 2.90 (2H, t, J = 6.9 Hz), 3.72-3.78 (2H, m), 3.86 (6H, s), 5.20 (1H, t, J = 5.7 Hz), 6.77-6.83 (3H, m), 6.96 (1H, d, J = 5.4 Hz), 7.40 (1 H, t, J = 7.8 Hz), 7.70 - 7.75 (2H, m), 8.10 (1 H, s), 8.32 (1 H, d, J
= 5.1 Hz), 10.03 (1 H, s).
Working Example 19 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-4-pyrrolidin- l -yl butanamide Pyrrolidine (1 mL) was added to an N-methyl pyrrolidone (10 mL) solution of 4-bromo-N-(3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide synthesized in Working Example 18 (200 mg, 0.4 mmol), and the mixture was heated to 80 C for 16 hours. Ethyl acetate was added to the reaction solution, and the solution was washed with water and with saturated brine, dried, and concentrated. The residue was purified by basic silica gel column chromatography (ethyl acetate -> ethyl acetate-methanol 95:5) and recrystallized from ethyl acetate-diisopropyl ether to give 118 mg of the titled compound (yield 60%). Melting point:
121 - 122 C.
' H-NMR (CDC13) 6: 1.84-1.96 (6H, m), 2.52-2.65 (8H, m), 2.90 (2H, t, J = 6.9 Hz), 3.72-3.78 (2H, m), 3.86 (6H, s), 5.20 (1H, t, J = 5.7 Hz), 6.77-6.83 (3H, m), 6.96 (1H, d, J = 5.4 Hz), 7.40 (1 H, t, J = 7.8 Hz), 7.70 - 7.75 (2H, m), 8.10 (1 H, s), 8.32 (1 H, d, J
= 5.1 Hz), 10.03 (1 H, s).
[0197]
Working Example 20 Tert-butyl 4-(((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)carbonyl)piperidine-l-carboxylate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid in the same manner as in Working Example 2. Yield: 66%. Melting point: 117 - 118 C (ethyl acetate-diisopropyl ether).
'H-NMR (CDC13) 6: 1.47 (9H, s), 1.70 - 1.92 (4H, m), 2.36-2.44 (1 H, m), 2.78 (2H, br t, J = 11.4 Hz), 2.90 (2H, t, J = 6.9 Hz), 3.75 (2H, q, J = 6.6 Hz), 3.86 (6H, s), 4.16-4.20 (2H, br), 5.23 (1 H, t, J = 5.7 Hz), 6.78-6.81 (3H, m), 6.96 (1 H, d, J = 5.1 Hz), 7.39- 7.47 (2H, m), 7.72- 7.76 (2H, m), 8.13 (1 H, s), 8.32 (1 H, d, J = 5.1 Hz).
Working Example 20 Tert-butyl 4-(((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)carbonyl)piperidine-l-carboxylate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid in the same manner as in Working Example 2. Yield: 66%. Melting point: 117 - 118 C (ethyl acetate-diisopropyl ether).
'H-NMR (CDC13) 6: 1.47 (9H, s), 1.70 - 1.92 (4H, m), 2.36-2.44 (1 H, m), 2.78 (2H, br t, J = 11.4 Hz), 2.90 (2H, t, J = 6.9 Hz), 3.75 (2H, q, J = 6.6 Hz), 3.86 (6H, s), 4.16-4.20 (2H, br), 5.23 (1 H, t, J = 5.7 Hz), 6.78-6.81 (3H, m), 6.96 (1 H, d, J = 5.1 Hz), 7.39- 7.47 (2H, m), 7.72- 7.76 (2H, m), 8.13 (1 H, s), 8.32 (1 H, d, J = 5.1 Hz).
[0198]
Working Example 21 5-Amino-N-(3 -(2-((2-(3 ,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)pentanamide hydrochloride The titled compound was obtained from tert-butyl (5-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-5-oxopentyl)carbamate synthesized in Working Example 17 in the same manner as in Working Example 6.
Yield: 65%. Melting point: 115 - 117 C (methanol-ethyl acetate).
'H-NMR (DMSO-d6) 6: 1.18-1.12 (4H, br s), 2.38-2.41 (2H, m), 2.80 - 2.89 (4H, m), 3.45-3.73 (8H, m), 6.82-6.91 (3H, m), 7.26 (1H, br s), 7.42- 7.56 (1H, m), 7.82- 7.93 (5H, m), 8.20 (111, br s), 8.42-8.50 (2H, m), 10.36 (1H, s).
Working Example 21 5-Amino-N-(3 -(2-((2-(3 ,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)pentanamide hydrochloride The titled compound was obtained from tert-butyl (5-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-5-oxopentyl)carbamate synthesized in Working Example 17 in the same manner as in Working Example 6.
Yield: 65%. Melting point: 115 - 117 C (methanol-ethyl acetate).
'H-NMR (DMSO-d6) 6: 1.18-1.12 (4H, br s), 2.38-2.41 (2H, m), 2.80 - 2.89 (4H, m), 3.45-3.73 (8H, m), 6.82-6.91 (3H, m), 7.26 (1H, br s), 7.42- 7.56 (1H, m), 7.82- 7.93 (5H, m), 8.20 (111, br s), 8.42-8.50 (2H, m), 10.36 (1H, s).
[0199]
Working Example 22 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)piperidine-carboxamide hydrochloride The titled compound was obtained from tert-butyl 4-(((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)carbonyl)piperidine-l-carboxylate synthesized in Working Example 20 in the same manner as in Working Example 6. Yield: quantitative. Melting point: 178 - 179 C (methanol-ethyl acetate).
'H-NMR (DMSO-d6) 6: 1.81 - 2.02 (4H, m), 2.69-2.76 (1H, m), 2.84-2.97 (4H, m), 3.31 - 3.43 (2H, m), 3.69-3.73 (814, m), 6.80 - 6.91 (3H, m), 7.28 (1H, br s), 7.50 (1H, t, J = 8.1 Hz), 7.83 (2H, br s), 8.31 ( I H, br), 8,43 (1 H, d, J = 6.0 Hz), 8.53 (1 H, s), 8.81 - 8.83 (1 H, brd), 9.11 (1 H, br s), 10.49 (1 H, s).
Working Example 22 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)piperidine-carboxamide hydrochloride The titled compound was obtained from tert-butyl 4-(((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)carbonyl)piperidine-l-carboxylate synthesized in Working Example 20 in the same manner as in Working Example 6. Yield: quantitative. Melting point: 178 - 179 C (methanol-ethyl acetate).
'H-NMR (DMSO-d6) 6: 1.81 - 2.02 (4H, m), 2.69-2.76 (1H, m), 2.84-2.97 (4H, m), 3.31 - 3.43 (2H, m), 3.69-3.73 (814, m), 6.80 - 6.91 (3H, m), 7.28 (1H, br s), 7.50 (1H, t, J = 8.1 Hz), 7.83 (2H, br s), 8.31 ( I H, br), 8,43 (1 H, d, J = 6.0 Hz), 8.53 (1 H, s), 8.81 - 8.83 (1 H, brd), 9.11 (1 H, br s), 10.49 (1 H, s).
[0200]
Working Example 23 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-4-morpholin-4-yl butanamide The titled compound was obtained from 4-bromo-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide synthesized in Working Example 18 and morpholine in the same manner as in Working Example 19.
Yield: 49%. Melting point: 109 - 110 C (ethyl acetate-diisopropyl ether).
' H-NMR (CDC13) 6: 1.89-1.97 (2H, m), 2.45-2.50 (8H, m), 2.90 (2H, t, J = 6.9 Hz), 3.72-3.78 (6H, m), 3.86 (6H, s), 5.29 (1H, br t), 6.69-6.81 (3H, m), 6.97 (1H, d, J = 5.4 Hz), 7.41 (1 H, t, J = 7.8 Hz), 7.71 - 7.79 (2H, m), 8.16 (1 H, s), 8.3 3 (1 H, d, J = 5.1 Hz), 8.60 (1 H, s).
Working Example 23 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-4-morpholin-4-yl butanamide The titled compound was obtained from 4-bromo-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide synthesized in Working Example 18 and morpholine in the same manner as in Working Example 19.
Yield: 49%. Melting point: 109 - 110 C (ethyl acetate-diisopropyl ether).
' H-NMR (CDC13) 6: 1.89-1.97 (2H, m), 2.45-2.50 (8H, m), 2.90 (2H, t, J = 6.9 Hz), 3.72-3.78 (6H, m), 3.86 (6H, s), 5.29 (1H, br t), 6.69-6.81 (3H, m), 6.97 (1H, d, J = 5.4 Hz), 7.41 (1 H, t, J = 7.8 Hz), 7.71 - 7.79 (2H, m), 8.16 (1 H, s), 8.3 3 (1 H, d, J = 5.1 Hz), 8.60 (1 H, s).
[0201]
Working Example 24 Tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-1-methyl-3 -oxopropyl)carbamate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 3-((tert-butoxycarbonyl)amino)butanoic acid in the same manner as in Working Example 2.
Yield: 73%. Melting point: 138 - 140 C (ethyl acetate-hexane).
1 H-NMR (CDC13) 6 : 2.38 (6H, s), 2.53 (2H, dd, J = 6.0, 4.2 Hz), 2.68 (2H, dd, J = 6.0, 5.1 Hz), 1.31 (3H, d, J = 6.6 Hz), 1.43 (9H, s), 2.62 (1H, d, J = 5.7 Hz), 2.91 (2H, t, J =
6.6 Hz), 3.76 (1 H, m), 3.86 (6H, s), 4.10 (1 H, m), 5.06 (1 H, br d, J = 6.9 Hz), 5.21 (1 H, m), 6.78 (1 H, s), 6.81 (2H, s), 7.40 (1 H, t, J = 8.1 Hz), 7.67- 7.80 (2H, m), 8.18 (br s), 8.3 2 (1 H, d, J = 5.4 Hz).
Working Example 24 Tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-1-methyl-3 -oxopropyl)carbamate The titled compound was obtained from (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine synthesized in Reference Example 3 and 3-((tert-butoxycarbonyl)amino)butanoic acid in the same manner as in Working Example 2.
Yield: 73%. Melting point: 138 - 140 C (ethyl acetate-hexane).
1 H-NMR (CDC13) 6 : 2.38 (6H, s), 2.53 (2H, dd, J = 6.0, 4.2 Hz), 2.68 (2H, dd, J = 6.0, 5.1 Hz), 1.31 (3H, d, J = 6.6 Hz), 1.43 (9H, s), 2.62 (1H, d, J = 5.7 Hz), 2.91 (2H, t, J =
6.6 Hz), 3.76 (1 H, m), 3.86 (6H, s), 4.10 (1 H, m), 5.06 (1 H, br d, J = 6.9 Hz), 5.21 (1 H, m), 6.78 (1 H, s), 6.81 (2H, s), 7.40 (1 H, t, J = 8.1 Hz), 7.67- 7.80 (2H, m), 8.18 (br s), 8.3 2 (1 H, d, J = 5.4 Hz).
[0202]
Working Example 25 N-(3-(2-((2-(3,4-Dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-2-pyrrolidin-2-yl acetamide hydrochloride WSC (200 mg, 1.1 mmol) and HOBt (142 mg, 1.1 mmol) were added while cooled on ice to a DMF (6.0 mL) solution of Boc-L-(3-homoproline (200 mg, 0.87 mmol) and (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine (305 mg, 0.87 mmol) synthesized in Reference Example 3. The mixture was stirred for another 12 hours at room temperature, and the solvent was then distilled off at reduced pressure.
The residue was diluted with ethyl acetate, washed with water and with saturated brine, and dried over magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate) to give 415 mg of tert-butyl (2-(2-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-2-oxoethyl)pyrrolidin-l-carboxylate (yield: 85%). This compound (400 mg, 0.71 mmol) was dissolved in chloroform (5.0 mL), and 4 N hydrogen chloride-ethyl acetate solution (1.5 mL) was added at room temperature. The mixture was stirred for another 5 hours at room temperature, the solvent was then distilled off at reduced pressure, diethyl ether was added to the residue, and the precipitated solids were filtered off to give 345 mg of the titled compound (yield: 97%). Amorphous powder.
1 H-NMR (DMSO-d6) 8 : 1.55-1.73 (1H, m), 1.78-2.00 (3H, m), 2.05 - 2.21 (1H, m), 2.80 - 2.99 (4H, m), 3.11 - 3.35 (2H, m), 3.60 - 3.90 (8H, m), 6.78-6.89 (2H, m), 6.90 (1 H, s), 7.24 (1 H, br s), 7.51 (1 H, t, J = 8.1 Hz), 7.85 (2H, br s), 8.15 (111, br s), 8.43 (1H, s), 8.45 (1H, s), 9.08 (1H, br s), 9.24 (1H, br s), 10.63 (1H, s ).
Working Example 25 N-(3-(2-((2-(3,4-Dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-2-pyrrolidin-2-yl acetamide hydrochloride WSC (200 mg, 1.1 mmol) and HOBt (142 mg, 1.1 mmol) were added while cooled on ice to a DMF (6.0 mL) solution of Boc-L-(3-homoproline (200 mg, 0.87 mmol) and (4-(3-aminophenyl)pyrimidin-2-yl)-(2-(3,4-dimethoxyphenyl)ethyl)amine (305 mg, 0.87 mmol) synthesized in Reference Example 3. The mixture was stirred for another 12 hours at room temperature, and the solvent was then distilled off at reduced pressure.
The residue was diluted with ethyl acetate, washed with water and with saturated brine, and dried over magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate) to give 415 mg of tert-butyl (2-(2-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-2-oxoethyl)pyrrolidin-l-carboxylate (yield: 85%). This compound (400 mg, 0.71 mmol) was dissolved in chloroform (5.0 mL), and 4 N hydrogen chloride-ethyl acetate solution (1.5 mL) was added at room temperature. The mixture was stirred for another 5 hours at room temperature, the solvent was then distilled off at reduced pressure, diethyl ether was added to the residue, and the precipitated solids were filtered off to give 345 mg of the titled compound (yield: 97%). Amorphous powder.
1 H-NMR (DMSO-d6) 8 : 1.55-1.73 (1H, m), 1.78-2.00 (3H, m), 2.05 - 2.21 (1H, m), 2.80 - 2.99 (4H, m), 3.11 - 3.35 (2H, m), 3.60 - 3.90 (8H, m), 6.78-6.89 (2H, m), 6.90 (1 H, s), 7.24 (1 H, br s), 7.51 (1 H, t, J = 8.1 Hz), 7.85 (2H, br s), 8.15 (111, br s), 8.43 (1H, s), 8.45 (1H, s), 9.08 (1H, br s), 9.24 (1H, br s), 10.63 (1H, s ).
[0203]
Working Example 26 N-(3 -(2-((2-(3,4-Dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-3-(dimethylamino)butanamide hydrochloride Sodium cyanoborohydride (160 mg, 2.5 mmol) was added at room temperature to a mixture of 3-amino-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride (300 mg, 0.64 mmol) synthesized in Working Example 25, 37% formalin aqueous solution (155 mg, 1.9 mmol), triethylamine (115 L, 0.83 mmol), acetic acid (0.3 mL), and methanol (6.0 mL), and the mixture was stirred for another 4 hours at room temperature. The solvent was distilled off at reduced pressure, saturated aqueous sodium bicarbonate was added to the residue, and the product was extracted with chloroform. The chloroform extract solution was washed with water and with saturated brine, and was dried over magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography (basic silica gel, ethyl acetate). The resulting oily substance was dissolved in methylene chloride (3.0 mL), and a 4 N hydrogen chloride-ethyl acetate solution (1.0 mL) was added. The mixture was stirred for 10 min at room temperature, and the solvent was then distilled off at reduced pressure. Ethyl acetate (3.0 mL) was added to the residue, and the precipitated solids were filtered off to give 130 mg of the titled compound (yield: 41%). Amorphous powder.
1 H-NMR (DMSO-d6) S : 1.31 (3H, d, J = 6.6 Hz), 2.65-2.79 (7H, m), 2.80 - 2.91 (2H, m), 3.10 (1H, dd, J = 15.0, 3.6 Hz), 3.50 - 3.90 (9H, m), 6.75-6.88 (2H, m), 6.91 (1H, s), 7.29 (1 H, br s), 7.52 (1 H, t, J = 8.1 Hz), 7.85 (2H, br s), 8.30 (1 H, br s), 8.44 (1 H, d, J = 5.7 Hz), 8.51 (1 H, br s).
Working Example 26 N-(3 -(2-((2-(3,4-Dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-3-(dimethylamino)butanamide hydrochloride Sodium cyanoborohydride (160 mg, 2.5 mmol) was added at room temperature to a mixture of 3-amino-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride (300 mg, 0.64 mmol) synthesized in Working Example 25, 37% formalin aqueous solution (155 mg, 1.9 mmol), triethylamine (115 L, 0.83 mmol), acetic acid (0.3 mL), and methanol (6.0 mL), and the mixture was stirred for another 4 hours at room temperature. The solvent was distilled off at reduced pressure, saturated aqueous sodium bicarbonate was added to the residue, and the product was extracted with chloroform. The chloroform extract solution was washed with water and with saturated brine, and was dried over magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography (basic silica gel, ethyl acetate). The resulting oily substance was dissolved in methylene chloride (3.0 mL), and a 4 N hydrogen chloride-ethyl acetate solution (1.0 mL) was added. The mixture was stirred for 10 min at room temperature, and the solvent was then distilled off at reduced pressure. Ethyl acetate (3.0 mL) was added to the residue, and the precipitated solids were filtered off to give 130 mg of the titled compound (yield: 41%). Amorphous powder.
1 H-NMR (DMSO-d6) S : 1.31 (3H, d, J = 6.6 Hz), 2.65-2.79 (7H, m), 2.80 - 2.91 (2H, m), 3.10 (1H, dd, J = 15.0, 3.6 Hz), 3.50 - 3.90 (9H, m), 6.75-6.88 (2H, m), 6.91 (1H, s), 7.29 (1 H, br s), 7.52 (1 H, t, J = 8.1 Hz), 7.85 (2H, br s), 8.30 (1 H, br s), 8.44 (1 H, d, J = 5.7 Hz), 8.51 (1 H, br s).
[0204]
Working Example 27 3 -Amino-N-(3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride 4 N hydrogen chloride-ethyl acetate solution (3 mL) was added to a chloroform (10 mL) solution of tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-1-methyl-3 -oxopropyl)carbamate (1.0 g, 1.86 mmol) synthesized in Working Example 24, and the mixture was stirred for hours at room temperature. The solvent was distilled off at reduced pressure, and the residue was then washed with diethyl ether to give 790 mg of the titled compound (yield: 73%). Amorphous powder.
1 H-NMR (DMSO-d6) 8: 1.27 (3H, d, J = 6.6 Hz), 2.65-2.91 (4H, m), 3.55-3.69 (3H, m), 3.70 (31-1, s), 3.73 (3H, s), 6.75-6.88 (2H. m), 6.91 (1H, br s), 7.27 (1H, br s), 7.51 (1H, t, J = 8.1 Hz), 7.85 (2H, br s), 8.05-8.30 (4H, m), 8.45 (1H, d, J = 6.0 Hz), 8.50 (1 H, br s), 10.65 (1H, br s).
Working Example 27 3 -Amino-N-(3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride 4 N hydrogen chloride-ethyl acetate solution (3 mL) was added to a chloroform (10 mL) solution of tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-1-methyl-3 -oxopropyl)carbamate (1.0 g, 1.86 mmol) synthesized in Working Example 24, and the mixture was stirred for hours at room temperature. The solvent was distilled off at reduced pressure, and the residue was then washed with diethyl ether to give 790 mg of the titled compound (yield: 73%). Amorphous powder.
1 H-NMR (DMSO-d6) 8: 1.27 (3H, d, J = 6.6 Hz), 2.65-2.91 (4H, m), 3.55-3.69 (3H, m), 3.70 (31-1, s), 3.73 (3H, s), 6.75-6.88 (2H. m), 6.91 (1H, br s), 7.27 (1H, br s), 7.51 (1H, t, J = 8.1 Hz), 7.85 (2H, br s), 8.05-8.30 (4H, m), 8.45 (1H, d, J = 6.0 Hz), 8.50 (1 H, br s), 10.65 (1H, br s).
[0205]
Working Example 28 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-2-(1-methylpyrrolidin-2-yl)acetamide hydrochloride Sodium cyanoborohydride (50 mg, 0.80 mmol) was added at room temperature to a mixture of N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-2-pyrrolidin-2-ylacetamide hydrochloride (100 mg, 0.20 mmol) synthesized in Working Example 27, 37% formalin aqueous solution (49 mg, 0.60 mmol), triethylamine (36 L, 0.26 mmol), acetic acid (0.1 mL), and methanol (2.0 ml), and the mixture was stirred for another 4 hours at room temperature. The solvent was distilled off at reduced pressure, saturated aqueous sodium bicarbonate was added to the residue, and the product was extracted with chloroform. The chloroform extract solution was washed with water and with saturated brine, and was dried over magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography (basic silica gel, ethyl acetate). The resulting oily substance was dissolved in methylene chloride (3.0 mL), and a 4 N hydrogen chloride-ethyl acetate solution (1.0 mL) was added. The mixture was stirred for 10 min at room temperature, and the solvent was then distilled off at reduced pressure. Ethyl acetate (3.0 mL) was added to the residue, and the precipitated solids were filtered off to give 40 mg of the titled compound (yield: 39%). Amorphous powder.
' H-NMR (DMSO-d6) 8 : 1.68 - 1.81 (1H, m), 1.85 - 2.10 (3H, m), 2.20 - 2.40 (1H, m), 2.79 - 2.95 (5H, m), 2.98 - 3.22 (2H, m), 3.45 - 3.80 (8H, m), 6.75-6.95 (3H, m), 7.23 (1H, br s), 7.50 (1H, t, J = 8.1 Hz), 7.73 - 7.94 (2H, br s), 8.08 (1H, br s), 8.48 - 8.55 (2H, m).
Working Example 28 N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-2-(1-methylpyrrolidin-2-yl)acetamide hydrochloride Sodium cyanoborohydride (50 mg, 0.80 mmol) was added at room temperature to a mixture of N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-2-pyrrolidin-2-ylacetamide hydrochloride (100 mg, 0.20 mmol) synthesized in Working Example 27, 37% formalin aqueous solution (49 mg, 0.60 mmol), triethylamine (36 L, 0.26 mmol), acetic acid (0.1 mL), and methanol (2.0 ml), and the mixture was stirred for another 4 hours at room temperature. The solvent was distilled off at reduced pressure, saturated aqueous sodium bicarbonate was added to the residue, and the product was extracted with chloroform. The chloroform extract solution was washed with water and with saturated brine, and was dried over magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography (basic silica gel, ethyl acetate). The resulting oily substance was dissolved in methylene chloride (3.0 mL), and a 4 N hydrogen chloride-ethyl acetate solution (1.0 mL) was added. The mixture was stirred for 10 min at room temperature, and the solvent was then distilled off at reduced pressure. Ethyl acetate (3.0 mL) was added to the residue, and the precipitated solids were filtered off to give 40 mg of the titled compound (yield: 39%). Amorphous powder.
' H-NMR (DMSO-d6) 8 : 1.68 - 1.81 (1H, m), 1.85 - 2.10 (3H, m), 2.20 - 2.40 (1H, m), 2.79 - 2.95 (5H, m), 2.98 - 3.22 (2H, m), 3.45 - 3.80 (8H, m), 6.75-6.95 (3H, m), 7.23 (1H, br s), 7.50 (1H, t, J = 8.1 Hz), 7.73 - 7.94 (2H, br s), 8.08 (1H, br s), 8.48 - 8.55 (2H, m).
[0206]
Working Example 29 N-(3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3,N3-dimethyl-[3-alaninamide WSC (356 mg, 1.85 mmol) and HOBt (250 mg, 1.85 mmol) were added, in that order, while cooled on ice to a DMF (8 mL) solution of 4-(3-aminophenyl)-N-(2-(3,4-dimethoxyphenyl)ethyl)pyrimidine-2-amine (500 mg, 1.43 mmol) synthesized in Reference Example 3, and N,N-dimethyl-(3-alanine (263 mg, 1.71 mmol) and the mixture was then stirred for another 13 hours at room temperature. The reaction solution was concentrated at reduced pressure, saturated aqueous sodium bicarbonate was added to the residue, and the product was extracted with ethyl acetate.
The ethyl acetate extract solution was washed with water and with saturated brine, was dried over magnesium sulfate, and was then concentrated at reduced pressure. The residue was purified by silica gel column chromatography (basic silica gel, ethyl acetate:hexane =
1:1 -* ethyl acetate) to give the titled compound (400 mg, yield: 62%).
Melting point:
(ethyl acetate-hexane).
1 H-NMR (CDC13) 6 : 2.38 (6H, s), 2.53 (2H, dd, J = 6.0, 4.2 Hz), 2.68 (2H, dd, J = 6.0, 5.1 Hz), 2.92 (2H, t, J = 6.9 Hz), 3.76 (2H, q, J = 6.9 Hz), 3.86 (6H, s), 5.20 (1 H, t, J =
5.7 Hz), 6.77 - 6.85 (3H, m), 6.98 (1 H, d, J = 5.1 Hz), 7.40 (1 H, t, J = 8.1 Hz), 7.65 (1H,dd,J=7.2, 1.2 Hz), 7.74 (1 H, d, J = 7.8 Hz), 8.16 (1 H, br s), 8.3 3 (1 H, d, J = 5.1 Hz),_ 11.06 (1 H, br s).
Working Example 29 N-(3 -(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3,N3-dimethyl-[3-alaninamide WSC (356 mg, 1.85 mmol) and HOBt (250 mg, 1.85 mmol) were added, in that order, while cooled on ice to a DMF (8 mL) solution of 4-(3-aminophenyl)-N-(2-(3,4-dimethoxyphenyl)ethyl)pyrimidine-2-amine (500 mg, 1.43 mmol) synthesized in Reference Example 3, and N,N-dimethyl-(3-alanine (263 mg, 1.71 mmol) and the mixture was then stirred for another 13 hours at room temperature. The reaction solution was concentrated at reduced pressure, saturated aqueous sodium bicarbonate was added to the residue, and the product was extracted with ethyl acetate.
The ethyl acetate extract solution was washed with water and with saturated brine, was dried over magnesium sulfate, and was then concentrated at reduced pressure. The residue was purified by silica gel column chromatography (basic silica gel, ethyl acetate:hexane =
1:1 -* ethyl acetate) to give the titled compound (400 mg, yield: 62%).
Melting point:
(ethyl acetate-hexane).
1 H-NMR (CDC13) 6 : 2.38 (6H, s), 2.53 (2H, dd, J = 6.0, 4.2 Hz), 2.68 (2H, dd, J = 6.0, 5.1 Hz), 2.92 (2H, t, J = 6.9 Hz), 3.76 (2H, q, J = 6.9 Hz), 3.86 (6H, s), 5.20 (1 H, t, J =
5.7 Hz), 6.77 - 6.85 (3H, m), 6.98 (1 H, d, J = 5.1 Hz), 7.40 (1 H, t, J = 8.1 Hz), 7.65 (1H,dd,J=7.2, 1.2 Hz), 7.74 (1 H, d, J = 7.8 Hz), 8.16 (1 H, br s), 8.3 3 (1 H, d, J = 5.1 Hz),_ 11.06 (1 H, br s).
[0207]
Working Example 30 N-(3-(2-((2-(3,4-Dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3,N3-dimethyl-3-alaninamide hydrochloride 4 N hydrogen chloride-ethyl acetate solution (194 L, 7.78 mmol) was added at room temperature to a methylene chloride (4 mL) solution of N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3 N3 -dimethyl-(3-alaninamide (350 mg, 0.78 mmol) synthesized in Working Example 29. The mixture was stirred for another 10 min at room temperature, and the solvent was then distilled off at reduced pressure to give 290 mg of the titled compound (yield: 77%). Amorphous powder.
1 H-NMR (CDC13) 6: 2.41 (6H, s), 2.91 (4H, t, J = 6.6 Hz), 3.10 - 3.19 (2H, m), 3.70 -3.80 (2H, m), 3.86 (6H, s), 5.70 - 5.82 (1H, m), 6.75-6.87 (3H, m), 6.97 (1H, d, J = 5.4 Hz), 7.3 5 - 7.48 (1 H, m), 7.68- 7.81 (2H, m), 8.26 (1 H, br s), 8.31 (1 H, d, J = 5.1 Hz), 10.28 (1H, br s).
Working Example 30 N-(3-(2-((2-(3,4-Dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3,N3-dimethyl-3-alaninamide hydrochloride 4 N hydrogen chloride-ethyl acetate solution (194 L, 7.78 mmol) was added at room temperature to a methylene chloride (4 mL) solution of N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3 N3 -dimethyl-(3-alaninamide (350 mg, 0.78 mmol) synthesized in Working Example 29. The mixture was stirred for another 10 min at room temperature, and the solvent was then distilled off at reduced pressure to give 290 mg of the titled compound (yield: 77%). Amorphous powder.
1 H-NMR (CDC13) 6: 2.41 (6H, s), 2.91 (4H, t, J = 6.6 Hz), 3.10 - 3.19 (2H, m), 3.70 -3.80 (2H, m), 3.86 (6H, s), 5.70 - 5.82 (1H, m), 6.75-6.87 (3H, m), 6.97 (1H, d, J = 5.4 Hz), 7.3 5 - 7.48 (1 H, m), 7.68- 7.81 (2H, m), 8.26 (1 H, br s), 8.31 (1 H, d, J = 5.1 Hz), 10.28 (1H, br s).
[0208]
Working Example 31 N-(3-(2-(2-(3,4-Dimethoxy-phenyl)ethylamino)pyrimidin-4-yl)phenyl)-4-(piperidin- l -yl)butanamide The titled compound was obtained from 4-bromo-N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)butanamide and piperidine in the same manner as in Working Example 19. Yield: 59%. Melting point: 111 - 112 C
(ethyl acetate-diisopropyl ether).
1 H-NMR (CDC13) 8 : 1.46 - 1.49 (21-1, m), 1.60 - 1.67 (4H, m), 1.87 - 1.95 (2H, m), 2.42 - 2.50 (8H, m), 2.91 (2H, t, J = 6.9 Hz), 3.73 - 3.79 (2H, m), 3.87 (6H, s), 5.17 (1H, t, J = 5.7 Hz), 6.78 -6.81 (3H, m), 6.98 (1H, d, J = 5.1 Hz), 7.41 (1H, t, J = 7.8 Hz), 7.72 - 7.75 (211, m), 8.14 (1 H, s), 8.32 (1 H, d, J = 5.1 Hz), 9.48 (1 H, s).
Working Example 31 N-(3-(2-(2-(3,4-Dimethoxy-phenyl)ethylamino)pyrimidin-4-yl)phenyl)-4-(piperidin- l -yl)butanamide The titled compound was obtained from 4-bromo-N-(3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)phenyl)butanamide and piperidine in the same manner as in Working Example 19. Yield: 59%. Melting point: 111 - 112 C
(ethyl acetate-diisopropyl ether).
1 H-NMR (CDC13) 8 : 1.46 - 1.49 (21-1, m), 1.60 - 1.67 (4H, m), 1.87 - 1.95 (2H, m), 2.42 - 2.50 (8H, m), 2.91 (2H, t, J = 6.9 Hz), 3.73 - 3.79 (2H, m), 3.87 (6H, s), 5.17 (1H, t, J = 5.7 Hz), 6.78 -6.81 (3H, m), 6.98 (1H, d, J = 5.1 Hz), 7.41 (1H, t, J = 7.8 Hz), 7.72 - 7.75 (211, m), 8.14 (1 H, s), 8.32 (1 H, d, J = 5.1 Hz), 9.48 (1 H, s).
[0209]
Working Example 32 N-(3-(2-(2-(3,4-dimethoxy-phenyl)ethylamino)pyrimidin-4-yl)phenyl)-4-(piperidin- l -yl)butanamide hydrochloride N-(3-(2-(2-(3,4-Dimethoxy-phenyl)ethylamino)pyrimidin-4-yl)phenyl)-4-(piperidin-1-yl)butanamide (72 mg, 0.14 mmol) synthesized in Working Example was dissolved in ethyl acetate-methanol (10:1, 22 mL), 4 N hydrogen chloride-ethyl acetate solution (36 L, 0.14 mmol) was added, and the mixture was concentrated to give the titled compound. Yield: 84%. Amorphous powder.
'H-NMR (DMSO-d6) 6 : 1.30 - 1.45 (1H, m), 1.67 - 1.77 (5H, m), 1.99 - 2.05 (2H, m), 2.47 (2H, t, J = 7.0Hz), 2.81 - 2.85 (4H, m), 3.00 - 3.08 (2H, m), 3.37 - 3.47 (2H, m), 3.53 - 3.65 (2H, m), 3.71 (3H, s), 3.73 (3H, s), 6.77-6.88 (3H, m), 7.01 (1H, d, J = 5.1 Hz), 7.22 (1 H, br s), 7.43 (1 H, t, J = 7.9 Hz), 7.75 (2H, brd, J = 7.9Hz), 8.37 (2H, br s), 10.12 (1 H, br s), 10.32 (1 H, s).
Working Example 32 N-(3-(2-(2-(3,4-dimethoxy-phenyl)ethylamino)pyrimidin-4-yl)phenyl)-4-(piperidin- l -yl)butanamide hydrochloride N-(3-(2-(2-(3,4-Dimethoxy-phenyl)ethylamino)pyrimidin-4-yl)phenyl)-4-(piperidin-1-yl)butanamide (72 mg, 0.14 mmol) synthesized in Working Example was dissolved in ethyl acetate-methanol (10:1, 22 mL), 4 N hydrogen chloride-ethyl acetate solution (36 L, 0.14 mmol) was added, and the mixture was concentrated to give the titled compound. Yield: 84%. Amorphous powder.
'H-NMR (DMSO-d6) 6 : 1.30 - 1.45 (1H, m), 1.67 - 1.77 (5H, m), 1.99 - 2.05 (2H, m), 2.47 (2H, t, J = 7.0Hz), 2.81 - 2.85 (4H, m), 3.00 - 3.08 (2H, m), 3.37 - 3.47 (2H, m), 3.53 - 3.65 (2H, m), 3.71 (3H, s), 3.73 (3H, s), 6.77-6.88 (3H, m), 7.01 (1H, d, J = 5.1 Hz), 7.22 (1 H, br s), 7.43 (1 H, t, J = 7.9 Hz), 7.75 (2H, brd, J = 7.9Hz), 8.37 (2H, br s), 10.12 (1 H, br s), 10.32 (1 H, s).
[0210]
Working Example 33 4-Amino-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride The titled compound was obtained from tert-butyl (4-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-4-oxobutyl)carbamate synthesized in Working Example 8 in the same manner as in Working Example 6.
Yield: quantitative; melting point: 141 - 143 C (methanol-ethyl acetate).
' H-NMR (DMSO-d6) 6 : 1.86 - 1.93 (2H, m), 2.48 - 2.51 (2H, m), 2.82 - 2.89 (4H, m), 3.69 - 3.73 (8H, m), 6.80 - 6.91 (3H, m), 7.28 (1H, br s), 7.50 (1H, t, J =
7.8 Hz), 7.83 (2H, br s), 8.04 (3H, br s), 8.31 (1 H, br s), 8.44 (1 H, d, J = 6.0 Hz), 8.50 (1 H, br s), 10.47 (1 H, s).
Working Example 33 4-Amino-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride The titled compound was obtained from tert-butyl (4-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)amino)-4-oxobutyl)carbamate synthesized in Working Example 8 in the same manner as in Working Example 6.
Yield: quantitative; melting point: 141 - 143 C (methanol-ethyl acetate).
' H-NMR (DMSO-d6) 6 : 1.86 - 1.93 (2H, m), 2.48 - 2.51 (2H, m), 2.82 - 2.89 (4H, m), 3.69 - 3.73 (8H, m), 6.80 - 6.91 (3H, m), 7.28 (1H, br s), 7.50 (1H, t, J =
7.8 Hz), 7.83 (2H, br s), 8.04 (3H, br s), 8.31 (1 H, br s), 8.44 (1 H, d, J = 6.0 Hz), 8.50 (1 H, br s), 10.47 (1 H, s).
[0211]
Working Example 34 (3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)-N-(3-dimethylaminopropyl)benzamide The titled compound was obtained from 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid synthesized in Reference Example 6 and N,N-dimethyl-1,3-propane diamine in the same manner as in Working Example 2. Yield: 58%. Melting point: 110 - 111 C (ethyl acetate-diisopropyl ether).
1 H-NMR (CDC13) 6 : 1.74-1.82 (211, m), 2.29 (6H, s), 2.51 (2H, t, J = 5.7 Hz), 2.91 (2H, t, J = 6.9 Hz), 3.60 (2H, q, J = 5.7 Hz), 3.77 (2H, q, J = 6.9 Hz), 3.87 (6H, s), 5.20 (1 H, t, J = 5.7 Hz), 6.78 - 6.82 (3 H, m), 7.01 (1 H, d, J = 5.4 Hz), 7.52 (1 H, t, J = 7.5 Hz), 7.85 (1 H, d, J = 7.8 Hz), 8.16 (1 H, brd, J = 7.8 Hz), 8.36 (1 H, d, J =
5.4 Hz), 8.42 (1 H, s), 8.65 (1 H, s).
Working Example 34 (3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)-N-(3-dimethylaminopropyl)benzamide The titled compound was obtained from 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid synthesized in Reference Example 6 and N,N-dimethyl-1,3-propane diamine in the same manner as in Working Example 2. Yield: 58%. Melting point: 110 - 111 C (ethyl acetate-diisopropyl ether).
1 H-NMR (CDC13) 6 : 1.74-1.82 (211, m), 2.29 (6H, s), 2.51 (2H, t, J = 5.7 Hz), 2.91 (2H, t, J = 6.9 Hz), 3.60 (2H, q, J = 5.7 Hz), 3.77 (2H, q, J = 6.9 Hz), 3.87 (6H, s), 5.20 (1 H, t, J = 5.7 Hz), 6.78 - 6.82 (3 H, m), 7.01 (1 H, d, J = 5.4 Hz), 7.52 (1 H, t, J = 7.5 Hz), 7.85 (1 H, d, J = 7.8 Hz), 8.16 (1 H, brd, J = 7.8 Hz), 8.36 (1 H, d, J =
5.4 Hz), 8.42 (1 H, s), 8.65 (1 H, s).
[0212]
Working Example 35 Tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)benzoyl) amino)propyl)carbamate The titled compound was obtained from 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid synthesized in Reference Example 6 and N-(tert-butoxycarbonyl)-1,3-diaminopropane in the same manner as in Working Example 2. Yield: 85%. Melting point: 152 - 153 C (ethyl acetate-diisopropyl ether).
1 H-NMR (CDC13) 6 : 1.46 (91-1, s), 1.62 - 1.78 (21-1, m), 2.92 (2H, t, J =
6.9 Hz), 3.28 (2H, q, J = 6.3 Hz), 3.54 (2H, q, J = 6.0 Hz), 3.77 (2H, q, J = 6.3 Hz), 3.87 (61-1, s), 4.88 (1 H, br t), 5.21 (1 H, t, J = 5.4 Hz), 6.78-6.82 (31-1, m), 7.11 (1 H, d, J =
5.1 Hz), 7.49 (1 H, br s), 7.55 (1 H, t, J = 7.8 Hz), 7.97 (1 H, d, J = 7.5 Hz), 8.23 (1 H, brd, J = 7.8 Hz), 8.35 (1H, t, J = 5.1 Hz), 8.53 (1H, s).
Working Example 35 Tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)benzoyl) amino)propyl)carbamate The titled compound was obtained from 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid synthesized in Reference Example 6 and N-(tert-butoxycarbonyl)-1,3-diaminopropane in the same manner as in Working Example 2. Yield: 85%. Melting point: 152 - 153 C (ethyl acetate-diisopropyl ether).
1 H-NMR (CDC13) 6 : 1.46 (91-1, s), 1.62 - 1.78 (21-1, m), 2.92 (2H, t, J =
6.9 Hz), 3.28 (2H, q, J = 6.3 Hz), 3.54 (2H, q, J = 6.0 Hz), 3.77 (2H, q, J = 6.3 Hz), 3.87 (61-1, s), 4.88 (1 H, br t), 5.21 (1 H, t, J = 5.4 Hz), 6.78-6.82 (31-1, m), 7.11 (1 H, d, J =
5.1 Hz), 7.49 (1 H, br s), 7.55 (1 H, t, J = 7.8 Hz), 7.97 (1 H, d, J = 7.5 Hz), 8.23 (1 H, brd, J = 7.8 Hz), 8.35 (1H, t, J = 5.1 Hz), 8.53 (1H, s).
[0213]
Working Example 36 N-(3-Aminopropyl)-3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzamide dihydrochloride The titled compound was obtained from tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)benzoyl) amino)propyl)carbamate synthesized in Working Example 35 in the same manner as in Working Example 6.
Yield: quantitative; melting point: 167 - 168 C (methanol-ethyl acetate).
'H-NMR (DMSO-d6) 6 : 1.83-1.87 (2H, m), 2.83-2.88 (4H, m), 3.35-3.41 (2H, m), 3.66-3.73 (8H, m), 6.79-6.89 (4H, m), 7.43 (1 H, br s), 7.66 (1 H, t, J = 7.8 Hz), 7.94 (4H, br s), 8.07 (1 H, d, J = 7.8 Hz), 8.31 - 8.3 3 (1 H, m), 8.46 (1 H, d, J
= 5.7 Hz), 8.65 (1 H, s), 8.96 (1 H, br s).
Working Example 36 N-(3-Aminopropyl)-3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzamide dihydrochloride The titled compound was obtained from tert-butyl (3-((3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)benzoyl) amino)propyl)carbamate synthesized in Working Example 35 in the same manner as in Working Example 6.
Yield: quantitative; melting point: 167 - 168 C (methanol-ethyl acetate).
'H-NMR (DMSO-d6) 6 : 1.83-1.87 (2H, m), 2.83-2.88 (4H, m), 3.35-3.41 (2H, m), 3.66-3.73 (8H, m), 6.79-6.89 (4H, m), 7.43 (1 H, br s), 7.66 (1 H, t, J = 7.8 Hz), 7.94 (4H, br s), 8.07 (1 H, d, J = 7.8 Hz), 8.31 - 8.3 3 (1 H, m), 8.46 (1 H, d, J
= 5.7 Hz), 8.65 (1 H, s), 8.96 (1 H, br s).
[0214]
Working Example 37 3-(2-(2-(3,4-Dimethoxyphenyl)ethylamino)pyrimidin-4-yl)-N-(3-dimethylaminopropyl)-N-methylbenzamide hydrochloride The titled compound was obtained from 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid and N,N,N'-trimethyl-1,3-propanediamine in the same manner as in Working Example 2. Yield: 81 %.
Melting point: 121 - 123 C (ethanol-ethyl acetate).
'H-NMR (DMSO-d6) 6 : 1.99-2.03 (2H, br s), 2.51 - 3.27 (13H, m), 3.55-3.37 (10H, m), 6.78 - 6.90 (3H, m), 7.46 (1H, br s), 7.64 - 7.66 (2H, m), 8.22 - 8.25 (3H, m), 8.47 (1H,d,J=5.7Hz), 10.51 (1H,brs).
Working Example 37 3-(2-(2-(3,4-Dimethoxyphenyl)ethylamino)pyrimidin-4-yl)-N-(3-dimethylaminopropyl)-N-methylbenzamide hydrochloride The titled compound was obtained from 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid and N,N,N'-trimethyl-1,3-propanediamine in the same manner as in Working Example 2. Yield: 81 %.
Melting point: 121 - 123 C (ethanol-ethyl acetate).
'H-NMR (DMSO-d6) 6 : 1.99-2.03 (2H, br s), 2.51 - 3.27 (13H, m), 3.55-3.37 (10H, m), 6.78 - 6.90 (3H, m), 7.46 (1H, br s), 7.64 - 7.66 (2H, m), 8.22 - 8.25 (3H, m), 8.47 (1H,d,J=5.7Hz), 10.51 (1H,brs).
[0215]
Working Example 38 3-(2-(2-(3,4-Dimethoxyphenyl)ethylamino)pyrimidin-4-yl)-N-(3 -pyrrolidin- l -ylpropyl)benzamide The titled compound was obtained from 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid and 1-(3-aminopropyl)pyrrolidine in the same manner as in Working Example 2. Yield:
52%.
Melting point: 109 - 110 C (ethyl acetate-diisopropyl ether).
i H-NMR (CDC13) 6: 1.71 - 1.84 (6H, m), 2.55 (4H, br t), 2.71 (2H, t, J = 5.7 Hz), 2.91 (2H, t, J = 6.9 Hz), 3.61 (2H, q, J = 5.7 Hz), 3.77 (21-1, q, J = 6.9 Hz), 3.87 (6H, s), 5.23 (11-1,t,J=5.7Hz),6.78-6.82(3H,m),7.02(1H, d, J = 5.1Hz),7.50(11-1,t,J=7.8 Hz), 7.81 (1 H, d, J = 7.8 Hz), 8.15 (1 H, brd, J = 7.5 Hz), 8.36 (1 H, d, J =
5.1 Hz), 8.44 (1H, s), 8.85 (1H, br s).
Working Example 38 3-(2-(2-(3,4-Dimethoxyphenyl)ethylamino)pyrimidin-4-yl)-N-(3 -pyrrolidin- l -ylpropyl)benzamide The titled compound was obtained from 3-(2-(2-(3,4-dimethoxyphenyl)ethylamino)pyrimidin-4-yl)benzoic acid and 1-(3-aminopropyl)pyrrolidine in the same manner as in Working Example 2. Yield:
52%.
Melting point: 109 - 110 C (ethyl acetate-diisopropyl ether).
i H-NMR (CDC13) 6: 1.71 - 1.84 (6H, m), 2.55 (4H, br t), 2.71 (2H, t, J = 5.7 Hz), 2.91 (2H, t, J = 6.9 Hz), 3.61 (2H, q, J = 5.7 Hz), 3.77 (21-1, q, J = 6.9 Hz), 3.87 (6H, s), 5.23 (11-1,t,J=5.7Hz),6.78-6.82(3H,m),7.02(1H, d, J = 5.1Hz),7.50(11-1,t,J=7.8 Hz), 7.81 (1 H, d, J = 7.8 Hz), 8.15 (1 H, brd, J = 7.5 Hz), 8.36 (1 H, d, J =
5.1 Hz), 8.44 (1H, s), 8.85 (1H, br s).
[0216]
Working Example 39 3 -(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield: 45%; melting point: 126 - 127 C (ethyl acetate-hexane).
H-NMR (CDC13) 6 : 1.73 - 1.82 (41-1, m), 2.47 - 2.61 (41-1, m), 2.70 (2H, t, J
= 6.0 Hz), 3.09 (21-1, t, J = 6.9 Hz), 3.57 (21-1, q, J = 6.0 Hz), 3.86 (31-1, s), 3.87 (31-1, s), 4.63 (2H, t, J = 6.9 Hz), 6.70 (1 H, d, J = 7.8 Hz), 6.81 - 6.88 (4H, m), 7.38 (1 H, d, J = 7.2 Hz), 7.5 0 (1 H, t, J = 7.5 Hz), 7.64 (1 H, t, J = 8.1 Hz), 7.76 (1 H, d, J =
8.4 Hz), 8.16 (1H,d,J=8.4Hz),8.42(1H,t,J=1.5Hz).
Working Example 39 3 -(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield: 45%; melting point: 126 - 127 C (ethyl acetate-hexane).
H-NMR (CDC13) 6 : 1.73 - 1.82 (41-1, m), 2.47 - 2.61 (41-1, m), 2.70 (2H, t, J
= 6.0 Hz), 3.09 (21-1, t, J = 6.9 Hz), 3.57 (21-1, q, J = 6.0 Hz), 3.86 (31-1, s), 3.87 (31-1, s), 4.63 (2H, t, J = 6.9 Hz), 6.70 (1 H, d, J = 7.8 Hz), 6.81 - 6.88 (4H, m), 7.38 (1 H, d, J = 7.2 Hz), 7.5 0 (1 H, t, J = 7.5 Hz), 7.64 (1 H, t, J = 8.1 Hz), 7.76 (1 H, d, J =
8.4 Hz), 8.16 (1H,d,J=8.4Hz),8.42(1H,t,J=1.5Hz).
[0217]
Working Example 40 3'-(2-(3,4-Dimethoxyphenyl)ethoxy)-N-(2-pyrrolidin- l -ylethyl)biphenyl-3-carboxamide The titled compound was obtained using 3'-(2-(3,4-dimethoxyphenyl)ethoxy)biphenyl-3-carboxylic acid obtained in Reference Example 24 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
30%. Melting point: 101 - 102 C. (Ethyl acetate-hexane).
I H-NMR (CDC13) 6: 1.75 - 1.82 (41-1, m), 2.52 - 2.61 (4H, m), 2.72 (21-1, t, J = 6.0 Hz), 3.08 (2H, t, J = 6.9 Hz), 3.58 (21-1, q, J = 6.0 Hz), 3.87 (31-1, s), 3.89 (31-1, s), 4.22 (2H, t, J = 6.9 Hz), 5.22 (1 H, brs), 6.86 -6.94 (5 H, m), 7.12 - 7.15 (1 H, m), 7.20 (1 H, d, J = 8.4 Hz), 7.3 6 (1 H, t, J = 7.8 Hz), 7.48 (1 H, t, J = 7.8 Hz), 7.70 (1 H, dt, J = 7.8, 1.2 Hz), 8.01 (1 H, d, J = 1.2 Hz).
Working Example 40 3'-(2-(3,4-Dimethoxyphenyl)ethoxy)-N-(2-pyrrolidin- l -ylethyl)biphenyl-3-carboxamide The titled compound was obtained using 3'-(2-(3,4-dimethoxyphenyl)ethoxy)biphenyl-3-carboxylic acid obtained in Reference Example 24 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
30%. Melting point: 101 - 102 C. (Ethyl acetate-hexane).
I H-NMR (CDC13) 6: 1.75 - 1.82 (41-1, m), 2.52 - 2.61 (4H, m), 2.72 (21-1, t, J = 6.0 Hz), 3.08 (2H, t, J = 6.9 Hz), 3.58 (21-1, q, J = 6.0 Hz), 3.87 (31-1, s), 3.89 (31-1, s), 4.22 (2H, t, J = 6.9 Hz), 5.22 (1 H, brs), 6.86 -6.94 (5 H, m), 7.12 - 7.15 (1 H, m), 7.20 (1 H, d, J = 8.4 Hz), 7.3 6 (1 H, t, J = 7.8 Hz), 7.48 (1 H, t, J = 7.8 Hz), 7.70 (1 H, dt, J = 7.8, 1.2 Hz), 8.01 (1 H, d, J = 1.2 Hz).
[0218]
Working Example 41 3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide The titled compound was obtained using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and tetrahydro-2H-pyran-4-amine in the same manner as in Working Example 2.
Yield:
68%. Melting point: 172 - 173 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 1.50 - 1.64 (21-1, m), 1.95-2.07 (2H, m), 3.09 (2H, t, J =
6.9 Hz), 3.49 - 3.59 (2H, m), 3.86 (6H, s), 3.97 - 4.04 (2H, m), 4.18 - 4.32 (1H, m), 4.62 (21-1, t, J = 6.9 Hz), 6.03 (1H, d, J = 8.1 Hz), 6.71 (1H, d, J = 8.1 Hz), 6.79 - 6.85 (31-1, m), 7.38 (1H,d,J=7.2Hz),7.50(11-1,t,J=7.8Hz),7.65(11-1,t, J = 7.8Hz),7.73(1H,d,J=
8.4 Hz), 8.16 (1 H, d, J = 8.1 Hz), 8.38 (1 H, s).
Working Example 41 3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide The titled compound was obtained using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and tetrahydro-2H-pyran-4-amine in the same manner as in Working Example 2.
Yield:
68%. Melting point: 172 - 173 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 1.50 - 1.64 (21-1, m), 1.95-2.07 (2H, m), 3.09 (2H, t, J =
6.9 Hz), 3.49 - 3.59 (2H, m), 3.86 (6H, s), 3.97 - 4.04 (2H, m), 4.18 - 4.32 (1H, m), 4.62 (21-1, t, J = 6.9 Hz), 6.03 (1H, d, J = 8.1 Hz), 6.71 (1H, d, J = 8.1 Hz), 6.79 - 6.85 (31-1, m), 7.38 (1H,d,J=7.2Hz),7.50(11-1,t,J=7.8Hz),7.65(11-1,t, J = 7.8Hz),7.73(1H,d,J=
8.4 Hz), 8.16 (1 H, d, J = 8.1 Hz), 8.38 (1 H, s).
[0219]
Working Example 42 3-(2-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-4-yl)-N-(2-pyrrolidin-l -ylethyl)benzamide The titled compound was obtained using 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-4-yl)benzoic acid obtained in Reference Example and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
50%. Melting point: 116 - 117 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 1.70 - 1.82 (4H, m), 2.50 - 2.64 (41-1, m), 2.72 (2H, t, J
= 6.0 Hz), 3.06 (21-1, t, J = 7.2 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.55 (2H,t,J=7.2Hz),6.77-6.98(5H,m),7.12(111, d, J = 6.9Hz),7.50(1H,t,J=7.5 Hz), 7.71 (1 H, t, J = 8.7 Hz), 7.79 (1 H, d, J = 7.5 Hz), 8.06 (1 H, s), 8.20 (1 H, d, J = 6.0 Hz).
Working Example 42 3-(2-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-4-yl)-N-(2-pyrrolidin-l -ylethyl)benzamide The titled compound was obtained using 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-4-yl)benzoic acid obtained in Reference Example and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
50%. Melting point: 116 - 117 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 1.70 - 1.82 (4H, m), 2.50 - 2.64 (41-1, m), 2.72 (2H, t, J
= 6.0 Hz), 3.06 (21-1, t, J = 7.2 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.55 (2H,t,J=7.2Hz),6.77-6.98(5H,m),7.12(111, d, J = 6.9Hz),7.50(1H,t,J=7.5 Hz), 7.71 (1 H, t, J = 8.7 Hz), 7.79 (1 H, d, J = 7.5 Hz), 8.06 (1 H, s), 8.20 (1 H, d, J = 6.0 Hz).
[0220]
Working Example 43 3-(4-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
77%. Melting point: 114 - 115 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 1.70 - 1.82 (4H, m), 2.52 - 2.62 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.09 (2H, t, J = 6.9 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.87(3H, s), 3.89 (3H, s), 4.27 (2H,t,J=6.9Hz),6.75 - 6.90(5H,m),7.27(1H,d,J=2.4Hz),7.52(1H,t,J=8.1 Hz), 7.81 (1 H, dd, J = 7.8, 1.2 Hz), 8.10 (1 H, dd, J = 7.8, 1.2 Hz), 8.34 (1 H, t, J = 1.5 Hz), 8.49 (1 H, d, J = 6.0 Hz).
Working Example 43 3-(4-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
77%. Melting point: 114 - 115 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 1.70 - 1.82 (4H, m), 2.52 - 2.62 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.09 (2H, t, J = 6.9 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.87(3H, s), 3.89 (3H, s), 4.27 (2H,t,J=6.9Hz),6.75 - 6.90(5H,m),7.27(1H,d,J=2.4Hz),7.52(1H,t,J=8.1 Hz), 7.81 (1 H, dd, J = 7.8, 1.2 Hz), 8.10 (1 H, dd, J = 7.8, 1.2 Hz), 8.34 (1 H, t, J = 1.5 Hz), 8.49 (1 H, d, J = 6.0 Hz).
[0221]
Working Example 44 3-(5-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-3-yl)-N-(2-pyrrolidin-l -ylethyl)benzamide The titled compound was obtained using 3-(5-(2-(3,4-dimethoxyphenyl)ethoxy)pyri din- 3-yl)benzoic acid obtained in Reference Example 32 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
77%. Melting point: 112 - 113 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 1.72 - 1.8 (4H, m), 2.50 - 2.62 (4H, m), 2.72 (2H, t, J =
6.0 Hz), 3.09 (2H, t, J = 6.9 Hz), 3.57 (21-1, q, J = 6.0 Hz), 3.87(3H, s), 3.89 (3H, s), 4.27 (2H, t, J
= 6.9 Hz), 6.80 - 6.91 (4H, m), 7.23 - 7.39 (1 H, m), 7.52 (1 H, t, J = 7.5 Hz), 7.68 (1 H, dd, J = 6.6, 1.5 Hz), 7.74 (1 H, d, J = 7.5 Hz), 8.00 - 8.02 (1 H, m), 8.31 (1 H, d, J = 2.7 Hz), 8.45 (1 H, d, J = 1.5 Hz).
Working Example 44 3-(5-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-3-yl)-N-(2-pyrrolidin-l -ylethyl)benzamide The titled compound was obtained using 3-(5-(2-(3,4-dimethoxyphenyl)ethoxy)pyri din- 3-yl)benzoic acid obtained in Reference Example 32 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
77%. Melting point: 112 - 113 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 1.72 - 1.8 (4H, m), 2.50 - 2.62 (4H, m), 2.72 (2H, t, J =
6.0 Hz), 3.09 (2H, t, J = 6.9 Hz), 3.57 (21-1, q, J = 6.0 Hz), 3.87(3H, s), 3.89 (3H, s), 4.27 (2H, t, J
= 6.9 Hz), 6.80 - 6.91 (4H, m), 7.23 - 7.39 (1 H, m), 7.52 (1 H, t, J = 7.5 Hz), 7.68 (1 H, dd, J = 6.6, 1.5 Hz), 7.74 (1 H, d, J = 7.5 Hz), 8.00 - 8.02 (1 H, m), 8.31 (1 H, d, J = 2.7 Hz), 8.45 (1 H, d, J = 1.5 Hz).
[0222]
Working Example 45 3 -(4-(2-(3,4-Dimethoxyphenyl)ethoxy)pyrimidin-2-yl)-N-(2-pyrrolidin- I -ylethyl)benzamide The titled compound was obtained using 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoic acid obtained in Reference Example 22 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield: 47%. Melting point: 147 - 148 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 8: 1.73 - 1.82 (4H, m), 2.50 - 2.61 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.09 (2H, t, J = 6.9 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.70 (2H, t, J = 6.9 Hz), 6.63 (1 H, d, J = 5.7 Hz), 6.80 - 6.91 (4H, m), 7.53 (111, t, J = 7.5 Hz), 7.91 (1H, t, J = 7.5 Hz), 8.47 - 8.55 (2H, m), 8.78 (1H, s).
Working Example 45 3 -(4-(2-(3,4-Dimethoxyphenyl)ethoxy)pyrimidin-2-yl)-N-(2-pyrrolidin- I -ylethyl)benzamide The titled compound was obtained using 3-(4-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-2-yl)benzoic acid obtained in Reference Example 22 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield: 47%. Melting point: 147 - 148 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 8: 1.73 - 1.82 (4H, m), 2.50 - 2.61 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.09 (2H, t, J = 6.9 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.86 (3H, s), 3.88 (3H, s), 4.70 (2H, t, J = 6.9 Hz), 6.63 (1 H, d, J = 5.7 Hz), 6.80 - 6.91 (4H, m), 7.53 (111, t, J = 7.5 Hz), 7.91 (1H, t, J = 7.5 Hz), 8.47 - 8.55 (2H, m), 8.78 (1H, s).
[0223]
Working Example 46 3-(2-(2-(3,4-Dimethoxyphenyl)ethoxy)pyrimidin-4-yl)-N-(2-pyrrolidin-1-ylethyl)benzamide The titled compound was obtained. using 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoic acid obtained in Reference Example 21 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield: 24%. Melting point: 86 - 87 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 1.75 - 1.83 (4H, m), 2.50 - 2.63 (4H, m), 2.72 (2H, t, J =
6.0 Hz), 3.13 (2H, t, J = 7.2 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.85 (3H, s), 3.88 (3H, s), 4.65 (2H, t, J = 7.2 Hz), 6.78 - 6.89 (4H, m), 7.40 (1 H, d, J = 5.4 Hz), 7.55 (1 H, t, J = 7.5 Hz), 7.88 (1 H, d, J = 7.8 Hz), 8.22 (1 H, d, J = 7.8 Hz), 8.48 (1 H, s), 8.56 (1 H, d, J = 5.4 Hz).
Working Example 46 3-(2-(2-(3,4-Dimethoxyphenyl)ethoxy)pyrimidin-4-yl)-N-(2-pyrrolidin-1-ylethyl)benzamide The titled compound was obtained. using 3-(2-(2-(3,4-dimethoxyphenyl)ethoxy)pyrimidin-4-yl)benzoic acid obtained in Reference Example 21 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield: 24%. Melting point: 86 - 87 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 1.75 - 1.83 (4H, m), 2.50 - 2.63 (4H, m), 2.72 (2H, t, J =
6.0 Hz), 3.13 (2H, t, J = 7.2 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.85 (3H, s), 3.88 (3H, s), 4.65 (2H, t, J = 7.2 Hz), 6.78 - 6.89 (4H, m), 7.40 (1 H, d, J = 5.4 Hz), 7.55 (1 H, t, J = 7.5 Hz), 7.88 (1 H, d, J = 7.8 Hz), 8.22 (1 H, d, J = 7.8 Hz), 8.48 (1 H, s), 8.56 (1 H, d, J = 5.4 Hz).
[0224]
Working Example 47 3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-ethylbenzamide The titled compound was obtained using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and ethylamine in the same manner as in Working Example 2. Yield: 72%. Melting point: 137 - 138 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6 : 1.26 (3H, t, J = 8.1 Hz), 3.09 (21-1, t, J = 7.2 Hz), 3.45-3.57 (2H, m), 3.86(3H, s), 3.87 (3H, s), 4.63 (2H, t, J = 7.2 Hz), 6.16 (1H, br s), 6.70 (1H, d, J =
8.1 Hz), 6.81 - 6.89 (3H, m), 7.37 (1 H, d, J = 7.5 Hz), 7.49 (1 H, t, J = 7.8 Hz), 7.64 (1 H, t, J = 7.8 Hz), 7.74 (1 H, dt, J = 7.5, 1.5 Hz), 8.15 (1 H, dt, J = 7.5, 1.5 Hz), 8.3 8 (1 H, t, J = 1.8 Hz).
Working Example 47 3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-ethylbenzamide The titled compound was obtained using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and ethylamine in the same manner as in Working Example 2. Yield: 72%. Melting point: 137 - 138 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6 : 1.26 (3H, t, J = 8.1 Hz), 3.09 (21-1, t, J = 7.2 Hz), 3.45-3.57 (2H, m), 3.86(3H, s), 3.87 (3H, s), 4.63 (2H, t, J = 7.2 Hz), 6.16 (1H, br s), 6.70 (1H, d, J =
8.1 Hz), 6.81 - 6.89 (3H, m), 7.37 (1 H, d, J = 7.5 Hz), 7.49 (1 H, t, J = 7.8 Hz), 7.64 (1 H, t, J = 7.8 Hz), 7.74 (1 H, dt, J = 7.5, 1.5 Hz), 8.15 (1 H, dt, J = 7.5, 1.5 Hz), 8.3 8 (1 H, t, J = 1.8 Hz).
[0225]
Working Example 48 N-Cyclopropyl-3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and cyclopropanamine in the same manner as in Working Example 2. Yield: 76%.
Melting point: 163 - 164 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 0.59 - 0.66 (2H, m), 0.84 - 0.91 (2H, m), 2.82 - 3.00 (1H, m), 3.09 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.87 (3H, s), 4.62 (2H, t, J = 7.2 Hz), 6.27 (1H, br s),6.70(1H,d,J=8.4Hz),6.82-6.88(3H,m),7.37(1H,d, J= 7.5Hz),7.48(1H,t,J
= 8.1 Hz), 7.64 (1 H, t, J = 7.8 Hz), 7.71 (1 H, d, J = 7.5 Hz), 8.15 (1 H, dd, J = 6.3, 0.9 Hz), 8.35 (1H, s).
Working Example 48 N-Cyclopropyl-3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and cyclopropanamine in the same manner as in Working Example 2. Yield: 76%.
Melting point: 163 - 164 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 0.59 - 0.66 (2H, m), 0.84 - 0.91 (2H, m), 2.82 - 3.00 (1H, m), 3.09 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.87 (3H, s), 4.62 (2H, t, J = 7.2 Hz), 6.27 (1H, br s),6.70(1H,d,J=8.4Hz),6.82-6.88(3H,m),7.37(1H,d, J= 7.5Hz),7.48(1H,t,J
= 8.1 Hz), 7.64 (1 H, t, J = 7.8 Hz), 7.71 (1 H, d, J = 7.5 Hz), 8.15 (1 H, dd, J = 6.3, 0.9 Hz), 8.35 (1H, s).
[0226]
Working Example 49 (3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)benzamide A mixture of 2-chloro-6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine (300 mg, 1.02 mmol) obtained in Reference Example 7, (3-carbamoylphenyl)boronic acid (203 mg, 1.23 mmol), and tetrakis(triphenylphosphine)palladium (0) (59 mg, 0.051 mmol) in 2 N
sodium carbonate aqueous solution (10 mL)-1,2-dimethoxyethane (10 mL) was reacted for 16 hours at 90 C in a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, then dried over anhydrous sodium sulfate, and then concentrated at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 1:1) to give 240 mg of the titled compound (yield 62%). Melting point: 141 - 142 C.
' H-NMR (CDC13) 6: 3.09 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.87 (3H, s), 4.63 (2H, t, J
= 7.2 Hz), 5.80 (1 H, br s), 6.20 (1 H, br s), 6.71 (1 H, d, J = 8.4 Hz), 6.79 - 6.89 (3H, m), 7.3 8 (1 H, d, J = 7.2 Hz), 7.52 (1 H, t, J = 7.8 Hz), 7.64 (1 H, t, J = 7.8 Hz), 7.81 (1H,d,J
= 7.5 Hz), 8.19 (1 H, d, J = 7.8 Hz), 8.45 (1 H, s).
Working Example 49 (3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)benzamide A mixture of 2-chloro-6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridine (300 mg, 1.02 mmol) obtained in Reference Example 7, (3-carbamoylphenyl)boronic acid (203 mg, 1.23 mmol), and tetrakis(triphenylphosphine)palladium (0) (59 mg, 0.051 mmol) in 2 N
sodium carbonate aqueous solution (10 mL)-1,2-dimethoxyethane (10 mL) was reacted for 16 hours at 90 C in a nitrogen atmosphere. Water was added to the reaction solution, and the product was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, then dried over anhydrous sodium sulfate, and then concentrated at reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate-hexane 1:1) to give 240 mg of the titled compound (yield 62%). Melting point: 141 - 142 C.
' H-NMR (CDC13) 6: 3.09 (2H, t, J = 7.2 Hz), 3.86 (3H, s), 3.87 (3H, s), 4.63 (2H, t, J
= 7.2 Hz), 5.80 (1 H, br s), 6.20 (1 H, br s), 6.71 (1 H, d, J = 8.4 Hz), 6.79 - 6.89 (3H, m), 7.3 8 (1 H, d, J = 7.2 Hz), 7.52 (1 H, t, J = 7.8 Hz), 7.64 (1 H, t, J = 7.8 Hz), 7.81 (1H,d,J
= 7.5 Hz), 8.19 (1 H, d, J = 7.8 Hz), 8.45 (1 H, s).
[0227]
Working Example 50 3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-prop-2-yn-1-ylbenzamide WSC (123 mg, 0.64 mmol) and HOBt (86.5 mg, 0.64 mmol) were added a DMF (3 mL) solution of 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid (200 mg, 0.53 mmol) obtained in Reference Example 23 and prop-2-yn-l-amine (0.0439 mL, 0.64 mmol), and the mixture was stirred for 16 hours at room temperature. The addition of saturated aqueous sodium bicarbonate to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure.
The residue was purified by silica gel column chromatography and recrystallized from ethyl acetate-hexane to give 195 mg of the titled compound (yield: 88%).
Melting point:
142 - 143 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6 ):S 3.03 (2H, t, J = 7.0 Hz), 3.15 (1H, t, J = 2.5 Hz), 3.72 (3H, s), 3.74 (3H, s), 4.10 (2H, dd, J = 5.5, 2.5 Hz), 4.57 (2H, t, J = 7.0 Hz), 6.81 (1H, d, J = 8.0 Hz), 6.83 - 6.91 (2H, m), 6.95 (1 H, d, J = 1.5 Hz), 7.59 (1 H, t, J = 8.0 Hz), 7.63 (1 H, d, J = 7.2 Hz), 7.79 - 7.86 (1 H, m), 7.90 (1 H, d, J = 8.0 Hz), 8.25 (1 H, d, J
= 8.0 Hz), 8.53 (1 H, s), 9.07 (1 H, t, J = 5.7 Hz).
Working Example 50 3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-prop-2-yn-1-ylbenzamide WSC (123 mg, 0.64 mmol) and HOBt (86.5 mg, 0.64 mmol) were added a DMF (3 mL) solution of 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid (200 mg, 0.53 mmol) obtained in Reference Example 23 and prop-2-yn-l-amine (0.0439 mL, 0.64 mmol), and the mixture was stirred for 16 hours at room temperature. The addition of saturated aqueous sodium bicarbonate to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure.
The residue was purified by silica gel column chromatography and recrystallized from ethyl acetate-hexane to give 195 mg of the titled compound (yield: 88%).
Melting point:
142 - 143 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6 ):S 3.03 (2H, t, J = 7.0 Hz), 3.15 (1H, t, J = 2.5 Hz), 3.72 (3H, s), 3.74 (3H, s), 4.10 (2H, dd, J = 5.5, 2.5 Hz), 4.57 (2H, t, J = 7.0 Hz), 6.81 (1H, d, J = 8.0 Hz), 6.83 - 6.91 (2H, m), 6.95 (1 H, d, J = 1.5 Hz), 7.59 (1 H, t, J = 8.0 Hz), 7.63 (1 H, d, J = 7.2 Hz), 7.79 - 7.86 (1 H, m), 7.90 (1 H, d, J = 8.0 Hz), 8.25 (1 H, d, J
= 8.0 Hz), 8.53 (1 H, s), 9.07 (1 H, t, J = 5.7 Hz).
[0228]
Working Example 51 2,2,2-Trichloroethyl 3 -(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)carbamate The titled compound was synthesized using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)aniline obtained in Reference Example 19 in the same manner as in Reference Example 60. Yield: 93%. Melting point: 91 - 92 C
(ethyl acetate).
'H-NMR (CDC13 ):8 3.09 (2H, t, J = 7.2 Hz), 3.87 (3H, s), 3.87 (3H, s), 4.63 (2H, t, J =
7.2 Hz), 4.85 (2H, s), 6.69 (1H, d, J = 8.3 Hz), 6.81 - 6.90 (3H, m), 6.98 (1H, br s), 7.33 (1H,d,J=7.6Hz),7.42(1H,t,J=8.0Hz),7.55(1H,d,J=7.2Hz),7.59-7.66(1H, m), 7.76 (1 H, d, J = 8.0 Hz), 8.03 (1 H, s).
Working Example 51 2,2,2-Trichloroethyl 3 -(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)carbamate The titled compound was synthesized using 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)aniline obtained in Reference Example 19 in the same manner as in Reference Example 60. Yield: 93%. Melting point: 91 - 92 C
(ethyl acetate).
'H-NMR (CDC13 ):8 3.09 (2H, t, J = 7.2 Hz), 3.87 (3H, s), 3.87 (3H, s), 4.63 (2H, t, J =
7.2 Hz), 4.85 (2H, s), 6.69 (1H, d, J = 8.3 Hz), 6.81 - 6.90 (3H, m), 6.98 (1H, br s), 7.33 (1H,d,J=7.6Hz),7.42(1H,t,J=8.0Hz),7.55(1H,d,J=7.2Hz),7.59-7.66(1H, m), 7.76 (1 H, d, J = 8.0 Hz), 8.03 (1 H, s).
[0229]
Working Example 52 1-3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)-3-(6-fluoropyridin-yl)urea A DMSO (3 mL) solution of 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)aniline (200 mg, 0.57 mmol) obtained in Reference Example 19, 2,2,2-trichloroethyl (6-fluoropyridin-3-yl)carbamate (196 mg, 0.68 mmol) obtained in Reference Example 60, and diisopropylethylamine (0.118 mL, 0.68 mmol) was heated and stirred for hours at 70 C. The addition of water to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and saturated brine, and was dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography and recrystallized from ethyl acetate-hexane to give 160 mg of the titled compound (yield:
57%). Melting point: 97 - 98 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6 ):8 3.03 (2H, t, J = 7.2 Hz), 3.70 (3H, s), 3.73 (3H, s), 4.56 (2H, t, J = 7.2 Hz), 6.77 (1 H, d, J = 8.0 Hz), 6.86 (2H, s), 6.94 (1 H, s), 7.13 (1 H, dd, J = 8.9, 3.2Hz),7.39(1H,t,J=8.0Hz),7.48(1H,d,J=7.6Hz),7.54(1H,d,J=9.1 Hz), 7.68 (1 H, d, J = 7.6 Hz), 7.74 - 7.83 (1 H, m), 8.03 - 8.11 (1 H, m), 8.17 (1 H, s), 8.29 (1 H, s), 8.95 (2H, d, J = 5.7 Hz).
Working Example 52 1-3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)-3-(6-fluoropyridin-yl)urea A DMSO (3 mL) solution of 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)aniline (200 mg, 0.57 mmol) obtained in Reference Example 19, 2,2,2-trichloroethyl (6-fluoropyridin-3-yl)carbamate (196 mg, 0.68 mmol) obtained in Reference Example 60, and diisopropylethylamine (0.118 mL, 0.68 mmol) was heated and stirred for hours at 70 C. The addition of water to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and saturated brine, and was dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography and recrystallized from ethyl acetate-hexane to give 160 mg of the titled compound (yield:
57%). Melting point: 97 - 98 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6 ):8 3.03 (2H, t, J = 7.2 Hz), 3.70 (3H, s), 3.73 (3H, s), 4.56 (2H, t, J = 7.2 Hz), 6.77 (1 H, d, J = 8.0 Hz), 6.86 (2H, s), 6.94 (1 H, s), 7.13 (1 H, dd, J = 8.9, 3.2Hz),7.39(1H,t,J=8.0Hz),7.48(1H,d,J=7.6Hz),7.54(1H,d,J=9.1 Hz), 7.68 (1 H, d, J = 7.6 Hz), 7.74 - 7.83 (1 H, m), 8.03 - 8.11 (1 H, m), 8.17 (1 H, s), 8.29 (1 H, s), 8.95 (2H, d, J = 5.7 Hz).
[0230]
Working Example 53 1-3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)-3-(2-(dimethylamino)ethyl)urea The titled compound was synthesized using 2,2,2-trichloroethyl 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)carbamate obtained in Working Example 51 and N,N-dimethylethane-1,2-diamine in the same manner as in Working Example 52. Yield: 67%. Melting point: 93 - 122 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6 ):8 2.17 (6H, s), 2.33 (2H, t, J = 6.1 Hz), 3.02 (2H, t, J =
7.0 Hz), 3.19 (2H, q, J = 5.9 Hz), 3.72 (3H, s), 3.74 (3H, s), 4.55 (2H, t, J = 7.0 Hz), 6.11 (1H, t, J = 5.1 Hz), 6.75 (1 H, d, J = 8.3 Hz), 6.87 (2H, d, J = 2.3 Hz), 6.94 (1 H, s), 7.31 (1 H, t, J = 8.0 Hz), 7.43 (1 H, d, J = 7.2 Hz), 7.49 (1 H, d, J = 8.3 Hz), 7.56 (1 H, d, J = 7.6 Hz), 7.77 (1 H, t, J = 8.0 Hz), 8.05 (1 H, s), 8.77 (1 H, s).
Working Example 53 1-3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)-3-(2-(dimethylamino)ethyl)urea The titled compound was synthesized using 2,2,2-trichloroethyl 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)carbamate obtained in Working Example 51 and N,N-dimethylethane-1,2-diamine in the same manner as in Working Example 52. Yield: 67%. Melting point: 93 - 122 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6 ):8 2.17 (6H, s), 2.33 (2H, t, J = 6.1 Hz), 3.02 (2H, t, J =
7.0 Hz), 3.19 (2H, q, J = 5.9 Hz), 3.72 (3H, s), 3.74 (3H, s), 4.55 (2H, t, J = 7.0 Hz), 6.11 (1H, t, J = 5.1 Hz), 6.75 (1 H, d, J = 8.3 Hz), 6.87 (2H, d, J = 2.3 Hz), 6.94 (1 H, s), 7.31 (1 H, t, J = 8.0 Hz), 7.43 (1 H, d, J = 7.2 Hz), 7.49 (1 H, d, J = 8.3 Hz), 7.56 (1 H, d, J = 7.6 Hz), 7.77 (1 H, t, J = 8.0 Hz), 8.05 (1 H, s), 8.77 (1 H, s).
[0231]
Working Example 54 3-3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)-1-(2-(dimethylamino)ethyl)-1-methyl urea The titled compound was synthesized using 2,2,2-trichloroethyl 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)carbamate obtained in Working Example 51 and N,N,N'-trimethylethane-1,2-diamine in the same manner as in Working Example 52. Yield: 70%. Melting point: 119 - 120 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6 ):8 2.19 (6H, s), 2.43 (2H, t, J = 5.7 Hz), 2.93 (3H, s), 3.01 (2H, t, J = 7.0 Hz), 3.38 (2H, t, J = 5.7 Hz), 3.72 (3H, s), 3.73 (3H, s), 4.54 (2H, t, J = 7.2 Hz), 6.75 (1 H, d, J = 8.0 Hz), 6.81 - 6.90 (21-1, m), 6.94 (1 H, s), 7.32 (1 H, t, J = 7.8 Hz), 7.44 (1H,d,J=7.2Hz),7.51 (1H,d,J=8.3Hz),7.60(1H,d,J=7.6Hz),7.77(1H,t,J=
7.8 Hz), 8.02 (1 H, s), 9.3 8 (1 H, br s).
Working Example 54 3-3-(6-(2-(3,4-Dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)-1-(2-(dimethylamino)ethyl)-1-methyl urea The titled compound was synthesized using 2,2,2-trichloroethyl 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)carbamate obtained in Working Example 51 and N,N,N'-trimethylethane-1,2-diamine in the same manner as in Working Example 52. Yield: 70%. Melting point: 119 - 120 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6 ):8 2.19 (6H, s), 2.43 (2H, t, J = 5.7 Hz), 2.93 (3H, s), 3.01 (2H, t, J = 7.0 Hz), 3.38 (2H, t, J = 5.7 Hz), 3.72 (3H, s), 3.73 (3H, s), 4.54 (2H, t, J = 7.2 Hz), 6.75 (1 H, d, J = 8.0 Hz), 6.81 - 6.90 (21-1, m), 6.94 (1 H, s), 7.32 (1 H, t, J = 7.8 Hz), 7.44 (1H,d,J=7.2Hz),7.51 (1H,d,J=8.3Hz),7.60(1H,d,J=7.6Hz),7.77(1H,t,J=
7.8 Hz), 8.02 (1 H, s), 9.3 8 (1 H, br s).
[0232]
Working Example 55 3-(6-(2-(2,4-Dichlorophenyl)ethoxy)pyridin-2-yl)-N-pyridin-2-ylbenzamide 2-Aminopyridine (80 mg, 0.85 mmol), HATU (323 mg, 0.85 mmol), and diisopropylethylamine (0.148 mL, 0.85 mmol) were added to a DMF (3 mL) solution of 3-(6-(2-(2,4-dichlorophenyl)ethoxy)pyridin-2-yl)benzoic acid (0.30 g, 0.77 mmol) obtained in Reference Example 28, and the mixture was stirred for 16 hours at 80 C.
Ethyl acetate was added to the reaction solution, the solution was washed with water and with saturated brine, and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate = 80:20 - 30:70) and was recrystallized from ethyl acetate-hexane to give 61 mg of the titled compound in the form of crystals (yield 17%). Melting point: 113 - 115 C.
' H-NMR (CDC13) 6: 3.25 (2H, t, J = 7.2 Hz), 4.68 (2H, t, J = 7.2 Hz), 6.70 (1 H, d, J =
8.1 Hz), 7.05 - 7.19 (2H, m), 7.21 - 7.42 (3 H, m), 7.61 (1 H, t, J = 7.2 Hz), 7.68 (1 H, t, J
= 7.2 Hz), 7.78 (1 H, t, J = 7.8 Hz), 7.92 (1 H, d, J = 7.8 Hz), 8.19 - 8.32 (2H, m), 8.41 (1H, d, J = 9.0 Hz), 8.55 (1H, s), 8.65 (1H, br s).
Working Example 55 3-(6-(2-(2,4-Dichlorophenyl)ethoxy)pyridin-2-yl)-N-pyridin-2-ylbenzamide 2-Aminopyridine (80 mg, 0.85 mmol), HATU (323 mg, 0.85 mmol), and diisopropylethylamine (0.148 mL, 0.85 mmol) were added to a DMF (3 mL) solution of 3-(6-(2-(2,4-dichlorophenyl)ethoxy)pyridin-2-yl)benzoic acid (0.30 g, 0.77 mmol) obtained in Reference Example 28, and the mixture was stirred for 16 hours at 80 C.
Ethyl acetate was added to the reaction solution, the solution was washed with water and with saturated brine, and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate = 80:20 - 30:70) and was recrystallized from ethyl acetate-hexane to give 61 mg of the titled compound in the form of crystals (yield 17%). Melting point: 113 - 115 C.
' H-NMR (CDC13) 6: 3.25 (2H, t, J = 7.2 Hz), 4.68 (2H, t, J = 7.2 Hz), 6.70 (1 H, d, J =
8.1 Hz), 7.05 - 7.19 (2H, m), 7.21 - 7.42 (3 H, m), 7.61 (1 H, t, J = 7.2 Hz), 7.68 (1 H, t, J
= 7.2 Hz), 7.78 (1 H, t, J = 7.8 Hz), 7.92 (1 H, d, J = 7.8 Hz), 8.19 - 8.32 (2H, m), 8.41 (1H, d, J = 9.0 Hz), 8.55 (1H, s), 8.65 (1H, br s).
[0233]
Working Example 56 3 -(6-(2-(2,4-Dichlorophenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2-(2,4-dichlorophenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 28 in the same manner as in Working Example 2. Yield: 55%. Melting point: 115 - 116 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.72-1.85 (4H, m), 2.50 - 2.62 (4H, m), 2.72 (2H, t, J =
6.0 Hz), 3.24(2H,t,J=6.3Hz),3.59(2H,q,J=6.0Hz),4.66(2H,t, J = 6.9 Hz), 6.68 (1 H, d, J
= 8.1 Hz), 6.89 (1 H, br s), 7.17 (1 H, dd, J = 8.4, 2.1 Hz), 7.25 - 7.29 (1 H, m), 7.33 -7.38(2H,m),7.51 (1H,t,J=7.8Hz),7.64(1H,t,J=8.4Hz),7.77(1H,d,J=8.4Hz), 8.14 (1 H, d, J = 6.9 Hz), 8.42 (1 H, s).
Working Example 56 3 -(6-(2-(2,4-Dichlorophenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2-(2,4-dichlorophenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 28 in the same manner as in Working Example 2. Yield: 55%. Melting point: 115 - 116 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.72-1.85 (4H, m), 2.50 - 2.62 (4H, m), 2.72 (2H, t, J =
6.0 Hz), 3.24(2H,t,J=6.3Hz),3.59(2H,q,J=6.0Hz),4.66(2H,t, J = 6.9 Hz), 6.68 (1 H, d, J
= 8.1 Hz), 6.89 (1 H, br s), 7.17 (1 H, dd, J = 8.4, 2.1 Hz), 7.25 - 7.29 (1 H, m), 7.33 -7.38(2H,m),7.51 (1H,t,J=7.8Hz),7.64(1H,t,J=8.4Hz),7.77(1H,d,J=8.4Hz), 8.14 (1 H, d, J = 6.9 Hz), 8.42 (1 H, s).
[0234]
Working Example 57 3-(6-((2,4-Dichlorobenzyl)oxy)pyridin-2-yl)-N-pyridin-2-ylbenzamide The titled compound was obtained using 3-(6-((2,4-dichlorobenzyl)oxy)pyridin-2-yl)benzoic acid obtained in Reference Example 30 and 2-aminopyridine in the same manner as in Working Example 55. Yield: 12%. Melting point: 133 - 134 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 5.60 (2H, s), 6.82 (1H, d, J = 8.4 Hz), 7.00 - 7.10 (1H, m), 7.20 - 7.30 (1 H, m), 7.28 - 7.80 (6H, m), 7.90 - 7.96 (1 H, m), 8.17 - 8.22 (1 H, m), 8.29 -8.3 3 (1 H, m), 8.46 (1 H, d, J = 8.4 Hz), 8.54 (1 H, t, J = 2.1 Hz), 8.69 (1 H, br s).
Working Example 57 3-(6-((2,4-Dichlorobenzyl)oxy)pyridin-2-yl)-N-pyridin-2-ylbenzamide The titled compound was obtained using 3-(6-((2,4-dichlorobenzyl)oxy)pyridin-2-yl)benzoic acid obtained in Reference Example 30 and 2-aminopyridine in the same manner as in Working Example 55. Yield: 12%. Melting point: 133 - 134 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 5.60 (2H, s), 6.82 (1H, d, J = 8.4 Hz), 7.00 - 7.10 (1H, m), 7.20 - 7.30 (1 H, m), 7.28 - 7.80 (6H, m), 7.90 - 7.96 (1 H, m), 8.17 - 8.22 (1 H, m), 8.29 -8.3 3 (1 H, m), 8.46 (1 H, d, J = 8.4 Hz), 8.54 (1 H, t, J = 2.1 Hz), 8.69 (1 H, br s).
[0235]
Working Example 58 3-(6-((2,4-Dichlorobenzyl)oxy)pyridin-2-yl)-N-(2-pyrrolidin-1-ylethyl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorobenzyl)oxy)pyridin-2-yl)benzoic acid obtained in Reference Example 30 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2. Yield: 42%. Melting point: 96 - 97 C.
(Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 1.70 - 1.82 (4H, m), 2.48-2.62 (4H, m), 2.73 (2H, t, J =
6.0 Hz), 3.59 (2H, q, J = 6.0 Hz), 5.58 (2H, s), 6.76 - 6.90 (2H, m), 7.20 - 7.30 (1H, m), 7.41 -7.5 8 (4H, m), 7.64 - 7.79 (21-1, m), 8.13 (1 H, dt, J = 8.4, 1.8 Hz), 8.41 (1 H, t, J = 1.8 Hz).
Working Example 58 3-(6-((2,4-Dichlorobenzyl)oxy)pyridin-2-yl)-N-(2-pyrrolidin-1-ylethyl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorobenzyl)oxy)pyridin-2-yl)benzoic acid obtained in Reference Example 30 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2. Yield: 42%. Melting point: 96 - 97 C.
(Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 1.70 - 1.82 (4H, m), 2.48-2.62 (4H, m), 2.73 (2H, t, J =
6.0 Hz), 3.59 (2H, q, J = 6.0 Hz), 5.58 (2H, s), 6.76 - 6.90 (2H, m), 7.20 - 7.30 (1H, m), 7.41 -7.5 8 (4H, m), 7.64 - 7.79 (21-1, m), 8.13 (1 H, dt, J = 8.4, 1.8 Hz), 8.41 (1 H, t, J = 1.8 Hz).
[0236]
Working Example 59 N-(2-Hydroxyethyl)-3-(6-(2-(3-methylphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methylphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 27 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 68%. Melting point: 97 - 98 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 2.35 (3H, s), 2.42 - 2.62 (11-1, m), 3.11 (2H, t, J = 7.2 Hz), 3.64 (2H, t, J = 5.4 Hz), 3.77 - 3.85 (2H, m), 4.62 (21-1, t, J = 7.2 Hz), 6.67-6.80 (2H, m), 7.05(1H,d,J=7.5Hz),7.09-7.14(2H,m),7.17-7.24(1H,m),7.36(1H,d,J=7.2 Hz), 7.5 0 (1 H, t, J = 7.5 Hz), 7.63 (1 H, d, J = 7.8 Hz), 7.98 (1 H, d, J =
7.2 Hz), 8.16 (1 H, d, J = 7.2 Hz), 8.40 (1 H, s).
Working Example 59 N-(2-Hydroxyethyl)-3-(6-(2-(3-methylphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methylphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 27 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 68%. Melting point: 97 - 98 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 2.35 (3H, s), 2.42 - 2.62 (11-1, m), 3.11 (2H, t, J = 7.2 Hz), 3.64 (2H, t, J = 5.4 Hz), 3.77 - 3.85 (2H, m), 4.62 (21-1, t, J = 7.2 Hz), 6.67-6.80 (2H, m), 7.05(1H,d,J=7.5Hz),7.09-7.14(2H,m),7.17-7.24(1H,m),7.36(1H,d,J=7.2 Hz), 7.5 0 (1 H, t, J = 7.5 Hz), 7.63 (1 H, d, J = 7.8 Hz), 7.98 (1 H, d, J =
7.2 Hz), 8.16 (1 H, d, J = 7.2 Hz), 8.40 (1 H, s).
[0237]
Working Example 60 3-(6-(2-(3-Methylphenyl)ethoxy)pyridin-2-yl)-N-(2-methylpyridin-4-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methylphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 27 and 2-methylpyridine-4-amine in the same manner as in Working Example 55. Yield: 36%. Melting point: 134 - 135 C.
(Ethyl acetate-hexane).
H-NMR (CDC13) 6 : 2.31 (3H, s), 2.51 (3H, s), 3.10 (2H, t, J = 6.9 Hz), 4.61 (2H, t, J
= 6.9 Hz), 6.71 (1H, d, J = 7.5 Hz), 7.02 (111, d, J = 7.2 Hz), 7.10 - 7.25 (3H, m), 7.30 - 7.34 (2H, m), 7.49 - 7.55 (2H, m), 7.62 (1 H, t, J = 7.8 Hz), 7.82 (1 H, d, J = 6.9 Hz), 8.18 (1 H, d, J = 7.8 Hz), 8.31 (1 H, s), 8.3 8 (1 H, d, J = 5.1 Hz), 8.45 (1 H, s).
Working Example 60 3-(6-(2-(3-Methylphenyl)ethoxy)pyridin-2-yl)-N-(2-methylpyridin-4-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methylphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 27 and 2-methylpyridine-4-amine in the same manner as in Working Example 55. Yield: 36%. Melting point: 134 - 135 C.
(Ethyl acetate-hexane).
H-NMR (CDC13) 6 : 2.31 (3H, s), 2.51 (3H, s), 3.10 (2H, t, J = 6.9 Hz), 4.61 (2H, t, J
= 6.9 Hz), 6.71 (1H, d, J = 7.5 Hz), 7.02 (111, d, J = 7.2 Hz), 7.10 - 7.25 (3H, m), 7.30 - 7.34 (2H, m), 7.49 - 7.55 (2H, m), 7.62 (1 H, t, J = 7.8 Hz), 7.82 (1 H, d, J = 6.9 Hz), 8.18 (1 H, d, J = 7.8 Hz), 8.31 (1 H, s), 8.3 8 (1 H, d, J = 5.1 Hz), 8.45 (1 H, s).
[0238]
Working Example 61.
3-(6-(2-(3 -Fluorophenyl)ethoxy)pyridin-2-yl)-N- 1,3 -thiazol-2-ylbenzamide The titled compound was obtained using 3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 26 and 1,3-thiazole-2-amine in the same manner as in Working Example 55. Yield: 62%. Melting point: 115 - 116 C.
(Ethyl acetate-hexane).
'H-NMR(CDC13)6:3.09(2H,t,J=6.0Hz),4.56(2H,t, J = 6.9Hz),6.70(1H,d,J=
8.4 Hz), 6.81 - 6.90 (2H, m), 6.94 - 7.02 (2H, m), 7.06 (1 H, d, J = 7.8 Hz), 7.16 - 7.26 (1 H, m), 7.32 (1 H, d, J = 6.9 Hz), 7.56 - 7.65 (2H, m), 8.01 (1 H, d, J =
7.8 Hz), 8.30 (1 H, d, J = 7.5 Hz), 8.64 (1 H, s), 12.9 (1 H, s).
Working Example 61.
3-(6-(2-(3 -Fluorophenyl)ethoxy)pyridin-2-yl)-N- 1,3 -thiazol-2-ylbenzamide The titled compound was obtained using 3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 26 and 1,3-thiazole-2-amine in the same manner as in Working Example 55. Yield: 62%. Melting point: 115 - 116 C.
(Ethyl acetate-hexane).
'H-NMR(CDC13)6:3.09(2H,t,J=6.0Hz),4.56(2H,t, J = 6.9Hz),6.70(1H,d,J=
8.4 Hz), 6.81 - 6.90 (2H, m), 6.94 - 7.02 (2H, m), 7.06 (1 H, d, J = 7.8 Hz), 7.16 - 7.26 (1 H, m), 7.32 (1 H, d, J = 6.9 Hz), 7.56 - 7.65 (2H, m), 8.01 (1 H, d, J =
7.8 Hz), 8.30 (1 H, d, J = 7.5 Hz), 8.64 (1 H, s), 12.9 (1 H, s).
[0239]
Working Example 62 3-(6-(2-(3-Fluorophenyl)ethoxy)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 26 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 32%. Melting point: 85 - 86 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 8 : 2.60 (1H, br s), 3.14 (2H, t, J = 6.6 Hz), 3.65 (2H, t, J
= 5.1 Hz), 3.84 (2H, t, J = 5.1 Hz), 4.64 (2H, t, J = 6.6 Hz), 6.67 - 6.81 (2H, m), 6.88 -6.96 (1H, m), 7.03 (1 H, d, J = 10.2 Hz), 7.08 (1 H, d, J = 8.1 Hz), 7.21 - 7.30 (1 H, m), 7.36 (1 H, d, J = 7.8 Hz), 7.49 (1 H, d, J = 7.5 Hz), 7.63 (1 H, d, J = 7.5 Hz), 7.77 (1 H, d, J = 8.4 Hz), 8.14 (1 H, d, J = 7.2 Hz), 8.41 (1 H, s).
Working Example 62 3-(6-(2-(3-Fluorophenyl)ethoxy)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 26 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 32%. Melting point: 85 - 86 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 8 : 2.60 (1H, br s), 3.14 (2H, t, J = 6.6 Hz), 3.65 (2H, t, J
= 5.1 Hz), 3.84 (2H, t, J = 5.1 Hz), 4.64 (2H, t, J = 6.6 Hz), 6.67 - 6.81 (2H, m), 6.88 -6.96 (1H, m), 7.03 (1 H, d, J = 10.2 Hz), 7.08 (1 H, d, J = 8.1 Hz), 7.21 - 7.30 (1 H, m), 7.36 (1 H, d, J = 7.8 Hz), 7.49 (1 H, d, J = 7.5 Hz), 7.63 (1 H, d, J = 7.5 Hz), 7.77 (1 H, d, J = 8.4 Hz), 8.14 (1 H, d, J = 7.2 Hz), 8.41 (1 H, s).
[0240]
Working Example 63 N-(2-Cyanoethyl)-3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 26 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 73%.
Melting point: 142 - 143 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6 ):S 2.81 (2H, t, J = 6.5 Hz), 3.13 (2H, t, J = 6.8 Hz), 3.54 (2H, q, J
= 6.4 Hz), 4.63 (2H, t, J = 6.8 Hz), 6.80 (1 H, d, J = 7.9 Hz), 7.01 - 7.12 (1 H, m), 7.15 -7.25 (2H, m), 7.28 - 7.41 (1 H, m), 7.56 - 7.68 (2H, m), 7.83 (1 H, t, J = 7.8 Hz), 7.90 (1 H, d, J = 8.1 Hz), 8.26 (1 H, d, J = 7.9 Hz), 8.54 (1 H, s), 8.99 (1 H, t, J = 5.6 Hz).
Working Example 63 N-(2-Cyanoethyl)-3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(2-(3-fluorophenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 26 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 73%.
Melting point: 142 - 143 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6 ):S 2.81 (2H, t, J = 6.5 Hz), 3.13 (2H, t, J = 6.8 Hz), 3.54 (2H, q, J
= 6.4 Hz), 4.63 (2H, t, J = 6.8 Hz), 6.80 (1 H, d, J = 7.9 Hz), 7.01 - 7.12 (1 H, m), 7.15 -7.25 (2H, m), 7.28 - 7.41 (1 H, m), 7.56 - 7.68 (2H, m), 7.83 (1 H, t, J = 7.8 Hz), 7.90 (1 H, d, J = 8.1 Hz), 8.26 (1 H, d, J = 7.9 Hz), 8.54 (1 H, s), 8.99 (1 H, t, J = 5.6 Hz).
[0241]
Working Example 64 N-(2-Cyanoethyl)-3 -(6-(2-(3 -(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 25 and 3-aminopropanenitrile in the same manner as in Working Example 2.
Yield: 75%. Melting point: 104 - 105 C. (Ethyl acetate-hexane).
'H-NMR(CDC13)6:2.77(2H,t,J=6.0Hz),3.20(2H,t, J = 6.9Hz),3.75(2H,q,J
6.0 Hz), 4.67 (2H, t, J = 6.9 Hz), 6.60 - 6.72 (2H, m), 7.34 - 7.59 (6H, m), 7.65 (1H, t, J
= 7.8 Hz), 7.76 (1 H, d, J = 6.9 Hz), 8.17 (1 H, d, J = 7.8 Hz), 8.42 (1 H, s).
Working Example 64 N-(2-Cyanoethyl)-3 -(6-(2-(3 -(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 25 and 3-aminopropanenitrile in the same manner as in Working Example 2.
Yield: 75%. Melting point: 104 - 105 C. (Ethyl acetate-hexane).
'H-NMR(CDC13)6:2.77(2H,t,J=6.0Hz),3.20(2H,t, J = 6.9Hz),3.75(2H,q,J
6.0 Hz), 4.67 (2H, t, J = 6.9 Hz), 6.60 - 6.72 (2H, m), 7.34 - 7.59 (6H, m), 7.65 (1H, t, J
= 7.8 Hz), 7.76 (1 H, d, J = 6.9 Hz), 8.17 (1 H, d, J = 7.8 Hz), 8.42 (1 H, s).
[0242]
Working Example 65 N-(2-Hydroxyethyl)-3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 25 and 2-aminoethanol in the same manner as in Working Example 2.
Yield:
21%. Melting point: 106 - 107 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 2.55 (1 H, br s), 3.20 (2H, t, J = 6.9 Hz), 3.66 (2H, t, J
= 5.1 Hz), 3.78 - 3.90 (2H, m), 4.66 (2H, t, J = 6.9 Hz), 6.64 - 6.79 (2H, m), 7.35 -7.67 (7H, m), 7.76 (1 H, d, J = 7.2 Hz), 8.15 (1 H, d, J = 7.5 Hz), 8.41 (1 H, s).
Working Example 65 N-(2-Hydroxyethyl)-3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 25 and 2-aminoethanol in the same manner as in Working Example 2.
Yield:
21%. Melting point: 106 - 107 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 2.55 (1 H, br s), 3.20 (2H, t, J = 6.9 Hz), 3.66 (2H, t, J
= 5.1 Hz), 3.78 - 3.90 (2H, m), 4.66 (2H, t, J = 6.9 Hz), 6.64 - 6.79 (2H, m), 7.35 -7.67 (7H, m), 7.76 (1 H, d, J = 7.2 Hz), 8.15 (1 H, d, J = 7.5 Hz), 8.41 (1 H, s).
[0243]
Working Example 66 N-(2-Methoxyethyl)-3 -(6-(2-(3 -methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example .29 and 2-methoxyethanamine in the same manner as in Working Example 2. Yield:
34%.
Melting point: 70 - 71 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 3.12 (2H, t, J = 6.9 Hz), 3.37 (3H, s), 3.58 (2H, t, J = 4.8 Hz), 3.68 (21-1, t, J = 4.8 Hz), 3.79 (3H, s), 4.65 (2H, t, J = 6.9 Hz), 6.50 -6.97 (5H, m), 7.23 (1H,t,J=8.1 Hz),7.37(1H,d,J=7.2Hz),7.50(1H,t,J=7.8Hz),7.63 (11-1,t,J=7.8 Hz), 7.77 (1 H, d, J = 7.5 Hz), 8.16 (1 H, d, J = 8.4 Hz), 8.39 (1 H, s).
Working Example 66 N-(2-Methoxyethyl)-3 -(6-(2-(3 -methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example .29 and 2-methoxyethanamine in the same manner as in Working Example 2. Yield:
34%.
Melting point: 70 - 71 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 3.12 (2H, t, J = 6.9 Hz), 3.37 (3H, s), 3.58 (2H, t, J = 4.8 Hz), 3.68 (21-1, t, J = 4.8 Hz), 3.79 (3H, s), 4.65 (2H, t, J = 6.9 Hz), 6.50 -6.97 (5H, m), 7.23 (1H,t,J=8.1 Hz),7.37(1H,d,J=7.2Hz),7.50(1H,t,J=7.8Hz),7.63 (11-1,t,J=7.8 Hz), 7.77 (1 H, d, J = 7.5 Hz), 8.16 (1 H, d, J = 8.4 Hz), 8.39 (1 H, s).
[0244]
Working Example 67 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and tetrahydro-2H-pyran-4-amine in the same manner as in Working Example 2.
Yield:
76%. Melting point: 136 - 137 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.50 - 1.64 (21-1, m), 1.97 - 2.07 (2H, m), 3.13 (2H, t, J
= 7.2 Hz), 3.54 (21-1, t, J = 11.7 Hz), 3.79 (3H, s), 3.95-4.05 (2H, m), 4.15-4.30 (1H, m), 4.65 (2H, t, J = 6.6 Hz), 6.05 (1 H, d, J = 8.1 Hz), 6.71 (1 H, d, J = 7.2 Hz), 6.74 - 6.80 (1 H, m), 6.8 6 (1 H, s), 6.90 (1 H, d, J = 7.5 Hz), 7.2 0 - 7.2 5 (1 H, m), 7.3 7 (1 H, d, J = 8.1 Hz), 7.51 (1 H, t, J = 7.5 Hz), 7.61 - 7.68 (1 H, m), 7.71 - 7.77 (1 H, m), 8.13-8.18 (1 H, m), 8.27 (1H, s).
Working Example 67 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and tetrahydro-2H-pyran-4-amine in the same manner as in Working Example 2.
Yield:
76%. Melting point: 136 - 137 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.50 - 1.64 (21-1, m), 1.97 - 2.07 (2H, m), 3.13 (2H, t, J
= 7.2 Hz), 3.54 (21-1, t, J = 11.7 Hz), 3.79 (3H, s), 3.95-4.05 (2H, m), 4.15-4.30 (1H, m), 4.65 (2H, t, J = 6.6 Hz), 6.05 (1 H, d, J = 8.1 Hz), 6.71 (1 H, d, J = 7.2 Hz), 6.74 - 6.80 (1 H, m), 6.8 6 (1 H, s), 6.90 (1 H, d, J = 7.5 Hz), 7.2 0 - 7.2 5 (1 H, m), 7.3 7 (1 H, d, J = 8.1 Hz), 7.51 (1 H, t, J = 7.5 Hz), 7.61 - 7.68 (1 H, m), 7.71 - 7.77 (1 H, m), 8.13-8.18 (1 H, m), 8.27 (1H, s).
[0245]
Working Example 68 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-methylbenzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and methylamine in the same manner as in Working Example 2. Yield: 19%.
Melting point: 90 - 91 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 3.04 (3H, d, J = 4.8 Hz), 3.13 (2H, t, J = 7.2 Hz), 3.80 (3H, s), 4.65 (2H, t, J = 7.2 Hz), 6.18 (1 H, br s), 6.70 (1 H, d, J = 7.5 Hz), 6.78 (1 H, d, J 7.8 Hz), 6.87 (1 H, s), 6.91 (1 H, d, J = 8.1 Hz), 7.23 (1 H, d, J = 7.5 Hz), 7.37 (1 H, d, J = 8.1 Hz), 7.50 (1 H, d, J = 7.8 Hz), 7.64 (1 H, t, J = 7.8 Hz), 7.76 (1 H, d, J =
7.8 Hz), 8.15 (1H, d, J = 7.5 Hz), 8.37 (1H, s).
Working Example 68 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-methylbenzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and methylamine in the same manner as in Working Example 2. Yield: 19%.
Melting point: 90 - 91 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 3.04 (3H, d, J = 4.8 Hz), 3.13 (2H, t, J = 7.2 Hz), 3.80 (3H, s), 4.65 (2H, t, J = 7.2 Hz), 6.18 (1 H, br s), 6.70 (1 H, d, J = 7.5 Hz), 6.78 (1 H, d, J 7.8 Hz), 6.87 (1 H, s), 6.91 (1 H, d, J = 8.1 Hz), 7.23 (1 H, d, J = 7.5 Hz), 7.37 (1 H, d, J = 8.1 Hz), 7.50 (1 H, d, J = 7.8 Hz), 7.64 (1 H, t, J = 7.8 Hz), 7.76 (1 H, d, J =
7.8 Hz), 8.15 (1H, d, J = 7.5 Hz), 8.37 (1H, s).
[0246]
Working Example 69 N-(2-Hydroxyethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-aminoethanol in the same manner as in Working Example 2. Yield: 18%.
Melting point: 95 - 96 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 2.65 (1 H, br s), 3.12 (2H, t, J = 7.2 Hz), 3.64 (2H, q, J
= 6.0 Hz), 3.72-3.85 (5H, m), 4.64 (2H, t, J = 7.2 Hz), 6.67-6.94 (5H, m), 7.24 (1H, d, J
= 8.1 Hz), 7.3 6 (1 H, d, J = 7.5 Hz), 7.49 (1 H, t, J = 7.5 Hz), 7.63 (1 H, t, J = 7.5 Hz), 7.79 (1 H, d, J
=7.8Hz),8.14(1H,d,J=7.8Hz),8.41 (1H,s).
Working Example 69 N-(2-Hydroxyethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-aminoethanol in the same manner as in Working Example 2. Yield: 18%.
Melting point: 95 - 96 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 2.65 (1 H, br s), 3.12 (2H, t, J = 7.2 Hz), 3.64 (2H, q, J
= 6.0 Hz), 3.72-3.85 (5H, m), 4.64 (2H, t, J = 7.2 Hz), 6.67-6.94 (5H, m), 7.24 (1H, d, J
= 8.1 Hz), 7.3 6 (1 H, d, J = 7.5 Hz), 7.49 (1 H, t, J = 7.5 Hz), 7.63 (1 H, t, J = 7.5 Hz), 7.79 (1 H, d, J
=7.8Hz),8.14(1H,d,J=7.8Hz),8.41 (1H,s).
[0247]
Working Example 70 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
49%. Melting point: 95 - 96 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 1.70 - 1.89 (4H, m), 2.43 - 2.62 (4H, m), 2.71 (21-1, t, J
= 6.0 Hz), 3.12 (2H, t, J = 7.2 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.80 (3H, s), 4.65 (2H, t, J = 7.2 Hz), 6.70 (111, d, J = 8.4 Hz), 6.77 (1 H, dd, J = 8.4, 2.4 Hz), 6.85-6.93 (3 H, m), 7.22 (1H,d,J=8.1 Hz),7.38(1H,d,J=7.2Hz),7.50(1H,t,J=7.8Hz),7.64(1H,t,J=
8.1 Hz), 7.77 (1 H, d, J = 7.5 Hz), 8.16 (1 H, d, J = 7.8 Hz), 8.41 (1 H, s).
Working Example 70 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2.
Yield:
49%. Melting point: 95 - 96 C. (Ethyl acetate-hexane).
1 H-NMR (CDC13) 6: 1.70 - 1.89 (4H, m), 2.43 - 2.62 (4H, m), 2.71 (21-1, t, J
= 6.0 Hz), 3.12 (2H, t, J = 7.2 Hz), 3.58 (2H, q, J = 6.0 Hz), 3.80 (3H, s), 4.65 (2H, t, J = 7.2 Hz), 6.70 (111, d, J = 8.4 Hz), 6.77 (1 H, dd, J = 8.4, 2.4 Hz), 6.85-6.93 (3 H, m), 7.22 (1H,d,J=8.1 Hz),7.38(1H,d,J=7.2Hz),7.50(1H,t,J=7.8Hz),7.64(1H,t,J=
8.1 Hz), 7.77 (1 H, d, J = 7.5 Hz), 8.16 (1 H, d, J = 7.8 Hz), 8.41 (1 H, s).
[0248]
Working Example 71 N-(2-Cyanoethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield:
90%.
Melting point: 107 - 108 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6 ):S 2.81 (2H, t, J = 6.6 Hz), 3.07 (2H, t, J = 7.0 Hz), 3.53 (2H, q, J
= 6.4 Hz), 3.74 (3H, s), 4.60 (2H, t, J = 7.0 Hz), 6.77-6.83 (2H, m), 6.89 -6.96 (2H, m), 7.23 (1 H, t, J = 8.1 Hz),7.56-7.65(2H,m),7.79-7.86(1H,m),7.89(1H,d,J=8.0 Hz),8.25(1H,d,J=8.0Hz),8.53(1H,t,J=1.5Hz),8.98(1H,t,J=5.7Hz) [0249]
Working Example 72 Tert-butyl (2-((3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoyl)amino)ethyl)carbamate WSC (130 mg, 0.68 mmol) and HOBt (91.8 mg, 0.68 mmol) were added to a DMF
(2 mL) solution of 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid (200 mg, 0.57 mmol) obtained in Reference Example 29 and tert-butyl (2-aminoethyl)carbamate (0.108 mL, 0.68 mmol), and the mixture was stirred for 3 hours at room temperature. The addition of saturated aqueous sodium bicarbonate to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography to give 230 g of the titled compound (yield: 82%). Melting point: 128 -129 C (ethyl acetate).
' H-NMR (CDC13 ):8 1.41 (9H, s), 3.13 (2H, t, J = 7.0 Hz), 3.42 (2H, q, J =
5.6 Hz), 3.55-3.63 (2H, m), 3.80 (3H, s), 4.67 (2H, t, J = 7.2 Hz), 4.99 (1 H, br s), 6.70 (1 H, d, J
= 8.3 Hz), 6.78 (1 H, dd, J = 8.0, 2.3 Hz), 6.86-6.90 (1 H, m), 6.92 (1 H, d, J = 7.6 Hz), 7.22 (1 H, d, J = 8.0 Hz), 7.31 (1 H, br s), 7.43 (1 H, d, J = 7.6 Hz), 7.51 (1H,t,J=7.8 Hz), 7.59 - 7.68 (114, m), 7.83 (1 H, d, J = 7.6 Hz), 8.21 (111, d, J = 8.0 Hz), 8.45 (1 H, s) [0250]
Working Example 73 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-methylpyridin-4-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-methylpyridine-4-amine in the same manner as in Working Example 55.
Yield:
44%. Melting point: 125 - 126 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 8 :2.56 (3H, s), 3.13 (2H, t, J = 7.2 Hz), 3.76 (3H, s), 4.66 (2H, t, J
= 7.2 Hz), 6.70 - 6.78 (2H, m), 6.87 - 6.92 (2H, m), 7.20 (1 H, t, J = 7.8 Hz), 7.33 (1 H, dd, J = 6:0, 1.8 Hz), 7.3 8 (1 H, d, J = 7.5 Hz), 7.53 (1 H, d, J = 1.8 Hz), 7.57 (1 H, d, J =
7.8 Hz), 7.66 (1 H, t, J = 7.8 Hz), 7.86 (1 H, d, J = 7.5 Hz), 8.04 (1 H, br s), 8.20 (1 H, d, J
= 7.8 Hz), 8.42 (1 H, d, J = 5.7 Hz), 8.48 (1 H, s).
Working Example 71 N-(2-Cyanoethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield:
90%.
Melting point: 107 - 108 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6 ):S 2.81 (2H, t, J = 6.6 Hz), 3.07 (2H, t, J = 7.0 Hz), 3.53 (2H, q, J
= 6.4 Hz), 3.74 (3H, s), 4.60 (2H, t, J = 7.0 Hz), 6.77-6.83 (2H, m), 6.89 -6.96 (2H, m), 7.23 (1 H, t, J = 8.1 Hz),7.56-7.65(2H,m),7.79-7.86(1H,m),7.89(1H,d,J=8.0 Hz),8.25(1H,d,J=8.0Hz),8.53(1H,t,J=1.5Hz),8.98(1H,t,J=5.7Hz) [0249]
Working Example 72 Tert-butyl (2-((3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoyl)amino)ethyl)carbamate WSC (130 mg, 0.68 mmol) and HOBt (91.8 mg, 0.68 mmol) were added to a DMF
(2 mL) solution of 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid (200 mg, 0.57 mmol) obtained in Reference Example 29 and tert-butyl (2-aminoethyl)carbamate (0.108 mL, 0.68 mmol), and the mixture was stirred for 3 hours at room temperature. The addition of saturated aqueous sodium bicarbonate to the reaction solution was followed by extraction with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography to give 230 g of the titled compound (yield: 82%). Melting point: 128 -129 C (ethyl acetate).
' H-NMR (CDC13 ):8 1.41 (9H, s), 3.13 (2H, t, J = 7.0 Hz), 3.42 (2H, q, J =
5.6 Hz), 3.55-3.63 (2H, m), 3.80 (3H, s), 4.67 (2H, t, J = 7.2 Hz), 4.99 (1 H, br s), 6.70 (1 H, d, J
= 8.3 Hz), 6.78 (1 H, dd, J = 8.0, 2.3 Hz), 6.86-6.90 (1 H, m), 6.92 (1 H, d, J = 7.6 Hz), 7.22 (1 H, d, J = 8.0 Hz), 7.31 (1 H, br s), 7.43 (1 H, d, J = 7.6 Hz), 7.51 (1H,t,J=7.8 Hz), 7.59 - 7.68 (114, m), 7.83 (1 H, d, J = 7.6 Hz), 8.21 (111, d, J = 8.0 Hz), 8.45 (1 H, s) [0250]
Working Example 73 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-methylpyridin-4-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-methylpyridine-4-amine in the same manner as in Working Example 55.
Yield:
44%. Melting point: 125 - 126 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 8 :2.56 (3H, s), 3.13 (2H, t, J = 7.2 Hz), 3.76 (3H, s), 4.66 (2H, t, J
= 7.2 Hz), 6.70 - 6.78 (2H, m), 6.87 - 6.92 (2H, m), 7.20 (1 H, t, J = 7.8 Hz), 7.33 (1 H, dd, J = 6:0, 1.8 Hz), 7.3 8 (1 H, d, J = 7.5 Hz), 7.53 (1 H, d, J = 1.8 Hz), 7.57 (1 H, d, J =
7.8 Hz), 7.66 (1 H, t, J = 7.8 Hz), 7.86 (1 H, d, J = 7.5 Hz), 8.04 (1 H, br s), 8.20 (1 H, d, J
= 7.8 Hz), 8.42 (1 H, d, J = 5.7 Hz), 8.48 (1 H, s).
[0251]
Working Example 74 3 -(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N- 1,3 -thiazol-2-ylbenzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 1,3-thiazole-2-amine in the same manner as in Working Example 55. Yield:
69%.
Melting point: 123 - 125 C. (Ethyl acetate-hexane).
'H - NMR (CDC13) 6 : 3.09 (2H, t, J = 7.2 Hz), 3.76 (3H, s), 4.59 (2H, t, J =
7.2 Hz), 6.69 - 6.79 (2H, m), 6.86 (2H, d, J = 2.4 Hz), 6.90 (1 H, d, J = 7.5 Hz), 7.05 (1 H, br s), 7.19(i1-1,t,J=7.8Hz),7.32(1H,d,J=7.8Hz),7.56-7.66(2H,m),7.98(1H,d,J=
7.5 Hz), 8.31 (i H, d, J = 7.5 Hz), 8.61 (1 H, s), I H unconfirmed.
Working Example 74 3 -(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N- 1,3 -thiazol-2-ylbenzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 1,3-thiazole-2-amine in the same manner as in Working Example 55. Yield:
69%.
Melting point: 123 - 125 C. (Ethyl acetate-hexane).
'H - NMR (CDC13) 6 : 3.09 (2H, t, J = 7.2 Hz), 3.76 (3H, s), 4.59 (2H, t, J =
7.2 Hz), 6.69 - 6.79 (2H, m), 6.86 (2H, d, J = 2.4 Hz), 6.90 (1 H, d, J = 7.5 Hz), 7.05 (1 H, br s), 7.19(i1-1,t,J=7.8Hz),7.32(1H,d,J=7.8Hz),7.56-7.66(2H,m),7.98(1H,d,J=
7.5 Hz), 8.31 (i H, d, J = 7.5 Hz), 8.61 (1 H, s), I H unconfirmed.
[0252]
Working Example 75 N-(6-Fluoropyridin-3-yl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 6-fluoropyridine-3-amine in the same manner as in Working Example 55.
Yield:
68%. Melting point: 127 - 128 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 8 : 3.13 (2H, t, J = 6.9 Hz), 3.77 (3H, s), 4.66 (2H, t, J =
6.9 Hz), 6.70 - 6.78 (2H, m), 6.86 - 6.93 (2H, m), 6.97 (1 H, dd, J = 8.7, 2.2 Hz), 7.21 (1 H, t, J =
7.8 Hz), 7.3 8 (1 H, d, J = 7.2 Hz), 7.5 8 (1 H, t, J = 7.8 Hz), 7.66 (1 H, t, J = 7.8 Hz), 7.8 8 (1 H, t, J = 7.8 Hz), 8.00 (1 H, br s), 8.16 - 8.22 (1 H, m), 8.30 - 8.35 (2H, m), 8.49 (1 H, t, J = 1.5 Hz).
Working Example 75 N-(6-Fluoropyridin-3-yl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 6-fluoropyridine-3-amine in the same manner as in Working Example 55.
Yield:
68%. Melting point: 127 - 128 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 8 : 3.13 (2H, t, J = 6.9 Hz), 3.77 (3H, s), 4.66 (2H, t, J =
6.9 Hz), 6.70 - 6.78 (2H, m), 6.86 - 6.93 (2H, m), 6.97 (1 H, dd, J = 8.7, 2.2 Hz), 7.21 (1 H, t, J =
7.8 Hz), 7.3 8 (1 H, d, J = 7.2 Hz), 7.5 8 (1 H, t, J = 7.8 Hz), 7.66 (1 H, t, J = 7.8 Hz), 7.8 8 (1 H, t, J = 7.8 Hz), 8.00 (1 H, br s), 8.16 - 8.22 (1 H, m), 8.30 - 8.35 (2H, m), 8.49 (1 H, t, J = 1.5 Hz).
[0253]
Working Example 76 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-pyridin-2-ylbenzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-aminopyridine in the same manner as in Working Example 55. Yield: 71%.
Oily substance.
'H-NMR(CDC13)6:3.13(2H,t,J=7.2Hz),3.79(3H,s), 4.67 (2H, t, J = 7.2 Hz), 6.69 - 6.79 (2H, m), 6.87 (1 H, s), 6.92 (1 H, d, J = 7.5 Hz), 7.05 -7.12 (1 H, m), 7.21 (1 H, t, J = 8.4 Hz), 7.40 (1 H, d, J = 7.8 Hz), 7.5 8 (1 H, t, J = 7.8 Hz), 7.65 (1 H, t, J = 8.4 Hz), 7.78(1H,t,J=7.8Hz),7.92(1H,d,J=7.5Hz),8.25(11-1,d, J = 6.9Hz),8.30(11-1,d,J
= 4.2 Hz), 8.42 (1 H, d, J = 8.7 Hz), 8.5 5 (1 H, s), 8.77 (1 H, s).
Working Example 76 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-pyridin-2-ylbenzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 2-aminopyridine in the same manner as in Working Example 55. Yield: 71%.
Oily substance.
'H-NMR(CDC13)6:3.13(2H,t,J=7.2Hz),3.79(3H,s), 4.67 (2H, t, J = 7.2 Hz), 6.69 - 6.79 (2H, m), 6.87 (1 H, s), 6.92 (1 H, d, J = 7.5 Hz), 7.05 -7.12 (1 H, m), 7.21 (1 H, t, J = 8.4 Hz), 7.40 (1 H, d, J = 7.8 Hz), 7.5 8 (1 H, t, J = 7.8 Hz), 7.65 (1 H, t, J = 8.4 Hz), 7.78(1H,t,J=7.8Hz),7.92(1H,d,J=7.5Hz),8.25(11-1,d, J = 6.9Hz),8.30(11-1,d,J
= 4.2 Hz), 8.42 (1 H, d, J = 8.7 Hz), 8.5 5 (1 H, s), 8.77 (1 H, s).
[0254]
Working Example 77 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(3-methylisothiazol-5-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 3-methylisothiazole-5-amine in the same manner as in Working Example 55.
Yield:
25%; melting point: 46 - 47 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.37 (3H, s), 3.08 (2H, t, J = 7.1 Hz), 3.73 (3H, s), 4.62 (2H, t, J = 7.1 Hz ), 6.75 - 6.87 (2H, m), 6.89 - 6.98 (3H, m), 7.16 - 7.26 (1H, m), 7.65 - 7.76 (2H, m), 7.86 (1 H, t, J = 7.8 Hz), 8.08 (1 H, d, J = 7.8 Hz), 8.3 5 (1 H, d, J = 7.8 Hz), 8.71 (1H, s), 12.37 (1H, s).
Working Example 77 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(3-methylisothiazol-5-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 3-methylisothiazole-5-amine in the same manner as in Working Example 55.
Yield:
25%; melting point: 46 - 47 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.37 (3H, s), 3.08 (2H, t, J = 7.1 Hz), 3.73 (3H, s), 4.62 (2H, t, J = 7.1 Hz ), 6.75 - 6.87 (2H, m), 6.89 - 6.98 (3H, m), 7.16 - 7.26 (1H, m), 7.65 - 7.76 (2H, m), 7.86 (1 H, t, J = 7.8 Hz), 8.08 (1 H, d, J = 7.8 Hz), 8.3 5 (1 H, d, J = 7.8 Hz), 8.71 (1H, s), 12.37 (1H, s).
[0255]
Working Example 78 3-(6-(2-(3 -Methoxyphenyl)ethoxy)pyridin-2-yl)-N- 1,3,4-thiadiazol-2-ylbenzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 1,3,4-thiadiazole-2-amine in the same manner as in Working Example 55.
Yield:
65%; melting point: 141 - 142 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6) 8: 3.08 (2H, t, J = 6.9 Hz), 3.73 (3H, s), 4.62 (2H, t, J =
6.9 Hz ), 6.75 - 6.87 (2H, m), 6.88 - 6.98 (2H, m), 7.22 (1 H, t, J = 7.9 Hz), 7.64 -7.77 (2H, m), 7.86 (1 H, t, J = 7.9 Hz), 8.16 (1 H, d, J = 7.9 Hz), 8.39 (1 H, d, J = 7.9 Hz), 8.82 (1 H, s), 9.26 (1 H, s), 13.23 (1 H, br s).
Working Example 78 3-(6-(2-(3 -Methoxyphenyl)ethoxy)pyridin-2-yl)-N- 1,3,4-thiadiazol-2-ylbenzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 1,3,4-thiadiazole-2-amine in the same manner as in Working Example 55.
Yield:
65%; melting point: 141 - 142 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6) 8: 3.08 (2H, t, J = 6.9 Hz), 3.73 (3H, s), 4.62 (2H, t, J =
6.9 Hz ), 6.75 - 6.87 (2H, m), 6.88 - 6.98 (2H, m), 7.22 (1 H, t, J = 7.9 Hz), 7.64 -7.77 (2H, m), 7.86 (1 H, t, J = 7.9 Hz), 8.16 (1 H, d, J = 7.9 Hz), 8.39 (1 H, d, J = 7.9 Hz), 8.82 (1 H, s), 9.26 (1 H, s), 13.23 (1 H, br s).
[0256]
Working Example 79 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(3-methyl-1 H-pyrazol-5-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 3-methyl-lH-pyrazole-5-amine in the same manner as in Working Example 55.
Yield: 36%; melting point: 112 - 113 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.25 (3H, s), 3.08 (2H, t, J = 7.0 Hz), 3.73 (3H, s), 4.61 (2H, t, J = 7.0 Hz ), 6.44 (1 H, br s), 6.73 - 6.84 (2H, m), 6.86 - 6.97 (2H, m), 7.22 (1 H, t, J =
8.0 Hz), 7.60 (1 H, t, J = 7.7 Hz), 7.67 - 7.76 (1 H, m), 7.83 (1 H, t, J =
7.7 Hz), 8.03 (1 H, d, J = 7.7 Hz), 8.28 (1 H, d, J = 8.0 Hz), 8.66 (1 H, s), 10.86 (1 H, s), 12.13 (1 H, br s).
Working Example 79 3-(6-(2-(3-Methoxyphenyl)ethoxy)pyridin-2-yl)-N-(3-methyl-1 H-pyrazol-5-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 3-methyl-lH-pyrazole-5-amine in the same manner as in Working Example 55.
Yield: 36%; melting point: 112 - 113 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.25 (3H, s), 3.08 (2H, t, J = 7.0 Hz), 3.73 (3H, s), 4.61 (2H, t, J = 7.0 Hz ), 6.44 (1 H, br s), 6.73 - 6.84 (2H, m), 6.86 - 6.97 (2H, m), 7.22 (1 H, t, J =
8.0 Hz), 7.60 (1 H, t, J = 7.7 Hz), 7.67 - 7.76 (1 H, m), 7.83 (1 H, t, J =
7.7 Hz), 8.03 (1 H, d, J = 7.7 Hz), 8.28 (1 H, d, J = 8.0 Hz), 8.66 (1 H, s), 10.86 (1 H, s), 12.13 (1 H, br s).
[0257]
Working Example 80 N-(1,3-Dimethyl-1 H-pyrazol-5-yl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 1,3-dimethyl-lH-pyrazole-5-amine in the same manner as in Working Example 55.
Yield: 68%; melting point: 141 - 142 C (ethyl acetate-hexane).
1 H-NMR (DMSO-d6) 6: 2.14 (3H, s), 3.08 (2H, t, J = 7.0 Hz), 3.61 (3H, s), 3.73 (3H, s), 4.61 (2H, t, J = 7.0 Hz ), 6.06 (1 H, s), 6.74 - 6.85 (2H, m), 6.87 - 6.96 (2H, m), 7.16 - 7.26 (1 H, m), 7.60 - 7.71 (2H, m), 7.84 (1 H, t, J = 7.8 Hz), 8.00 (1 H, d, J = 7.8 Hz), 8.32 (1 H, d, J = 7.8 Hz), 8.64 (1 H, s), 10.39 (1 H, s).
Working Example 80 N-(1,3-Dimethyl-1 H-pyrazol-5-yl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example and 1,3-dimethyl-lH-pyrazole-5-amine in the same manner as in Working Example 55.
Yield: 68%; melting point: 141 - 142 C (ethyl acetate-hexane).
1 H-NMR (DMSO-d6) 6: 2.14 (3H, s), 3.08 (2H, t, J = 7.0 Hz), 3.61 (3H, s), 3.73 (3H, s), 4.61 (2H, t, J = 7.0 Hz ), 6.06 (1 H, s), 6.74 - 6.85 (2H, m), 6.87 - 6.96 (2H, m), 7.16 - 7.26 (1 H, m), 7.60 - 7.71 (2H, m), 7.84 (1 H, t, J = 7.8 Hz), 8.00 (1 H, d, J = 7.8 Hz), 8.32 (1 H, d, J = 7.8 Hz), 8.64 (1 H, s), 10.39 (1 H, s).
[0258]
Working Example 81 N-(2-Aminoethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide hydrochloride 4 N hydrogen chloride/ethyl acetate were added to an ethyl acetate (10 mL) solution of tert-butyl (2-((3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoyl)amino)ethyl)carbamate (220 mg, 0.45 mmol) obtained in Working Example 72, and the mixture was stirred for 5 hours at 30 C. The reaction solution was concentrated and recrystallized from methanol-diethyl ether to give 100 mg of the titled compound (yield: 52%). Melting point: 161 - 162 C (methanol-diethyl ether).
' H-NMR (DMSO-d6 ):8 2.95 - 3.13 (4H, m), 3.57 (2H, q, J = 5.8 Hz), 3.74 (3H, s), 4.60 (2H, t, J = 7.0 Hz), 6.80 (2H, d, J = 8.0 Hz), 6.89 - 6.97 (2H, m), 7.23 (1 H, t, J = 8.0 Hz), 7.6 0 (1 H, t, J = 7.8 Hz), 7.6 8 (1 H, d, J = 7.6 Hz), 7.8 2 (1 H, t, J
= 7.8 Hz), 7.9 6 (1 H, d, J = 7.6 Hz), 8.06 (3H, br s), 8.26 (1 H, d, J = 8.0 Hz), 8.59 (1 H, s), 8.92 (1 H, t, J
= 5.1 Hz).
Working Example 81 N-(2-Aminoethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide hydrochloride 4 N hydrogen chloride/ethyl acetate were added to an ethyl acetate (10 mL) solution of tert-butyl (2-((3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzoyl)amino)ethyl)carbamate (220 mg, 0.45 mmol) obtained in Working Example 72, and the mixture was stirred for 5 hours at 30 C. The reaction solution was concentrated and recrystallized from methanol-diethyl ether to give 100 mg of the titled compound (yield: 52%). Melting point: 161 - 162 C (methanol-diethyl ether).
' H-NMR (DMSO-d6 ):8 2.95 - 3.13 (4H, m), 3.57 (2H, q, J = 5.8 Hz), 3.74 (3H, s), 4.60 (2H, t, J = 7.0 Hz), 6.80 (2H, d, J = 8.0 Hz), 6.89 - 6.97 (2H, m), 7.23 (1 H, t, J = 8.0 Hz), 7.6 0 (1 H, t, J = 7.8 Hz), 7.6 8 (1 H, d, J = 7.6 Hz), 7.8 2 (1 H, t, J
= 7.8 Hz), 7.9 6 (1 H, d, J = 7.6 Hz), 8.06 (3H, br s), 8.26 (1 H, d, J = 8.0 Hz), 8.59 (1 H, s), 8.92 (1 H, t, J
= 5.1 Hz).
[0259]
Working Example 82 3-(6-(3,4-Dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(3,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 41 and 2-pyrrolidin-1-ylethanamine in the same manner as in Working Example 2. Yield: 64%. Melting point: 114 - 115 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 1.70 - 1.90 (4H, m), 2.46-2.62 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.57 (2H, q, J = 6.0 Hz), 6.78 (1 H, br s), 6.88 (1 H, d, J = 8.1 Hz), 7.00 (1 H, dd, J = 9.0, 3.0 Hz), 7.37 - 7.51 (3H, m), 7.58 (1H, d, J = 6.9 Hz), 7.73 - 7.80 (2H, m), 7.98 - 8.03 (1 H, m), 8.29 (1 H, s).
Working Example 82 3-(6-(3,4-Dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(3,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 41 and 2-pyrrolidin-1-ylethanamine in the same manner as in Working Example 2. Yield: 64%. Melting point: 114 - 115 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 1.70 - 1.90 (4H, m), 2.46-2.62 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.57 (2H, q, J = 6.0 Hz), 6.78 (1 H, br s), 6.88 (1 H, d, J = 8.1 Hz), 7.00 (1 H, dd, J = 9.0, 3.0 Hz), 7.37 - 7.51 (3H, m), 7.58 (1H, d, J = 6.9 Hz), 7.73 - 7.80 (2H, m), 7.98 - 8.03 (1 H, m), 8.29 (1 H, s).
[0260]
Working Example 83 3-(6-(2,3-Dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2,3-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 40 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2. Yield: 64%. Melting point: 118 - 119 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 1.70 - 1.89 (4H, m), 2.42 - 2.62 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.56 (2H, q, J = 6.0 Hz), 6.73 (1 H, br s), 6.91 (1 H, d, J = 8.4 Hz), 7.18-7.31 (2H, m), 7.37 (1 H, dd, J = 7.8, 2.1 Hz), 7.44 (1 H, t, J = 7.8 Hz), 7.55 (1 H, t, J = 7.5 Hz), 7.75 (I H, d, J = 8.1 Hz), 7.80 (1 H, t, J = 7.8 Hz), 7.93 (1 H, d, J = 8.1 Hz), 8.23 (1 H, s).
Working Example 83 3-(6-(2,3-Dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2,3-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 40 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2. Yield: 64%. Melting point: 118 - 119 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 1.70 - 1.89 (4H, m), 2.42 - 2.62 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.56 (2H, q, J = 6.0 Hz), 6.73 (1 H, br s), 6.91 (1 H, d, J = 8.4 Hz), 7.18-7.31 (2H, m), 7.37 (1 H, dd, J = 7.8, 2.1 Hz), 7.44 (1 H, t, J = 7.8 Hz), 7.55 (1 H, t, J = 7.5 Hz), 7.75 (I H, d, J = 8.1 Hz), 7.80 (1 H, t, J = 7.8 Hz), 7.93 (1 H, d, J = 8.1 Hz), 8.23 (1 H, s).
[0261]
Working Example 84 3-(6-(3,5 -Dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- I -ylethyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2. Yield: 56%. Melting point: 111 - 112 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 1.70 - 1.90 (4H, m), 2.47 - 2.61 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.57 (2H, q, J = 6.0 Hz), 6.77 (1 H, br s), 6.89 (1 H, d, J = 7.8 Hz), 7.15-7.22 (3H, m), 7.48 (1 H, t, J = 7.5 Hz), 7.60 (1 H, d, J = 7.5 Hz), 7.76 - 7.85 (2H, m), 8.02 (1 H, d, J
= 7.8 Hz), 8.29 (1 H, s).
Working Example 84 3-(6-(3,5 -Dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- I -ylethyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 2-pyrrolidin-l-ylethanamine in the same manner as in Working Example 2. Yield: 56%. Melting point: 111 - 112 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6 : 1.70 - 1.90 (4H, m), 2.47 - 2.61 (4H, m), 2.71 (2H, t, J =
6.0 Hz), 3.57 (2H, q, J = 6.0 Hz), 6.77 (1 H, br s), 6.89 (1 H, d, J = 7.8 Hz), 7.15-7.22 (3H, m), 7.48 (1 H, t, J = 7.5 Hz), 7.60 (1 H, d, J = 7.5 Hz), 7.76 - 7.85 (2H, m), 8.02 (1 H, d, J
= 7.8 Hz), 8.29 (1 H, s).
[0262]
Working Example 85 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and 2-pyrrolidin-1-ylethanamine in the same manner as in Working Example 2. Yield: 33%. Melting point: 125 - 126 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) b : 1.74 - 1.83 (4H, m), 2.51 - 2.61 (4H, m), 2.71 (2H, t, J =
6.3 Hz), 3.57 (2H, q, J = 6.3 Hz), 6.76 (111, br s), 6.90 (111, d, J = 8.1 Hz), 7.23-7.32 (2H, m), 7.40 - 7.56 (3H, m), 7.71 - 7.82 (2H, m), 7.93 (1H, dd, J = 6.6, 1.5 Hz), 8.24 (1H, t, J = 1.5 Hz).
Working Example 85 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin- l -ylethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and 2-pyrrolidin-1-ylethanamine in the same manner as in Working Example 2. Yield: 33%. Melting point: 125 - 126 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) b : 1.74 - 1.83 (4H, m), 2.51 - 2.61 (4H, m), 2.71 (2H, t, J =
6.3 Hz), 3.57 (2H, q, J = 6.3 Hz), 6.76 (111, br s), 6.90 (111, d, J = 8.1 Hz), 7.23-7.32 (2H, m), 7.40 - 7.56 (3H, m), 7.71 - 7.82 (2H, m), 7.93 (1H, dd, J = 6.6, 1.5 Hz), 8.24 (1H, t, J = 1.5 Hz).
[0263]
Working Example 86 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and tetrahydro-2H-pyran-4-amine in the same manner as in Working Example 2. Yield: 74%. Melting point: 193 - 194 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.47 - 1.65 (2H, m), 1.96 - 2.07 (2H, m), 3.50 - 3.59 (2H, m), 3.96 - 4.05 (2H, m), 4.09 - 4.27 (1 H, m), 5.96 (1 H, t, J = 7.8 Hz), 6.92 (1 H, d, J = 8.4 Hz), 7.21 - 7.33 (2H, m), 7.42 - 7.56 (3H, m), 7.76 - 7.83 (2H, m), 7.94 (1H, d, J = 7.8 Hz), 8.15 (1 H, s).
Working Example 86 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and tetrahydro-2H-pyran-4-amine in the same manner as in Working Example 2. Yield: 74%. Melting point: 193 - 194 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.47 - 1.65 (2H, m), 1.96 - 2.07 (2H, m), 3.50 - 3.59 (2H, m), 3.96 - 4.05 (2H, m), 4.09 - 4.27 (1 H, m), 5.96 (1 H, t, J = 7.8 Hz), 6.92 (1 H, d, J = 8.4 Hz), 7.21 - 7.33 (2H, m), 7.42 - 7.56 (3H, m), 7.76 - 7.83 (2H, m), 7.94 (1H, d, J = 7.8 Hz), 8.15 (1 H, s).
[0264]
Working Example 87 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 15%. Melting point: 163 - 164 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 2.60 - 2.70 (1H, m), 3.65 (2H, q, J = 5.4 Hz), 3.85 (2H, q, J = 5.4 Hz),6.60-6.70(1H,m),6.90(1H,d,J=8.4Hz),7.17-7.26(3H,m),7.50(1H,t,J
7.5 Hz), 7.58 (1 H, d, J = 7.2 Hz), 7.77 - 7.86 (2H, m), 8.02 (1 H, d, J = 7.8 Hz), 8.27 (1 H, s).
Working Example 87 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 15%. Melting point: 163 - 164 C. (Ethyl acetate-hexane).
'H-NMR (CDC13) 6: 2.60 - 2.70 (1H, m), 3.65 (2H, q, J = 5.4 Hz), 3.85 (2H, q, J = 5.4 Hz),6.60-6.70(1H,m),6.90(1H,d,J=8.4Hz),7.17-7.26(3H,m),7.50(1H,t,J
7.5 Hz), 7.58 (1 H, d, J = 7.2 Hz), 7.77 - 7.86 (2H, m), 8.02 (1 H, d, J = 7.8 Hz), 8.27 (1 H, s).
[0265]
Working Example 88 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(3-hydroxypropyl)benzamide 3-aminopropan-l-ol (90 mg, 1.2 mmol) and DMTMM (324 mg, 1.1 mmol) were added to a 3-methanol (5 mL) solution of 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid (0.355 g, 0.97 mmol) obtained in Reference Example 39, and the mixture was stirred for 3 hours at room temperature. The solvent was distilled off at reduced pressure, ethyl acetate was added to the residue, the solution was washed with water and with saturated brine, and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate 80:20 -* 0:100) and was recrystallized from ethyl acetate-hexane to give 0.27 g of the titled compound (yield 81 %).
Melting point: 101 - 102 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.81 (2H, quint, J = 5.7 Hz), 3.20 (1H, br s), 3.65 (2H, q, J = 5.7 Hz), 3.71 (2H, q, J = 5.4 Hz), 6.65 (1H, br s), 6.90 (1H, d, J = 8.1 Hz), 7.18 - 7.24 (3H, m), 7.50 (1H, t, J = 7.5 Hz), 7.59 (1H, d, J = 7.5 Hz), 7.78 - 7.87 (2H, m), 8.02 (1H, d, J
= 7.8 Hz), 8.27 (1 H, t, J = 1.8 Hz).
Working Example 88 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(3-hydroxypropyl)benzamide 3-aminopropan-l-ol (90 mg, 1.2 mmol) and DMTMM (324 mg, 1.1 mmol) were added to a 3-methanol (5 mL) solution of 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid (0.355 g, 0.97 mmol) obtained in Reference Example 39, and the mixture was stirred for 3 hours at room temperature. The solvent was distilled off at reduced pressure, ethyl acetate was added to the residue, the solution was washed with water and with saturated brine, and concentrated. The residue was purified by silica gel column chromatography (hexane-ethyl acetate 80:20 -* 0:100) and was recrystallized from ethyl acetate-hexane to give 0.27 g of the titled compound (yield 81 %).
Melting point: 101 - 102 C. (Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.81 (2H, quint, J = 5.7 Hz), 3.20 (1H, br s), 3.65 (2H, q, J = 5.7 Hz), 3.71 (2H, q, J = 5.4 Hz), 6.65 (1H, br s), 6.90 (1H, d, J = 8.1 Hz), 7.18 - 7.24 (3H, m), 7.50 (1H, t, J = 7.5 Hz), 7.59 (1H, d, J = 7.5 Hz), 7.78 - 7.87 (2H, m), 8.02 (1H, d, J
= 7.8 Hz), 8.27 (1 H, t, J = 1.8 Hz).
[0266]
Working Example 89 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2,3 -dihydroxypropyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 3-aminopropane-1,2-diol in the same manner as in Working Example 88. Yield: 60%. Melting point: 124 - 126 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.89 (2H, br s), 3.58 - 3.71 (4H, m), 3.81 - 3.92 (1H, m), 6.73 (114, br s), 6.90 (1 H, d, J = 8.1 Hz), 7.17 - 7.24 (3H, m), 7.51 (1 H, t, J =
7.8 Hz), 7.59 (1 H, d, J = 7.5 Hz), 7.78 - 7.86 (2H, m), 8.03 (111, d, J = 7.8 Hz), 8.28 (1 H, t, J = 1.5 Hz).
Working Example 89 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2,3 -dihydroxypropyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 3-aminopropane-1,2-diol in the same manner as in Working Example 88. Yield: 60%. Melting point: 124 - 126 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.89 (2H, br s), 3.58 - 3.71 (4H, m), 3.81 - 3.92 (1H, m), 6.73 (114, br s), 6.90 (1 H, d, J = 8.1 Hz), 7.17 - 7.24 (3H, m), 7.51 (1 H, t, J =
7.8 Hz), 7.59 (1 H, d, J = 7.5 Hz), 7.78 - 7.86 (2H, m), 8.03 (111, d, J = 7.8 Hz), 8.28 (1 H, t, J = 1.5 Hz).
[0267]
Working Example 90 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(6-fluoropyridin-3-yl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 6-fluoropyridine-3-amine in the same manner as in Working Example 55. Yield: 50%. Melting point: 179 - 180 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 6.92 (1 H, d, J = 8.4 Hz), 6.98 (1 H, dd, J = 8.4, 1.8 Hz), 7.18 (2H, d, J = 1.8 Hz), 7.20 (1 H, t, J = 1.8 Hz), 7.53 - 7.63 (2H, m), 7.84 (1 H, dt, J = 7.8, 0.9 Hz), 7.94 (1 H, d, J = 7.5 Hz), 8.01 (1 H, br s), 8.07 (1 H, d, J = 8.1 Hz), 8.26 - 8.40 (3H, m).
Working Example 90 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(6-fluoropyridin-3-yl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 6-fluoropyridine-3-amine in the same manner as in Working Example 55. Yield: 50%. Melting point: 179 - 180 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) 6 : 6.92 (1 H, d, J = 8.4 Hz), 6.98 (1 H, dd, J = 8.4, 1.8 Hz), 7.18 (2H, d, J = 1.8 Hz), 7.20 (1 H, t, J = 1.8 Hz), 7.53 - 7.63 (2H, m), 7.84 (1 H, dt, J = 7.8, 0.9 Hz), 7.94 (1 H, d, J = 7.5 Hz), 8.01 (1 H, br s), 8.07 (1 H, d, J = 8.1 Hz), 8.26 - 8.40 (3H, m).
[0268]
Working Example 91 3 -(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxy- 1, 1 -dimethylethyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 2-amino -2-methylpropan-l-ol in the same manner as in Working Example 88. Yield: 39%. Melting point: 155 - 156 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.42 (6H, s), 3.71 (2H, d, J = 5.7 Hz), 4.72 (1 H, t, J =
5.7 Hz), 6.17(1H,brs),6.91(1H,d,J=8.1Hz),7.16(2H,d,J=1.5Hz), 7.21(1H,t,J=1.5 Hz), 7.49 (1 H, t, J = 7.5 Hz), 7.58 (1 H, d, J = 7.5 Hz), 7.74 - 7.85 (2H, m), 8.01 (1 H, d, J = 7.8 Hz), 8.19 (1 H, t, J = 1. 8 Hz).
Working Example 91 3 -(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxy- 1, 1 -dimethylethyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 2-amino -2-methylpropan-l-ol in the same manner as in Working Example 88. Yield: 39%. Melting point: 155 - 156 C.
(Ethyl acetate-hexane).
' H-NMR (CDC13) 6: 1.42 (6H, s), 3.71 (2H, d, J = 5.7 Hz), 4.72 (1 H, t, J =
5.7 Hz), 6.17(1H,brs),6.91(1H,d,J=8.1Hz),7.16(2H,d,J=1.5Hz), 7.21(1H,t,J=1.5 Hz), 7.49 (1 H, t, J = 7.5 Hz), 7.58 (1 H, d, J = 7.5 Hz), 7.74 - 7.85 (2H, m), 8.01 (1 H, d, J = 7.8 Hz), 8.19 (1 H, t, J = 1. 8 Hz).
[0269]
Working Example 92 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxy- l -(hydroxymethyl)ethyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 2-aminopropane-1,3-diol in the same manner as in Working Example 88. Yield: 61 %. Melting point: 150 - 151 C.
(Ethyl acetatt-hexane).
'H-NMR (CDC13) 6: 3.53 (4H, t, J = 5.7 Hz), 3.90 - 4.07 (1 H, m), 4.67 (2H, t, J = 5.7 Hz), 7.09 (1H, d, J = 7.8 Hz), 7.40 (2H, d, J = 2.1 Hz), 7.47 - 7.56 (2H, m), 7.85 - 7.91 (2H, m), 7.96 - 8.11 (3H, m), 8.38 (1H, s).
Working Example 92 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxy- l -(hydroxymethyl)ethyl)benzamide The titled compound was obtained using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 2-aminopropane-1,3-diol in the same manner as in Working Example 88. Yield: 61 %. Melting point: 150 - 151 C.
(Ethyl acetatt-hexane).
'H-NMR (CDC13) 6: 3.53 (4H, t, J = 5.7 Hz), 3.90 - 4.07 (1 H, m), 4.67 (2H, t, J = 5.7 Hz), 7.09 (1H, d, J = 7.8 Hz), 7.40 (2H, d, J = 2.1 Hz), 7.47 - 7.56 (2H, m), 7.85 - 7.91 (2H, m), 7.96 - 8.11 (3H, m), 8.38 (1H, s).
[0270]
Working Example 93 N-((1 S)-2-Cyano- l -methylethyl)-3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and (3S)-3-aminobutanenitrile in the same manner as in Working Example 2. Yield: 65%. Melting point: 160 - 161 C
(ethyl acetate-hexane).
'H-NMR (CDC13 ):6 1.49 (3H, d, J = 6.8 Hz), 2.63 - 2.73 (1H, m), 2.93 (1H, dd, J =
16.8, 5.9 Hz), 4.38 - 4.53 (1 H, m), 6.19 (1 H, d, J = 7.2 Hz), 6.91 (1 H, d, J = 8.0 Hz), 7.18(2H,d,J=1.9Hz),7.23(1H,t,J=1.9Hz),7.52(1H,t, J = 7.8 Hz), 7.60 (1 H, d, J
= 7.6 Hz), 7.78 - 7.87 (2H, m), 8.05 (1 H, d, J = 8.0 Hz), 8.24 (1 H, s).
Working Example 93 N-((1 S)-2-Cyano- l -methylethyl)-3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and (3S)-3-aminobutanenitrile in the same manner as in Working Example 2. Yield: 65%. Melting point: 160 - 161 C
(ethyl acetate-hexane).
'H-NMR (CDC13 ):6 1.49 (3H, d, J = 6.8 Hz), 2.63 - 2.73 (1H, m), 2.93 (1H, dd, J =
16.8, 5.9 Hz), 4.38 - 4.53 (1 H, m), 6.19 (1 H, d, J = 7.2 Hz), 6.91 (1 H, d, J = 8.0 Hz), 7.18(2H,d,J=1.9Hz),7.23(1H,t,J=1.9Hz),7.52(1H,t, J = 7.8 Hz), 7.60 (1 H, d, J
= 7.6 Hz), 7.78 - 7.87 (2H, m), 8.05 (1 H, d, J = 8.0 Hz), 8.24 (1 H, s).
[0271]
Working Example 94 N-((1 R)-2-Cyano-l -methylethyl)-3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and (3R)-3-aminobutanenitrile in the same manner as in Working Example 2. Yield: 79%. Melting point: 149 - 150 C
(ethyl acetate-hexane).
' H-NMR (CDC13 ):6 1.49 (3H, d, J = 7.2 Hz), 2.68 (H, dd, J = 16.7, 4.2 Hz), 2.93 (1 H, dd, J = 16.7, 6.1 Hz), 4.40 - 4.53 (I H, m), 6.19 (1 H, d, J = 6.8 Hz), 6.91 (1H,d,J=8.0 Hz), 7.18 (2H, d, J = 1.9 Hz), 7.23 (1 H, t, J = 1.7 Hz), 7.52 (1 H, t, J =
7.8 Hz), 7.60 (1 H, d, J = 7.6 Hz), 7.78 - 7.87 (2H, m), 8.05 (1 H, d, J = 8.0 Hz), 8.24 (1 H, s).
Working Example 94 N-((1 R)-2-Cyano-l -methylethyl)-3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and (3R)-3-aminobutanenitrile in the same manner as in Working Example 2. Yield: 79%. Melting point: 149 - 150 C
(ethyl acetate-hexane).
' H-NMR (CDC13 ):6 1.49 (3H, d, J = 7.2 Hz), 2.68 (H, dd, J = 16.7, 4.2 Hz), 2.93 (1 H, dd, J = 16.7, 6.1 Hz), 4.40 - 4.53 (I H, m), 6.19 (1 H, d, J = 6.8 Hz), 6.91 (1H,d,J=8.0 Hz), 7.18 (2H, d, J = 1.9 Hz), 7.23 (1 H, t, J = 1.7 Hz), 7.52 (1 H, t, J =
7.8 Hz), 7.60 (1 H, d, J = 7.6 Hz), 7.78 - 7.87 (2H, m), 8.05 (1 H, d, J = 8.0 Hz), 8.24 (1 H, s).
[0272]
Working Example 95 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-(methylthio)ethyl)benzamide The titled compound was obtained using methyl 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 30 in the same manner as in Working Example 2. Yield: 86%. Melting point: 123 - 124 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) S : 2.15 (3H, s), 2.77 (2H, t, J = 6.3 Hz), 3.69 (2H, q, J =
6.3 Hz), 6.60(1H,brs),6.90(1H,d,J=7.8Hz),7.18(2H,d,J= 1.8Hz),7.22(11-1,t,J= 1.8 Hz), 7.50 (1 H, t, J = 7.8 Hz), 7.59 (1 H, dd, J = 7.8, 0.6 Hz), 7.78 - 7.86 (2H, m), 7.99 -8.05 (1H, m), 8.27 (1H, t, J = 1.8 Hz).
Working Example 95 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-(methylthio)ethyl)benzamide The titled compound was obtained using methyl 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 30 in the same manner as in Working Example 2. Yield: 86%. Melting point: 123 - 124 C.
(Ethyl acetate-hexane).
'H-NMR (CDC13) S : 2.15 (3H, s), 2.77 (2H, t, J = 6.3 Hz), 3.69 (2H, q, J =
6.3 Hz), 6.60(1H,brs),6.90(1H,d,J=7.8Hz),7.18(2H,d,J= 1.8Hz),7.22(11-1,t,J= 1.8 Hz), 7.50 (1 H, t, J = 7.8 Hz), 7.59 (1 H, dd, J = 7.8, 0.6 Hz), 7.78 - 7.86 (2H, m), 7.99 -8.05 (1H, m), 8.27 (1H, t, J = 1.8 Hz).
[0273]
Working Example 96 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-(methylsulfinyl)ethyl)benzamide Meta-chloroperbenzoic acid (70% 114 mg, 0.462 mmol) was added at 0 C to a methylene chloride (5 mL) solution of 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-(methylthio)ethyl)benzamide (200 mg, 0.462 mmol) obtained in Working Example 95, and the mixture was stirred for 1 hour at 0 C. Saturated aqueous sodium bicarbonate was added to the reaction solution, and the mixture was extracted with methylene chloride. The extract was washed with water, dried over anhydrous magnesium sulfate, and then passed through a small amount of silica gel to distill the solvent off at reduced pressure. The resulting residue was crystallized from ethyl acetate-hexane to give 120 mg of the titled compound in the form of crystals (yield 58%). Melting point:
159 C.
' H-NMR (CDC13) S : 2.67 (3H, s), 2.83 - 2.97 (1H, m), 3.13- 3.23 (1H, m), 4.02 (2H, q,J=5.7Hz),6.89(1H,d,J=7.8Hz),7.15-7.18(2H,m),7.22(IH,t,J=2.1Hz), 7.39 (1 H, br s), 7.48 (1 H, t, J = 7.8 Hz), 7.59 (1 H, d, J = 7.5 Hz), 7.77 -7.84 (2H, m), 8.04 (1 H, d, J = 7.8 Hz), 8.29 (1 H, t, J = 2.1 Hz).
Working Example 96 3-(6-(3,5-Dichlorophenoxy)pyridin-2-yl)-N-(2-(methylsulfinyl)ethyl)benzamide Meta-chloroperbenzoic acid (70% 114 mg, 0.462 mmol) was added at 0 C to a methylene chloride (5 mL) solution of 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-(methylthio)ethyl)benzamide (200 mg, 0.462 mmol) obtained in Working Example 95, and the mixture was stirred for 1 hour at 0 C. Saturated aqueous sodium bicarbonate was added to the reaction solution, and the mixture was extracted with methylene chloride. The extract was washed with water, dried over anhydrous magnesium sulfate, and then passed through a small amount of silica gel to distill the solvent off at reduced pressure. The resulting residue was crystallized from ethyl acetate-hexane to give 120 mg of the titled compound in the form of crystals (yield 58%). Melting point:
159 C.
' H-NMR (CDC13) S : 2.67 (3H, s), 2.83 - 2.97 (1H, m), 3.13- 3.23 (1H, m), 4.02 (2H, q,J=5.7Hz),6.89(1H,d,J=7.8Hz),7.15-7.18(2H,m),7.22(IH,t,J=2.1Hz), 7.39 (1 H, br s), 7.48 (1 H, t, J = 7.8 Hz), 7.59 (1 H, d, J = 7.5 Hz), 7.77 -7.84 (2H, m), 8.04 (1 H, d, J = 7.8 Hz), 8.29 (1 H, t, J = 2.1 Hz).
[0274]
Working Example 97 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(3-hydroxy-3-methylbutyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and 4-amino-2-methylbutan-2-ol in the same manner as in Working Example 2. Yield: 55%. Melting point: 139 - 140 C
(ethyl acetate-hexane).
1 H-NMR (DMSO-d6) 6: 1.15 (6H, s), 1.60 - 1.70 (2H, m), 3.28 - 3.41 (2H, m), 4.35 (1H,s),7.11 (1H,d,J=8.0Hz),7.41 -7.57(3H,m),7.75-7.84(3H,m),7.89(IH,d, J = 8.0 Hz), 8.02 (1 H, t, J = 8.0 Hz), 8.29 (1 H, s), 8.46 (1 H, t, J = 5.3 Hz).
Working Example 97 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(3-hydroxy-3-methylbutyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and 4-amino-2-methylbutan-2-ol in the same manner as in Working Example 2. Yield: 55%. Melting point: 139 - 140 C
(ethyl acetate-hexane).
1 H-NMR (DMSO-d6) 6: 1.15 (6H, s), 1.60 - 1.70 (2H, m), 3.28 - 3.41 (2H, m), 4.35 (1H,s),7.11 (1H,d,J=8.0Hz),7.41 -7.57(3H,m),7.75-7.84(3H,m),7.89(IH,d, J = 8.0 Hz), 8.02 (1 H, t, J = 8.0 Hz), 8.29 (1 H, s), 8.46 (1 H, t, J = 5.3 Hz).
[0275]
Working Example 98 N-(Cyanomethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and aminoacetonitrile in the same manner as in Working Example 2. Yield: 81 %. Melting point: 165 - 166 C
(tetrahydrofuran-hexane).
'H-NMR (DMSO-d6) 6: 4.35 (2H, d, J = 5.7 Hz), 7.12 (1 H, d, J = 8.3 Hz), 7.42 -7.60 (3H, m), 7.78 - 7.91 (3H, m), 7.93 - 8.07 (2H, m), 8.37 (iH, s), 9.30 (1H, t, J = 5.7 Hz).
Working Example 98 N-(Cyanomethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and aminoacetonitrile in the same manner as in Working Example 2. Yield: 81 %. Melting point: 165 - 166 C
(tetrahydrofuran-hexane).
'H-NMR (DMSO-d6) 6: 4.35 (2H, d, J = 5.7 Hz), 7.12 (1 H, d, J = 8.3 Hz), 7.42 -7.60 (3H, m), 7.78 - 7.91 (3H, m), 7.93 - 8.07 (2H, m), 8.37 (iH, s), 9.30 (1H, t, J = 5.7 Hz).
[0276]
Working Example 99 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(3,3,3-trifluoropropyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and 3,3,3-trifluoropropan-l-amine in the same manner as in Working Example 2. Yield: 50%; melting point: 169 - 170 C
(ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.50 - 2.66 (2H, m), 3.46 - 3.56 (21-1, m), 7.11 (1H, d, J
= 8.0 Hz), 7.41 - 7.58 (3H, m), 7.76 - 7.86 (3H, m), 7.93 (1H, d, J = 8.0 Hz), 8.02 (1H, t, J =
8.0 Hz), 8.3 0 (1 H, s), 8.76 (1 H, t, J = 5.5 Hz).
Working Example 99 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(3,3,3-trifluoropropyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 38 and 3,3,3-trifluoropropan-l-amine in the same manner as in Working Example 2. Yield: 50%; melting point: 169 - 170 C
(ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.50 - 2.66 (2H, m), 3.46 - 3.56 (21-1, m), 7.11 (1H, d, J
= 8.0 Hz), 7.41 - 7.58 (3H, m), 7.76 - 7.86 (3H, m), 7.93 (1H, d, J = 8.0 Hz), 8.02 (1H, t, J =
8.0 Hz), 8.3 0 (1 H, s), 8.76 (1 H, t, J = 5.5 Hz).
[0277]
Working Example 100 N-(2-Cyanoethyl)-3 -(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorophenyl)thio)pyridin-yl)benzoic acid obtained in Reference Example 77 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 56%. Melting point: 161 - 162 C
(ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.81 (2H, t, J = 6.5 Hz), 3.54 (2H, q, J = 6.5 Hz), 7.03 -7.11 (1 H, m), 7.52 - 7.61(2H, m), 7.76 - 7.93 (5H, m), 8.02 - 8.10 (1 H, m), 8.41 (1 H, br s), 8.91 - 9.00 (1 H, m).
Working Example 100 N-(2-Cyanoethyl)-3 -(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorophenyl)thio)pyridin-yl)benzoic acid obtained in Reference Example 77 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 56%. Melting point: 161 - 162 C
(ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.81 (2H, t, J = 6.5 Hz), 3.54 (2H, q, J = 6.5 Hz), 7.03 -7.11 (1 H, m), 7.52 - 7.61(2H, m), 7.76 - 7.93 (5H, m), 8.02 - 8.10 (1 H, m), 8.41 (1 H, br s), 8.91 - 9.00 (1 H, m).
[0278]
Working Example 101 3-(6-(2,4-Dichlorophenyl)thio)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorophenyl)thio)pyridin-yl)benzoic acid obtained in Reference Example 77 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 62%. Melting point: 117 - 118 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.32 - 3.41 (2H, m), 3.54 (2H, q, J = 5.9 Hz), 4.75 (1H, t, J =
5.9 Hz), 7.07 (1H, dd, J = 6.7, 1.8 Hz), 7.49 - 7.61 (21-1, m), 7.75 - 7.93 (5H, m), 7.99 - 8.07 (1 H, m), 8.41 (1 H, br s), 8.51 - 8.61 (1 H, m).
Working Example 101 3-(6-(2,4-Dichlorophenyl)thio)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorophenyl)thio)pyridin-yl)benzoic acid obtained in Reference Example 77 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 62%. Melting point: 117 - 118 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.32 - 3.41 (2H, m), 3.54 (2H, q, J = 5.9 Hz), 4.75 (1H, t, J =
5.9 Hz), 7.07 (1H, dd, J = 6.7, 1.8 Hz), 7.49 - 7.61 (21-1, m), 7.75 - 7.93 (5H, m), 7.99 - 8.07 (1 H, m), 8.41 (1 H, br s), 8.51 - 8.61 (1 H, m).
[0279]
Working Example 102 1-(2-((2-(3,4-Dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-N-(2-(dimethylamino)ethyl)- 1 H-indole-5-carboxamide The titled compound was obtained using 1-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-1H-indole-5-carboxylic acid obtained in Reference Example 78 and N,N-dimethylethane-1,2-diamine in the same manner as in Working Example 2. Yield: 50%. Melting point: 140 - 141 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.19 (6H, s), 2.42 (2H, t, J = 6.8 Hz), 2.81 - 2.91 (2H, m), 3.34 - 3.43 (2H, m), 3.54 - 3.66 (21-1, m), 3.71 (61-1, s), 6.74 - 6.91 (41-1, m), 6.98 (1H, d, J = 5.7 Hz), 7.55 (1 H, br s), 7.76 (1 H, dd, J = 8.9, 1.7 Hz), 8.11 - 8.18 (2H, m), 8.29 -8.40 (2H, m), 8.60 - 8.92 (1 H, m).
Working Example 102 1-(2-((2-(3,4-Dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-N-(2-(dimethylamino)ethyl)- 1 H-indole-5-carboxamide The titled compound was obtained using 1-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)-1H-indole-5-carboxylic acid obtained in Reference Example 78 and N,N-dimethylethane-1,2-diamine in the same manner as in Working Example 2. Yield: 50%. Melting point: 140 - 141 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.19 (6H, s), 2.42 (2H, t, J = 6.8 Hz), 2.81 - 2.91 (2H, m), 3.34 - 3.43 (2H, m), 3.54 - 3.66 (21-1, m), 3.71 (61-1, s), 6.74 - 6.91 (41-1, m), 6.98 (1H, d, J = 5.7 Hz), 7.55 (1 H, br s), 7.76 (1 H, dd, J = 8.9, 1.7 Hz), 8.11 - 8.18 (2H, m), 8.29 -8.40 (2H, m), 8.60 - 8.92 (1 H, m).
[0280]
Working Example 103 N-(2-Cyanoethyl)-3 -(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzoic acid obtained in Reference Example 79 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 88%. Melting point: 137 - 138 C
(ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.81 (2H, t, J = 6.4 Hz), 3.54 (2H, q, J = 6.4 Hz), 7.02 -7.08 (114, m), 7.37 - 7.51(2H, m), 7.54 - 7.65 (2H, m), 7.70 - 7.79 (1 H, m), 7.87 (114, d, J =
7.7 Hz), 8.16 (1 H, d, J = 7.7 Hz), 8.26 (1 H, d, J = 8.9 Hz), 8.46 (1 H, s), 8.64 (1 H, s), 8.95 (1 H, t, J = 5.7 Hz).
Working Example 103 N-(2-Cyanoethyl)-3 -(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzoic acid obtained in Reference Example 79 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 88%. Melting point: 137 - 138 C
(ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.81 (2H, t, J = 6.4 Hz), 3.54 (2H, q, J = 6.4 Hz), 7.02 -7.08 (114, m), 7.37 - 7.51(2H, m), 7.54 - 7.65 (2H, m), 7.70 - 7.79 (1 H, m), 7.87 (114, d, J =
7.7 Hz), 8.16 (1 H, d, J = 7.7 Hz), 8.26 (1 H, d, J = 8.9 Hz), 8.46 (1 H, s), 8.64 (1 H, s), 8.95 (1 H, t, J = 5.7 Hz).
[0281]
Working Example 104 3-(6-((2,4-Dichlorophenyl)amino)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzoic acid obtained in Reference Example 79 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 71 %. Melting point: 131 - 132 C
(tetrahydrofuran-hexane).
'H-NMR (DMSO-d6) 6: 3.33 - 3.41 (2H, m), 3.54 (2H, q, J = 5.9 Hz), 4.75 (1 H, t, J =
5.9 Hz ), 7.04 (1 H, d, J = 8.3 Hz), 7.41 (1 H, dd, J = 8.9, 2.5 Hz), 7.47 -7.5 8 (2H, m), 7.63 (1 H, d, J = 2.5 Hz), 7.75 (1 H, t, J = 8.3 Hz), 7.86 (1 H, d, J = 7.9 Hz ), 8.13 (1 H, d, J = 7.9 Hz ), 8.23 - 8.3 0 (1 H, m), 8.45 (1 H, s), 8.54 (1 H, t, J = 5.6 Hz), 8.63 (1 H, s).
Working Example 104 3-(6-((2,4-Dichlorophenyl)amino)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)benzoic acid obtained in Reference Example 79 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 71 %. Melting point: 131 - 132 C
(tetrahydrofuran-hexane).
'H-NMR (DMSO-d6) 6: 3.33 - 3.41 (2H, m), 3.54 (2H, q, J = 5.9 Hz), 4.75 (1 H, t, J =
5.9 Hz ), 7.04 (1 H, d, J = 8.3 Hz), 7.41 (1 H, dd, J = 8.9, 2.5 Hz), 7.47 -7.5 8 (2H, m), 7.63 (1 H, d, J = 2.5 Hz), 7.75 (1 H, t, J = 8.3 Hz), 7.86 (1 H, d, J = 7.9 Hz ), 8.13 (1 H, d, J = 7.9 Hz ), 8.23 - 8.3 0 (1 H, m), 8.45 (1 H, s), 8.54 (1 H, t, J = 5.6 Hz), 8.63 (1 H, s).
[0282]
Working Example 105 N-(2-Cyanoethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoic acid obtained in Reference Example 80 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 58%. Melting point: 139 - 140 C
(ethyl acetate-hexane).
' H-NMR (DMSO-d6) 8: 2.13 (3H, s), 2.76 (2H, t, J = 6.5 Hz ), 3.48 (2H, q, J =
6.5 Hz), 7.18(1H,d,J=8.1Hz),7.32(1H,d,J=8.1Hz),7.36-7.42(2H,m),7.44-7.50(1H, m),7.72-7.79(2H,m),7.83(1H,d,J1.7Hz),8.03(1H, t, J= 7.9Hz),8.83(1H,t, J = 5.6 Hz).
Working Example 105 N-(2-Cyanoethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoic acid obtained in Reference Example 80 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 58%. Melting point: 139 - 140 C
(ethyl acetate-hexane).
' H-NMR (DMSO-d6) 8: 2.13 (3H, s), 2.76 (2H, t, J = 6.5 Hz ), 3.48 (2H, q, J =
6.5 Hz), 7.18(1H,d,J=8.1Hz),7.32(1H,d,J=8.1Hz),7.36-7.42(2H,m),7.44-7.50(1H, m),7.72-7.79(2H,m),7.83(1H,d,J1.7Hz),8.03(1H, t, J= 7.9Hz),8.83(1H,t, J = 5.6 Hz).
[0283]
Working Example 106 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxyethyl)-4-methylbenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoic acid obtained in Reference Example 80 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 58%. Melting point: 159 - 160 C
(ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.11 (3H, s), 3.26 - 3.35 (2H, m), 3.49 (2H, q, J = 6.0 Hz), 4.70(1H,t,J=6.0Hz),7.17(1H,d,J=8.1 Hz), 7.29(1H,d,J=8.1 Hz), 7.36 - 7.42 (2H, m), 7.44 - 7.50 (1 H, m), 7.72 - 7.78 (2H, m), 7.83 (1 H, d, J = 1.7 Hz ), 8.03 (1 H, t, J = 7.8Hz), 8.43 (1 H, t, J = 5.6 Hz).
Working Example 106 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxyethyl)-4-methylbenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-methylbenzoic acid obtained in Reference Example 80 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 58%. Melting point: 159 - 160 C
(ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.11 (3H, s), 3.26 - 3.35 (2H, m), 3.49 (2H, q, J = 6.0 Hz), 4.70(1H,t,J=6.0Hz),7.17(1H,d,J=8.1 Hz), 7.29(1H,d,J=8.1 Hz), 7.36 - 7.42 (2H, m), 7.44 - 7.50 (1 H, m), 7.72 - 7.78 (2H, m), 7.83 (1 H, d, J = 1.7 Hz ), 8.03 (1 H, t, J = 7.8Hz), 8.43 (1 H, t, J = 5.6 Hz).
[0284]
Working Example 107 N-(2-Cyanoethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5-fluorobenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5-fluorobenzoic acid obtained in Reference Example 81 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 32%. Melting point: 173 - 174 C
(ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.79 (2H, t, J = 6.4 Hz ), 3.52 (2H, q, J = 6.4 Hz), 7.16 (1H, d, J = 8.0 Hz ), 7.44 - 7.57 (2H, m), 7.62 - 7.74 (2H, m), 7.80 - 7.89 (2H, m), 8.05 (1H, t, J = 8.0 Hz), 8.23 (1 H, s), 9.02 (1 H, t, J = 5.5 Hz).
Working Example 107 N-(2-Cyanoethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5-fluorobenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5-fluorobenzoic acid obtained in Reference Example 81 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 32%. Melting point: 173 - 174 C
(ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.79 (2H, t, J = 6.4 Hz ), 3.52 (2H, q, J = 6.4 Hz), 7.16 (1H, d, J = 8.0 Hz ), 7.44 - 7.57 (2H, m), 7.62 - 7.74 (2H, m), 7.80 - 7.89 (2H, m), 8.05 (1H, t, J = 8.0 Hz), 8.23 (1 H, s), 9.02 (1 H, t, J = 5.5 Hz).
[0285]
Working Example 108 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-5-fluoro-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5-fluorobenzoic acid obtained in Reference Example 81 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 69%. Melting point: 166 - 167 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.30 - 3.39 (2H, m); 3.53 (2H, q, J = 5.9 Hz), 4.75 (1H, t, J =
5.9Hz),7.15(1H,d,J=8.0Hz ),7.45-7.57(2H,m),7.66(2H,d,J=10.2Hz),7.81 - 7.91 (2H, m), 8.05 (1 H, t, J = 8.0 Hz ), 8.24 (1 H, s), 8.63 (1 H, t, J =
5.7 Hz).
Working Example 108 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-5-fluoro-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-5-fluorobenzoic acid obtained in Reference Example 81 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 69%. Melting point: 166 - 167 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.30 - 3.39 (2H, m); 3.53 (2H, q, J = 5.9 Hz), 4.75 (1H, t, J =
5.9Hz),7.15(1H,d,J=8.0Hz ),7.45-7.57(2H,m),7.66(2H,d,J=10.2Hz),7.81 - 7.91 (2H, m), 8.05 (1 H, t, J = 8.0 Hz ), 8.24 (1 H, s), 8.63 (1 H, t, J =
5.7 Hz).
[0286]
Working Example 109 N-(2-Cyanoethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoic acid obtained in Reference Example 82 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 82%. Melting point: 192 - 193 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 2.77 (21-1, t, J = 6.4 Hz), 3.44 - 3.54 (21-1, m), 7.16 (1H, d, J =
8.0 Hz ), 7.3 8 - 7.52 (3 H, m), 7.60 (1 H, dd, J = 7.6, 1.5 Hz), 7.78 (1 H, d, J = 2.2 Hz), 7.86-7.94(1H,m),8.04(1H,t,J=7.6Hz),8.13(1H,dd, J=7.6,2.2Hz),8.88(1H,t, J = 5.5 Hz).
Working Example 109 N-(2-Cyanoethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoic acid obtained in Reference Example 82 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 82%. Melting point: 192 - 193 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 2.77 (21-1, t, J = 6.4 Hz), 3.44 - 3.54 (21-1, m), 7.16 (1H, d, J =
8.0 Hz ), 7.3 8 - 7.52 (3 H, m), 7.60 (1 H, dd, J = 7.6, 1.5 Hz), 7.78 (1 H, d, J = 2.2 Hz), 7.86-7.94(1H,m),8.04(1H,t,J=7.6Hz),8.13(1H,dd, J=7.6,2.2Hz),8.88(1H,t, J = 5.5 Hz).
[0287]
Working Example 110 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-4-fluoro-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoic acid obtained in Reference Example 82 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 62%. Melting point: 176 - 177 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.26 - 3.37 (2H, m), 3.51 (2H, q, J = 6.2 Hz), 4.72 (1 H, t, J =
6.2 Hz), 7.15 (1H, d, J = 8.3 Hz ), 7.34 - 7.52 (31-1, m), 7.60 (1H, dd, J =
7.6, 1.5 Hz), 7.78 (1 H, d, J = 2.2 Hz), 7.86 - 7.95 (1 H, m), 8.03 (1 H, t, J =
7.6Hz),8.13(1H,dd,J=
7.6, 2.2 Hz), 8.46 (1 H, t, J = 5.3 Hz).
Working Example 110 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-4-fluoro-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-4-fluorobenzoic acid obtained in Reference Example 82 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 62%. Melting point: 176 - 177 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.26 - 3.37 (2H, m), 3.51 (2H, q, J = 6.2 Hz), 4.72 (1 H, t, J =
6.2 Hz), 7.15 (1H, d, J = 8.3 Hz ), 7.34 - 7.52 (31-1, m), 7.60 (1H, dd, J =
7.6, 1.5 Hz), 7.78 (1 H, d, J = 2.2 Hz), 7.86 - 7.95 (1 H, m), 8.03 (1 H, t, J =
7.6Hz),8.13(1H,dd,J=
7.6, 2.2 Hz), 8.46 (1 H, t, J = 5.3 Hz).
[0288]
Working Example 111 N-(2-Cyanoethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid obtained in Reference -Example 83 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 76%. Melting point: 151 - 152 C
(ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.77 (2H, t, J = 6.6 Hz), 3.50 (2H, q, J = 6.6 Hz), 7.19 (1H, d, J = 8.0 Hz ), 7.33 (1H, t, J = 7.8 Hz), 7.42 - 7.53 (2H, m), 7.55 - 7.67 (3H, m), 7.80 (1 H, d, J = 2.7 Hz), 8.03 (1 H, t, J = 7.8 Hz), 8.77 (1H, t, J = 5.7 Hz).
Working Example 111 N-(2-Cyanoethyl)-3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid obtained in Reference -Example 83 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 76%. Melting point: 151 - 152 C
(ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.77 (2H, t, J = 6.6 Hz), 3.50 (2H, q, J = 6.6 Hz), 7.19 (1H, d, J = 8.0 Hz ), 7.33 (1H, t, J = 7.8 Hz), 7.42 - 7.53 (2H, m), 7.55 - 7.67 (3H, m), 7.80 (1 H, d, J = 2.7 Hz), 8.03 (1 H, t, J = 7.8 Hz), 8.77 (1H, t, J = 5.7 Hz).
[0289]
Working Example 112 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-2-fluoro-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid obtained in Reference Example 83 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 62%; melting point: 162 - 163 C
(tetrahydrofuran-hexane).
'H-NMR (DMSO-d6) 6: 3.27 - 3.37 (2H, m), 3.50 (2H, q, J = 5.8 Hz), 4.72 (1H, t, J =
5.8Hz),7.18(1H,d,J=8.3Hz),7.26-7.33(1H,m),7.41 -7.53(2H,m),7.54-7.64 (3H, m), 7.80 (1H, d, J = 2.3 Hz), 8.03 (1H, t, J = 8.0 Hz), 8.33 (1H, t, J =
5.3Hz).
Working Example 112 3-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-2-fluoro-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid obtained in Reference Example 83 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 62%; melting point: 162 - 163 C
(tetrahydrofuran-hexane).
'H-NMR (DMSO-d6) 6: 3.27 - 3.37 (2H, m), 3.50 (2H, q, J = 5.8 Hz), 4.72 (1H, t, J =
5.8Hz),7.18(1H,d,J=8.3Hz),7.26-7.33(1H,m),7.41 -7.53(2H,m),7.54-7.64 (3H, m), 7.80 (1H, d, J = 2.3 Hz), 8.03 (1H, t, J = 8.0 Hz), 8.33 (1H, t, J =
5.3Hz).
[0290]
Working Example 113 N-(2-Cyanoethyl)-5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzamide The titled compound was obtained using 5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid obtained in Reference Example 84 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 72%. Melting point: 165 - 166 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 2.77 (2H, t, J = 6.6 Hz), 3.50 (2H, q, J = 6.6 Hz), 7.10 (1H, d, J = 8.0 Hz ), 7.33 - 7.56 (3H, m), 7.72 - 7.83 (2H, m), 7.90 - 8.03 (2H, m), 8.07 (1H, dd, J = 6.8, 2.3 Hz), 8.73 (1H, br s).
Working Example 113 N-(2-Cyanoethyl)-5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzamide The titled compound was obtained using 5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid obtained in Reference Example 84 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 72%. Melting point: 165 - 166 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 2.77 (2H, t, J = 6.6 Hz), 3.50 (2H, q, J = 6.6 Hz), 7.10 (1H, d, J = 8.0 Hz ), 7.33 - 7.56 (3H, m), 7.72 - 7.83 (2H, m), 7.90 - 8.03 (2H, m), 8.07 (1H, dd, J = 6.8, 2.3 Hz), 8.73 (1H, br s).
[0291]
Working Example 114 5-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-2-fluoro-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid obtained in Reference Example 84 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 61%. Melting point: 142 - 143 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.28 - 3.37 (2H, m), 3.51 (2H, q, J = 5.8 Hz), 4.73 (1 H, t, J =
5.8 Hz), 7.09 (1 H, d, J = 8.3 Hz ), 7.29 - 7.39 (1 H, m), 7.41 -7.56(21-1,m),7.74-7.83 (2H, m), 7.87 - 7.94 (1 H, m), 7.99 (1 H, t, J = 8.0 Hz), 8.07 (1 H, dd, J =
6.8, 2.3 Hz), 8.29 (1 H, br s).
Working Example 114 5-(6-(2,4-Dichlorophenoxy)pyridin-2-yl)-2-fluoro-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 5-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-2-fluorobenzoic acid obtained in Reference Example 84 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 61%. Melting point: 142 - 143 C
(tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.28 - 3.37 (2H, m), 3.51 (2H, q, J = 5.8 Hz), 4.73 (1 H, t, J =
5.8 Hz), 7.09 (1 H, d, J = 8.3 Hz ), 7.29 - 7.39 (1 H, m), 7.41 -7.56(21-1,m),7.74-7.83 (2H, m), 7.87 - 7.94 (1 H, m), 7.99 (1 H, t, J = 8.0 Hz), 8.07 (1 H, dd, J =
6.8, 2.3 Hz), 8.29 (1 H, br s).
[0292]
Working Example 115 N-(2-Cyanoethyl)-3 -(6-(2,4-dichlorophenoxy)-3 -(trifluoromethyl)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoic acid obtained in Reference Example 85 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 61%.
Melting point: 155 - 156 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.77 (2H, t, J = 6.5 Hz), 3.49 (2H, q, J = 6.5 Hz), 7.37 (1H, d, J=8.7Hz ),7.46-7.60(4H,m),7.78(1H,t,J=1.4Hz),7.85(1H,s),7.89-7.96(1H, m), 8.40 (1 H, d, J = 8.7 Hz), 8.90 (1 H, t, J = 5.6 Hz).
Working Example 115 N-(2-Cyanoethyl)-3 -(6-(2,4-dichlorophenoxy)-3 -(trifluoromethyl)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoic acid obtained in Reference Example 85 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 61%.
Melting point: 155 - 156 C (ethyl acetate-hexane).
' H-NMR (DMSO-d6) 6: 2.77 (2H, t, J = 6.5 Hz), 3.49 (2H, q, J = 6.5 Hz), 7.37 (1H, d, J=8.7Hz ),7.46-7.60(4H,m),7.78(1H,t,J=1.4Hz),7.85(1H,s),7.89-7.96(1H, m), 8.40 (1 H, d, J = 8.7 Hz), 8.90 (1 H, t, J = 5.6 Hz).
[0293]
Working Example 116 3-(6-(2,4-Dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoic acid obtained in Reference Example 85 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 47%. Melting point: 130 - 131 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 3.27 - 3.37 (2H, m), 3.50 (2H, q, J = 6.0 Hz), 4.71 (1 H, t, J =
6.0 Hz), 7.37 (1 H, d, J = 8.7 Hz ), 7.43 - 7.57 (4H, m), 7.78 (1 H, s), 7.84 (1 H, s), 7.93 (1H, d, J = 7.7 Hz), 8.39 (1H, d, J = 8.7. Hz), 8.48 (1H, t, J = 5.5Hz).
Working Example 116 3-(6-(2,4-Dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)-3-(trifluoromethyl)pyridin-2-yl)benzoic acid obtained in Reference Example 85 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 47%. Melting point: 130 - 131 C (ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 3.27 - 3.37 (2H, m), 3.50 (2H, q, J = 6.0 Hz), 4.71 (1 H, t, J =
6.0 Hz), 7.37 (1 H, d, J = 8.7 Hz ), 7.43 - 7.57 (4H, m), 7.78 (1 H, s), 7.84 (1 H, s), 7.93 (1H, d, J = 7.7 Hz), 8.39 (1H, d, J = 8.7. Hz), 8.48 (1H, t, J = 5.5Hz).
[0294]
Working Example 117 N-(2-Cyanoethyl)-6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxamide The titled compound was obtained using 6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxylic acid obtained in Reference Example 86 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 43%. Melting point: 152 - 153 C
(ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.80 (2H, t, J = 6.4 Hz), 3.54 (2H, q, J = 6.4 Hz), 7.19 (1H, d, J=7.9Hz ),7.45-7.58(2H,m),7.83(1H,d,J=2.4Hz),7.90(1H,d,J=7.5Hz), 8.03 - 8.11 (1H,m),8.60(1H,t,J=2.2Hz),9.00(1H,d,J=2.2Hz),9.08(1H,d,J=
2.2 Hz), 9.13 (1 H, t, J = 5.5 Hz).
Working Example 117 N-(2-Cyanoethyl)-6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxamide The titled compound was obtained using 6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxylic acid obtained in Reference Example 86 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 43%. Melting point: 152 - 153 C
(ethyl acetate-hexane).
'H-NMR (DMSO-d6) 6: 2.80 (2H, t, J = 6.4 Hz), 3.54 (2H, q, J = 6.4 Hz), 7.19 (1H, d, J=7.9Hz ),7.45-7.58(2H,m),7.83(1H,d,J=2.4Hz),7.90(1H,d,J=7.5Hz), 8.03 - 8.11 (1H,m),8.60(1H,t,J=2.2Hz),9.00(1H,d,J=2.2Hz),9.08(1H,d,J=
2.2 Hz), 9.13 (1 H, t, J = 5.5 Hz).
[0295]
Working Example 118 6-(2,4-dichlorophenoxy)-N-(2-hydroxyethyl)-2,3'-bipyridine-5'-carboxamide The titled compound was obtained using 6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxylic acid obtained in Reference Example 86 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 43%. Melting point: 180 - 181 C
(tetrahydrofuran-hexane).
'H-NMR (DMSO-d6) 6: 3.32 - 3.40 (2H, m), 3.54 (2H, q, J = 5.8 Hz), 4.77 (1H, t, J =
5.8 Hz), 7.18 (1 H, d, J = 8.1 Hz ), 7.45 - 7.58 (2H, m), 7.83 (1 H, d, J =
2.3 Hz), 7.90 (1H,d,J=7.5Hz),8.07(1H,t,J=7.5Hz),8.61 (1H,t,J=2.3 Hz),8.74(1H,t,J=
5.4Hz), 8.97 - 9.06 (2H, m).
Working Example 118 6-(2,4-dichlorophenoxy)-N-(2-hydroxyethyl)-2,3'-bipyridine-5'-carboxamide The titled compound was obtained using 6-(2,4-dichlorophenoxy)-2,3'-bipyridine-5'-carboxylic acid obtained in Reference Example 86 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 43%. Melting point: 180 - 181 C
(tetrahydrofuran-hexane).
'H-NMR (DMSO-d6) 6: 3.32 - 3.40 (2H, m), 3.54 (2H, q, J = 5.8 Hz), 4.77 (1H, t, J =
5.8 Hz), 7.18 (1 H, d, J = 8.1 Hz ), 7.45 - 7.58 (2H, m), 7.83 (1 H, d, J =
2.3 Hz), 7.90 (1H,d,J=7.5Hz),8.07(1H,t,J=7.5Hz),8.61 (1H,t,J=2.3 Hz),8.74(1H,t,J=
5.4Hz), 8.97 - 9.06 (2H, m).
[0296]
Working Example 119 N-(2-Cyanoethyl)-3 -(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoic acid obtained in Reference Example 87 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 78%.
Melting point: 231 - 232 C (tetrahydrofuran-hexane).
I H-NMR (DMSO-d6) 6: 2.80 (2H, t, J = 6.5 Hz), 3.53 (2H, q, J = 6.5 Hz), 7.53 -7.63 (4H, m), 7.86 (1 H, d, J = 1.3 Hz), 7.91 (1 H, d, J = 7.9 Hz), 7.98 (1 H, d, J
= 7.9 Hz), 8.14 (1 H, s), 8.39 (1 H, s), 8.95 (1 H, t, J = 5.6 Hz).
Working Example 119 N-(2-Cyanoethyl)-3 -(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoic acid obtained in Reference Example 87 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 78%.
Melting point: 231 - 232 C (tetrahydrofuran-hexane).
I H-NMR (DMSO-d6) 6: 2.80 (2H, t, J = 6.5 Hz), 3.53 (2H, q, J = 6.5 Hz), 7.53 -7.63 (4H, m), 7.86 (1 H, d, J = 1.3 Hz), 7.91 (1 H, d, J = 7.9 Hz), 7.98 (1 H, d, J
= 7.9 Hz), 8.14 (1 H, s), 8.39 (1 H, s), 8.95 (1 H, t, J = 5.6 Hz).
[0297]
Working Example 120 3-(6-(2,4-Dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoic acid obtained in Reference Example 87 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 84%. Melting point: 197 - 198 C (tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.32 - 3.41 (2H, m), 3.54 (21-1, q, J = 5.8 Hz), 4.77 (11-1, t, J =
5.8 Hz), 7.48 - 7.62 (4H, m), 7.86 (1 H, d, J = 1.1 Hz), 7.88 - 7.96 (2H, m), 8.16 (1 H, s), 8.40 (1 H, s), 8.57 (1 H, t, J = 5.6Hz).
Working Example 120 3-(6-(2,4-Dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-(2,4-dichlorophenoxy)-4-(trifluoromethyl)pyridin-2-yl)benzoic acid obtained in Reference Example 87 and 2-aminoethanol in the same manner as in Working Example 2. Yield: 84%. Melting point: 197 - 198 C (tetrahydrofuran-hexane).
' H-NMR (DMSO-d6) 6: 3.32 - 3.41 (2H, m), 3.54 (21-1, q, J = 5.8 Hz), 4.77 (11-1, t, J =
5.8 Hz), 7.48 - 7.62 (4H, m), 7.86 (1 H, d, J = 1.1 Hz), 7.88 - 7.96 (2H, m), 8.16 (1 H, s), 8.40 (1 H, s), 8.57 (1 H, t, J = 5.6Hz).
[0298]
Working Example 121 N-(2-Cyanoethyl)-3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 60%. Melting point: 171 - 172 C
(THF-diethyl ether).
'H-NMR (DMSO-d6 ):S 1.98-2.10 (21-1, m), 2.81 (2H, t, J = 6.4 Hz), 3.46 (2H, br s), 3.61 (3H, s), 5.68 (1 H, d, J = 2.7 Hz), 6.24 (1 H, dd, J = 8.3 Hz and 2.7 Hz), 6.93 (1 H, d, J = 8.0 Hz), 7.24 - 7.26 (2H, m), 7.49 (1H, s).
Working Example 121 N-(2-Cyanoethyl)-3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 39 and 3-aminopropanenitrile in the same manner as in Working Example 2. Yield: 60%. Melting point: 171 - 172 C
(THF-diethyl ether).
'H-NMR (DMSO-d6 ):S 1.98-2.10 (21-1, m), 2.81 (2H, t, J = 6.4 Hz), 3.46 (2H, br s), 3.61 (3H, s), 5.68 (1 H, d, J = 2.7 Hz), 6.24 (1 H, dd, J = 8.3 Hz and 2.7 Hz), 6.93 (1 H, d, J = 8.0 Hz), 7.24 - 7.26 (2H, m), 7.49 (1H, s).
[0299]
Working Example 122 N-(2-Cyanoethyl)-3-(6-(2,4-dimethylphenoxy)pyridin-2-yl)benzamide Tetrakistriphenylphosphine palladium (0) (58.9 mg, 0.051 mmol) was added to a mixture of 2-chloro-6-(2,4-dimethylphenoxy)pyridine (300 mg, 1.28 mmol) obtained in Reference Example 44, N-(2-cyanoethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (462 mg, 1.54 mmol) obtained in Reference Example 43, 2 N sodium carbonate aqueous solution (2.56 mL), and DME (7 mL), and the mixture was heated and stirred for 18 hours to 90 C in a nitrogen atmosphere. Saturated aqueous sodium bicarbonate was added to the reaction solution, and the product was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography to give 126 mg of the titled compound (yield: 27%). Melting point:
114 - 115 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):S 2.19 (3H, s), 2.37 (3H, s), 2.77 (2H, t, J = 6.2 Hz), 3.73 (2H, q, J =
6.2 Hz), 6.66 (1 H, d, J = 8.0 Hz), 6.71 (1 H, br s), 6.98- 7.16 (3 H, m), 7.46 - 7.55 (2H, m), 7.68 - 7.76 (1H, m), 7.85 (1H, d, J = 8.3 Hz), 8.07 (1H, d, J = 8.0 Hz), 8.34 (1H, s).
Working Example 122 N-(2-Cyanoethyl)-3-(6-(2,4-dimethylphenoxy)pyridin-2-yl)benzamide Tetrakistriphenylphosphine palladium (0) (58.9 mg, 0.051 mmol) was added to a mixture of 2-chloro-6-(2,4-dimethylphenoxy)pyridine (300 mg, 1.28 mmol) obtained in Reference Example 44, N-(2-cyanoethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (462 mg, 1.54 mmol) obtained in Reference Example 43, 2 N sodium carbonate aqueous solution (2.56 mL), and DME (7 mL), and the mixture was heated and stirred for 18 hours to 90 C in a nitrogen atmosphere. Saturated aqueous sodium bicarbonate was added to the reaction solution, and the product was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, and the solvent was then distilled off at reduced pressure. The residue was purified by silica gel column chromatography to give 126 mg of the titled compound (yield: 27%). Melting point:
114 - 115 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):S 2.19 (3H, s), 2.37 (3H, s), 2.77 (2H, t, J = 6.2 Hz), 3.73 (2H, q, J =
6.2 Hz), 6.66 (1 H, d, J = 8.0 Hz), 6.71 (1 H, br s), 6.98- 7.16 (3 H, m), 7.46 - 7.55 (2H, m), 7.68 - 7.76 (1H, m), 7.85 (1H, d, J = 8.3 Hz), 8.07 (1H, d, J = 8.0 Hz), 8.34 (1H, s).
[0300]
Working Example 123 N-(2-Cyanoethyl)-3-(6-(2,4-difluorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(2,4-difluorophenoxy)pyridine obtained in Reference Example 45 in the same manner as in Working Example 122. Yield: 45%. Melting point: 133 - 1324 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):S 2.76 (2H, t, J = 6.2 Hz), 3.72 (2H, q, J = 6.2 Hz), 6.57 (1H, br s), 6.90 - 7.08 (2H, m), 6.94 (1 H, d, J = 8.3 Hz), 7.22 - 7.32 (1 H, m), 7.47 (1 H, t, J = 7.8 Hz), 7.54 (1 H, d, J = 7.2 Hz), 7.74 - 7.84 (2H, m), 7.98 (1 H, d, J = 8.0 Hz), 8.21 (1 H, s).
Working Example 123 N-(2-Cyanoethyl)-3-(6-(2,4-difluorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(2,4-difluorophenoxy)pyridine obtained in Reference Example 45 in the same manner as in Working Example 122. Yield: 45%. Melting point: 133 - 1324 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):S 2.76 (2H, t, J = 6.2 Hz), 3.72 (2H, q, J = 6.2 Hz), 6.57 (1H, br s), 6.90 - 7.08 (2H, m), 6.94 (1 H, d, J = 8.3 Hz), 7.22 - 7.32 (1 H, m), 7.47 (1 H, t, J = 7.8 Hz), 7.54 (1 H, d, J = 7.2 Hz), 7.74 - 7.84 (2H, m), 7.98 (1 H, d, J = 8.0 Hz), 8.21 (1 H, s).
[0301]
Working Example 124 3-(6-(4-chlorophenoxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 2-chloro-6-(4-chlorophenoxy)pyridine obtained in Reference Example 46 in the same manner as in Working Example 122.
Yield: 44%. Melting point: 143 - 144 C (ethyl acetate-hexane).
H-NMR (CDC13 ):8 2.77 (2H, t, J = 6.3 Hz), 3.74 (2H, q, J = 6.2 Hz), 6.62 (1H, br s), 6.86 (1 H, d, J = 8.3 Hz), 7.18 (2H, d, J = 8.9 Hz), 7.41 (2H, d, J = 8.9 Hz), 7.47 - 7.60 (21-1, m), 7.75 - 7.87 (2H, m), 8.02 - 8.08 (1 H, m), 8.28 (1 H, s).
Working Example 124 3-(6-(4-chlorophenoxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 2-chloro-6-(4-chlorophenoxy)pyridine obtained in Reference Example 46 in the same manner as in Working Example 122.
Yield: 44%. Melting point: 143 - 144 C (ethyl acetate-hexane).
H-NMR (CDC13 ):8 2.77 (2H, t, J = 6.3 Hz), 3.74 (2H, q, J = 6.2 Hz), 6.62 (1H, br s), 6.86 (1 H, d, J = 8.3 Hz), 7.18 (2H, d, J = 8.9 Hz), 7.41 (2H, d, J = 8.9 Hz), 7.47 - 7.60 (21-1, m), 7.75 - 7.87 (2H, m), 8.02 - 8.08 (1 H, m), 8.28 (1 H, s).
[0302]
Working Example 125 3-(6-(3-Chlorophenoxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 2-chloro-6-(3-chlorophenoxy)pyridine obtained in Reference Example 47 in the same manner as in Working Example 122.
Yield: 41%. Melting point: 139 - 140 C (ethyl acetate-hexane).
H-NMR (CDC13 ):S 2.77 (2H, t, J = 6.2 Hz), 3.74 (2H, q, J = 6.4 Hz), 6.66 (1 H, br s), 6.8 8 (1 H, d, J = 8. 0 Hz), 7.12 (1 H, dd, J = 8.7 Hz and 1. 9 Hz), 7.2 0 -7.2 5 (1 H, m), 7.3 1 (1H,t,J=2.1 Hz), 7.3 7 (1 H, t, J = 8.1 Hz), 7.51 (1 H, t, J = 7.8 Hz), 7.5 6 (1 H, d, J = 7.6 Hz), 7.77 - 7.88 (2H, m), 8.06 (1H, d, J = 8.0 Hz), 8.29 (1H, s).
Working Example 125 3-(6-(3-Chlorophenoxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 2-chloro-6-(3-chlorophenoxy)pyridine obtained in Reference Example 47 in the same manner as in Working Example 122.
Yield: 41%. Melting point: 139 - 140 C (ethyl acetate-hexane).
H-NMR (CDC13 ):S 2.77 (2H, t, J = 6.2 Hz), 3.74 (2H, q, J = 6.4 Hz), 6.66 (1 H, br s), 6.8 8 (1 H, d, J = 8. 0 Hz), 7.12 (1 H, dd, J = 8.7 Hz and 1. 9 Hz), 7.2 0 -7.2 5 (1 H, m), 7.3 1 (1H,t,J=2.1 Hz), 7.3 7 (1 H, t, J = 8.1 Hz), 7.51 (1 H, t, J = 7.8 Hz), 7.5 6 (1 H, d, J = 7.6 Hz), 7.77 - 7.88 (2H, m), 8.06 (1H, d, J = 8.0 Hz), 8.29 (1H, s).
[0303]
Working Example 126 3-(6-(2-Chlorophenoxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 2-chloro-6-(2-chlorophenoxy)pyridine obtained in Reference Example 48 in the same manner as in Working Example 122.
Yield: 51%. Melting point: 82 - 83 C (ethyl acetate-hexane).
H-NMR (CDC13 ):S 2.75 (21-1, t, J = 6.4 Hz), 3.71 (21-1, q, J = 6.4 Hz), 6.64 (1H, t, J =
5.5 Hz), 6.87 (1 H, d, J = 8.0 Hz), 7.20 - 7.27 (1 H, m), 7.27 - 7.40 (2H, m), 7.46 (1 H, t, J = 7.8 Hz), 7.53 (2H, d, J = 8.0 Hz), 7.79 (2H, t, J = 8.0 Hz), 8.00 (1H, d, J = 8.0 Hz), 8.24 (1 H, s).
Working Example 126 3-(6-(2-Chlorophenoxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 2-chloro-6-(2-chlorophenoxy)pyridine obtained in Reference Example 48 in the same manner as in Working Example 122.
Yield: 51%. Melting point: 82 - 83 C (ethyl acetate-hexane).
H-NMR (CDC13 ):S 2.75 (21-1, t, J = 6.4 Hz), 3.71 (21-1, q, J = 6.4 Hz), 6.64 (1H, t, J =
5.5 Hz), 6.87 (1 H, d, J = 8.0 Hz), 7.20 - 7.27 (1 H, m), 7.27 - 7.40 (2H, m), 7.46 (1 H, t, J = 7.8 Hz), 7.53 (2H, d, J = 8.0 Hz), 7.79 (2H, t, J = 8.0 Hz), 8.00 (1H, d, J = 8.0 Hz), 8.24 (1 H, s).
[0304]
Working Example 127 N-(2-Cyanoethyl)-3-(6-(3-trifluoromethyl)phenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(3-trifluoromethyl)phenoxy)pyridine in the same manner as in Working Example 122.
Yield: 33%. Melting point: 136 - 137 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):8 2.76 (2H, t, J = 6.4 Hz), 3.72 (2H, q, J = 6.1 Hz), 6.56 (1H, br s), 6.93 (1 H, d, J = 8.3 Hz), 7.42 (1 H, d, J = 8.0 Hz), 7.45 - 7.62 (5H, m), 7.83 (2H, t, J =
7.8 Hz), 8.03 (1 H, d, J = 8.0 Hz), 8.23 (1 H, s).
Working Example 127 N-(2-Cyanoethyl)-3-(6-(3-trifluoromethyl)phenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(3-trifluoromethyl)phenoxy)pyridine in the same manner as in Working Example 122.
Yield: 33%. Melting point: 136 - 137 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):8 2.76 (2H, t, J = 6.4 Hz), 3.72 (2H, q, J = 6.1 Hz), 6.56 (1H, br s), 6.93 (1 H, d, J = 8.3 Hz), 7.42 (1 H, d, J = 8.0 Hz), 7.45 - 7.62 (5H, m), 7.83 (2H, t, J =
7.8 Hz), 8.03 (1 H, d, J = 8.0 Hz), 8.23 (1 H, s).
[0305]
Working Example 128 N-(2-Cyanoethyl)-3-(6-(3-methoxyphenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(3-methoxyphenoxy)pyridine obtained in Reference Example 49 in the same manner as in Working Example 122. Yield: 17%. Melting point: 85 - 86 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):8 2.77 (2H, t, J = 6.2 Hz), 3.73 (2H, q, J = 6.4 Hz), 3.82 (3H, s), 6.68 (1 H, br s), 6.77 - 6.84 (4H, m), 7.29 - 7.37 (1 H, m), 7.47-7.57 (2H, m), 7.77 (1 H, t, J = 7.8 Hz), 7.84 (1 H, d, J = 8.0 Hz), 8.09 (1 H, d, J = 8.0 Hz), 8.34 (1 H, s).
Working Example 128 N-(2-Cyanoethyl)-3-(6-(3-methoxyphenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(3-methoxyphenoxy)pyridine obtained in Reference Example 49 in the same manner as in Working Example 122. Yield: 17%. Melting point: 85 - 86 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):8 2.77 (2H, t, J = 6.2 Hz), 3.73 (2H, q, J = 6.4 Hz), 3.82 (3H, s), 6.68 (1 H, br s), 6.77 - 6.84 (4H, m), 7.29 - 7.37 (1 H, m), 7.47-7.57 (2H, m), 7.77 (1 H, t, J = 7.8 Hz), 7.84 (1 H, d, J = 8.0 Hz), 8.09 (1 H, d, J = 8.0 Hz), 8.34 (1 H, s).
[0306]
Working Example 129 N-(2-Cyanoethyl)-3-(6-(cyclohexyloxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(cyclohexyloxy)pyridine obtained in Reference Example 50 in the same manner as in Working Example 122.
Yield: 72%. Melting point: 131 - 132 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):6 1.24 - 1.69 (6H, m), 1.77 - 1.90 (2H, m), 2.05 - 2.16 (21-1, m), 2.78 (2H, t, J = 6.2 Hz), 3.76 (21-1, q, J = 6.1 Hz), 5.12 - 5.25 (1H, m), 6.65 - 6.77 (2H, m),7.35(IH,d,J=6.8Hz),7.54(1H,t,J=7.8Hz),7.59-7.68(1H,m),7.78(1H,d,J
= 8.3 Hz), 8.19 (1 H, d, J = 8.0 Hz), 8.41 (1 H, s).
Working Example 129 N-(2-Cyanoethyl)-3-(6-(cyclohexyloxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(cyclohexyloxy)pyridine obtained in Reference Example 50 in the same manner as in Working Example 122.
Yield: 72%. Melting point: 131 - 132 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):6 1.24 - 1.69 (6H, m), 1.77 - 1.90 (2H, m), 2.05 - 2.16 (21-1, m), 2.78 (2H, t, J = 6.2 Hz), 3.76 (21-1, q, J = 6.1 Hz), 5.12 - 5.25 (1H, m), 6.65 - 6.77 (2H, m),7.35(IH,d,J=6.8Hz),7.54(1H,t,J=7.8Hz),7.59-7.68(1H,m),7.78(1H,d,J
= 8.3 Hz), 8.19 (1 H, d, J = 8.0 Hz), 8.41 (1 H, s).
[0307]
Working Example 130 N-(2-Cyanoethyl)-3 -(6-(1 H-indol-5 -yloxy)pyridin-2-yl)benzamide The titled compound was synthesized using 5-((6-chloropyridin-2-yl)oxy)-1H-indole obtained in Reference Example 51 in the same manner as in Working Example 122. Yield: 77%. Melting point: 150 - 151 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):6 2.69 (2H, t, J = 6.5 Hz), 3.63 (2H, q, J = 6.2 Hz), 6.54 (1H, br s.), 6.58 (1 H, br s), 6.76 (1 H, d, J = 8.3 Hz), 7.08 (111, dd, J = 8.8 Hz and 2.0 Hz), 7.30 (111, t, J = 2.6 Hz), 7.41 - 7.54 (4H, m), 7.71 (1 H, t, J = 7.9 Hz), 7.86 (1 H, d, J = 7.9 Hz), 8.08 (1 H, d, J = 7.5 Hz), 8.31 (1 H, s), 8.3 7 (1 H, br s).
Working Example 130 N-(2-Cyanoethyl)-3 -(6-(1 H-indol-5 -yloxy)pyridin-2-yl)benzamide The titled compound was synthesized using 5-((6-chloropyridin-2-yl)oxy)-1H-indole obtained in Reference Example 51 in the same manner as in Working Example 122. Yield: 77%. Melting point: 150 - 151 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):6 2.69 (2H, t, J = 6.5 Hz), 3.63 (2H, q, J = 6.2 Hz), 6.54 (1H, br s.), 6.58 (1 H, br s), 6.76 (1 H, d, J = 8.3 Hz), 7.08 (111, dd, J = 8.8 Hz and 2.0 Hz), 7.30 (111, t, J = 2.6 Hz), 7.41 - 7.54 (4H, m), 7.71 (1 H, t, J = 7.9 Hz), 7.86 (1 H, d, J = 7.9 Hz), 8.08 (1 H, d, J = 7.5 Hz), 8.31 (1 H, s), 8.3 7 (1 H, br s).
[0308]
Working Example 131 N-(2-Cyanoethyl)-3 -(6-(2,3 -dihydro- I H-inden-5 -yloxy)pyridin-2-yl)benzamide The titled compound was synthesized 2-chloro-6-(2,3-dihydro-lH-inden-5-yloxy)pyridine obtained in Reference Example 52 in the same manner as in Working Example 122. Yield: 55%. Melting point: 122 - 123 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):8 2.05-2.24 (21-1, m), 2.77 (2H, t, J = 6.4 Hz), 2.93 (4H, t, J = 7.4 Hz), 3.73 (2H, q, J = 6.3 Hz), 6.74 (2H, d, J = 8.1 Hz), 6.98 (1H, d, J = 8.1 Hz), 7.06 (1H, s), 7.22 - 7.29 (1H, m), 7.47 - 7.57 (2H, m), 7.73 (1H, t, J = 7.9 Hz), 7.84 (1H, d, J
= 7.7 Hz), 8.11 (1 H, d, J = 7.9 Hz), 8.37 (1 H, s).
Working Example 131 N-(2-Cyanoethyl)-3 -(6-(2,3 -dihydro- I H-inden-5 -yloxy)pyridin-2-yl)benzamide The titled compound was synthesized 2-chloro-6-(2,3-dihydro-lH-inden-5-yloxy)pyridine obtained in Reference Example 52 in the same manner as in Working Example 122. Yield: 55%. Melting point: 122 - 123 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):8 2.05-2.24 (21-1, m), 2.77 (2H, t, J = 6.4 Hz), 2.93 (4H, t, J = 7.4 Hz), 3.73 (2H, q, J = 6.3 Hz), 6.74 (2H, d, J = 8.1 Hz), 6.98 (1H, d, J = 8.1 Hz), 7.06 (1H, s), 7.22 - 7.29 (1H, m), 7.47 - 7.57 (2H, m), 7.73 (1H, t, J = 7.9 Hz), 7.84 (1H, d, J
= 7.7 Hz), 8.11 (1 H, d, J = 7.9 Hz), 8.37 (1 H, s).
[0309]
Working Example 132 3-(6-(3-Acetylphenoxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 1-(3-((6-chloropyridin-2-yl)oxy)phenyl)ethanone obtained in Reference Example 53 in the same manner as in Working Example 122. Yield: 50%. Melting point: 140 - 141 C (ethyl acetate-hexane).
H-NMR (CDC13 ):b 2.68 (31-1, s), 2.78 (21-1, t, J = 6.5 Hz), 3.76 (2H, q, J =
6.4 Hz), 6.94 (1 H, d, J = 7.5 Hz), 7.18 (1 H, br s), 7.3 8 - 7.46 (1 H, m), 7.47 - 7.5 8 (3 H, m), 7.76 - 7.86 (2H, m), 7.91 - 8.03 (2H, m), 8.20 - 8.25 (1 H, m), 8.32 (1 H, t, J =
1.6 Hz).
Working Example 132 3-(6-(3-Acetylphenoxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 1-(3-((6-chloropyridin-2-yl)oxy)phenyl)ethanone obtained in Reference Example 53 in the same manner as in Working Example 122. Yield: 50%. Melting point: 140 - 141 C (ethyl acetate-hexane).
H-NMR (CDC13 ):b 2.68 (31-1, s), 2.78 (21-1, t, J = 6.5 Hz), 3.76 (2H, q, J =
6.4 Hz), 6.94 (1 H, d, J = 7.5 Hz), 7.18 (1 H, br s), 7.3 8 - 7.46 (1 H, m), 7.47 - 7.5 8 (3 H, m), 7.76 - 7.86 (2H, m), 7.91 - 8.03 (2H, m), 8.20 - 8.25 (1 H, m), 8.32 (1 H, t, J =
1.6 Hz).
[0310]
Working Example 133 N-(2-Cyanoethyl)-3-(6-(3-(dimethylamino)phenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using (3-((6-chloropyridin-2-yl)oxy)-N,N-dimethylaniline obtained in Reference Example 54 in the same manner as in Working Example 122. Yield: 68%.. Melting point: 95 - 96 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):S 2.77 (2H, t, J = 6.4 Hz), 2.98 (6H, s), 3.74 (2H, q, J =
6.4 Hz), 6.58 (3H, br s), 6.78 (2H, d, J = 8.3 Hz), 7.23 - 7.34 (1H, m), 7.52 (2H, t, J
= 7.1 Hz), 7.74 (1 H, t, J = 7.8 Hz), 7.8 7 (1 H, d, J = 7.5 Hz), 8. 11 (1 H, d, J = 7. 0 Hz), 8.3 8 (1 H, t, J
= 1.7 Hz).
Working Example 133 N-(2-Cyanoethyl)-3-(6-(3-(dimethylamino)phenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using (3-((6-chloropyridin-2-yl)oxy)-N,N-dimethylaniline obtained in Reference Example 54 in the same manner as in Working Example 122. Yield: 68%.. Melting point: 95 - 96 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):S 2.77 (2H, t, J = 6.4 Hz), 2.98 (6H, s), 3.74 (2H, q, J =
6.4 Hz), 6.58 (3H, br s), 6.78 (2H, d, J = 8.3 Hz), 7.23 - 7.34 (1H, m), 7.52 (2H, t, J
= 7.1 Hz), 7.74 (1 H, t, J = 7.8 Hz), 7.8 7 (1 H, d, J = 7.5 Hz), 8. 11 (1 H, d, J = 7. 0 Hz), 8.3 8 (1 H, t, J
= 1.7 Hz).
[0311]
Working Example 134 3-(6-((5-Chloropyridin-3-yl)oxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 2-chloro-6-((5-chloropyridin-3-yl)oxy)pyridine obtained in Reference Example 55 in the same manner as in Working Example 122. Yield: 45%. Melting point: 143 - 144 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):8 2.78 (2H, t, J = 6.2 Hz), 3.75 (2H, q, J = 6.4 Hz), 6.64 (1H, br s), 6.98 (1 H, d, J = 8.3 Hz), 7.51 (1 H, t, J = 7.8 Hz), 7.61 (1 H, d, J = 7.6 Hz), 7.70 (1 H, t, J
= 2.3 Hz), 7.78 - 7.90 (2H, m), 8.02 (1 H, d, J = 8.0 Hz), 8.26 (1 H, s), 8.46 (1 H, d, J =
2.3 Hz), 8.54 (1H, d, J = 2.3 Hz).
Working Example 134 3-(6-((5-Chloropyridin-3-yl)oxy)pyridin-2-yl)-N-(2-cyanoethyl)benzamide The titled compound was synthesized using 2-chloro-6-((5-chloropyridin-3-yl)oxy)pyridine obtained in Reference Example 55 in the same manner as in Working Example 122. Yield: 45%. Melting point: 143 - 144 C (ethyl acetate-hexane).
'H-NMR (CDC13 ):8 2.78 (2H, t, J = 6.2 Hz), 3.75 (2H, q, J = 6.4 Hz), 6.64 (1H, br s), 6.98 (1 H, d, J = 8.3 Hz), 7.51 (1 H, t, J = 7.8 Hz), 7.61 (1 H, d, J = 7.6 Hz), 7.70 (1 H, t, J
= 2.3 Hz), 7.78 - 7.90 (2H, m), 8.02 (1 H, d, J = 8.0 Hz), 8.26 (1 H, s), 8.46 (1 H, d, J =
2.3 Hz), 8.54 (1H, d, J = 2.3 Hz).
[0312]
Working Example 135 N-(2-Cyanoethyl)-3-(6-(2,5-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(2,5-dichlorophenoxy)pyridine obtained in Reference Example 56 in the same manner as in Working Example 122. Yield: 27%. Melting point: 149 - 150 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):8 2.77 (2H, t, J = 6.3 Hz), 3.73 (2H, q, J = 6.2 Hz), 6.61 (1H, br s), 6.94 (1 H, d, J = 8.1 Hz), 7.22 (1 H, dd, J = 8.6 Hz and 2.4 Hz), 7.3 7 (1 H, d, J = 2.4 Hz), 7.42 - 7.52(2H,m),7.56(1H,d,J=7.5Hz),7.78-7.87(2H,m),7.99(1H,d,J=7.7 Hz), 8.23 (1 H, s).
Working Example 135 N-(2-Cyanoethyl)-3-(6-(2,5-dichlorophenoxy)pyridin-2-yl)benzamide The titled compound was synthesized using 2-chloro-6-(2,5-dichlorophenoxy)pyridine obtained in Reference Example 56 in the same manner as in Working Example 122. Yield: 27%. Melting point: 149 - 150 C (ethyl acetate-hexane).
' H-NMR (CDC13 ):8 2.77 (2H, t, J = 6.3 Hz), 3.73 (2H, q, J = 6.2 Hz), 6.61 (1H, br s), 6.94 (1 H, d, J = 8.1 Hz), 7.22 (1 H, dd, J = 8.6 Hz and 2.4 Hz), 7.3 7 (1 H, d, J = 2.4 Hz), 7.42 - 7.52(2H,m),7.56(1H,d,J=7.5Hz),7.78-7.87(2H,m),7.99(1H,d,J=7.7 Hz), 8.23 (1 H, s).
[0313]
Working Examples 136 - 166 The compounds of Working Examples 136 through 166 were synthesized by reacting ethyl 3-(2-chloropyrimidin-4-yl)benzoate obtained in Reference Example 4 with various amines and- 2-pyrrolidin-l-ylethanamine in the same manner as in Reference Example 5, Reference Example 6, and Working Example 2.
Working Examples 136 - 166 The compounds of Working Examples 136 through 166 were synthesized by reacting ethyl 3-(2-chloropyrimidin-4-yl)benzoate obtained in Reference Example 4 with various amines and- 2-pyrrolidin-l-ylethanamine in the same manner as in Reference Example 5, Reference Example 6, and Working Example 2.
[0314]
Working Examples 167 - 233 The compounds of Working Examples 167 through 234 were synthesized by reacting 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 23 with various amines in the same manner as in Working Example 2.
Working Examples 167 - 233 The compounds of Working Examples 167 through 234 were synthesized by reacting 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)benzoic acid obtained in Reference Example 23 with various amines in the same manner as in Working Example 2.
[0315]
Working Examples 234 - 324 The compounds of Working Examples 234 through 324 were synthesized by reacting 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)aniline obtained in Reference Example 19 with various carboxylic acids in the same manner as in Working Example 2.
Working Examples 234 - 324 The compounds of Working Examples 234 through 324 were synthesized by reacting 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)aniline obtained in Reference Example 19 with various carboxylic acids in the same manner as in Working Example 2.
[0316]
Working Example 325 3-(6-((2,4-Dichlorobenzyl)amino)pyridine-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-((2-(3-(trifluoromethyl)phenyl)ethyl)amino)pyridin-2-yl)benzoic acid obtained in Reference Example 93 and 2-aminoethanol in the same manner as in Working Example 2.
Melting point: 173 - 174 C.
'H-NMR (DMSO-d6) 6 : 3.52 (2H, q, J = 5.9 Hz), 4.63 (2H, d, J = 5.8 Hz), 4.71 (1H, t, J = 5.6 Hz), 6.54 (1 H, d, J = 8.2 Hz), 7.16 (1 H, d, J = 7.1 Hz), 7.27 (1 H, t, J = 5.2 Hz), 7.32-7.40(1H,m),7.41 -7.55(3H,m),7.58(1H,d,J=2.2Hz),7.80(1H,d,J=8.0 Hz), 8.04 (1 H, d, J = 7.7 Hz), 8.3 8 (1 H, s), 8.48 (1 H, t, J = 5.2 Hz) 2H
unconfirmed [0317]
Working Example 326 N-(2-hydroxyethyl)-3-(6-((2-(3-(trifluoromethyl)phenyl)ethyl)amino)pyridine-2-yl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorobenzyl)amino)pyridin-yl)benzoic acid obtained in Reference Example 92 and 2-aminoethanol in the same manner as in Working Example 2.
Melting point: 112 - 113 C.
1 H-NMR (CDC13) 6 : 3.05 (2H, t, J = 7.0 Hz), 3.60 - 3.75 (4H, m), 3.85 (2H, d, J = 5.5 Hz), 4.69 (1 H, br. s.), 6.38 (1 H, d, J = 8.0 Hz), 6.71 (1 H, br. s.), 7.11 (1 H, d, J = 7.4 Hz), 7.40 - 7.56 (6H, m), 7.72 - 7.83 (1H, m), 8.12 (1H, dd, J = 7.8, 1.2 Hz), 8.39 (1H, t, J = 1.8 Hz) [0318]
Working Example 327 3-{6-[(2,4-Dichlorobenzyl)(ethyl)amino]pyridin-2-yl}-N-(2-hydroxyethyl)benzamide 3-{6-[(2,4-dichlorobenzyl)amino]pyridin-2-yl}-N-(2-hydroxyethyl)benzamide (150 mg, 0.36 mmol) obtained in Working Example 325 was reacted with an ethanol (4 mL) solution of acetaldehyde (0.65 mL) and acetic acid (108 mg, 1.8 mmol) for 15 min at 50 C, and sodium cyanotrihydroborate (28.3 mg, 0.45 mmol) was then added, and the mixture was reacted for another hour. To bring the reaction to conclusion, acetaldehyde (0.65 mL) and sodium cyanotrihydroborate (28.3 mg, 0.45 mmol) were added, and the mixture was reacted for one hour and then concentrated at reduced pressure.
Ethyl acetate was added to the resulting residue, which was washed with saturated sodium bicarbonate aqueous solution and then dried over anhydrous sodium sulfate. The solvent was distilled off at reduced pressure, and the resulting residue was purified by NH silica gel column chromatography (hexane-ethyl acetate 1:1 --> 1:9) and recrystallized from ethyl acetate-hexane to give 35.2 mg of the titled compound in the form of crystals (yield: 22%). Melting point: 118 - 119 C.
H-NMR (CDCI3) 6: 1.29 (3H, t, J = 7.0 Hz), 2.56 (1H, t, J = 5.1 Hz), 3.60 -3.76 (4H, m), 3.86 (2H, q, J = 4.8 Hz), 4.84 (2H, s), 6.44 (1H, d, J = 8.8 Hz), 6.54 (1H, br.s.), 7.08 - 7.16 (3H, m), 7.42 (1 H, s), 7.44 - 7.57 (2H, m), 7.79 (1 H, d, J = 7.7 Hz), 8.08 (1 H, d, J = 7.7 Hz), 8.29 (1 H, s).
Table 1 shows the chemical formulas of the compounds synthesized in Working Examples 1 through-327 ("Working Example" is abbreviated as "Ex." in the table).
Table 2 also shows the measured results for the LCMS of the compounds synthesized in Working Examples 136 through 324 ("Working Example No." is abbreviated as "Ex. No." in the table).
Working Example 325 3-(6-((2,4-Dichlorobenzyl)amino)pyridine-2-yl)-N-(2-hydroxyethyl)benzamide The titled compound was obtained using 3-(6-((2-(3-(trifluoromethyl)phenyl)ethyl)amino)pyridin-2-yl)benzoic acid obtained in Reference Example 93 and 2-aminoethanol in the same manner as in Working Example 2.
Melting point: 173 - 174 C.
'H-NMR (DMSO-d6) 6 : 3.52 (2H, q, J = 5.9 Hz), 4.63 (2H, d, J = 5.8 Hz), 4.71 (1H, t, J = 5.6 Hz), 6.54 (1 H, d, J = 8.2 Hz), 7.16 (1 H, d, J = 7.1 Hz), 7.27 (1 H, t, J = 5.2 Hz), 7.32-7.40(1H,m),7.41 -7.55(3H,m),7.58(1H,d,J=2.2Hz),7.80(1H,d,J=8.0 Hz), 8.04 (1 H, d, J = 7.7 Hz), 8.3 8 (1 H, s), 8.48 (1 H, t, J = 5.2 Hz) 2H
unconfirmed [0317]
Working Example 326 N-(2-hydroxyethyl)-3-(6-((2-(3-(trifluoromethyl)phenyl)ethyl)amino)pyridine-2-yl)benzamide The titled compound was obtained using 3-(6-((2,4-dichlorobenzyl)amino)pyridin-yl)benzoic acid obtained in Reference Example 92 and 2-aminoethanol in the same manner as in Working Example 2.
Melting point: 112 - 113 C.
1 H-NMR (CDC13) 6 : 3.05 (2H, t, J = 7.0 Hz), 3.60 - 3.75 (4H, m), 3.85 (2H, d, J = 5.5 Hz), 4.69 (1 H, br. s.), 6.38 (1 H, d, J = 8.0 Hz), 6.71 (1 H, br. s.), 7.11 (1 H, d, J = 7.4 Hz), 7.40 - 7.56 (6H, m), 7.72 - 7.83 (1H, m), 8.12 (1H, dd, J = 7.8, 1.2 Hz), 8.39 (1H, t, J = 1.8 Hz) [0318]
Working Example 327 3-{6-[(2,4-Dichlorobenzyl)(ethyl)amino]pyridin-2-yl}-N-(2-hydroxyethyl)benzamide 3-{6-[(2,4-dichlorobenzyl)amino]pyridin-2-yl}-N-(2-hydroxyethyl)benzamide (150 mg, 0.36 mmol) obtained in Working Example 325 was reacted with an ethanol (4 mL) solution of acetaldehyde (0.65 mL) and acetic acid (108 mg, 1.8 mmol) for 15 min at 50 C, and sodium cyanotrihydroborate (28.3 mg, 0.45 mmol) was then added, and the mixture was reacted for another hour. To bring the reaction to conclusion, acetaldehyde (0.65 mL) and sodium cyanotrihydroborate (28.3 mg, 0.45 mmol) were added, and the mixture was reacted for one hour and then concentrated at reduced pressure.
Ethyl acetate was added to the resulting residue, which was washed with saturated sodium bicarbonate aqueous solution and then dried over anhydrous sodium sulfate. The solvent was distilled off at reduced pressure, and the resulting residue was purified by NH silica gel column chromatography (hexane-ethyl acetate 1:1 --> 1:9) and recrystallized from ethyl acetate-hexane to give 35.2 mg of the titled compound in the form of crystals (yield: 22%). Melting point: 118 - 119 C.
H-NMR (CDCI3) 6: 1.29 (3H, t, J = 7.0 Hz), 2.56 (1H, t, J = 5.1 Hz), 3.60 -3.76 (4H, m), 3.86 (2H, q, J = 4.8 Hz), 4.84 (2H, s), 6.44 (1H, d, J = 8.8 Hz), 6.54 (1H, br.s.), 7.08 - 7.16 (3H, m), 7.42 (1 H, s), 7.44 - 7.57 (2H, m), 7.79 (1 H, d, J = 7.7 Hz), 8.08 (1 H, d, J = 7.7 Hz), 8.29 (1 H, s).
Table 1 shows the chemical formulas of the compounds synthesized in Working Examples 1 through-327 ("Working Example" is abbreviated as "Ex." in the table).
Table 2 also shows the measured results for the LCMS of the compounds synthesized in Working Examples 136 through 324 ("Working Example No." is abbreviated as "Ex. No." in the table).
[0319]
[Table 1]
[Table 1-1]
------- - ------ ------Ex.1 Ex.2 Ex.3 , r r H H
N_ r N\/\p/ H / i i ( II / N \
O p r i r O
, r t t \ I \ i \ I //\\\// \ ( I
H N H 0 N N \ O
H
+ , r r + r r , ---------------------------- ------------------------------------ ---------------------------------------Ex.4 Ex.5 Ex.6 0' F
H
t , r r , r , r N 0 N ~0\ N
H H
'----- -- -- - - - ----__-_ ----------------------------------- ---------------Ex 7 - ----~ Ex 8 ------------ Ex.9 -------H
N 0 N lll` N Ok O
0\ N
N H O NN p N H 0 H \ r r r ------------- ----------- ------------------------- ------- ---- ---------------------------------------Ex.10 Ex.11 Ex.12 Hlr~\N 0 / 0/
/N 11 H~ / N 1r\ I
0\ a0 t r I
\N N \ O N N N o + H , H I r H
--------------------------------------- ---------------------------------- ---------------------------------------Ex.13 Ex. 14 Ex.15 NN\n/O N NHZ
/ N~i~ + / I II II / i , 0\ N / I O/ / I O\
N N N \ p` N N Q
------- -------------- ---------------------------------------H H +---------------------------------------- ----------E x.16 Ex.17 Ex.18 N Br / N\ N NYO N
K
, + I \
N~ O\ N O\ N O\
\N/N 0 N H
H I N H
----------------------------------------- ---------------------------------------- ----------------------------------------[0320]
[Table 1 (continued)]
[Table 1-2]
--------------------------------------------------------------------------------------------------------------------------Ex.19 Ex.20 Ex.21 r H
N
N N p II
\ 0 / q \ 0 N /
O
N N \ I 0 I~ \ \ N \ 0 H H
t t ~.- y--'---------------------------------------------------------------------------Ex.22 Ex.23 Ex.24 / H
~jINH N NN
N II
t e \ I 0 0 O 0 0\ N 0\
\N N O N N 0 N N 0 H f , H H
-------------'''---Ex.25 Ex.26 Ex.27 N N H \ \ N NH2 N\~/N \!
0 'I I t / p , , , N / 0\ / IIN O\ N O\
'I i \ ' , 1` 'A \ I r \ \
N N \\\/// ~~/// `0 N N O
H N H It H
-------- ---- -------Ex.28 Ex.29 Ex.30 H H ;
N f T N\ NN\
-ja N QI N
H ~ H I FFF111III ~
--------------------------------------- ---------------------------------------- ---------------------------------------r Ex.31 ; Ex.32 Ex.33 H H
/ I N NJ N~\/\No Ny NH2 , N N HIl/ O / N H O\ / O\
/1'~..//~i \ \ I \ O N H O
I t I I r {
Ex.34 Ex.35 Ex.36 r H H/\/\H 0 H~\-\NH2 / r H H 0\ N H 0\ ----_ '------------------ -- -_-_----^------------------------------------ - --------------------------_-----[0321]
[Table 1 (continued)]
[Table 1-3]
--------------------------------------------------------------------------------------------------------------------------Ex.37 ; Ex.38 Ex.39 , f NN \ O \ \ /N N O \ 1 0 H H
t L
-------------------------I -----'---....----------- ---------------------------------------E x.40 Ex.41 Ex.42 r O rJ
\ \ H O
/ / /
, / t -NN 1 , 7 t I 1 , , -----------------------------------------------------^^------------------------------------------- --- ----------------------------------------E x.43 Ex.44 Ex.45 I
O oo O ND
1 , O O O , O O
t ------Ex.46 Ex.47 Ex.48 O 0 0 N/\/N H
H H
r , N O O
; ( , ----------------------------------------i-----^^'^----------------^------------- }----------------^'----------------------Ir Ex.49 ; Ex.50 E Ex.51 NH2 \ NTC11~CI
/ Ct r 11 It O O C C
, , -------Ex.52 Ex.53 Ex.54 t N Na,,, N H
N N, N F ~IO
, , r / I~ O\ N O\ N O\
-------^- ------[0322]
[Table I (continued)]
[Table 1-4]
-------------------------------------------------------------------1 Ex.57 Ex.55 Ex.56 , \
I\ N
H
/ / f cl CI CI \ N CI CI U lo,, N II ` O\
t t---------------------------------------q----------_-==_-------------------- r-----------------==
Ex.58 Ex.59 Ex.60 , 0 p t , r t , f{ \ N I
/ H \ \
t O I/ / \ I/ \ I
CI O O --------------- --------------------------------------- ---------------------------------------Ex.61 Ex.63 0 N--\\ 0 \\ ~N
NS/) N~/OH \ Nom/
H I H
H
, t , t N O \ I F N O \ F I/ O \ I F
---------------------------------------- ------------- - -----------------------------------------------------------------Ex.64 Ex.65 Ex.66 o o o f &
F F
F F o Ex.67 Ex.68 Ex.69 o I / / / ( \N / ~ \N / ( \N /
O \ O / O \ 0 / O \ O
----------------------------------------X .70 Ex.71 Ex.72 , o ~\ H H v I N I I ~
, 0,0 f , ---------------------------- ----------------------------------- ------------------[0323]
[Table 1 (continued)]
[Table 1-5]
-------------------------------------------------------------------------------------------------------------------------Ex.73 1 Ex.74 Ex.75 O N- F
S , It / \N / II I \N / I
O O O O O t ---------------------------------------- ---------------------------------------- ----------------------------------------t t Ex.76 Ex.77 Ex.78 O N~ p ~~N =;
N \ 1 J 'N I\ N N
I H \ `ry S H
H p p p O O , , ~ 1 ; I
t ---------------------------- i--------------------------------------- -,.-----__-_-__---___-___---_--__-__-_..__-;
Ex.79 - Ex.80 ; Ex.81 r r ~J\ N 0 N
N F, I\ i f H
H / t t , r \N / I \N / I N
o \ o I
O
, r ____==----------------------------------- --------------------=-------------------t----------------------------------------4 Ex.82 Ex.83 Ex.84 N N
CI CL~L. \ / , /N N
t r ---- r Ex.85 Ex.86 \ N \ N / \ N
H I H I H
CI
CI
\N /
G ICf O \ CI
------------------------------ --------- -------------------- -------------------------------------X --------; -' E.88 Ex.89 x.90 0 0 ,N F
o N-------OH N~\OH N' v i H H
N
OH
CI CI
\N N / ( ~0x50, O CI
--------------------- ---- ---------------[03241 [Table 1 (continued)]
[Table 1-6]
Ex.91 Ex.92 Ex.93 NY,OH fOH N
H ~ ~ I H
CI GI CI N N \N
/ O CI / D \ CI / O \ CI ----- __________------------ -----------------------------------------------------/
' Ex.94 Ex.95 Ex.96 D o 0 II~ H^/S\ H/\/S\ CI CI
I
!
N
N
o CI o CI o CI
t , -------------------- ---------------- -------A------------------ --------------Ex. 99 Ex.98 QNYOH N
r- Y, ~~X I i `p \ N p CI CI CI
Ex.100 Ex.101 Ex.102 o 0 OH
, /
CI CI N
~
C \N N
/ S \ \ / N N O
CI CI
------------------ - ------ ------------------------------- Y-^ --Ex.103 ; Ex. 104 Ex.105 0 o D
I /~ 1 1 /N 1 H
H
, E N \ CI \ I N U \ N O \ CI
H H
, CI CI CI ------------------------------------------------------------------------------- ----------------------------------------Ex.106 Ex.107 Ex.108 , 0 0 NF N- F \N --,_,OH
3 H H ( H
-Y CI CI
, O Y
O
e iii CI CI CI ---------------------------------------- ---------------------------------------[Table 1 (continued)]
[Table 1-7]
----------- ------ ---Ex.109 Ex.110 Ex.111 O
I H I ^ ( H
/ / f /
F F F
N CI N CI N CI
/
I
O \ I I 0 /\ I I O I
r r CI CI CI ----------------------------------------t--------------------------------------------------------------------------------*
Ex.112 Ex.113 Ex.114 /N
OH
N^'OH \ H \ H^' H
F r r , CI CI
N \ IN
O O \ \ I \ I
, O r CI CI CI
Ex.115 Ex.116 Ex.117 f o o o N
N N^,~ N
H H
F F
-N / iCI F ~N / CI -N / CI
CI CI CI
f , -------------- ._-_.._.._______-________-.._.._--_________-__---_-------___--______-___--___----___~
Ex.118 ; Ex.119 ; Ex.120 o o 0 OH ~
N
N N^/ I\ N I\ N
H Fi li /
r , CI CI
`N F \ \ I F \ I \ I
O O
F F
cl F CI F CI
f --------------------------------------- ------------- ----Ex.121 Ex.122 Ex.123 O O O -N
H
g~"N H CI \N
O CI F
-------------------- -------- --------------- ---------------------------------------Ex.124 Ex.125 Ex.126 f r \ N \ N I\ H
H
r / / r CI N /
N ~co 0 ----------------- --------------------------------- -----------------[0326]
[Table 1 (continued)]
[Table 1-8]
-------------------------------------------------------------------------------------------------------------------------Ex.127 Ex.128 Ex.129 O N
N
H \ N \
H r ~ H r -N / Q O
r r t I ------------------ ------------ -^--`--------------------------------Ex.130 Ex.131 Ex.132 O p o r N r N N
{ H H H
/
r r r H -I N N \N / II /N
O O O
'---------------------------------------- --------------------------------------- ----------------------------------------I Ex. 133 Ex.134 Ex.135 Q o Q
N /%N
H H
H r / r CI
/ /N N
~~ I /
O N O
O rI/ I CI CI
'--------------------- `----------__`_-_;_"_--^----------------------------------'---------------------------------------Ex.136 Ex.137 Ex.138 J rJ
N N^/N~
H H H
\ \ r r e r N I\ N I\ i N~-H O N H / N O
r r r - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -E x . ; E x . ; E x . O
O
I--N' H H
, \ r r \ r r r r r r r r r N N \ \ , H O
r r .-------------------------------------- ------------------------------------------------------------------------------Ex.142 Ex.143 Ex.144 , , r r N---/N- N--hl H H
r r r r p r r r N V A r r r N
\
N H
N N \ / F N N + CI
H H
r r r r r r r --------------------------- --------------------------------- -----------------[0327]
[Table I (continued)]
[Table 1-9]
--------------------------- - ----------------------------------- --Ex.145- ; Ex.146 ; Ex.147 N
H I H
\ I \ \
\ \ I \H I\ N \ F
N~N / F I I/ I\
N N / H F N N F
F
H F
~-__--- --^----------Ex.148 Ex.149 Ex.150 -------------------------H~\~N
\ I I H H
N
H \ I i N N- N H
-------- ---------------- -----------Ex.151 Ex.152 Ex.153 H I H \ H
N N N N S N N
H
---------------------------------------- ------------------------ ---------_----------------------__------Ex.154 ; Ex.155 Ex.156 ,NJ
H F / Ham/
NH \ F\ F \
N~
F
H N H N~N / icI
H F H
---------_ ------Ex.157 6 Ex.158 Ex.159 N-/No N/~/NJ
/ I H I H H
F CI
H F N H N H
----------------- ---------Ex.160 Ex.161 \\\\ Ex.162 NJ ND NJ
H I H
F
I t ~N \ \N \ N.
NN `~ F N~N~'U \% \ N H YF
H H F
---- "'----------------__'-_---------_^''__--------------------------------- -"- "-^---------------------------[0328]
[Table 1 (continued)]
[Table 1-10]
--------------------------------------------------------------- ---------------------------------------------------------Ex.163 'Ex. 164 Ex.165 / N N / N} N / N N
H Fi H
(,I \ F C1 I I (/ i ( I/
N N I/F N N CI N F
H H H
r -------------------------------- ----------------- ----------------------------Ex.166 Ex.167 Ex.168 NIL
No N/ \
N^/ H
~ H / /
F 'N
\N \
N N /
H Ex.169 Ex.170 Ex.171 / OH p r r \ N ~ H /
/ ' / t / N / _ r r O
\ o~ \ t ---------------------------------------Ex.172 Ex.173 Ex.174 H
= r ~A/ o ~ \
t --------------------------------------- ---------- ---------------------------------------Ex. 175 Ex.176 Ex.177 ~
r ~ N ~ ~ I ~ q t~ \ o\ \ p~ p~
t r r ---------------------------------------Ex.178 Ex.179 ! Ex.180 cr off r ~~ r r / N t-r t ~- \_. ~ r \ ~_ ~~
t O
~ \ \
r ----------------- ------------------------------------- ---------------------------[0329]
[Table 1 (continued)]
[Table 1 -11]
Ex.181 Ex.182 Ex.183 O
O\ \ O\
------------------------------ --------------------- ----------------------------------------'Ex. Ex.185 Ex.186 O ON
f O I t O O O
, ~~r~ \N~ I{ J 1xI f N ~.u. 1 / N ' N N
, O , O \O
----------------------------------------------------------------------- ---------------------------------------Ex.187 Ex.188 ~ / ~ / r / I /~'N
\ _ , O , O O
\ \ \ ----------------------------------------i------------------------.-.------------y------.--..-..-----------------------.--=
Ex.190 Ex.191 Ex.192 IO IO
D r O r 1 JYON
\ I ~\ O~ \ O~ \ IN ^'~) O' \ It I \
-----------------------Ex.193 Ex.194 Ex.195 I H ,J I/ F I/
/ I\ H
/ f -- ----- --------------------------------------------------------------Ex.196 Ex.197 Ex.198 p , O , N
N/.'N\~
/ \ I/ \ N N
/
/ 1~ N / r / N
` \ \
-------------------------- --------------------------------- -----------------[0330]
[Table I (continued)]
[Table 1-12]
---------------------------------------- --------------------------------------------------------------------------------1 Ex.199 Ex.200 Ex.201 J' /j H
H
( . l \ \ /
J
lI~ N ~/ ~ /
t I\
0 0 , ------------- --------------------------------------------------------- ----------------Ex.202 6 Ex.203 Ex.204 t 1 1 J `~ , \ O~ r CAN
;---------------------------------------- -------____ ________---__--Ex.205 x=~?6 -+-- Ex.207 / /NH, ^ ~N I
Q)O / _ O\ 0 , Ex.208 Ex.209 Ex.210 (o I N) N^/N
, \
H
/ /
/ i -----------------------------' ----------------------------------- - ---------------------------------------Ex 211 Ex.212 Ex.213 \~~ N. tb" \ J ~
( J M' ~ N J
J O If t ~ 1 / 1f J/ I
/~N / f \ .~ / N ( r t Ex.214 Ex.215 Ex.216 ----------------------------------------------------------------------------------------------------------N_l JNN N/
C 'N
~/(1 ~I\O O
p \ \ I
----------------- -----------------------------=
[0331]
[Table 1 (continued)]
[Table 1-13]
----------------------------------------------------------------------------------------------------------------Ex.217 Ex.218 Ex.219 , /
~ IN _ \ O' I r \ O` , \ p \ 1 \ r a~ !r -------------' ---------------- ------------------------------ ----------------------------x.220 Ex.221 Ex.222 H O \~N "\
q~s ~ H H I/
/ /
/ / N / N
/ N ( \ J J
____-----I
Ex.223 Ex.224 1Ex.225 p N\ N \
/ N NNN / N
---------------------------------------------------_----_=---------_----------_=- ---------------------------------------Ex.226 1 Ex.227 Ex.228 N
O \ %N \ N\i //E\1 / ~ ~~ ~1N /r\}
~- O ~. \\O O
t ,. ----- ---"----""-____----'-----'-----'-Y--_.------------------------------------Ex.229 ; Ex.230 e Ex.231 ( H I Fi ~\ H~
N~
L. _-N
I ~N ^ / N
\i\ r ------------------------------------------------------------------- ------"_-___----__-___'' Ex.232 Ex.233 Ex.234 , ~.l O F H
0/ I\ 11'4F Nl I
/ N
O\ 0 ----------------- ------------------------------------- ----------------------------[0332]
[Table 1 (continued)]
[Table 1-14]
-------------------^----------------------------------------------------------------------------------------------------Ex.235 Ex.236 Ex.237 I ~~
N O\
NH "N
0 O/ \ I O \ O/
, -------------------------------------Ex.238 Ex.239 Ex.240 O N
O O\Y1 t NH KN \ p/ \ ~ p \ I p/
--, d____________________ ____ _-__-____--___--Ex.241 Ex.242 ; Ex.243 fl \
NH
O /
\ \ / N O\
\ I
O O o O 0 0 ------1 -------------^
Ex.244 Ex.245 Ex.246 H a N
Ng--N
O
I , Ex.247 ' Ex.248 ; Ex.249 H H H
N ~\ \ N O N
OH
, O\ O OH 0 / IN / / IN / ~ \
\ O 0/ O O
r ----------------- ---------------------Ex.250 Ex.251 Ex.252 N O\ N O H r0 N
KH
O O OO t / \ ON
'=------------------------------------------------- ---------------------------'^------------------------`-------------[0333]
- - ---- ---------- --[Table 1 (continued)]
[Table 1-15]
----------------------------------------`-----------------------------------------------------------------------------Ex.253 Ex.254 Ex.255 N\ NH ll~
r r f~ r N
, IN / I O
r --'-- ' -'--1 --- - --- -------------- --------- -- .._^__--------------Ex.256 Ex.257 Ex.258 r H N
N \
I/ p `
o / I IN \ / f O
------- ------------------Ex.259 Ex.260 Ex.261 S
-Y(/\' 0 g \ N~\% 1 O \ OH
NH
\ O 0 O/ o o/
t ----Ex.262 Ex.263 Ex.264 O I/ '' NH
p H 0 NH N~
-Yam g-N 0 pO/ \ O \ O/ \ \ /
--------- --------------Ex.265 Ex.266 Ex.267 O r~~p H py \ I OH I{ \
NH O NH
0,11 ~
N p\ IN
Op /
p O pi Lxx -------------------------------- -------- ------------------------ --- --------' Ex.268 Ex.269 Ex.270 K-N N/ H NH
p N \ NH 0 0 o O \ O/ \ o \ O/
r 1 ---------------------------"----------- --'_'--'---_----------------[0334]
[Table 1 (continued)]
[Table 1-16]
Ex.271 Ex.272 Ex.273 t H
N H
t IN O\ IN
O\
\ O \ O~ t \ O 0/ \ 0 O/ ----------------------- ----------------- ---------------- --- -----------------------------------------Ex.274 Ex.275 Ex.276 H
H N I \ N
!J ~~ N iN
t ~ O
N r \ 0 \ O/ \ o o/ O 0 Ex.277 Ex.278 Ex.279 N
~ H I ~ I
t ( H
g-N' N o/ 0 0 t O 0 -------------------------------------------------------------------------------- ----------------- ----------Ex.280 Ex.281 Ex.282 n i / N\
~ \ I O \
\ NH \
I \ ` /
0 01, f t t ---- --------------------' ------------ - -------Ex.283 Ex.284 Ex.285 I o 0 \ \
N O\
o o o o ----------^---------------------------'---'---------_--------------------------~-_-------_--- ----_-' Ex.286 Ex.287 Ex.288 `\ 1 H N~
Y 1 N~ /~ N
NH 1 / 0 \ NN
/ ~ / N / /O\ o t --------------------------- ---------------------------------[0335]
[Table 1 (continued)]
[Table 1-17]
------------------------------------------------------------------------Ex.289 Ex.290 Ex.291 H
N N N
O \N ' / 0 \ I
I \
/ O\ Q
N i O
\ o \ o/ O 0 -- --Ex.292 Ex.293 Ex.294 t N O
HN~~ ._..
C) N N y I ''(( / 0 \ NH \
, /
i / I p / / O\ / N / t]\
0 \ p/ \ I o \ ~ o/ \ o \ a/
------------- ------------------------ ---------------Ex.295 Ex.296 Ex.297 Y N~ N
\ /
N O )DIO
\ \ NH \ ' I
It f / N / I O\ / / I \ / / O\
\ O \ O/ \ O \ O/ \ O \ CO/
-----_--_----._...-..-----------------------------------------------------------_---_---_-----Ex.298 Ex.299 Ex.300 N-H N N-N
N
J ~ \
~~N1 O
N 0\
N
I p \( p/ \ I p \ p/
----------- -----Ex.301 Ex.302 Ex.303 H N
N ry 0 H HN I \ N~ N \
N\ ~/N II \ 0 N0\ / I / \ / ( / 0\
\ I p/ O \
--------`-- Ex.304 Ex.305 Ex.306 N
O \~ I Q
NH \ ~~ .S
1 I f NH O y N
gfl0g0cc / 0 \ 0 --- - ---------------------[0336]
[Table I (continued)]
[Table 1-18]
--------------------------i Ex.307 Ex.308 Ex.309 0 N H
N
N OH N~~ I `
f / 0 O
0 \
e \ 0 \ O/ \ 0 O/
^------------------------------ --------------------------------------- -------^------------------Ex.310 Ex.311 1 Ex.312 L Y 11 fNHi N ~ H
\
NH
O\
/ IH
\ 0 \ O/ ~ 1 0 \ f o \ O \ O/
---^
Ex.313 Ex.314 Ex.315 H
N/ H
N
N 0\
O
Ex.316 Ex.317 Ex.318 S /
\ ~ ~/ ~/ N1 , 0 N 1 \
OY/ I/ O
/ , r Y, ---------Ex.319 ' Ex.320 ; Ex.321 H
N
o~~-J
o NH It .NH
0 \ O/
-------------------- - ---------------------------------------------------------------- ----------Ex.322 Ex.323 ' Ex.324 H NON HN
I ~N gj gIN
NN 0 O 0 0\ 00 0IN I
0 0/ i 0 \ I O/
---------- -------------------------------------------- -----------------------------[0337]
[Table 1 (continued)]
[Table 1-19]
----------- ---------------------------------------- ^^_ --------------------^^---~ --------------------------------------Ex.325 Ex.326 Ex.327 CH N/\/~
~N CI IN / N Ci N
H N \ H F F
:.--------- --- --------------------- -------- -----------------[0338]
[Table 2]
[Table 2-1]
Ex. No. LGMS Ex. No. LGMS
[0339]
[Table 2 (continued)]
[Table 2-2]
Ex. No. LCMS Ex. No. LCMS
[0340]
[Table 2 (continued)]
[Table 2-3]
Ex. No. LCMS Ex. No. LCMS
[0341]
[Table 2 (continued)]
[Table 2-4]
Ex. No. LCMS Ex. No. LCMS
[0342]
[Table 2 (continued)]
[Table 2-5]
Ex. No. LCMS Ex.No. LCMS
[0343]
[Table 2 (continued)]
[Table 2-6]
Ex. No. LCMS Ex. No. LCMS
[0344]
[Table 2 (continued)]
[Table 2-7]
Ex. No. LCMS Ex. No. LCMS
[0345]
[Table 2 (continued)]
[Table 2-8]
Ex. No. LCMS Ex. No. LCMS
Preparation Example 1 [0346]
Preparation Example 1 (1) Compound of Working Example 1 10.0 g (2) Lactose 70.0 g (3) Corn starch 50.0 g (4) Soluble starch 7.0 g (5) Magnesium stearate 3.0 g [0347]
The compound of Working Example 1 (10.0 g) and magnesium stearate (3.0 g) were granulated in a 70 mL aqueous solution of soluble starch (7.0 g as soluble starch), and the granules were then dried and mixed with the lactose (70.0 g) and corn starch (50.0 g) (the lactose, corn starch, soluble starch, and magnesium stearate were all compliant with the Japanese Pharmacopoeia, Fourteenth Edition). The mixture was compressed to obtain tablets.
[0348]
Test Example 1 Increased intracellular cAMP levels in human GPR52 expression CHO cells 1 X 104 human GPR52 expression CHO (dhfr-) cells were incubated with 1 gM test compound for 30 min at 37 C in 30 L assay buffer (HBSS (containing Cat + and Mgt + ), 0.5% BSA, 100 gM IBMX, 100 M Ro 20-1724, 5mM HEPES (pH 7.55)) using an OptiPlate-384 (by PerkinElmer). The intracellular cAMP level was then assayed with an EnVision (by PerkinElmer) according to the protocol of the AiphaScreen cAMP Assay Kit (by PerkinElmer). The GPR52 agonist activity was calculated, assuming the intracellular cAMP level to be 100% in the presence of 1 M
of 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin-l -ylethyl)benzamide obtained in Reference Example 39 and assuming the intracellular cAMP level to be 0% when DMSO was added instead of test compound.
The results are shown in Table 3.
[0349]
[Table 3]
[Table 3-1]
Working Example No. GPR52 agonist activity (%) Working Example 1 6 9 Working Example 1 2 4 7 Working Example 1 9 8 5 Working Example 2 2 8 0 Working Example 2 5 7 1 Working Example 2 8 7 4 Working Example 2 9 8 5 Working Example 3 1 9 8 Working Example 3 7 9 2 Working Example 3 9 1 0 6 Working Example 4 0 8 7 Working Example 4 1 5 6 Working Example 4 2 7 1 Working Example 4 4 6 8 Working Example 4 5 8 5 Working Example 4 6 9 9 Working Example 4 9 5 5 Working Example 5 3 1 1 3 Working Example 5 9 8 4 Working Example 6 1 4 3 Working Example 6 5 6 4 Working Example 6 7 4 8 Working Example 6 9 6 5 Working Example 7 5 6 0 Working Example 7 6 5 2 Working Example 8 2 6 4 Working Example 8 3 9 7 Working Example 8 7 7 9 Working Example 8 8 6 2 Working Example 9 1 6 1 Working Example 9 4 5 8 Working Example 9 6 6 6 [0350]
[Table 3 (continued)]
[Table 3-2]
Working Example 1 0 1 5 3 Working Example 1 0 2 8 9 Working Example 1 1 3 7 7 Working Example 1 2 1 5 1 Working Example 1 2 5 5 5 Working Example 1 3 4 4 8 Working Example 1 3 8 1 0 4 Working Example 1 4 1 1 1 3 Working Example 1 4 3 7 2 Working Example 1 4 6 1 3 5 Working Example 1 5 2 6 4 Working Example 1 6 4 1 0 7 Working Example 1 6 5 6 8 Working Example 1 6 6 1 0 9 Working Example 1 6 7 6 8 Working Example 1 7 0 7 9 Working Example 1 7 5 1 1 0 Working Example 2 0 1 8 5 Working Example 2 0 3 9 7 Working Example 2 0 8 6 7 Working Example 2 1 9 9 4 Working Example 2 2 7 6 5 Working Example 2 3 4 6 7 Working Example 2 4 5 5 8 Working Example 3 0 2 5 7 Working Example 3 1 8 8 2 [Industrial Applicability]
[03511 The compounds of the present invention have GPR52 agonist activity and are useful as agents for preventing and treating schizophrenia or the like.
[Table 1]
[Table 1-1]
------- - ------ ------Ex.1 Ex.2 Ex.3 , r r H H
N_ r N\/\p/ H / i i ( II / N \
O p r i r O
, r t t \ I \ i \ I //\\\// \ ( I
H N H 0 N N \ O
H
+ , r r + r r , ---------------------------- ------------------------------------ ---------------------------------------Ex.4 Ex.5 Ex.6 0' F
H
t , r r , r , r N 0 N ~0\ N
H H
'----- -- -- - - - ----__-_ ----------------------------------- ---------------Ex 7 - ----~ Ex 8 ------------ Ex.9 -------H
N 0 N lll` N Ok O
0\ N
N H O NN p N H 0 H \ r r r ------------- ----------- ------------------------- ------- ---- ---------------------------------------Ex.10 Ex.11 Ex.12 Hlr~\N 0 / 0/
/N 11 H~ / N 1r\ I
0\ a0 t r I
\N N \ O N N N o + H , H I r H
--------------------------------------- ---------------------------------- ---------------------------------------Ex.13 Ex. 14 Ex.15 NN\n/O N NHZ
/ N~i~ + / I II II / i , 0\ N / I O/ / I O\
N N N \ p` N N Q
------- -------------- ---------------------------------------H H +---------------------------------------- ----------E x.16 Ex.17 Ex.18 N Br / N\ N NYO N
K
, + I \
N~ O\ N O\ N O\
\N/N 0 N H
H I N H
----------------------------------------- ---------------------------------------- ----------------------------------------[0320]
[Table 1 (continued)]
[Table 1-2]
--------------------------------------------------------------------------------------------------------------------------Ex.19 Ex.20 Ex.21 r H
N
N N p II
\ 0 / q \ 0 N /
O
N N \ I 0 I~ \ \ N \ 0 H H
t t ~.- y--'---------------------------------------------------------------------------Ex.22 Ex.23 Ex.24 / H
~jINH N NN
N II
t e \ I 0 0 O 0 0\ N 0\
\N N O N N 0 N N 0 H f , H H
-------------'''---Ex.25 Ex.26 Ex.27 N N H \ \ N NH2 N\~/N \!
0 'I I t / p , , , N / 0\ / IIN O\ N O\
'I i \ ' , 1` 'A \ I r \ \
N N \\\/// ~~/// `0 N N O
H N H It H
-------- ---- -------Ex.28 Ex.29 Ex.30 H H ;
N f T N\ NN\
-ja N QI N
H ~ H I FFF111III ~
--------------------------------------- ---------------------------------------- ---------------------------------------r Ex.31 ; Ex.32 Ex.33 H H
/ I N NJ N~\/\No Ny NH2 , N N HIl/ O / N H O\ / O\
/1'~..//~i \ \ I \ O N H O
I t I I r {
Ex.34 Ex.35 Ex.36 r H H/\/\H 0 H~\-\NH2 / r H H 0\ N H 0\ ----_ '------------------ -- -_-_----^------------------------------------ - --------------------------_-----[0321]
[Table 1 (continued)]
[Table 1-3]
--------------------------------------------------------------------------------------------------------------------------Ex.37 ; Ex.38 Ex.39 , f NN \ O \ \ /N N O \ 1 0 H H
t L
-------------------------I -----'---....----------- ---------------------------------------E x.40 Ex.41 Ex.42 r O rJ
\ \ H O
/ / /
, / t -NN 1 , 7 t I 1 , , -----------------------------------------------------^^------------------------------------------- --- ----------------------------------------E x.43 Ex.44 Ex.45 I
O oo O ND
1 , O O O , O O
t ------Ex.46 Ex.47 Ex.48 O 0 0 N/\/N H
H H
r , N O O
; ( , ----------------------------------------i-----^^'^----------------^------------- }----------------^'----------------------Ir Ex.49 ; Ex.50 E Ex.51 NH2 \ NTC11~CI
/ Ct r 11 It O O C C
, , -------Ex.52 Ex.53 Ex.54 t N Na,,, N H
N N, N F ~IO
, , r / I~ O\ N O\ N O\
-------^- ------[0322]
[Table I (continued)]
[Table 1-4]
-------------------------------------------------------------------1 Ex.57 Ex.55 Ex.56 , \
I\ N
H
/ / f cl CI CI \ N CI CI U lo,, N II ` O\
t t---------------------------------------q----------_-==_-------------------- r-----------------==
Ex.58 Ex.59 Ex.60 , 0 p t , r t , f{ \ N I
/ H \ \
t O I/ / \ I/ \ I
CI O O --------------- --------------------------------------- ---------------------------------------Ex.61 Ex.63 0 N--\\ 0 \\ ~N
NS/) N~/OH \ Nom/
H I H
H
, t , t N O \ I F N O \ F I/ O \ I F
---------------------------------------- ------------- - -----------------------------------------------------------------Ex.64 Ex.65 Ex.66 o o o f &
F F
F F o Ex.67 Ex.68 Ex.69 o I / / / ( \N / ~ \N / ( \N /
O \ O / O \ 0 / O \ O
----------------------------------------X .70 Ex.71 Ex.72 , o ~\ H H v I N I I ~
, 0,0 f , ---------------------------- ----------------------------------- ------------------[0323]
[Table 1 (continued)]
[Table 1-5]
-------------------------------------------------------------------------------------------------------------------------Ex.73 1 Ex.74 Ex.75 O N- F
S , It / \N / II I \N / I
O O O O O t ---------------------------------------- ---------------------------------------- ----------------------------------------t t Ex.76 Ex.77 Ex.78 O N~ p ~~N =;
N \ 1 J 'N I\ N N
I H \ `ry S H
H p p p O O , , ~ 1 ; I
t ---------------------------- i--------------------------------------- -,.-----__-_-__---___-___---_--__-__-_..__-;
Ex.79 - Ex.80 ; Ex.81 r r ~J\ N 0 N
N F, I\ i f H
H / t t , r \N / I \N / I N
o \ o I
O
, r ____==----------------------------------- --------------------=-------------------t----------------------------------------4 Ex.82 Ex.83 Ex.84 N N
CI CL~L. \ / , /N N
t r ---- r Ex.85 Ex.86 \ N \ N / \ N
H I H I H
CI
CI
\N /
G ICf O \ CI
------------------------------ --------- -------------------- -------------------------------------X --------; -' E.88 Ex.89 x.90 0 0 ,N F
o N-------OH N~\OH N' v i H H
N
OH
CI CI
\N N / ( ~0x50, O CI
--------------------- ---- ---------------[03241 [Table 1 (continued)]
[Table 1-6]
Ex.91 Ex.92 Ex.93 NY,OH fOH N
H ~ ~ I H
CI GI CI N N \N
/ O CI / D \ CI / O \ CI ----- __________------------ -----------------------------------------------------/
' Ex.94 Ex.95 Ex.96 D o 0 II~ H^/S\ H/\/S\ CI CI
I
!
N
N
o CI o CI o CI
t , -------------------- ---------------- -------A------------------ --------------Ex. 99 Ex.98 QNYOH N
r- Y, ~~X I i `p \ N p CI CI CI
Ex.100 Ex.101 Ex.102 o 0 OH
, /
CI CI N
~
C \N N
/ S \ \ / N N O
CI CI
------------------ - ------ ------------------------------- Y-^ --Ex.103 ; Ex. 104 Ex.105 0 o D
I /~ 1 1 /N 1 H
H
, E N \ CI \ I N U \ N O \ CI
H H
, CI CI CI ------------------------------------------------------------------------------- ----------------------------------------Ex.106 Ex.107 Ex.108 , 0 0 NF N- F \N --,_,OH
3 H H ( H
-Y CI CI
, O Y
O
e iii CI CI CI ---------------------------------------- ---------------------------------------[Table 1 (continued)]
[Table 1-7]
----------- ------ ---Ex.109 Ex.110 Ex.111 O
I H I ^ ( H
/ / f /
F F F
N CI N CI N CI
/
I
O \ I I 0 /\ I I O I
r r CI CI CI ----------------------------------------t--------------------------------------------------------------------------------*
Ex.112 Ex.113 Ex.114 /N
OH
N^'OH \ H \ H^' H
F r r , CI CI
N \ IN
O O \ \ I \ I
, O r CI CI CI
Ex.115 Ex.116 Ex.117 f o o o N
N N^,~ N
H H
F F
-N / iCI F ~N / CI -N / CI
CI CI CI
f , -------------- ._-_.._.._______-________-.._.._--_________-__---_-------___--______-___--___----___~
Ex.118 ; Ex.119 ; Ex.120 o o 0 OH ~
N
N N^/ I\ N I\ N
H Fi li /
r , CI CI
`N F \ \ I F \ I \ I
O O
F F
cl F CI F CI
f --------------------------------------- ------------- ----Ex.121 Ex.122 Ex.123 O O O -N
H
g~"N H CI \N
O CI F
-------------------- -------- --------------- ---------------------------------------Ex.124 Ex.125 Ex.126 f r \ N \ N I\ H
H
r / / r CI N /
N ~co 0 ----------------- --------------------------------- -----------------[0326]
[Table 1 (continued)]
[Table 1-8]
-------------------------------------------------------------------------------------------------------------------------Ex.127 Ex.128 Ex.129 O N
N
H \ N \
H r ~ H r -N / Q O
r r t I ------------------ ------------ -^--`--------------------------------Ex.130 Ex.131 Ex.132 O p o r N r N N
{ H H H
/
r r r H -I N N \N / II /N
O O O
'---------------------------------------- --------------------------------------- ----------------------------------------I Ex. 133 Ex.134 Ex.135 Q o Q
N /%N
H H
H r / r CI
/ /N N
~~ I /
O N O
O rI/ I CI CI
'--------------------- `----------__`_-_;_"_--^----------------------------------'---------------------------------------Ex.136 Ex.137 Ex.138 J rJ
N N^/N~
H H H
\ \ r r e r N I\ N I\ i N~-H O N H / N O
r r r - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -E x . ; E x . ; E x . O
O
I--N' H H
, \ r r \ r r r r r r r r r N N \ \ , H O
r r .-------------------------------------- ------------------------------------------------------------------------------Ex.142 Ex.143 Ex.144 , , r r N---/N- N--hl H H
r r r r p r r r N V A r r r N
\
N H
N N \ / F N N + CI
H H
r r r r r r r --------------------------- --------------------------------- -----------------[0327]
[Table I (continued)]
[Table 1-9]
--------------------------- - ----------------------------------- --Ex.145- ; Ex.146 ; Ex.147 N
H I H
\ I \ \
\ \ I \H I\ N \ F
N~N / F I I/ I\
N N / H F N N F
F
H F
~-__--- --^----------Ex.148 Ex.149 Ex.150 -------------------------H~\~N
\ I I H H
N
H \ I i N N- N H
-------- ---------------- -----------Ex.151 Ex.152 Ex.153 H I H \ H
N N N N S N N
H
---------------------------------------- ------------------------ ---------_----------------------__------Ex.154 ; Ex.155 Ex.156 ,NJ
H F / Ham/
NH \ F\ F \
N~
F
H N H N~N / icI
H F H
---------_ ------Ex.157 6 Ex.158 Ex.159 N-/No N/~/NJ
/ I H I H H
F CI
H F N H N H
----------------- ---------Ex.160 Ex.161 \\\\ Ex.162 NJ ND NJ
H I H
F
I t ~N \ \N \ N.
NN `~ F N~N~'U \% \ N H YF
H H F
---- "'----------------__'-_---------_^''__--------------------------------- -"- "-^---------------------------[0328]
[Table 1 (continued)]
[Table 1-10]
--------------------------------------------------------------- ---------------------------------------------------------Ex.163 'Ex. 164 Ex.165 / N N / N} N / N N
H Fi H
(,I \ F C1 I I (/ i ( I/
N N I/F N N CI N F
H H H
r -------------------------------- ----------------- ----------------------------Ex.166 Ex.167 Ex.168 NIL
No N/ \
N^/ H
~ H / /
F 'N
\N \
N N /
H Ex.169 Ex.170 Ex.171 / OH p r r \ N ~ H /
/ ' / t / N / _ r r O
\ o~ \ t ---------------------------------------Ex.172 Ex.173 Ex.174 H
= r ~A/ o ~ \
t --------------------------------------- ---------- ---------------------------------------Ex. 175 Ex.176 Ex.177 ~
r ~ N ~ ~ I ~ q t~ \ o\ \ p~ p~
t r r ---------------------------------------Ex.178 Ex.179 ! Ex.180 cr off r ~~ r r / N t-r t ~- \_. ~ r \ ~_ ~~
t O
~ \ \
r ----------------- ------------------------------------- ---------------------------[0329]
[Table 1 (continued)]
[Table 1 -11]
Ex.181 Ex.182 Ex.183 O
O\ \ O\
------------------------------ --------------------- ----------------------------------------'Ex. Ex.185 Ex.186 O ON
f O I t O O O
, ~~r~ \N~ I{ J 1xI f N ~.u. 1 / N ' N N
, O , O \O
----------------------------------------------------------------------- ---------------------------------------Ex.187 Ex.188 ~ / ~ / r / I /~'N
\ _ , O , O O
\ \ \ ----------------------------------------i------------------------.-.------------y------.--..-..-----------------------.--=
Ex.190 Ex.191 Ex.192 IO IO
D r O r 1 JYON
\ I ~\ O~ \ O~ \ IN ^'~) O' \ It I \
-----------------------Ex.193 Ex.194 Ex.195 I H ,J I/ F I/
/ I\ H
/ f -- ----- --------------------------------------------------------------Ex.196 Ex.197 Ex.198 p , O , N
N/.'N\~
/ \ I/ \ N N
/
/ 1~ N / r / N
` \ \
-------------------------- --------------------------------- -----------------[0330]
[Table I (continued)]
[Table 1-12]
---------------------------------------- --------------------------------------------------------------------------------1 Ex.199 Ex.200 Ex.201 J' /j H
H
( . l \ \ /
J
lI~ N ~/ ~ /
t I\
0 0 , ------------- --------------------------------------------------------- ----------------Ex.202 6 Ex.203 Ex.204 t 1 1 J `~ , \ O~ r CAN
;---------------------------------------- -------____ ________---__--Ex.205 x=~?6 -+-- Ex.207 / /NH, ^ ~N I
Q)O / _ O\ 0 , Ex.208 Ex.209 Ex.210 (o I N) N^/N
, \
H
/ /
/ i -----------------------------' ----------------------------------- - ---------------------------------------Ex 211 Ex.212 Ex.213 \~~ N. tb" \ J ~
( J M' ~ N J
J O If t ~ 1 / 1f J/ I
/~N / f \ .~ / N ( r t Ex.214 Ex.215 Ex.216 ----------------------------------------------------------------------------------------------------------N_l JNN N/
C 'N
~/(1 ~I\O O
p \ \ I
----------------- -----------------------------=
[0331]
[Table 1 (continued)]
[Table 1-13]
----------------------------------------------------------------------------------------------------------------Ex.217 Ex.218 Ex.219 , /
~ IN _ \ O' I r \ O` , \ p \ 1 \ r a~ !r -------------' ---------------- ------------------------------ ----------------------------x.220 Ex.221 Ex.222 H O \~N "\
q~s ~ H H I/
/ /
/ / N / N
/ N ( \ J J
____-----I
Ex.223 Ex.224 1Ex.225 p N\ N \
/ N NNN / N
---------------------------------------------------_----_=---------_----------_=- ---------------------------------------Ex.226 1 Ex.227 Ex.228 N
O \ %N \ N\i //E\1 / ~ ~~ ~1N /r\}
~- O ~. \\O O
t ,. ----- ---"----""-____----'-----'-----'-Y--_.------------------------------------Ex.229 ; Ex.230 e Ex.231 ( H I Fi ~\ H~
N~
L. _-N
I ~N ^ / N
\i\ r ------------------------------------------------------------------- ------"_-___----__-___'' Ex.232 Ex.233 Ex.234 , ~.l O F H
0/ I\ 11'4F Nl I
/ N
O\ 0 ----------------- ------------------------------------- ----------------------------[0332]
[Table 1 (continued)]
[Table 1-14]
-------------------^----------------------------------------------------------------------------------------------------Ex.235 Ex.236 Ex.237 I ~~
N O\
NH "N
0 O/ \ I O \ O/
, -------------------------------------Ex.238 Ex.239 Ex.240 O N
O O\Y1 t NH KN \ p/ \ ~ p \ I p/
--, d____________________ ____ _-__-____--___--Ex.241 Ex.242 ; Ex.243 fl \
NH
O /
\ \ / N O\
\ I
O O o O 0 0 ------1 -------------^
Ex.244 Ex.245 Ex.246 H a N
Ng--N
O
I , Ex.247 ' Ex.248 ; Ex.249 H H H
N ~\ \ N O N
OH
, O\ O OH 0 / IN / / IN / ~ \
\ O 0/ O O
r ----------------- ---------------------Ex.250 Ex.251 Ex.252 N O\ N O H r0 N
KH
O O OO t / \ ON
'=------------------------------------------------- ---------------------------'^------------------------`-------------[0333]
- - ---- ---------- --[Table 1 (continued)]
[Table 1-15]
----------------------------------------`-----------------------------------------------------------------------------Ex.253 Ex.254 Ex.255 N\ NH ll~
r r f~ r N
, IN / I O
r --'-- ' -'--1 --- - --- -------------- --------- -- .._^__--------------Ex.256 Ex.257 Ex.258 r H N
N \
I/ p `
o / I IN \ / f O
------- ------------------Ex.259 Ex.260 Ex.261 S
-Y(/\' 0 g \ N~\% 1 O \ OH
NH
\ O 0 O/ o o/
t ----Ex.262 Ex.263 Ex.264 O I/ '' NH
p H 0 NH N~
-Yam g-N 0 pO/ \ O \ O/ \ \ /
--------- --------------Ex.265 Ex.266 Ex.267 O r~~p H py \ I OH I{ \
NH O NH
0,11 ~
N p\ IN
Op /
p O pi Lxx -------------------------------- -------- ------------------------ --- --------' Ex.268 Ex.269 Ex.270 K-N N/ H NH
p N \ NH 0 0 o O \ O/ \ o \ O/
r 1 ---------------------------"----------- --'_'--'---_----------------[0334]
[Table 1 (continued)]
[Table 1-16]
Ex.271 Ex.272 Ex.273 t H
N H
t IN O\ IN
O\
\ O \ O~ t \ O 0/ \ 0 O/ ----------------------- ----------------- ---------------- --- -----------------------------------------Ex.274 Ex.275 Ex.276 H
H N I \ N
!J ~~ N iN
t ~ O
N r \ 0 \ O/ \ o o/ O 0 Ex.277 Ex.278 Ex.279 N
~ H I ~ I
t ( H
g-N' N o/ 0 0 t O 0 -------------------------------------------------------------------------------- ----------------- ----------Ex.280 Ex.281 Ex.282 n i / N\
~ \ I O \
\ NH \
I \ ` /
0 01, f t t ---- --------------------' ------------ - -------Ex.283 Ex.284 Ex.285 I o 0 \ \
N O\
o o o o ----------^---------------------------'---'---------_--------------------------~-_-------_--- ----_-' Ex.286 Ex.287 Ex.288 `\ 1 H N~
Y 1 N~ /~ N
NH 1 / 0 \ NN
/ ~ / N / /O\ o t --------------------------- ---------------------------------[0335]
[Table 1 (continued)]
[Table 1-17]
------------------------------------------------------------------------Ex.289 Ex.290 Ex.291 H
N N N
O \N ' / 0 \ I
I \
/ O\ Q
N i O
\ o \ o/ O 0 -- --Ex.292 Ex.293 Ex.294 t N O
HN~~ ._..
C) N N y I ''(( / 0 \ NH \
, /
i / I p / / O\ / N / t]\
0 \ p/ \ I o \ ~ o/ \ o \ a/
------------- ------------------------ ---------------Ex.295 Ex.296 Ex.297 Y N~ N
\ /
N O )DIO
\ \ NH \ ' I
It f / N / I O\ / / I \ / / O\
\ O \ O/ \ O \ O/ \ O \ CO/
-----_--_----._...-..-----------------------------------------------------------_---_---_-----Ex.298 Ex.299 Ex.300 N-H N N-N
N
J ~ \
~~N1 O
N 0\
N
I p \( p/ \ I p \ p/
----------- -----Ex.301 Ex.302 Ex.303 H N
N ry 0 H HN I \ N~ N \
N\ ~/N II \ 0 N0\ / I / \ / ( / 0\
\ I p/ O \
--------`-- Ex.304 Ex.305 Ex.306 N
O \~ I Q
NH \ ~~ .S
1 I f NH O y N
gfl0g0cc / 0 \ 0 --- - ---------------------[0336]
[Table I (continued)]
[Table 1-18]
--------------------------i Ex.307 Ex.308 Ex.309 0 N H
N
N OH N~~ I `
f / 0 O
0 \
e \ 0 \ O/ \ 0 O/
^------------------------------ --------------------------------------- -------^------------------Ex.310 Ex.311 1 Ex.312 L Y 11 fNHi N ~ H
\
NH
O\
/ IH
\ 0 \ O/ ~ 1 0 \ f o \ O \ O/
---^
Ex.313 Ex.314 Ex.315 H
N/ H
N
N 0\
O
Ex.316 Ex.317 Ex.318 S /
\ ~ ~/ ~/ N1 , 0 N 1 \
OY/ I/ O
/ , r Y, ---------Ex.319 ' Ex.320 ; Ex.321 H
N
o~~-J
o NH It .NH
0 \ O/
-------------------- - ---------------------------------------------------------------- ----------Ex.322 Ex.323 ' Ex.324 H NON HN
I ~N gj gIN
NN 0 O 0 0\ 00 0IN I
0 0/ i 0 \ I O/
---------- -------------------------------------------- -----------------------------[0337]
[Table 1 (continued)]
[Table 1-19]
----------- ---------------------------------------- ^^_ --------------------^^---~ --------------------------------------Ex.325 Ex.326 Ex.327 CH N/\/~
~N CI IN / N Ci N
H N \ H F F
:.--------- --- --------------------- -------- -----------------[0338]
[Table 2]
[Table 2-1]
Ex. No. LGMS Ex. No. LGMS
[0339]
[Table 2 (continued)]
[Table 2-2]
Ex. No. LCMS Ex. No. LCMS
[0340]
[Table 2 (continued)]
[Table 2-3]
Ex. No. LCMS Ex. No. LCMS
[0341]
[Table 2 (continued)]
[Table 2-4]
Ex. No. LCMS Ex. No. LCMS
[0342]
[Table 2 (continued)]
[Table 2-5]
Ex. No. LCMS Ex.No. LCMS
[0343]
[Table 2 (continued)]
[Table 2-6]
Ex. No. LCMS Ex. No. LCMS
[0344]
[Table 2 (continued)]
[Table 2-7]
Ex. No. LCMS Ex. No. LCMS
[0345]
[Table 2 (continued)]
[Table 2-8]
Ex. No. LCMS Ex. No. LCMS
Preparation Example 1 [0346]
Preparation Example 1 (1) Compound of Working Example 1 10.0 g (2) Lactose 70.0 g (3) Corn starch 50.0 g (4) Soluble starch 7.0 g (5) Magnesium stearate 3.0 g [0347]
The compound of Working Example 1 (10.0 g) and magnesium stearate (3.0 g) were granulated in a 70 mL aqueous solution of soluble starch (7.0 g as soluble starch), and the granules were then dried and mixed with the lactose (70.0 g) and corn starch (50.0 g) (the lactose, corn starch, soluble starch, and magnesium stearate were all compliant with the Japanese Pharmacopoeia, Fourteenth Edition). The mixture was compressed to obtain tablets.
[0348]
Test Example 1 Increased intracellular cAMP levels in human GPR52 expression CHO cells 1 X 104 human GPR52 expression CHO (dhfr-) cells were incubated with 1 gM test compound for 30 min at 37 C in 30 L assay buffer (HBSS (containing Cat + and Mgt + ), 0.5% BSA, 100 gM IBMX, 100 M Ro 20-1724, 5mM HEPES (pH 7.55)) using an OptiPlate-384 (by PerkinElmer). The intracellular cAMP level was then assayed with an EnVision (by PerkinElmer) according to the protocol of the AiphaScreen cAMP Assay Kit (by PerkinElmer). The GPR52 agonist activity was calculated, assuming the intracellular cAMP level to be 100% in the presence of 1 M
of 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin-l -ylethyl)benzamide obtained in Reference Example 39 and assuming the intracellular cAMP level to be 0% when DMSO was added instead of test compound.
The results are shown in Table 3.
[0349]
[Table 3]
[Table 3-1]
Working Example No. GPR52 agonist activity (%) Working Example 1 6 9 Working Example 1 2 4 7 Working Example 1 9 8 5 Working Example 2 2 8 0 Working Example 2 5 7 1 Working Example 2 8 7 4 Working Example 2 9 8 5 Working Example 3 1 9 8 Working Example 3 7 9 2 Working Example 3 9 1 0 6 Working Example 4 0 8 7 Working Example 4 1 5 6 Working Example 4 2 7 1 Working Example 4 4 6 8 Working Example 4 5 8 5 Working Example 4 6 9 9 Working Example 4 9 5 5 Working Example 5 3 1 1 3 Working Example 5 9 8 4 Working Example 6 1 4 3 Working Example 6 5 6 4 Working Example 6 7 4 8 Working Example 6 9 6 5 Working Example 7 5 6 0 Working Example 7 6 5 2 Working Example 8 2 6 4 Working Example 8 3 9 7 Working Example 8 7 7 9 Working Example 8 8 6 2 Working Example 9 1 6 1 Working Example 9 4 5 8 Working Example 9 6 6 6 [0350]
[Table 3 (continued)]
[Table 3-2]
Working Example 1 0 1 5 3 Working Example 1 0 2 8 9 Working Example 1 1 3 7 7 Working Example 1 2 1 5 1 Working Example 1 2 5 5 5 Working Example 1 3 4 4 8 Working Example 1 3 8 1 0 4 Working Example 1 4 1 1 1 3 Working Example 1 4 3 7 2 Working Example 1 4 6 1 3 5 Working Example 1 5 2 6 4 Working Example 1 6 4 1 0 7 Working Example 1 6 5 6 8 Working Example 1 6 6 1 0 9 Working Example 1 6 7 6 8 Working Example 1 7 0 7 9 Working Example 1 7 5 1 1 0 Working Example 2 0 1 8 5 Working Example 2 0 3 9 7 Working Example 2 0 8 6 7 Working Example 2 1 9 9 4 Working Example 2 2 7 6 5 Working Example 2 3 4 6 7 Working Example 2 4 5 5 8 Working Example 3 0 2 5 7 Working Example 3 1 8 8 2 [Industrial Applicability]
[03511 The compounds of the present invention have GPR52 agonist activity and are useful as agents for preventing and treating schizophrenia or the like.
Claims (17)
- [Claim 1]
A compound represented by formula (I):
wherein A represents -(CH2)n-CO-NR a- (n is an integer of 0 to 3) or -NR a-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-R
b, -S-R b, -S(O)-R b, optionally substituted C1-14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CR x=, or -N=, Y represents -O-, -S-, -S(O)-, -S(O)2-, or -NR y-, Z represents a bond, methylene, or ethylene, Ar1 represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and optionally halogenated C1-6 alkoxy groups, Ar2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and optionally halogenated C1-6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and R a, R b, R x, and R y represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1-6 alkyl groups, or optionally halogenated C1-6 alkoxy groups, providing that 1-{2-[(3-chlorobenzyl)oxy]-6-methylpyridin-4-yl}-2-methyl-1H-imidazole-4-carboxamide, tert-butyl {5-[6-(3-chlorophenoxy)pyrazin-2-yl]pyridin-3-yl}carbamate, 5-{6-[3-(trifluoromethyl)phenoxy]pyridin-2-yl}-1,3,4-oxadiazole- - 2-carboxamide, and N-hydroxy-5-{6-[methyl(2-phenylethyl)amino]pyridin-2-yl}thiophene-2-carboxamide are excluded, or a salt thereof.
[Claim 2]
The compound according to claim 1, wherein A is -CO-NH- or -NH-CO-. - [Claim 3]
The compound according to claim 1, wherein B is a (1) hydrogen atom, (2) C1-6 alkyl group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C1-6 alkyl groups, C6-10 aryl groups, C1-6 alkoxy-carbonyl groups, C1-6 alkyl-carbonyl groups, and carbamoyl groups, (e) C6-10 aryl groups which may be substituted with 1 to 3 substituents selected from halogen atoms, hydroxy group, and amino group, (f) C1-6 alkylsulfanyl groups, (g) C1-6 alkylsulfinyl groups, (h) C1-6 alkylsulfonyl groups, (i) C1-6 alkoxy groups, (j) C6-10 aryloxy groups, (k) C7-13 aralkyloxy groups, (l) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from C1-6 alkyl groups, C1-6 alkyl-carbonyl groups, and oxo group, and (m) carbamoyl, (3) C2-6 alkenyl group which may be substituted with a five- to six-membered heterocyclic group, (4) C3-10 cycloalkyl group, (5) C6-10 aryl group which may be substituted with one or more substituents selected from (a) hydroxy group, (b) cyano group, (c) C1-6 alkoxy groups, (d) mono- or di-C1-6 alkyl-amino groups, and (e) C1-6 alkyl-carbonylamino groups, (6) amino group which may be mono- or di-substituted with substituents selected from (a) C1-6 alkyl groups which may be substituted with mono- or di-C1-6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from halogen atoms and oxo group, or (7) five- to ten-membered heterocyclic group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) C1-6 alkyl groups which may be substituted with one or more substituents selected from hydroxy group and mono- or di-C1-6 alkylamino groups, (c) C1-6 alkoxy groups, (d) C1-6 alkyl-carbonyl groups, (e) C1-6 alkoxy-carbonyl groups, and (f) carbamoyl groups. - [Claim 4]
The compound according to claim 1, wherein one or two of X1, X2, X3, and X4 are -N=. - [Claim 5]
The compound according to claim 1, wherein Y is -O-. - [Claim 6]
The compound according to claim 1, wherein Ar1 is a benzene ring or indole ring which may be substituted with one or more substituents selected from halogen atoms and optionally halogenated C1-6 alkyl groups. - [Claim 7]
The compound according to claim 1, wherein R x is a hydrogen atom or optionally halogenated C1-6 alkyl group. - [Claim 8]
The compound according to claim 1, wherein A is -CO-NH- or -NH-CO-, B is a (1) hydrogen atom, (2) C1-6 alkyl group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) hydroxy group, (c) cyano group, (d) amino group which may be mono- or di-substituted with substituents selected from optionally hydroxy-substituted C1-6 alkyl groups, C6-10 aryl groups, C1-6 alkoxy-carbonyl groups, C1-6 alkyl-carbonyl groups, and carbamoyl groups, (e) C6-10 aryl groups which may be substituted with 1 to 3 substituents selected from halogen atoms, hydroxy group, and amino group, (f) C1-6 alkylsulfanyl groups, (g) C1-6 alkylsulfinyl groups, (h) C1-6 alkylsulfonyl groups, (i) C1-6 alkoxy groups, (j) C6-10 aryloxy groups, (k) C7-13 aralkyloxy groups, (l) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from C1-6 alkyl groups, C1-6 alkyl-carbonyl groups, and oxo group, and (m) carbamoyl, (3) C2-6 alkenyl group which may be substituted with a five- to six-membered heterocyclic group, (4) C3-10 cycloalkyl group, (5) C6-10 aryl group which may be substituted with one or more substituents selected from (a) hydroxy group, (b) cyano group, (c) C1-6 alkoxy groups, (d) mono- or di-C1-6 alkyl-amino groups, and (e) C1-6 alkyl-carbonylamino groups, (6) amino group which may be mono- or di-substituted with substituents selected from (a) C1-6 alkyl groups which may be substituted with mono- or di-C1-6 alkylamino groups, and (b) five- to ten-membered heterocyclic groups which may be substituted with one or more substituents selected from halogen atoms and oxo group, or (7) five- to ten-membered heterocyclic group which may be substituted with one or more substituents selected from (a) halogen atoms, (b) C1-6 alkyl groups which may be substituted with one or more substituents selected from hydroxy group and mono- or di-C1-6 alkylamino groups, (c) C1-6 alkoxy groups, (d) C1-6 alkyl-carbonyl groups, (e) C1-6 alkoxy-carbonyl groups, and (f) carbamoyl groups;
X1, X2, X3, and X4 are the same or different -CR x=, or -N=, and one or two of X1, X2, X3, and X4 are -N=, Y is -O-, Ar1 is a benzene ring or indole ring which may be substituted with one or more substituents selected from halogen atoms and optionally halogenated C1-6 alkyl groups, Ar2 is a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and optionally halogenated C1-6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and R x is a hydrogen atom or optionally halogenated C1-6 alkyl group. - [Claim 9]
The compound according to claim 1, selected from:
4-amino-N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)butanamide hydrochloride, N-(3-(2-((2-(3,4-dimethoxyphenyl)ethyl)amino)pyrimidin-4-yl)phenyl)-N3,N3-dimethyl-(3-alaninamide hydrochloride, 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(2-pyrrolidin-1-ylethyl)benzamide, N-(2-hydroxyethyl)-3-(6-(2-(3-(trifluoromethyl)phenyl)ethoxy)pyridin-2-yl)benzamide, N-(2-hydroxyethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide, 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide, N-(2-aminoethyl)-3-(6-(2-(3-methoxyphenyl)ethoxy)pyridin-2-yl)benzamide hydrochloride, 3-(6-(2,4-dichlorophenoxy)pyridin-2-yl)-N-(2-pyrrolidin-1-yl)benzamide, 3-(6-((2,4-dichlorophenyl)thio)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide, N-(2-pyrrolidin-1-ylethyl)-3-[2-({2-[3-(trifluoromethyl)phenyl]ethyl}amino)pyrimidin-4-yl]benzamide, N-cyclopropyl-3-{6-[2-(3,4-dimethoxyphenyl)ethoxy]pyridin-2-yl}benzamide, N-(3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)phenyl)acetamide, 3-(6-(2-(3,4-dimethoxyphenyl)ethoxy)pyridin-2-yl)-N-(pyridin-3-ylmethyl)benzamide, 3-(6-(3,5-dichlorophenoxy)pyridin-2-yl)-N-(2-(methylsulfinyl)ethyl)benzamide, and 3-(6-((2,4-dichlorophenyl)amino)pyridin-2-yl)-N-(2-hydroxyethyl)benzamide. - [Claim 10]
A prodrug of the compound according to claim 1. - [Claim 11]
A pharmaceutical agent comprising the compound according to claim 1 or the prodrug according to claim 10. - [Claim 12]
A GPR52 activating agent comprising a compound represented by formula (I):
wherein A represents -(CH2)n-CO-NR a- (n is an integer of 0 to 3) or -NR a-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-R
b, -S-R b, -S(O)-R b, optionally substituted C1-14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CR x=, or -N=, Y represents -O-, -S-, -S(O)-, -S(O)2-, or -NR y-, Z represents a bond, methylene, or ethylene, Ar1 represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and optionally halogenated C1-6 alkoxy groups, Ar2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and optionally halogenated C1-6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and R a, R b, R x, and R y represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1-6 alkyl groups, or optionally halogenated C1-6 alkoxy groups, or a salt or prodrug thereof. - [Claim 13]
The GPR52 activating agent according to claim 12, which is an agent for preventing or treating schizophrenia. - [Claim 14]
A method for preventing or treating diseases involving GPR52 activity in a mammal, comprising administering a compound represented by formula (I):
wherein A represents -(CH2)n-CO-NR a- (n is an integer of 0 to 3) or -NR a-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-R
b, -S-R b, -S(O)-R b, optionally substituted C1-14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CR x=, or -N=, Y represents -O-, -S-, -S(O)-, -S(O)2-, or -NR y-, Z represents a bond, methylene, or ethylene, Ar1 represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and optionally halogenated C1-6 alkoxy groups, Ar2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and optionally halogenated C1-6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and R a, R b, R x, and R y represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1-6 alkyl groups, or optionally halogenated C1-6 alkoxy groups, or a salt or prodrug thereof, to the mammal. - [Claim 15]
The method according to claim 14, wherein the disease involving GPR52 activity is schizophrenia. - [Claim 16]
The use of a compound represented by formula (I):
wherein A represents -(CH2)n-CO-NR a- (n is an integer of 0 to 3) or -NR a-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, -O-R
b, -S-R b, -S(O)-R b, optionally substituted C1-14 hydrocarbon group, optionally substituted five- to ten-membered heterocyclic group, optionally substituted amino group, or acyl group, X1, X2, X3, and X4 represent the same or different -CR x=, or -N=, Y represents -O-, -S-, -S(O)-, -S(O)2-, or -NR y-, Z represents a bond, methylene, or ethylene, Ar1 represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and optionally halogenated C1-6 alkoxy groups, Ar2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and optionally halogenated C1-6 alkoxy groups, and which may be condensed with an optionally substituted five- to six-membered ring, and R a, R b, R x, and R y represent the same or different hydrogen atom, halogen atoms, optionally halogenated C1-6 alkyl groups, or optionally halogenated C1-6 alkoxy groups, or a salt or prodrug thereof, for the manufacture of a GPR52 activating agent. - [Claim 17]
The use according to claim 16, wherein the GPR52 activating agent is as an agent for preventing or treating schizophrenia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-046757 | 2008-02-27 | ||
JP2008046757 | 2008-02-27 | ||
PCT/JP2009/000882 WO2009107391A1 (en) | 2008-02-27 | 2009-02-27 | Compound having 6-membered aromatic ring |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2716898A1 true CA2716898A1 (en) | 2009-09-03 |
Family
ID=41015798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2716898A Abandoned CA2716898A1 (en) | 2008-02-27 | 2009-02-27 | Compound having 6-membered aromatic ring |
Country Status (5)
Country | Link |
---|---|
US (1) | US20110009421A1 (en) |
EP (1) | EP2253618A1 (en) |
JP (1) | JPWO2009107391A1 (en) |
CA (1) | CA2716898A1 (en) |
WO (1) | WO2009107391A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9296701B2 (en) | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9340557B2 (en) | 2013-03-12 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
US10039761B2 (en) | 2013-10-17 | 2018-08-07 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
US11980633B2 (en) | 2021-07-29 | 2024-05-14 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110130384A1 (en) * | 2008-06-25 | 2011-06-02 | Takeda Pharmaceutical Company Limited | Amide compound |
AR073010A1 (en) * | 2008-08-12 | 2010-10-06 | Takeda Pharmaceutical | AMIDA COMPOUND WITH GPR52 AGONIST ACTIVITY |
EP2518054A1 (en) | 2009-12-24 | 2012-10-31 | Takeda Pharmaceutical Company Limited | Amide compound |
EP2530078A1 (en) | 2010-01-27 | 2012-12-05 | Takeda Pharmaceutical Company Limited | Thiazole derivative |
WO2011145735A1 (en) * | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | Thiazole derivative |
WO2012020738A1 (en) * | 2010-08-09 | 2012-02-16 | 武田薬品工業株式会社 | Heterocyclic compound and use thereof |
CN102452978A (en) * | 2010-11-01 | 2012-05-16 | 重庆康丁医药技术有限公司 | 2-chloro-substituted or unsubstituted aliphatic hydrocarbyl-oxy pyridine and preparation method thereof |
JP6368577B2 (en) * | 2014-07-31 | 2018-08-01 | 株式会社神戸製鋼所 | Compressed air storage power generation apparatus and compressed air storage power generation method |
ES2784316T3 (en) * | 2015-04-29 | 2020-09-24 | Arena Pharm Inc | 1-Heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related to it |
JOP20190233A1 (en) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase |
IL298250A (en) | 2018-04-12 | 2023-01-01 | Bayer Ag | N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides |
KR20220161454A (en) | 2020-03-30 | 2022-12-06 | 베링거 인겔하임 인터내셔날 게엠베하 | Substituted 3-phenoxyazetidin-1-yl-pyrazine with GPR52 agonistic activity |
TW202206413A (en) * | 2020-04-22 | 2022-02-16 | 美商紐羅克里生物科學有限公司 | Gpr52 modulators and methods of use |
CN117940420A (en) | 2021-09-14 | 2024-04-26 | 勃林格殷格翰国际有限公司 | 3-Phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and their use as pharmaceuticals |
CN113956240B (en) * | 2021-11-03 | 2023-02-14 | 陕西师范大学 | Pyrimidine derivatives and application thereof in preparing antitumor drugs |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2148931A1 (en) * | 1993-10-01 | 1995-04-13 | Jurg Zimmermann | Pyrimidineamine derivatives and processes for the preparation thereof |
AU3264695A (en) * | 1994-08-23 | 1996-03-14 | Nissan Chemical Industries Ltd. | Pyridine derivative |
WO1999031062A1 (en) * | 1997-12-17 | 1999-06-24 | Shionogi & Co., Ltd. | Novel pyridine compounds |
US20020049223A1 (en) * | 1999-11-05 | 2002-04-25 | Elmore Steven W. | Quinoline and naphthyridine carboxylic acid antibacterials |
CA2463822A1 (en) * | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
AU2003286876A1 (en) * | 2002-11-01 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
EP1560824A1 (en) * | 2002-11-05 | 2005-08-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
SE0203654D0 (en) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
EP1644365A2 (en) * | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
SE0301963D0 (en) * | 2003-07-02 | 2003-07-02 | Astrazeneca Ab | New compounds |
EP1648875A1 (en) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
US20080194574A1 (en) * | 2003-12-16 | 2008-08-14 | Axxima Pharmaceuticals Ag | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases |
TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
WO2006010637A2 (en) * | 2004-07-30 | 2006-02-02 | Gpc Biotech Ag | Pyridinylamines |
ES2352748T3 (en) * | 2004-09-06 | 2011-02-22 | Basilea Pharmaceutica Ag | PHENYLAMINOPIRIDINS AND PHENYLAMINOPIRACINES. |
GB0500226D0 (en) * | 2005-01-07 | 2005-02-16 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
EP1860185B1 (en) | 2005-03-18 | 2011-07-13 | Takeda Pharmaceutical Company Limited | Screening method |
PT1899333E (en) * | 2005-06-27 | 2009-04-23 | Sanofi Aventis | Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1 |
JP2007204458A (en) * | 2006-02-06 | 2007-08-16 | Dai Ichi Seiyaku Co Ltd | Three-ring heterocyclic compound having antifungal action |
ES2654847T3 (en) * | 2006-04-19 | 2018-02-15 | Novartis Ag | 6-O substituted benzoxazole and benzothiazole compounds and methods to inhibit CSF-1R signaling |
NL2000613C2 (en) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazole pyrazine derivatives. |
US20110130384A1 (en) * | 2008-06-25 | 2011-06-02 | Takeda Pharmaceutical Company Limited | Amide compound |
AR073010A1 (en) * | 2008-08-12 | 2010-10-06 | Takeda Pharmaceutical | AMIDA COMPOUND WITH GPR52 AGONIST ACTIVITY |
-
2009
- 2009-02-27 EP EP09715685A patent/EP2253618A1/en not_active Withdrawn
- 2009-02-27 US US12/919,400 patent/US20110009421A1/en not_active Abandoned
- 2009-02-27 CA CA2716898A patent/CA2716898A1/en not_active Abandoned
- 2009-02-27 JP JP2010500573A patent/JPWO2009107391A1/en not_active Abandoned
- 2009-02-27 WO PCT/JP2009/000882 patent/WO2009107391A1/en active Application Filing
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9296701B2 (en) | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US11021465B2 (en) | 2012-04-24 | 2021-06-01 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10501439B2 (en) | 2012-04-24 | 2019-12-10 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9376448B2 (en) | 2012-04-24 | 2016-06-28 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9592232B2 (en) | 2012-04-24 | 2017-03-14 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9878993B2 (en) | 2012-04-24 | 2018-01-30 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors for treatment of cancer |
US9925188B2 (en) | 2012-04-24 | 2018-03-27 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors and uses thereof |
US10442791B2 (en) | 2012-04-24 | 2019-10-15 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10391095B2 (en) | 2012-04-24 | 2019-08-27 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10076521B2 (en) | 2012-04-24 | 2018-09-18 | Vertex Pharamceuticals Incorporated | DNA-PK inhibitors |
US10258627B2 (en) | 2013-03-12 | 2019-04-16 | Vertex Pharmaceutical Incorporated | DNA-PK inhibitors |
US9987284B2 (en) | 2013-03-12 | 2018-06-05 | Vertex Pharmaceuticals Incorporated | Substituted benzooxadiazole DNA-PK inhibitors |
US9359380B2 (en) | 2013-03-12 | 2016-06-07 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10786512B2 (en) | 2013-03-12 | 2020-09-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10973830B2 (en) | 2013-03-12 | 2021-04-13 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
US9340557B2 (en) | 2013-03-12 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
US11813267B2 (en) | 2013-03-12 | 2023-11-14 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10039761B2 (en) | 2013-10-17 | 2018-08-07 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US10716789B2 (en) | 2013-10-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
US11980633B2 (en) | 2021-07-29 | 2024-05-14 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JPWO2009107391A1 (en) | 2011-06-30 |
US20110009421A1 (en) | 2011-01-13 |
WO2009107391A1 (en) | 2009-09-03 |
EP2253618A1 (en) | 2010-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2716898A1 (en) | Compound having 6-membered aromatic ring | |
WO2010018874A1 (en) | Amide compound | |
TWI714527B (en) | Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof | |
CA2442114C (en) | N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor | |
TWI536991B (en) | Inhibitors of focal adhesion kinase | |
TWI504604B (en) | Heterocyclic compound and use thereof | |
US20110130384A1 (en) | Amide compound | |
EP3154954B1 (en) | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof | |
WO2017170830A1 (en) | Heterocyclic compound | |
JP2007514759A (en) | Kinase inhibitor | |
JP5552121B2 (en) | Indolizine inhibitors of leukotriene production | |
NZ337698A (en) | Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases | |
EP3083631B1 (en) | Wnt pathway modulators | |
EA019641B1 (en) | Iminopyridine derivatives and use thereof | |
JP2010500332A (en) | 5,6-bisaryl-2-pyridine-carboxamide derivatives, their preparation and use in their treatment as urotensin II receptor antagonists | |
JP7114594B2 (en) | heterocyclic compound | |
JP2016540802A (en) | Maleimide derivatives as modulators of the WNT pathway | |
JP2021519263A (en) | Compounds and their use | |
JP2022526890A (en) | Compounds and their use | |
JP7317721B2 (en) | heterocyclic compound | |
KR20210022646A (en) | Cyanotriazole compounds and uses thereof | |
JP7114591B2 (en) | GSK-3 inhibitor | |
WO2021020363A1 (en) | Heterocyclic compound | |
WO2023227696A1 (en) | New derivatives for treating trpm3 mediated disorders | |
TWI415606B (en) | Inhibitors of histone deacetylase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20140227 |